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Summary
X
The main clinical problem in breast cancer is metastasis and the initial 
spread frequently involves the axillary lymph nodes. Surgical removal of the 
primary tumour is not always sufficient to prevent further spread of the disease 
and mortality is high in breast cancer. At present, lymph node metastasis 
(stage) remains the most important prognostic indicator but clinical staging can 
be inaccurate and 30% of node negative (without nodal metastasis) patients still 
die from their disease. The metastatic process is complex in breast cancer 
especially as primary tumours differ widely and while prognosis in some 
patients after surgery is good, in others there is early recurrence and 
widespread metastasis. Even within a tumour, much variation exists and it is 
believed that metastatic cells may represent only a subpopulation of the primary 
tumour. Various factors both contribute towards as well as act against the 
generation of such metastatic cells. Recent research has been directed towards 
identifying such features in breast tumours and their relationship to metastasis. 
The surgical practice at Western Infirmary includes axillary clearance in 
addition to removal of the primary tumour. It was, therefore, possible to 
design a study which involved analysis of both primary tumours and lymph 
node metastases from breast cancer patients. This study involved the 
measurement of different molecular parameters (including lymph node 
immunological responses, cell surface carbohydrate expression, DNA flow 
cytometric analysis, and DNA fingerprinting) in relation to metastasis to the 
lymph node.
The surgical removal of axillary lymph nodes along with the primary 
tumour still remains a matter of debate. Recent studies suggest that the lymph 
nodes may contribute to both a cellular and humoral immune response. There 
is a potential two-way interaction in lymph nodes in breast cancer patients. As
these nodes primarily drain the breast, they are ideally situated to encounter 
tumour cells and, as such, tumour antigen recognition leading to host-mediated 
immune response can occur. At the same time, however, invading tumour 
cells can adversely influence such a response. Alterations in both the 
phenotype and activation status of lymph node lymphocytes from breast cancer 
patients have been detected by flow cytometry with the use of fluorescent 
monoclonal antibodies against surface markers. In this study, in order to 
assess the effect of metastasis on lymph node response, lymphocytes from 
tumour-invaded and tumour-free lymph nodes from the same breast cancer 
patients have been analysed by flow cytometry for expression of phenotype 
and activation markers. Lymph node lymphocytes from 12 such patients 
(stage II) were also compared with lymphocytes from 14 patients without 
metastasis (stage I). High patient variability with respect to both the phenotype 
and activation status was observed, and there were differences in the 
proportion of T cell subsets and activated B cells between nodes that were 
invaded and those that were not. The proportion of CD8+ T cells was 
increased in tumour-invaded nodes compared to tumour-free nodes (p=0.002). 
In contrast, the proportion of CD4+ T cells, which was the predominant T cell 
subset in lymph nodes, was decreased in invaded nodes (p=0.003). In 
consequence, the CD4+/CD8+ ratio was markedly depressed in invaded nodes 
(p=0.001), while the ratio in tumour-free nodes was similar to those in stage I 
nodes. The proportions of both CD8+ and CD4+ T cells in tumour-free nodes 
were also similar to stage I nodes. Among the T cell activation markers, HLA 
DR, which was expressed on a higher percentage of CD8+ cells than CD4+ 
cells, was not significantly different between invaded and tumour-free nodes. 
Tac expression (IL-2 receptor), which was on a higher percentage of CD4+ T 
cells, was also not significantly different but was found on a higher proportion
of T cells in invaded nodes compared to tumour-free nodes. On the other 
hand, although the mean percentage of surface IgG-expressing B cells was 
slightly higher in invaded nodes when compared to both tumour-free nodes in 
the same patient (p<0.05) and nodes from stage I patients (p<0.05), such a 
difference was observed to be strong in some patients. The differences 
observed in the lymph nodes were not reflected in the peripheral blood 
lymphocytes from the same patient. These results suggest that the presence of 
metastatic tumour cells in a lymph node is associated with specific alterations 
of the phenotype and activation status of lymphocytes and may reflect the host- 
tumour interaction in breast cancer patients.
In previous immunohistochemical studies, lectin binding has been used 
to detect alterations related to malignancy in primary breast cancer. In this 
study, using fluorescently-labelled Helix pomatia (HPA) and Concanavalin A 
(Con A) lectins, cell surface carbohydrate expression on 32 fresh primary 
tumours and 12 lymph node metastases was analysed by flow cytometry. It 
was possible to quantitate the extent of lectin binding and the percentage of live 
positive cells was accurately determined from 10,000 and 5000 cells per 
sample for tumour and nodal metastasis respectively. While primary tumours 
were positive for both HPA and Con A binding (53% and 44% of analysed 
tumours, respectively), comparison with clinicopathological features showed 
that HPA, but not Con A correlated positively with lymph node metastasis 
(p<0.01). This association with nodal metastasis held for tumours of higher 
grade (II and HI), and HPA positive tumours were also more likely to be 
oestrogen receptor (ER) negative (p<0.05). In 12 patients, where both 
primary tumours and lymph node metastases were analysed, a strong positive 
correlation was found between the percentage of cells binding HPA in lymph
nodes and those in autologous primary tumours (p=0.001). This suggests that 
HPA binding defines an N-acetyl galactosamine-containing cell surface marker 
on breast tumours which may be associated with lymph node metastasis. The 
presence of HPA binding tumour cells in invaded nodes further substantiates 
the hypothesis that HPA binding represents a phenotypic marker of metastatic 
potential.
It is generally assumed that only a subpopulation of tumour cells has 
the capacity to metastasise, and it is possible that the generation of such 
subpopulations occurs as a result of alterations in the DNA. A number of 
studies have now shown that breast cancer patients with aneuploid, high S- 
phase tumour DNA profiles have a poor prognosis. Aneuploidy, which 
represents abnormal DNA content, and high SPF (S phase fraction), which 
represents a high proliferation rate, can be assessed by flow cytometric (FCM) 
DNA analysis. Although the prognostic relevance of FCM DNA analysis has 
been widely studied on primary tumours, very few studies have also analysed 
lymph node metastases from the same patient. Fresh paired primary tumours 
and lymph node metastases were compared in this study. In breast cancer, the 
occurrence of aneuploid tumours is frequent, and 63% of 57 primary breast 
tumours analysed in this study were found to be aneuploid. Comparison with 
histopathological prognostic factors showed no significant association between 
DNA ploidy and tumour grade (p<0.1), while diploid tumours were found 
more likely to be ER-positive (p<0.02). On the other hand, aneuploid tumours 
were found to behave more aggressively with respect to metastasis to the nodes 
(p<0.01). However, the detection of aneuploid peaks in corresponding nodal 
metastasis was rare in a single-parameter DNA analysis; in only 6 cases out of 
25 was an aneuploid peak, present in the primary tumour, also detected in the
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node. Using an anti-cytokeratin (CK) antibody and employing a dual­
parameter analysis the sensitivity of detection of aneuploid peaks in invaded 
nodes was increased by gating out the CK-negative lymphocytes. Moreover, it 
was also possible to assess whether the diploid peak in the primary tumour 
was also epithelial in nature. Examination of 12 primary tumours and lymph 
node metastases for CK+ cells revealed that tumour cells in invaded nodes can 
be either diploid or aneuploid, reflecting the ploidy of the primary tumour. In 
patients with multiploid primaiy tumours, only a subpopulation of the primary 
aneuploid cells was detected in the nodal metastases. The results suggest that 
aneuploidy is not a harmless feature of a cell's uncontrolled growth but is an 
integral feature of metastatic cells and that within a primary tumour a 
subpopulation may have a higher metastatic potential.
Using four different multi-locus DNA satellite probes, DNA from both 
primary tumours and lymph nodes from 13 patients was also analysed by DNA 
fingerprinting. DNA fingerprinting allows detection of individual-specific 
restriction fragment length polymorphisms (RFLP), which can be used to 
detect alterations in tumour DNA. Using the satellite probes, it is possible 
simultaneously to detect changes on regions widely dispersed in the human 
genome. The analysis in this study involved comparison of DNA samples 
from peripheral blood with those from primary tumours and lymph nodes in 
both stage I and stage II breast cancer patients. A number of instances of loss 
of bands and appearance of new bands was observed in both primary tumours 
and node metastasis, but these changes were observed in the case of both 
diploid and aneuploid tumours. Although DNA from only a small number of 
patients was analysed, the observed changes were found not to relate to either 
stage or tumour grade.
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Finally, it was possible to determine if there was a correlation between 
the different parameters analysed in patients where more than one parameter 
was studied. DNA aneuploidy was related with both HPA staining and the 
lymph node response. Although the association with HPA binding was not 
statistically significant in the 28 patients studied, aneuploid tumours were 
found to be positive for HPA staining in patients with lymph node metastasis. 
In 15 patients where both lymph node responses and DNA ploidy were 
analysed, the proportion of HLA DR-expressing T cells, both CD4+ and 
CD8+, was higher in patients with aneuploid tumours (p<0.05). Although no 
differences were observed in Tac expression, the proportion of IgG-expressing 
B cells was higher in patients with aneuploid tumours (p=0.05). This suggests 
that some aneuploid tumours may express certain antigens that can elicit a 
lymph node response.
This study provides evidence to suggest that in breast carcinoma 
patients, HPA binding and aneuploidy are parameters associated with 
metastasis to the lymph nodes and that metastatic cells may affect the 
immunological response in the lymph nodes. Analyses of HPA binding and 
DNA aneuploidy may help to identify aggressive tumours while immunological 
responses in the lymph node may be used to assess host-tumour interaction. 
These parameters have the potential to be used both in assessing prognosis and 
in designing therapeutic strategies in breast cancer patients.
CHAPTER 1 
Introduction
1.1 Introduction to breast cancer
1.1.1 History of breast cancer
Breast cancer is a disease which has been observed and recorded over 
many centuries. Although the early Egyptians did not perform any surgery, 
they left records of the description of the disease (Donegan, 1988). Breast 
cancer was also known to the Greek and Roman physicians, and its record 
continued through the Middle Ages and into modem times. During these times 
the knowledge about the cancer grew progressively. Early physicians 
discouraged treatment as such procedures as were available only aggravated it. 
There then followed a period when the cancer was believed to be a systemic 
disease which could not be expected to be cured. This was replaced by an 
optimistic view, when it was considered to be local and therefore curable. At 
present, one can only appreciate its complexity and the fact that yet more has to 
be learned about breast cancer in order to be able to understand it and devise 
local strategies for treatment.
1.1.2. Epidemiology and aetiology of breast cancer
Cancer of the breast affects almost exclusively females, although it can 
infrequently afflict the male. It ranks as one of the leading cause of cancer 
death in women. Although the disease occurs throughout the world, the 
incidence rates vary in different parts of the world. The incidence rate is 
reported to be increasing each year in almost all countries but there are also a 
few places like Bombay in India, where the rate is significantly lower. In 
general, breast cancer is regarded as a disease of the industrialised nations and
the current estimate is that one in every 12 women will develop breast cancer. 
A notable exception is Japan, a highly urban and industrialised nation but with 
a remarkably low death rate from breast cancer. The highest death rate has 
been reported for England and Wales and in the United States there has been 
no significant change in the death rate since 1930 (Donegan, 1988). The risk 
for the disease is age-related, with the majority of patients first presenting 
being women over the age of 40 years (Leis, 1978).
Apart from age other risk factors have also been associated with breast
cancer.
Genetic predisposition. Female relatives of breast cancer patients have a 
two-fold risk of developing cancer and that such a risk is highest for daughters 
(Anderson, 1974). There is also a difference observed between Oriental and 
Western women, but it appears that environmental factors also have an 
influencing effect as Japanese immigrants to the United States display a rise 
toward the higher risk observed in the United States (Seidman, 1972). It is 
difficult to examine familial influence as a risk factor as many other synergistic 
factors may affect the level of risk (Cairns, 1981).
Endocrine factors. As the mammary gland is an endocrine-dependent 
organ, an adverse hormonal environment may contribute towards the 
promotion of the disease. Although the possible involvement of androgen and 
prolactin have been suggested, the hormone oestrogen is most important in 
potentiating or promoting the disease (Lilienfeld, 1963). The level of estriol 
(E3) and abnormality in the metabolism of oestrogen may play a role in 
creating an adverse environment (Lemon, 1970).
Reproductive function. Since the first observation that the celibate life led 
by nuns may be a contributing factor to higher incidence of breast cancer, a 
number of observations now reveal that full-term pregnancy at an early age 
substantially reduces the risk of breast cancer. Women who give birth to then- 
first child at or after the age of 35 have a twofold higher risk of breast cancer 
than those who had their first child when less than 20 years of age (MacMahon 
et al., 1973). Childlessness is in itself a risk factor but if first pregnancy is 
delayed beyond age 30, then the risk for breast cancer increases above that of 
nulliparous women. This relationship reflects the complex interplay of 
hormones associated with breast cancer.
Diet and obesity. Although ingested food may contain small amounts of 
carcinogens, none of them have been linked with breast cancer in humans. It 
is more the quantity and the composition of the diet that has received much 
attention. In this respect, an excessive fatty diet appears to be influential. Mice 
made artificially obese are known to develop mammary cancers faster than 
controls (Carroll, 1975). Since the incidence and mortality rates for breast 
cancer vary in different countries, researchers have compared dietary fat intake 
in various countries. Several such studies indicate that breast cancer rates are 
positively correlated with total fat intake, animal protein, and animal fat 
(Reviewed by Gray et al., 1979). Moreover, studies carried out in various 
countries points to an increased risk of breast cancer in postmenopausal obese 
women (Boyle & Leake, 1988).
Viruses. Viruses are a very common cause of both benign and malignant 
neoplasms in animals and one retrovirus associated with breast cancer is the
mouse mammary tumour virus (MMTV). MMTV has proved to be an ideal 
model for investigating mammary tumours in animal models. Although viral 
particles morphologically similar to MMTV and a few other particles have often 
been found in human breast milk and in some human mammary cancers 
(Spratt et al., 1988), there is no conclusive evidence to suggest the role of any 
virus associated with breast cancer in humans. Recent studies concerning the 
minor lymphocyte stimulating (Mis) antigens in mice, however, have revealed 
that it is the retroviral MMTV genes that encode the "superantigens" 
responsible for the deletion of T cells bearing receptors with specific VP 
sequences (Acha-Orbea & Palmer, 1991; Choi et al., 1991; Acha-Orbea et al., 
1991). A significant finding is that the viral antigen is maternally transmitted in 
milk (Marrack et al., 1991).
1.1.3. Anatomy of the Breast
I.I.3.I. Cellular composition of normal breast
The mammary gland, or breast, is a modified sweat gland that has 
developed the specialised function of secreting milk instead of sweat. The 
gland overlies the pectoralis major muscle and is a complex arrangement of 
inter-connected secretory units surrounded by fat and connective tissue, and 
serviced by an extensive blood, lymphatic, and nervous system. The 
mammary gland has an epithelial component, which constitutes the essential 
glandular tissue (parenchyma), and a connective tissue component, which 
forms the supporting and enclosing framework, called stroma . Overlying the 
glandular tissue is a layer of adipose tissue. The breast is highly vascularised 
and well provided with lymphatic drainage, leading towards the axilla.
5The epithelial components are arranged as lobes, each with 16 to 24 
interconnected lactiferous ducts, which run radially from the base of the nipple 
and branch repeatedly (Figure 1.1.1). Each of these ducts dilate to form a 
lactiferous sinus, before opening separately on the nipple. Each lobe is made 
up of the glandular tissue that develops from a single duct and is subdivided 
into lobules corresponding to the branchings of the duct system. Each 
functional lobe is a separate gland operating within the environment of the
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Figure 1.1.1. The human mammary gland and its constituent parts.
6adjacent fat and stromal cells. The gland does not have a definite capsule, and 
its connective tissue component consequently merges with the subcutaneous 
connective tissue. The fundamental secretory units of each lobe are the many 
alveoli or saccular invaginations of the lactiferous ducts. These secretory 
units are responsive to hormonal modulations and as such show maximum 
growth and regression during various hormonal changes of puberty, 
pregnancy, and menopause. These alveoli are surrounded by a mesh of
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Figure 1.1.2. The lymphatic drainage of the breast.
myoepithelial cells which show some of the properties of epithelial and muscle 
cells and are involved in milk ejection. The whole structure is surrounded by 
the basal lamina which acts as a boundary between epithelium and stroma. The 
boundary is permeable to growth factors and metabolites but is normally 
breached only by migratory blood cells.
I.I.3.2. Lymphatic drainage of the breast
The breast has a well developed lymphatic system that drains mainly 
towards the axilla (Figure 1.1.2). The major lymphatics includes a superficial 
group draining the skin and a deep group draining the mammary lobules. In 
addition, there are the internal mammary nodes which accompany the internal 
mammary artery. Although the lymphatics pass in all direction from the breast, 
the main direction of lymphatic flow is towards the axilla. About 97 to 99% 
of the lymphatics pass laterally to the axillary nodes, with only 1 to 3% passing 
to the internal mammary nodes. At the axilla, the lymph nodes are arranged 
such that they can be grouped into three with respect to their position from the 
breast. They include the apical, which are located farthest away, the central 
(mid) axillary nodes, and those nearest to the gland, the anterior axillary nodes. 
The axillary lymph nodes play a very important role in breast cancer. 
Metastatic spread of the disease frequently involves the axillary nodes. The 
status of these nodes are, therefore, important features in assessing the 
prognosis of a breast cancer patient. In effect, the surgical management of 
breast cancer includes not only the removal of the primary tumour but removal 
and examination of the axillary lymph nodes. Whether nodes are involved in a 
cancer and the number of nodes involved are, at present, the most important 
prognostic indicator of breast cancer. Secondly, these lymph nodes are also
probably involved with generating and modulating immunological responses 
against the tumour. The deposition of metastatic tumour cells in the nodes 
means that these highly malignant tumour cells can be isolated and their 
characteristics studied and compared with the primary tumours.
1.1.4. Biological features of breast cancer
The growth of the breast depends on hormones and growth factors and 
the interaction of the various cell types in the gland. The glandular epithelium 
interacts through direct contact with the myoepithelium, and is acted upon by 
growth factors, which are secreted by the stroma, and blood-borne hormones. 
These interactions are important both in the development of the normal breast 
and in sustaining the growth of a malignant tumour.
1.1.4.1. Hormones
The principal hormones involved in the growth of the mammary gland 
are the steroids and the lactogenic hormones. The steroids include oestrogens, 
progesterone, and glucocorticoids, while the polypeptide lactogenic hormones 
include growth hormone, placental lactogen, and prolactin. Of these 
hormones, oestrogen and progesterone are important in breast cancer, as they 
not only control and promote the growth of the normal tissue but are also 
involved in sustaining the growth of some breast cancers.
Oestrogens act as mitogens and are responsible for the proliferation and 
differentiation of mammary epithelium, especially the ductile portions of the 
gland. In breast tissues, the oestrogens bind to specific oestrogen receptors
(ER) in the cytosol and the bound receptor then moves to the nucleus 
(Shaymala & Nandi, 1972). In addition to its effect on the gland, the 
hormones also promote prolactin secretion. Interestingly, oestrogen is 
believed to be produced in normal breast tissue as well as in breast cancer 
tissues (Edwards et al., 1979).
Progesterone combines with oestrogen and prolactin synergistically for 
lobuloalveolar development during pregnancy. An important physiological 
role of progesterone is believed to be the prevention of terminal differentiation 
of mammary epithelium during pregnancy.
The steroid receptors on breast tumour cells are now routinely 
monitored to assess prognosis in breast cancer patients.
1.1.4.2. Cell-cell interactions
Cell-cell adhesion plays an important role in maintaining the integrity of 
the mammary epithelium. Communications between the different cell types are 
mediated by the transmission of growth factors across cell junctions. In recent 
years, a number of adhesion molecules (Section 1.1.6.6) both on the surface 
of breast tumours and on cells interacting with them, such as lymphocytes 
(Section 1.2.7), have been identified. Some of these molecules appear to play 
an important role in the metastatic spread of the disease (Section 1.1.6.6).
1.1.4.3. Growth factors
The growth and differentiation of cells of the mammary gland is 
believed to be under the control of both positive and negative regulators of 
growth. Various such growth factors have been implicated with the growth of 
normal breast tissues and it is likely that in cancers there may exist an 
imbalance in the production of growth factors and/or a loss of responsiveness 
to negative growth regulators. Of the positive regulators, the role of epidermal 
growth factor (EGF) is well documented. EGF acts by binding to a specific 
cell-surface receptor (EGFR). The receptor has an external domain, which 
binds EGF, a transmembrane section, and a cytoplasmic portion, which 
contains a tyrosine-specific protein kinase (Downward et al., 1984). The 
growth factor acts in an autocrine fashion and the cytoplasmic portion of 
EGFRs contain sequences closely related to the v-erb B oncogene (Section
1.4.2.2.4) such that once the receptors are established, tumours might be able 
to sustain their own growth. In breast cancers, EGF receptors have been 
reported to be expressed in inverse proportion to ER (Sainsbury et al., 1987), 
although not all studies support this (Fitzpatrick et al., 1984). Prognosis in 
breast cancer patients has been found to be significantly related to EGFR 
status. Both relapse-free and overall survival were significantly worse for 
patients with EGFR-positive tumours compared with EGFR-negative tumours 
(Sainsbury et al., 1987; Nicholson et al., 1988).
A second growth factor, TGF-P (Transforming growth factor p), 
although originally described as a positive growth stimulator, can also act as a 
growth inhibitor depending on the target cell type (Spom et al., 1987). 
Furthermore, although many normal epithelial cells are inhibited by TGF-P,
several transformed cell lines, including breast cancer cells have been found to 
be resistant to its inhibitory effect (Knabble et al., 1987). This may support 
the idea that escape from negative control might be an important step during 
carcinogenesis (Roberts et al., 1985). Although a post receptor mechanism 
and not a loss of receptors is likely to be involved (Manning et al., 1991), the 
mechanism of inhibition of epithelial cell growth by TGF-p is currently 
unclear.
1.1.5. Clinical management and prognosis in breast cancer
I.I.5.I. Surgical practice
The primary tumour itself is not generally fatal to the patient and most 
clinical strategies are designed to minimise the possibilities of metastatic 
growth which causes the main damage. The initial signs of metastasis are 
usually to be found in the axillary nodes which drain the tumour. In most 
centres in the UK, the breast itself is removed entirely (mastectomy) or in part 
(lumpectomy) and, in addition, the axillary nodes are removed and examined 
for metastatic spread of the tumour. This axillary clearance is considered by 
surgeons to be necessary not only to remove the potential metastatic deposits 
but to aid decisions on patient management (Fentiman & Mansel, 1991). For 
example, a patient whose nodes are not invaded may be treated by local 
radiation therapy whereas one with invaded nodes is more likely to be given 
general chemotherapy. Other factors which influence clinical management 
include tumour size, tumour grade, and oestrogen receptor status, with 
receptor negative tumours having a poorer prognosis and therefore possibly 
requiring more aggressive therapy (Reviewed by Perren, 1991). While tumour
grade and lymph node involvement (Bloom & Richardson, 1970) are currently 
used as the main prognostic indicators, neither gives definitive information and 
much effort has been put into the search for other markers which may be used 
at the time of presentation to give more accurate forecasts of the outcome of the 
tumour.
I.I.5.2. Prognostic factors in breast cancer
As indicated above, a very difficult problem faced with breast cancer 
patients is in forecasting prognosis. The outcome of the disease is highly 
variable with some patients enjoying a recurrence-free life after having the 
tumour removed, while others experience rapid metastatic progression and a 
short survival time. Histological examination of the breast tissue not only aids 
in the diagnosis of breast cancer but once the cancer is detected, it also aids in 
the assessment of prognosis in breast cancer patients. Although a number of 
prognostic factors are currently in use, there is a definite need for other factors 
of higher prognostic value to be defined.
Stage
Stage has consistently been shown to be the most important factor 
influencing patient outcome in breast cancer. The commonly used staging 
system (TNM, Tumour Node Metastasis) employs four stage categories. In 
stage I, the tumour is small and limited to the breast, while in stage II, there is 
metastasis to axillary lymph nodes. In stage III, advanced locoregional disease 
is present, and in stage IV, there is widespread metastasis to distant places.
Axillary lymph node metastasis
Microscopic examination of an adequate number of axillary nodes to 
detect whether metastatic tumour is present, remains the single most important 
prognostic factor. The 5-year survival rate of patients without nodal metastasis 
varies from 67 to 85 percent, and drops significantly to 63 to 73 percent for 
patients with a single node metastasis (Silverberg, 1975; Fisher et al., 1983). 
Although patients with one to three node metastases are considered to have a 
similar prognosis, overall survival and disease-free survival declines in a 
steady, incremental manner as the number of involved nodes increases. 
Generally, cancers of the breast will metastasise first to the lower (anterior , 
Fig. 1.1.2) axillary nodes and although patients with metastases in multiple 
levels are in a poor prognostic group, there is no prognostic significance of 
'high level1 versus 'low' or 'middle level' involvement (Barth et al., 1991; 
Smith et al., 1977).
Tumour size
The diameter of a primary breast tumour is strongly related to the 
likelihood of axillary node metastasis. Moreover, tumour size has also been 
found to be a significant independent factor associated with disease-free and 
overall survival (McGuire, 1986).
Tumour grade (Differentiation)
The most commonly used tumour grading system was first introduced 
by Bloom & Richardson (1957). This grading system assigns equal
importance to three features: structural differentiation, cytological 
differentiation, and mitotic figure frequency. A numerical value (1,2, or 3) is 
assigned to each of these features and the sum of these defines the grade of a 
tumour. Points total of 3 to 5 represent grade I (low grade), 6 to 7 are grade II 
(intermediate grade), and 8 to 9 are grade III (high grade). Generally, grade I 
tumours are relatively less frequent compared to higher grade tumours (Bloom 
& Richardson, 1957).
Oestrogen receptor (ER)
The presence of ER in tumour cells is well established as a predictor of 
clinical response to endocrine therapy in breast carcinoma. In addition, there 
are also reports of a correlation between favourable patient outcome and 
positive ER status (Shek et al., 1988). Breast cancer patients whose tumours 
lack ERs appear to be at a disadvantage in terms of both disease-free survival 
and overall survival. However, there are also reports of ER not being an 
independent prognostic factor (Pari et al., 1984; Aamdal et al., 1984). ER 
status has not been correlated with node status, but the presence of ER protein 
has been related to histological differentiation (McCarty et al., 1980) and it is 
likely that the biological significance of ER is due to this association.
All of these tumour characteristics together are currently in use to 
provide prognostic information useful in managing patients with breast cancer. 
Although no single characteristic is, on its own, of value in assessing 
prognosis, axillary node status remains the most important one among them. 
Nonetheless, even this parameter, is of limited value since up to 30 percent of 
all women with node-negative breast cancer will eventually relapse and die 
from their disease (Fisher et al., 1985). Thus, the absence of regional lymph
node metastases does not ensure that distant or systemic seeding of tumour 
cells has not occurred (Redding et al., 1983), only that it is less likely. The 
major drawback of these factors is that they require histological assessment and 
as such are prone to observer subjectivity. Gilchrist et al. (1985) showed that 
pathological assessment is not a reproducible feature when the same tumour is 
viewed by a panel of pathologists using routine methodology. Other studies 
also report interobserver variation (Stenkvist et al., 1983) while Delides et al. 
(1982) found agreement among six pathologists on tumour grade in only 14.5 
percent of cases. In addition, these histological features are highly inter-related 
and often prognosis is relevant in certain patient groups. There is, therefore, a 
need for the development of other factors that would provide both a better 
understanding of the disease and help in assessing prognosis in breast cancer 
patients.
1.1.6. The metastatic spread of breast tumour cells
The majority of breast tumours result from transformation of ductal or 
lobular epithelial cells, with ductal breast cancer being dominant. After the 
initial transformation step and once the tumour is established, it continues to 
grow as carcinoma in situ. These are a confined group of cells still linked by 
cell-cell contact and contained within a basement membrane. At a later stage,
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Figure 1.1.3. The metastatic process.
cell-cell contact breaks down and the tumour becomes invasive and invades the 
surrounding tissues. Cells from such a tumour secrete digestive enzymes and 
progressively the metastatic process begins.
I .I .6 .I . The M etastatic process
The main clinical problem of cancer is metastasis, the migration in the 
blood and lymph system of tumour cells that give rise to tumours in other parts 
of the body. The dissemination of tumour cells is a complex and multistep 
process (Figure 1.1.3). This complex process can be represented in a 
simplified manner in the following sequences: i) release from the primary
tumour, which accompanies proteolytic degradation of basement membrane 
and surrounding tissues, ii) invasion into blood vessels, transport and survival 
of blood-borne cells, iii) homing to secondary sites and finally, iv) infiltration 
of the target tissues. Although these events are not clearly understood, a few 
characteristics of human tumours have been related to some of the events in the 
metastatic process.
In breast cancer, the metastatic process is even more complex. Primary 
tumours differ widely in nature, in some patients there is widespread 
metastasis while in others they are more or less contained at the primary site 
and thus surgically operable. Even within a tumour, much variation exists and 
the tumour gradually changes and finally evolves into a highly metastatic 
tumour. Various factors both contribute towards as well as act against the 
generation of such metastatic cells. Recent research has been directed towards 
identifying such features of breast tumours and their relationship to metastasis.
I.I.6.2. Generation of tumour heterogeneity and metastatic 
potential
It is generally believed that cancers develop from single transformed 
cells (Nicolson, 1987), whose transformation itself is initiated by a genetic 
event. Then as the tumour grows, multiple genetic alteration takes place and in 
a complex interplay with the selective pressures from the environment, one of 
which is likely to be host immunity, the tumour progresses from a less 
malignant to a higher malignant form. The underlying mechanism of the 
generation of the malignant phenotype is therefore alterations at the level of the 
gene. Gene expression, however, manifests itself in phenotypic expression
and with time a tumour acquires a heterogeneous nature, changing gradually 
and independently and eventually gaining autonomy from host controls, such 
as hormone regulation of cell growth and control of cellular differentiation. 
Thus, the tumour mass within a patient at surgery is a collection of cells of 
varying phenotype and the bulk of these cells may not contain the marker for 
the clonogenic cells (Figure 1.1.4). Tumour heterogeneity was first noted 
histologically and has now been extended to include a wide variety of genetic, 
biochemical, immunological, and biological properties. In breast cancer, 
heterogeneity in tumours has been established principally with the use of Mabs 
directed at antigens associated with a tumour (Reviewed by Moss et al., 1988; 
Edwards, 1985). A given antibody reacts with only some of the tumour cells 
and as such the antibody defines a distinct population of cells. It was this 
phenomenon of tumour heterogeneity that dampened the much optimistic view 
concerning the use of Mabs directed against tumour-associated antigen, most 
of which were expressed not only by some tumour cells but also by some 
normal tissues (Section 1.3.1). A key question concerning tumour 
heterogeneity is whether any particular subpopulation of tumour cells has a 
higher malignant potential. In the interplay of various selective processes, it is 
likely that the tumour subpopulation with a growth advantage will outgrow 
their counterpart and if it so happens these are the cells with a higher metastatic 
potential, then the secondary deposits will comprise of only these cells. That 
tumour cells can differ in their ability to metastasise have been shown by 
transplanting melanoma clones in mice and it was observed that certain clones 
produced more metastases than others (Fidler & Kripke, 1977). This also 
means that only a collection of cells are highly malignant and theoretically it 
only amounts to finding the right antigen on these cells to be able to identify
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Figure 1.1.4. Development of tumour cell heterogeneity.
them. Yet, after extensive search, no defined tumour-specific antigen have 
been described, much less defining a specific antigen associated with malignant 
potential. However, recent studies have identified genetic alterations 
associated with breast cancer and the involvement of at least one specific gene, 
the nm23 gene (Section I.4.2.4.), with metastasis have been reported. 
Moreover, heterogeneity in the expression of surface carbohydrates has been 
observed both with Mabs and the use of lectins and some of these expressions 
appear to be related to metastatic spread (Section 1.3.5.3).
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1.1.6.3. Tumour angiogenesis and metastasis
Angiogenesis involves the formation of new capillary blood vessels 
and a functional microcirculation, which allows further growth of the tumour 
and also increases the opportunity for these cells to enter the circulation. 
Generally, the growth of solid tumours beyond a certain size (usually a few 
millimeters) depends on the induction of such a functional microcirculation 
from surrounding host tissue (Folkman, 1990). Angiogenesis does not 
depend on the release of a single diffusible factor as was once thought, but 
rather on a more complex interaction which probably involves the release of 
several angiogenic polypeptides by both tumour cells and infiltrating normal 
cells (Furcht, 1986). Non-tumourigenic cells have been reported to produce 
both angiogenic factors and an inhibitor of such factors of Mr 140,000 
(Rastinejad et al., 1989). Loss of this inhibitor, which normally blocks 
angiogenesis, due to the loss of a tumour suppressor gene was found to 
correlate with simultaneous expression of angiogenesis and tumourigenicity. 
Recently, Weidner et al. (1991) reported that the assessment of tumour 
angiogenesis in breast cancer may predict the occurrence of metastatic disease 
in axillary lymph nodes or at distant sites. The investigators counted the 
numbers of microvessels per microscopic field in samples obtained from 49 
patients with invasive breast carcinoma and found a significant correlation 
between microvessel density and metastasis. Similar relationships between 
intensity of angiogenesis and probability of metastasis have also been reported 
in human melanomas (Srivastava et al., 1988).
I.I.6.4. The role of proteolytic enzymes in metastasis
One of the initial changes occurring after neoplastic transformation is an 
increase in cell-released and cell-surface degradative enzymes. Indirect 
evidence from model tumour systems suggest that proteolytic enzymes play a 
role in cancer invasion and metastasis (Duffy, 1987). It is believed that cells 
are invasive by virtue of their ability to secrete or induce secretion of 
proteinases capable of degrading the molecules which compose the barriers 
they must cross. These barriers include basement membranes and extracellular 
matrices, which are composed primarily of collagen, proteoglycans, and other 
glycoproteins. Thus various proteases, which include the collagenases, 
cathepsin D, and the urokinase form of plasminogen activator, have been 
studied as an indicator of metastatic potential. Recent reports indicate that the 
enzymes cathepsin D and plasminogen activator are related to metastatic spread 
in breast cancer. Assay of these enzymes is, however, made difficult by the 
fact that often it is difficult to distinguish between tumour-associated enzymatic 
activities and enzymes released from contaminating normal cells (Nicolson, 
1982).
Urokinase plasminogen activator (UK-PA)
UK-PA is a serine protease which converts plasminogen to the active 
plasmin, which can convert collagenase to the active enzyme and has a wide 
substrate specificity, cleaving most proteins. Therefore, PA through its 
activation of plasminogen can degrade many component molecules of the 
barrier that tumour cells must cross during metastasis. In most tissues PA
exists as two forms, the tissue type (t-PA) and the urokinase type (UK-PA), 
while either or both forms are variably found in tumours (Duffy et al., 1988a). 
The significance of this has been shown by Ossowski & Reich (1983),when 
they reported that antibodies against UK-PA, but not against t-PA, inhibited 
metastases of tumour cells into chick embryos. Compared with benign 
tumours, UK-PA has been found to be significantly higher in malignant breast 
tumours (O'Grady et al., 1985) and related to both size of tumour and number 
of axillary nodes with metastases (Duffy et al., 1988a). In a later report (Duffy 
et al., 1990), the latter group of investigators extended the study to reveal that 
cancers containing high levels of UK-PA antigen had significantly higher risk 
of early disease recurrence and shorter overall survival. Similar results have 
also been reported by Janicke et al. (1989). Interestingly, total plasminogen 
activator correlates with good prognosis (Duffy et al., 1988b). Further study 
with larger samples are needed to confirm the importance of this protease.
Cathepsin D
Cathepsin D is an oestrogen-induced lysosomal acidic protease. A 
precursor glycoprotein of Mr 52,000 was first described in the culture medium 
of a hormone-dependent cell line and later found to be constitutively produced 
in ER negative cancer cells (Rochefort et al., 1988). In normal cells, only a 
small amount of cathepsin D is secreted as the precursor. The bulk of the 
protein is targeted to the lysosomes, where it is proteolytically processed to an 
intermediate of Mr 48,000, and the mature, stable two-chain form of Mr 
34,000 and 14,000 (Yonezawa et al., 1988). Two distinct activities have been 
assigned to the secreted precursor. It has been found to have an oestrogen- 
regulated autocrine mitogenic effect on MCF-7 cells, and it has an acidic
proteolytic activity on various substrates, including proteoglycans and 
basement membranes (Rochefort et al., 1987). Both these properties may 
relate to metastatic capability in cancer cells. In a follow-up of about 4.6 years, 
the cytosolic cathepsin D concentration by radioimmunoassay in 122 primary 
breast cancers was found to be strongly related to both metastasis-free and 
disease-free survival (Spyratos et al., 1989). More recently, Tandon et al 
(1990) measured by western blotting the mature form of the enzyme (Mr 
34,000) and found that high levels of the enzyme in node-negative patients 
were a significant predictor of reduced disease-free survival. Moreover, high 
levels of cathepsin D were found more often in tumours with an abnormal 
DNA content (aneuploid, Section 1.4.3.3.1) than in diploid tumours, and 
among aneuploid tumours, higher levels of cathepsin D identified patients at 
extreme risk of recurrence.
I.I.6.5. Evasion of host immune response
Tumour cells encounter the cells of the immune system while growing 
locally, and throughout the metastatic process. With the initiation of the 
metastatic process, tumour cells have to evade immune surveillance as they 
enter blood vessels and in the circulation until they are finally able to settle at a 
secondary site. Evaluation of lymphocytic cells both for their phenotype and 
their activation state has therefore, been done on lymphocytes present locally 
(tumour infiltrating lymphocytes), in blood, and in draining lymph nodes 
(Section 1.2.9). In breast cancer, lymph nodes are important sites both for the 
modulation of an immune response and as a primary site for metastatic deposit. 
Evaluation of lymphocytes from the axillary nodes in breast cancer is thus 
important in understanding the effect of metastasis on the immune response 
(Section 1.2.10).
I.I.6.5.I. Lack of MHC class I expression
An alternative strategy to evaluate how tumour cells evade the immune 
response is to look for expression on the tumour surface themselves. One 
particular antigen, the MHC molecules has received much attention in this 
context. MHC class I and II genes encode for proteins which are intimately 
involved in intracellular communications, and in the discrimination of self from 
non-self or foreign. Class II MHC antigens have a restricted expression and 
are generally found on specialised cells of the immune response, while MHC 
class I antigens are normally present on all nucleated cells in the body 
(Benacerraf, 1981; Linsk & Goodenow, 1986). In breast tumour cells both 
MHC class I and II molecules are variably expressed (Whitford et al., 1992a; 
Goepel et al., 1991) with some tumours or cells within a tumour often failing 
to express them. The lack of expression of MHC class I on tumour cells has 
an important implication. Since immunological recognition of antigens by 
cytotoxic T lymphocytes (Tc) is restricted to MHC class I determinants 
(Zinkemagel & Doherty, 1979), failure to express class I, or the expression of 
inappropriate or altered MHC class I components on tumour cells, is a possible 
mechanism whereby tumour cells may escape killing by antigen specific Tc. 
Similar to many other human tumours, breast tumour cells have been found to 
lack MHC class I molecules (Perez et al., 1986; Wintzer et al., 1990; Whitford 
et al., 1992a; Goepel et al., 1991). Although the study of Goepel et al. (1991) 
involved a small number of samples, both primary tumours and lymph node 
metastases were analysed. Expression of HLA-A2 and the (3-2-microglobulin 
component of class I molecules were reduced or absent in the majority of 
primary tumours and in each of these cases their corresponding metastases 
showed a decreased expression.
I.I.6.5.2. Suppression of immune response
It is likely that in addition to evading immune surveillance, tumours 
may have a direct suppressive action on the cells of the immune system. Such 
immunosuppressive effect can possibly be mediated through inhibitory 
factors. A likely candidate is TGF-J3 (Section 1.1.4.3), which has been found 
to inhibit B and T-lymphocyte function and proliferation (Hsuan, 1989). A 
number of studies have now analysed lymphocytes from breast cancer patients 
and have reported a large variation both in terms of their phenotype and 
activation states (Section 1.2.9).
I.I.6.6. Expression of adhesion receptors and metastasis
The property of cell adhesion is important in any cell-cell interaction. 
Cells of the immune system adhere to other cells and extracellular matrix in the 
process of immunological recognition and recirculation (Reviewed by Dustin & 
Springer, 1991). Several adhesion receptors associated with lymphocytes 
have now been described (Section 1.2.7). Two such adhesion molecules, 
LFA-1 (Lymphocyte function antigen-1) and ICAM-1 (Intracellular adhesion 
molecules-1), both of which are specialised for use in immunological 
recognition, appear also to be involved with metastasis (Johnson et al., 1989). 
LFA-1 is expressed only on leukocytes (Krensky et al., 1983), while its 
counter-receptor ICAM-1, which binds LFA-1 directly , is expressed on 
diverse cell types (Dustin et al., 1988) including target tumour cells. Although 
found to be expressed on tumour cells, ICAM-1 is generally absent from most 
cells in normal, nonlymphoid tissues except for a low level expression on
endothelial cells. However, local immune responses can cause a rapid increase 
in ICAM-1 expression on endothelial cells and induction of ICAM-1 on 
epithelial cells (Dustin & Springer, 1988). Recently, Johnson et al. (1989) 
reported that a surface glycoprotein of Mr 89,000 and identical in sequence to 
ICAM-1 was expressed on advanced human melanomas but not on benign or 
early melanomas. The authors suggested that since ICAM-1 is a ligand for 
LFA-1, ICAM-1 positive tumour cells can interact with lymphocytes within a 
tumour infiltrate and as such reduce homotypic adhesion between tumour cells. 
This enhanced adhesion of tumour cells to migratory and invasive lymphocytes 
may aid in dissociating cells from the primary tumour, subsequently lodging 
them to a secondary site, for instance the lymph nodes, and thereby help in the 
metastatic spread of the disease. This suggests that tumour infiltrating 
lymphocytes not only can cause cytotoxic killing of cells but by inducing 
expression of adhesion molecules can also contribute to metastatic spread of 
the disease.
1.1.7. Basic research on breast cancer
Research on breast cancer involves a number of diverse aspects of a 
cancerous cell. It has generally been studied both at the cellular and the genetic 
level. At the cellular level, the cell surface has been at the focus, where the aim 
has been to detect biochemical alteration of surface molecules on a tumour cell. 
While such alterations has as yet not been found to be unique for breast cancer, 
tumour-associated changes have been detected (Section 1.3). At the genetic 
level, the principal aim is to define specific genetic defects and at the same time 
to be able to characterise the gene products in terms of their biochemical 
functions. Although the identification of oncogenes and their products and of
tumour suppressor-genes associated with breast cancer underlies the main 
efforts in this area, it is important to point out that defects at the DNA level in 
breast cancer is complex and involves gross chromosomal alterations (Section
1.4).
As indicated above the obvious importance of metastatic spread in 
breast cancer has led to much efforts to increase understanding of the process 
itself. Although the metastatic process can be outlined in a simple scheme 
(Fig. 1.3), there is very little known about the biochemical basis of these 
events. Here again, in a simplistic approach, the aim is to identify both 
specific cell surface changes and specific events at the level of the gene which 
are related to the metastatic process. Associated with the spread of the disease 
is the interaction of the host environment with the cancer cells. One such 
interaction which must play a very important part is host immunity (Section 
1.2). Both at the local site and during its detachment from the primary tumour 
cells leading to its spread to a secondary site, cancer cells have to deal with the 
host immune system. An understanding of the effect of cancer on the immune 
system is therefore, of much importance in breast cancer. Typically, the 
ultimate aim will be to assign a specific change to a specific defect at the DNA 
level and to be able to understand the role played by such a change in 
contributing towards tumourigenicity or metastatic potential.
1.2 Immune response to breast cancer
1.2.1. Historical background
As a consequence of elucidation of the role of the immune system in 
combating bacterial and viral infections, initial assumptions were that tumours 
also must elicit a host immune response which failed in tumour patients in the 
same way as it failed in those who succumbed to infections. Many 
experimental animal tumours appeared to be antigenic. Thus the prospect of 
augmenting this immune response and of vaccinating individuals against 
cancers appeared to be encouraging. Initially interest was focussed on the 
antibody response as antibodies are easy to handle and produce in large 
amounts, can be used between individuals of different genetic background, and 
were much better understood, until recently, than were T cell responses. In the 
1970s and early 1980s, it was hoped that antibodies to tumour specific 
antigens could be used to target on the tumour cells in the manner of "magic 
bullets". However, more than a decade later, there is limited direct evidence to 
suggest that an anti-tumour immune response is generated in patients with 
epithelial tumours. Apart from some tumour-associated antigens no well 
characterised tumour-specific antigen has been identified (Section 1.3). 
Negative evidence also comes from post transplant patients on long term 
immunosuppressive therapy or those suffering from acquired immune 
deficiency syndrome (AIDS). These patients have no increased incidence of 
malignancies such as breast carcinoma and only tumours thought to be caused 
by DNA viruses are more frequent (Penn, 1988). Finally, as increasing 
numbers of proto-oncogenes are discovered it has become apparent that very 
few of these have a product located on the surface of the cell (Section 1.4.2.5) 
and therefore vulnerable to attack by the B cell arm of the immune system, and 
of those within the cell, the changes from the normal cell product may be
minimal, making detection by the T cell arm of the immune system difficult. In 
addition, the slow rate of development of such tumours may well lead to 
immune tolerance and their heterogeneity could give them a natural means of 
evading total destruction by the immune system by a process of antigenic drift 
analogous to that occurring in viruses. It is, therefore, possible to argue that 
there is little proven human response, that one would not expect a strong 
response, and that any weak response that is mounted can readily be 
circumvented by the tumour.
To counter these arguments, it is possible to suggest that the follow-up 
of immunosuppressed transplant patients is still relatively short compared to 
the aetiology of breast cancer (Campbell & Leake, 1990). Clinical evidence is 
also available from many sources. Fisher et al (1980) showed that some 
patients having undergone surgical removal of the primary tumour had a long 
survival even with residual malignancy in their lymph nodes. Others showed 
that stress conditions which depress the immune system, like bereavement 
(Bartrop et al., 1977) can also cause recurrence of the disease. Finally, there is 
the evidence that 60% of primary breast cancers carry an infiltrate of T 
lymphocytes (Section 1.2.9.1.) which would appear to indicate an ongoing 
immune response at the time of removal. T cell recognition of antigen has 
become better understood in recent years and, since oncogene products are 
largely intracellular and only potentially visible to T cells, it is largely the T cell 
response that has become the focus of interest (Bodmer, 1991). Recent 
studies, therefore, have been directed towards the analysis of this infiltrating 
immune response both as an indicator of prognosis and in developing methods 
of immunotherapy (Rosenberg, 1988). The rationale behind such studies is 
the hope of augmenting the immune response in patients showing signs of 
mounting anti-tumour immunity and also the further understanding of the 
nature of this disease.
1.2.2 Assessment of the immune response in cancer patients
1.2.2.1 The B ceil immune response to tumours
While murine Mabs were being used to detect tumour-associated 
antigens (Section 1.3), it gradually appeared that these were mouse responses 
to human tumours (Section 1.3). It was realised that the relevant antibodies 
may perhaps be derived from cancer patients themselves and these would 
provide a correct assessment of the human B cell response to cancer. The 
investigation of humoral immune response to tumour antigens generally 
involved the use of two phenomena. The use of EB V infection to transform 
human lymphocytes which have recently been exposed to tumour antigens 
(Steinitz et al., 1979) and the cell fusion technique for Mab production (Kohler 
& Milstein, 1975). Theoretically, an advantage with this approach is that 
tumour-specific B-lymphocytes can be propagated indefinitely for the 
production of human Mabs and then these antibodies can be used to investigate 
the nature of the antigens that are stimulating the response and perhaps also in 
tumour diagnosis and therapy. The source of such lymphocytes for the 
generation of human Mabs has been either the peripheral blood or the lymph 
nodes from breast cancer patients. The antibodies were selected by using 
primary tumours, or more frequently tumour cell lines. Although a few of 
these antibodies from breast cancer patients were of IgG isotype (Imam & 
Taylor, 1989), the majority were of the IgM isotype, which reflect an early and 
immature immune response (Campbell et al., 1987). It, therefore, turned out 
that the human Mabs were of little use in tumour diagnosis or therapy 
(Reviewed by Campbell & Leake, 1990; Campbell et al., 1987). The difficulty 
in generating human Mabs stems from the limitations of hybridoma technology 
to provide a stable antibody and also from the poor selection methods used in
some early studies. As it is possible to generate irrelevant antibodies, with 
some degree of multispecificity for intracellular antigens, from both normal and 
diseased individuals (Ghosh & Campbell, 1987; Damato et al., 1988), it is 
likely that these were selected in some of the early studies involved with human 
Mabs. Although a number of human Mabs from breast cancer patients have 
been reported (Imam & Taylor, 1989; Ronai & Solitzeanu, 1986; Gentile & 
Flickinger, 1972), none of them are in use in either diagnosis or therapy of 
breast cancer. With the apparent failure of this technique, the existence of a 
human B cell response to breast tumours remains to be established.
1.2.2.2 The T cell immune response
A major problem faced by early workers involved with the study of 
immune response in cancer patients was the assessment of T cell-mediated host 
immunity. Both lack of sound methodology for the study and a poor 
understanding of the T cell response contributed to such difficulties. In early 
studies, chemically and virally-induced tumours in experimental animal models 
were used. These studies provided evidence to indicate that host immunity can 
protect from inoculation of tumour (Morton et al., 1969) and that such a 
protection could be transferred from the host to another test animal (Bard et al., 
1969). These experimentally induced tumours and those arising spontaneously 
in animals were, however, found not to resemble the human condition (Hewitt 
et al., 1976). This then led researchers to isolate lymphocytes from cancer 
patients themselves in order to test their effectivity using in vitro tests.
1.2.2.2.1 T cell effector function: in vitro assays
Although the current in vitro assay of T cell effector function involves 
the chromium release assay, some of the earlier studies employed the 
blastogenesis assay to assess immunocompetence of lymphocytes from cancer 
patients. The latter assay, which involves the use of mitogens such as 
phytohemagglutinin (PHA) to induce uptake of tritiated thymidine, is not very 
reliable and studies on breast cancer reveal conflicting results (Fisher et al., 
1972; Humphrey etal., 1981; Mandeville etal., 1982).
The chromium release assay is used to determine cytotoxic capability of 
test lymphocytes on target cells and as such an advantage with it is that 
autologous tumour cells can be tested. But this requires tumour cells to be 
grown in culture and then allowed to take up chromium (51Cr). On subsequent 
lysis by the test lymphocytes the labelled tumour cells release the isotope which 
is then assayed. There are a number of difficulties associated with this assay 
system. Firstly, lymphocytes from cancer patients have been found to be 
highly selective with respect to cells they can lyse (Topalian et al., 1987; 
Belldegrun et al., 1988; Balch et al., 1990) and that too at an effectontarget 
ratio of 40:1 (Topalian et al., 1987). Although lymphocytes from most tumour 
infiltrates can lyse target cell lines like K562, a more acceptable feature for 
cytotoxicity tests is to have the autologous tumour themselves as targets. This 
is not always the case as reported by Balch et al. (1990) with ULs from breast 
and colon cancer and often the cytotoxicity is much greater against cell lines 
when compared to autologous tumour (Yamaue et al., 1990). Secondly, the 
growth of the autologous tumour may not be an easy matter as quite often 
colonies of non-neoplastic cells such as fibroblasts overgrow the true epithelial 
tumours. Primary cells from epithelial tumours do not grow readily in culture 
(Section 1.4.1; Section 5.1.3) and it may be difficult to obtain a large number
of viable autologous tumour cells containing the chromium isotope. Finally, 
primary cultures have a high rate of background cell death, and in consequence 
the low signal/noise ratio may make it difficult to detect specific lymphocyte 
induced cytotoxicity. However, with no alternative assay to replace this 
method, the cytotoxicity assay is still very much in use.
1.2.3. Monoclonal antibodies against lymphocyte surface 
markers
One of the major developments to take place has been the discovery of 
the technology for the production of monoclonal antibodies by Kohler and 
Milstein (1975). Prior to this time, studies on lymphocytes thought to be 
associated with anti-tumour immune responses, took advantage of the fact that 
unlike B cells, human T cells form non-antigen-specific rosettes with sheep 
erythrocytes. Such ,'E-rosette"-forming cells provided a convenient method 
for obtaining relatively pure populations of T cells. This is reflected in some of 
the early studies involved in assessing immune response in cancer patients. 
However, with the advent of monoclonal antibody technology it became 
possible to characterise lymphocytes and their subgroups in terms of antibodies 
against markers on the cell membrane. More importantly these antibodies can 
be used to identify functional groups of the lymphocytes based on specific 
markers expressed on the cell surface.
1.2.3.1. Phenotypic markers
Lymphocytes express a large number of different molecules on their 
surfaces and some of these molecules are characteristic of different cell
lineages. Such molecules can be identified by monoclonal antibodies and are 
thus called "phenotypic markers". The CD (Cluster Designation) system for 
identification of human cells of haemopoietic lineage is one of the most 
advanced demonstrations of the extent to which Mabs can be used to chart cell 
phenotype and differentiation status. The system is a result of international 
workshops which meet regularly to group together monoclonal antibodies 
produced in different laboratories with the same antigen recognition 
characteristics. This "Cluster" of Mabs is then assigned a number according to 
the type of molecule identified by all the Mabs in the group. In consequence, 
the CD status of a molecule also defines the antigen itself. Such antigens not 
only define cell phenotype and lineage, but also the activation status of the cell 
bearing that phenotype and its possession of molecules with the ability to 
adhere to other cells through the LFA, ICAM and VLA family of adhesion 
molecules (Section 1.2.7). At the 4th International Workshop in 1989 the 
number of antigens defined in this way rose to a CD value of 78, with many 
having newly discovered subsets so that the total number of defined molecules 
is now close to 100 (Table 1.1) (Knapp et al., 1989).
1.2.4. Cells of the immune system and their phenotypic markers
T and B lymphocytes are the major cell components of the immune 
system. They however have different lineage pathways and functions. In the 
case of the B cell, the molecules responsible for specific recognition are the 
different classes of immunoglobulins that can be expressed either as cell 
surface molecules acting as receptors, or in secreted forms. The equivalent 
recognition molecule on T cells is the membrane-bound T cell antigen receptor 
(TCR) which is specific for a combination of foreign antigen with a molecule
Table 1.1. The CD classification of some of the human leucocyte 
differentiation antigens
CD Antigen Location Function where 
known
2 Mr 50,000,gp T cells Rosette receptor, LFA-3 
receptor
3 5 protein complex T cells Signal transduction for 
TCR
4 Mr 59,000, gp T helper MHC class H 
recognition
5 Mr 67,000, gp T, Bsubset
8 gp dimer, Mr 32,000 T cyt/sup MHC class I recognition
10 Mr 90,000, gp pre-B CALLA
11a Mr 180,000, gp leucocytes alpha-chain of LFA-1
lib Mr 155.00, gp Mono, Gran, 
NK
C3b complement 
receptor
11c Mr 150,000, gp Mono, Gran, 
NK
16 Mr 50-60,000, gp Gran, NK Fc gamma receptor III
18 Mr 96,000, gp Leukocytes Beta-chain for lla,b, & c
19 Mr 95,000, gp B cells
20 Mr 35,000, gp B cells
21 Mr 140,000, gp B subset EBV receptor, C3d 
receptor
22 Mr 135,000, gp B subset
23 Mr 45.000, gp Activated B Low affinity IgE 
receptor
25 Mr 55,000, gp Activated T TAC, IL-2 receptor, 
beta-chain
28 Mr 44,000, gp T subset
29 Mr 135,000, gp Broad VLA beta
32 (w) Mr 40,000, gp Mono, Gran, 
NK
Fc gamma receptor
35 Mr 2220,000, gp Gran, Mono, 
B
Leukocytes
Complement receptor 1
45 Leukocyte Common 
Antigen
45 RA 
45 RB
Mr 220,000, gp T subset, B, Gran, 
Mono
T subset, B,
Gran, Mono
45 RO Mr 180,000, gp T subset, B, 
Gran, Mono
52 (w) Mr 21-28,000, gp Leukocytes Campath 1
54 Broad ICAM-1
58 Mr 40-65,000, gp Leukocytes,
epithelial
LFA-3
71 Mr 97,000, gp Growing cells Transferrin receptor
CALLA= Common Acute Lymphoblastic Leukemia Antigen; gp= glycoprotein; 
Gran= granulocytes; ICAM= Intercellular Adhesion Molecule; LFA= 
Lymphocyte function Antigen; Mono= Monocytes; TCR= T cell receptor, 
VLA= Very Late Antigen; w= workshop.
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of the MHC (Katz et al., 1973; Rosenthal et al., 1973; Zinkernagel et al., 
1974).
1.2.4.1. T cell markers
The definitive T cell marker is the T cell receptor (TCR), which is 
expressed exclusively on the membrane surface of T lymphocytes. T cell 
recognition of antigen occurs through the TCR and forms the basis of a range 
of immunological phenomena including MHC-restricted cytotoxicity and T cell 
helper and suppressor activity (Davis and Bjorkman, 1988). The typical TCR 
molecule expressed on mature T cells is a disulphide-linked heterodimer 
consisting of two chains, a  and p (Fig 1.2.1). These two chains are of similar
size; both chains are transmembrane proteins and both show considerable 
homology with Ig and are thus viewed as part of the "Ig superfamily" 
(Koning, 1991; Sprent, 1989). A minority population of T cells expresses a 
quite different receptor molecule composed of y and 8 chains (Janeway, 1988) 
rather than the a  and P polypeptides. These cells are rare in the lymphoid 
tissues, comprising a few percent of cells in the thymus and peripheral blood 
but are found in large numbers in skin epidermis (Koning et al. 1987; Kuziel et 
al., 1987) and gut epithelium (Goodman & Lefrancois, 1988). The proportion 
of y8+ T cells however, have been reported to be elevated in coeliac disease 
(Spencer et al., 1989; Trejdosiewicz et al., 1989; Halstensen et al., 1989) 
while it was variable but generally small in breast cancer patients (Alam et al., 
1992a). Both aP  and y8 T lymphocytes express their TCR in a molecular 
complex involving polypeptide chains of the CD3 complex (Fig 1.2.1) 
(Reviewed by Clevers et al., 1988). In the mouse, the CD3 molecules 
comprise of five different polypeptide chains, y, 5, e, £, and p21, of which 
only the first three have been identified in man. The CD3 molecules are non- 
polymorphic polypeptides that are non-covalently associated with the TCR and 
to each other. Each chain is a transmembrane peptide and approximately one- 
third of the y chain is intracytoplasmic. There are active phosphorylation sites 
on the intracytoplasmic portions of the y chain and it is widely believed that the 
CD3 complex mediates signal transduction when T cells are activated by 
antigen to the TCR. Fluorescently labelled antibodies against the CD3 complex 
acts as a definitive tag for identifying T cells in a mixed population of 
lymphocytic cells.
1.2.4.2. T cell subsets
Based on definitive surface markers and associated functions, T cells 
can be subdivided further into two distinct non-overlapping populations: the T 
Helper (Th) subset which is CD4+ and the T suppressor/cytotoxic (Tc/s) 
subset which is CD8+ (Fig. 1.2.2). CD4+ T cells recognise antigens in 
association with the major histocompatibility complex (MHC) class II 
molecules, while the CD8+ T cells recognise antigens in association with class 
I MHC molecules. The CD8+ T cells are stimulated by endogenous antigens 
and therefore, can be expected to participate in defence against viruses, 
intracellular eukaryotic parasites and against tumour cells.
The ability of CD4+ T cells to secrete large amount of IL-2 and other 
lymphokines makes them a "helper" cell. The CD4+ Th cells control and 
modulate the development of immune responses and are thus involved in 
mediating both T-T and T-B cell interaction involving both direct cell-cell 
interaction and those mediated through diffusible lymphokines. CD4+ cells 
have been further subdivided in murine systems into Thl and Th2 subsets 
(Mossman & Coffman, 1989). The Thl subset secretes 11-2 and IFN-y while 
the Th2 subset secretes 11-4 and 11-5. The rationale is that Thl "helps" the T 
cell immune response while Th2 "helps" the B cell immune response and 
isotype switching of antibody class. In a less acceptable way, CD4+ Th cells 
have also been subdivided on the basis of expression of different isoforms of 
the common leukocyte antigen CD45, and a fibronectin receptor, CD29 (Rudd 
et al., 1987), which belongs to the integrin class (VLA (3) of adhesion 
molecules. Th cells which express the CD45RA isoform represents the 
'virgin1 or 'inducer of suppression' T cells (Tedder et al., 1985), while 
'memory' and 'inducer of help’ T cells express high density CD29 and high 
density CD45RO isoform (Sanders et al., 1988). According to this
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Fig. 1.2.2. Antigen recognition by CD4+ Helper and CD8+ cytotoxic T 
lymphocytes.
classification, CD45RA~CD29hi Th cells respond maximally to recall antigen 
and can induce optimal B cell differentiation and Ig production.
1.2.5. Activation m arkers and T cell activation
Presentation of an antigen on MHC class II molecules by an antigen 
presenting cell (APC) and subsequent recognition of this complex by Th cells 
via their TCR marks the activation of Th cells and the beginning of an effective 
immune response (Fig. 1.2.2). During the activation process the surface of T 
cells alters and the best documented of these alterations is the acquisition of 
receptors which mark the activation process and allow efficient interaction 
between cells of the immune system. Surface changes include the acquisition
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Fig. 1.2.3. Structure of MHC class I and II (HLA DR) antigens.
The three a  domains of the class I complex associates with p2 microglobulin
to be expressed on the cell membrane. The a  and P domains of class II 
structure are similar in size and are both transmembranous.
of receptors for IL-2 and of HLA class II antigens. Subsequently transferrin 
receptors appear as iron is essential for cell division.
I.2.5.I. HLA DR
HLA DR, which is the predominant antigen of the class II MHC 
complex, has four domains arranged on two transmembrane polypeptide 
chains (Fig. 1.2.3) of similar size (Brown et al., 1988). Antigens are presented
by this MHC class II determinant to CD4+ T cells (Guillet et al., 1986). 
Unlike MHC class I molecules, which are expressed on the majority of normal 
nucleated cells (Daar et al., 1984a), the distribution of class II molecules in 
normal tissue is more restricted (Daar et al., 1984b). The HLA DR molecule is 
generally expressed on the cell membrane of antigen presenting cells (APC), 
which include B cells and macrophages (Hammerling, 1976). Apart from its 
role in antigen presentation, HLA DR has also been found to be expressed on 
T cells following mitogenic stimulation (Ko et al., 1979) and in mixed 
lymphocyte cultures (Pawelec et al., 1982; Davey et al., 1984) but absent on 
resting T cells (Reinherz et al., 1979). Thus, the expression of HLA DR on T 
cells acts as a marker of T cell activation. The exact role played by this 
molecule when expressed on T cells is unknown.
I.2.5.2. Interleukin 2 (IL-2) receptor
The IL-2 receptor, which is expressed following T cell activation, is 
composed of two glycoprotein chains, a low affinity beta chain of Mr 55000 
(Urdal et al., 1984) and an intermediate affinity alpha chain (Mr 75000) which 
is involved in signal transduction (Tsudo et al., 1986). Together the a —p 
heterodimers form the high affinity receptors for IL-2 (Fig. 1.2.4), which are 
effective in driving T cell growth (Reviewed by Smith, 1989). The high 
affinity form represents a receptor with a thousand fold higher affinity and this 
is brought about by the kinetic cooperation between the a  and the p chain (Fig. 
1.2.4). Binding of the ligand (IL-2) to the receptor mediates G1 progression 
to S-phase of the cell cycle (Herzberg & Smith, 1987). A characteristic feature 
of the IL-2 receptor expression is that on stimulation, T cells express the low 
affinity p chain at a density 5 to 10 fold greater than the a  chain and IL-2 
binding to the high affinity receptor increases the expression of the p chain 10
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Fig. 1.2.4. Structure of the high affinity interleukin-2 receptor.
to 20 fold. The P chain (CD25), which is recognised by the use of anti-TAC 
monoclonal antibody, thus acts a marker of T cell activation and growth. 
However, IL-2 bound to high-affinity receptors also undergo internalisation 
and this leads to down regulation of the surface receptors (Duprez et al., 
1988).
1.2.6. B cells and their activation markers
The majority of B cells carry MHC class II antigens which function in 
antigen presentation to Th cells. CD 19, CD20 and CD22 are the main markers 
currently used to identify human B cells. Apart from these a few others like
the complement receptors for C3b and C3d, which are associated with 
activation and possibly homing of the cells, and the CD5 marker, which is 
expressed on both T cells and a subset of B cells, is believed to be involved 
with T-B cell interaction (van de Velde et al., 1991; Hayakawa & Hardy, 
1988).
B cells are classically defined by the presence of endogenously 
produced immunoglobulins (Ig). Activation of a B cell involves interaction of 
the surface Ig with an antigen coupled with lymphokines generated by Th cells, 
which drives the cell through stages of growth and differentiation. Although in 
the initial stages of a primary humoral immune response the IgM molecule 
appears, this Ig is polyvalent and of comparatively low affinity. Following 
isotype switching and affinity maturation, the production of the IgG marks the 
onset of a mature secondary humoral response. B cells at this stage secrete 
antibodies of much higher affinity. The expression of surface IgG on CD 19+ 
B cells can thus be utilised as an indicator of a mature humoral immune 
response.
1.2.7. Adhesion molecules
Implicit with the interaction of lymphocytes with antigen-presenting 
cells or target cells and the migratory nature of lymphocytes is the phenomenon 
of adhesion. In fact, multiple adhesive interactions are probably required both 
for homotypic and heterotypic interactions associated with the immune 
functions of lymphocytes. Although a number of adhesion molecules have 
now been described not all are well characterised and only a few have been 
given a CD designation. These adhesion markers were identified principally 
with the use of monoclonal antibodies to carbohydrate antigens on the
leukocyte surface and have been found to have lectin-like N-terminal domains 
with carbohydrate structures as their putative ligands (Reviewed by Springer, 
1990). Now it appears that they are members of three different families of 
cell-adhesion molecules: the integrins, the immunoglobulin superfamily, and 
selectins.
Receptors involved with the interactions of circulating leucocytes with 
endothelial cells and secondary lymphoid tissues have been designated the 
'selectins' or LECCAMS (Springer & Lasky, 1991), because of their lectin­
like nature. The homing receptor selectin, also called LAM-1, LEC-CAM-1, 
or LECAM-1, is expressed on leukocytes and facilitates their binding to 
endothelium during lymphocyte recirculation through peripheral lymph nodes. 
The PADGEM, GMP-140 or CD62 molecule, a glycoprotein of platelets and 
endothelial cells, is expressed following stimulation by thrombogenic agents 
and allows these cell to bind neutrophils and monocytes at the site of tissue 
injury (Larsen et al., 1989; Johnston et al., 1989). While the ELAM-1 
glycoprotein is synthesised by endothelial cells in response to inflammmatory 
agents and promotes adhesion of neutrophils, monocytes and a subpopulation 
of lymphocytes (Bevilacqua et al., 1989a).
Apart from the CD8 and CD4 molecules, other accessory molecules 
involved with cell-cell adhesion during immunological recognition and 
interactions have now been identified (Reviewed by Dustin & Springer, 1991) 
Among these LFA-1 and ICAM-1 are well documented.
LFA-1 (lymphocyte function-associated antigen-1) is a member of an 
integrin subfamily and is found exclusively on leucocytes. On lymphocytes, 
LFA-1 functions as an accessory molecule in a number of lymphocyte adhesive 
interactions, which include T cell and natural killer cell-mediated lysis of target 
cells, antibody-dependent cytotoxicity and the binding of lymphocytes to
cultured endothelium (Springer et al., 1987). LFA-1 is the counter-receptor of 
ICAM-1 and it is believed that LFA-1 works in concert with CD2, CD8, and 
the T cell receptor on cytotoxic cells to form a stable adhesive interaction with 
ICAM-1, LFA-3 and class IMHC plus antigen, respectively (Fig. 1.2.5).
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Fig. 1.2.5. Receptors in CD4+ T lymphocyte adhesion.
ICAM-1 (intercellular adhesion molecule-1), a ligand for LFA-1, 
(Marlin & Springer, 1987) along with LFA-3 and CD2 structurally resembles 
those of the immunoglobulin family. ICAM-1 is expressed on diverse cell 
types (Dustin et al., 1988) and prominently represented on the HEV of various 
lymphoid organs (Dustin et al., 1986). Lymphokines and monokines secreted 
during an immune response causes upregulation of ICAM-1 expression 
(Dustin & Springer, 1988).
The distribution of CD2, LFA-3, LFA-1, and ICAMs are such that 
CD2 and LFA-1 are specialised for use by leucocytes, while LFA-3 and 
ICAMs facilitate T cell interactions with any cell in the body. CD2 and LFA-3 
undergo alteration by surface charge and receptor density and are involved in 
the regulation and modulation of T lymphocyte activation. Interaction of 
LFA-1 with ICAM-1 is also regulated in concert with cell activation such that 
LFA-1 avidity for ICAM-1 is increased by T cell activation. Although the 
mechanism of signalling by these molecules are not defined, these adhesion 
molecules play an important role in antigen recognition and lymphocyte 
activation.
1.2.8. Lymph node homing receptors
The ability of lymphocytes to recirculate continuously is dependent on 
their ability to leave the circulation and enter lymphoid organs via specialised 
endothelial cells, which comprise the postcapillary high endothelial venules 
(HEV). Binding of lymphocytes to peripheral lymph nodes and other 
lymphoid organs is highly specific and believed to utilise distinct recognition 
mechanisms (Butcher et al., 1979). Evidence for such a mechanism was 
provided when a monoclonal antibody (MEL 14) recognising a cell surface 
molecule on murine lymphocytes with the capacity to "home" on the HE Vs of 
lymph nodes was described by Gallatin et al. (1983). The antibody was 
shown to block in vitro lymphocyte binding to HE Vs in peripheral lymph 
nodes but not in Peyer’s patches and inhibition of in vivo homing to peripheral 
lymph nodes suggest that the antigen involved is likely to be organ specific. 
The antigen appears to be a mammalian lectin and probably interacts with 
unique carbohydrate determinant on peripheral node HEVs (Sanders et al., 
1988). Recently, the human leucocyte antigen, Leu-8 has been identified as
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the human equivalent of Mel-14 (Camerini et al., 1989). The marker appears 
to be rapidly down-regulated upon cell activation (Kishimoto et al., 1990) and 
has been reported to be expressed by a proportion of human CD4+ cells with 
memory function (CD45RA"CD29hi) (Tedder et al., 1990). The marker, 
variously termed LAM-1, Leu-8, Mel-14, thus remains rather elusive and 
laboratories working on this antigen have all now agreed that it be called 
LECAM-1 and classed as an adhesion molecule (Anderson et al., 1991). It is 
likely that other accessory molecules act in concert to bring about the adhesion 
required for migration and homing of lymphocytes to specific lymphoid organs 
or sites of inflammation.
1.2.9. The immune response in breast cancer patients
In the case of breast carcinoma, the existence of an effective host 
response is considered to be shown by the presence of certain morphologically 
recognisable phenomena. One of these is the infiltration of the tumour mass by 
mononuclear cells (Section 1.2.7.1) and another is in the reaction of the 
axillary lymph nodes (Section 1.2.7.2). Histopathological examination 
showing micro-architectural and histologically observed lymph node responses 
have been found to be a favourable prognostic sign (Hamlin, 1968; Silverberg 
et al., 1970; Hunter et al., 1975; Riegrova & Jansa, 1982). Researchers have 
therefore, focussed on the analysis of lymphocytes, their phenotype and their 
functional competence, in both the tumour infiltrate and the axillary lymph 
nodes.
I.2.9.I. Tumour infiltrating lymphocytes (TILs)
Since the early observation of Sistrunk & MacCarty (1922) that breast 
cancer patients with a tumour infiltrate have an improved survival, a 
considerable number of studies have been carried to assess this response. The 
most recent of these has shown that about 60% of breast tumours have a 
detectable lymphocytic infiltrate and in some the infiltration may be as 
substantial as comprising 80% of the tumour cell suspension (Whitford et al., 
1990). Whether patients with a lymphocytic infiltrate in their tumours have a 
better prognosis is still a matter of debate. Studies have both confirmed 
(Bloom et al., 1970; Black et al., 1975; Ridolphi et al., 1977; Underwood, 
1974) and refuted the survival advantage (Roses et al., 1982; Champion et al., 
1972) for breast cancer patients with TILs. The presence of tumour infiltrate 
was found not to be as strong a prognostic indicator as tumour grade (Bloom 
& Richardson, 1957). However, immunohistochemical and flow cytometric 
analyses have revealed interesting data on the phenotype and the activation 
states of the TILs.
Early studies employing rosetting technique revealed that T cells 
comprise the major component of the infiltrate in breast cancer patients (Eremin 
et al., 1981; Eremin et al., 1982). Later studies using Mabs and employing 
both histochemistry and flow cytometry have also shown that in TILs, T cells 
predominate and there are fewer B cells (Bilik et al.t 1989; Whitford et al., 
1990). However, analyses of subsets of T cells reveal conflicting results. In 
some a predominance of CD4+ helper T cells was reported (von Kleist et al., 
1987; Underwood et al., 1987; Ben Ezra & Sheibani, 1987; Balch et al., 1990) 
while in others, a higher proportion of CD8+ T cells was found (Bilik et al., 
1989; Belldegrun et al., 1989; Whitford et al., 1990). Reports involving other
human solid tumours, however, favour CD8+ T cells as the predominant cell 
component (Itoh et al., 1986; Rosenberg et al., 1988; Heo et al., 1987; 
Belledegrun et al., 1988; Durie et al., 1990).
There have been fewer studies of the activation markers on the 
lymphocytes in patients with breast carcinoma. Although Whiteside et al. 
(1986) found very few HLA DR bearing cells, other studies (Rowe & Beverly, 
1984; Lwin et al., 1985; Ben-Ezra & Sheibani, 1987) have shown a fairly 
large proportions of TILs bearing this marker in breast cancer patients. This 
variability in reports is also seen with the expression of IL2-R (Tac), with most 
studies revealing few cells with this receptor and only Lwin et al. (1985) 
reporting Tac expression on an appreciable percentage (30%) of TILs. The 
most extensive study on TILs from breast cancer patients was carried out by 
Whitford et al. (1990). It was found that a large number of T cells express 
HLA DR, the marker was present on more CD8+ than CD4+ cells, and that 
these proportions were higher than in the peripheral blood. The Tac antigen 
was consistently present on greater numbers of CD4+ than CD8+ cells. The 
most interesting finding in this study was the strong correlation between 
tumour grade and HLA DR expression on the T cells. Furthermore, the 
presence of the activation marker correlated with both MHC class I and class II 
expression on the tumour cells (Whitford et al., 1992a). It was suggested that, 
in the tumour infiltrate, the cytotoxic T cells are able to detect tumour antigen in 
the context of MHC antigens on poorly differentiated cells. Thus, in patients 
with a lymphocytic infiltrate and a poorly differentiated tumour, there is 
evidence of a cell-mediated immune response with a possible cytotoxic activity 
against the tumour. The study suggested that some form of tumour antigen is 
present on breast carcinoma cells, particularly in poorly differentiated tumours 
(Whitford, P., 1991), which is attracting immune recognition.
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Fig. 1.2.6. Microanatomy of a lymph node.
I.2.9.2. The role of the axillary lymph nodes in breast cancer
The axillary lymph nodes draining the mammary gland occupy an 
important anatomical site. Lymphatics from the breast drain chiefly to nodes in 
the axilla, and in the female they are especially numerous and well developed 
(Section 1.1.3.2). As a secondary lymphoid tissue (Fig. 1.2.6), the tumour- 
draining lymph nodes are ideally situated to interact with tumour antigens and 
in modulating an immune response. Lymphocytes and antigens (if present) 
pass into the sinus via the afferent lymphatics from surrounding tissue spaces 
or adjacent nodes. The cortex contains aggregates of B cells (primary follicles) 
most of which have a site of active proliferation (germinal centres). The 
paracortex contains mainly T cells and are found in close apposition to the
antigen-presenting cells (interdigitating cells). Lymphocytes enter the node 
from the circulation through the specialised HEV (Section 1.2.8) in the 
paracortex and can re-enter the circulation through the efferent lymphatics.
In breast cancer, this lymphoid tissue is also susceptible to invasion by 
tumour cells as it drains the tumour tissue. If the tumour cells have the ability 
to metastasise, nodal invasion is the first sign of this capacity. Metastases in 
axillary lymph nodes are not life threatening in themselves. Rather their 
presence indicates the probability that carcinoma has spread beyond the local 
area and the greater the number of tumour positive nodes the greater that 
probability (Fisher et al., 1983). The surgical treatment of breast cancer 
(Section 1.1.5.1) not only involves the excision of the primary lesion but often 
also removal of the axillary nodes in order to examine whether the disease has 
spread to the nodes. In this respect, nodal involvement still remains the best 
prognostic guide in breast cancer patients ( Section 1.1.5.2; Bloom & 
Richardson, 1970). The role of the axillary lymph nodes in breast cancer has 
therefore, attracted much attention and investigators in this field have also been 
assessing the contribution of these nodes to the immune response in patients.
I.2.9.2.I. Phenotypic and activation marker studies
Early resetting techniques comparing nodally derived lymphocytes with 
peripheral blood lymphocytes showed a greater B cell population in the nodes 
(Eremin et al. 1976; Heidenreich et al., 1979). A more extensive phenotypic 
analysis was carried out using Mabs and flow cytometry by Morton et al. 
(1986), who reported an increased proportion of B cells and fewer CD4+ T 
cells in the lymph nodes with CD4+ T cells predominating in the Stage I 
patients while B cells predominated in the nodes of patients with stage II
disease. An increased B cell population, irrespective of metastatic 
involvement, was also observed by Mantovani et al. (1989) and Whitford et al. 
(1992b). The axillary lymph nodes were found not only to be the major source 
of B cells in breast cancer patients but also the site of a large proportion of 
mature B cells with surface IgG (Whitford et al., 1992b) suggesting a 
secondary humoral immune response against the tumour. Moreover, the 
proportion of HLA DR-expressing T cells in the nodes were higher than those 
in the peripheral blood (Morton et al., 1989; Whitford et al., 1992b). In the 
study of Whitford et al. (1992b) which covered 50 patients, CD4+ T cells 
expressing the CD25 IL 2-R were found to be in greater numbers than CD8+ 
cells and the expression of HLA DR on CD8+ cells related to the tumour stage. 
These studies provide evidence indicating that the axillary lymph node may 
have a role to play in mediating an immune response against breast cancer.
The limitation of the work of Whitford et al. (1992b) lies in having no 
indication of whether the nodes were invaded or not while the limitation of the 
work of Morton et al. (1986) lies not only in the unknown invasion status of 
the nodes but also the lack of normal controls and the comparatively crude 
development of flow cytometry at that time.
I.2.9.2.2. Cancer patients versus control subjects
Studies on the immune response in cancer patients often provide 
evidence to suggest that tumour antigen recognition may occur in some patients 
leading to the onset of a response. These studies have primarily determined the 
surface phenotypic and activation markers or observed major alterations in 
cancer patients with some changes being related to the progression of the 
disease. It is, however, of obvious importance to determine whether such
changes are due to the presence of cancer alone in these patients or whether 
similar alterations would also be observed in normal individuals. Both groups 
are outbred with different MHC antigens. Patients coming into the ward for 
surgery the next day may be mounting immune responses to a wide range of 
environmental antigens, for instance those encountered through contact with 
food or other individuals over the preceeding days. Likewise, "normal" 
controls come from different environments. In this context, TILs remain 
unique - the presence of lymphocytic infiltrate in the tumour is in itself a 
condition relating a response not to be seen other than in a diseased state. On 
the other hand, peripheral blood, although readily available from a healthy 
volunteer, may reflect too many of the central responses described above, and 
practical and ethical considerations limit the availability of truly normal locally 
responding nodes. This is reflected in the near absence of phenotyping studies 
on normal nodal lymphocytes in the literature. Although investigators go to the 
extent of making certain that the cancer patients selected for study are without 
any other ailment at the time of sampling, the only comparison of normal 
peripheral blood and lymph node lymphocytes with those of breast cancer 
patients comes from the study of Whitford et al. (1992b). Only a handful of 
other workers have previously done similar comparative studies, with Khuri et 
al. (1989) finding an increase in the CD8+ population in the nodes of breast 
cancer patients and, in contrast, Mantovani et al. (1989) finding no alteration in 
the phenotype of the nodal population. They, however, observed a slight 
increase in the number of HLA DR bearing cells in the PBL from breast cancer 
patients, and this is in agreement with the finding of Pattanapanyasat et al. 
(1988). In the study by Whitford et al. (1992b), lymph nodes taken from the 
iliac region of kidney transplant donors and patients undergoing vascular 
surgery served as control. The variations observed in terms of both the 
phenotypic and the activation markers in the cancer patients were much wider 
than the fairly narrow range observed in lymphocytes from both the peripheral
blood and the lymph nodes from the control patients. In the control nodes the 
CD4+/CD8+ ratio, which was lower than the average ratio in the cancer 
patients, fell within a fairly tight range, suggesting that the large variation 
observed in tumour patients reflected their disease. Much higher proportions 
of HLA DR- and IL-2- expressing T cells and of IgG-expressing B cells were 
observed in cancer patients when compared to the control subjects. In the 
absence of any other ailment in breast cancer patients, it could therefore be 
suggested that the alterations observed in the phenotype and the activation state 
of the lymphocytes from the axillary nodes is due to the presence of breast 
cancer cells and that this is a sign of host-mediated immunity against cancer. 
As high patient variability was observed, apparently in some breast cancer 
patients there may be an ongoing immune response against the cancer, while in 
others the response may not be generated or may even be impaired or 
suppressed.
1.2.10. Impairment of the immune response and metastasis
Apart from cases of advanced metastatic disease (Kansas et al., 1985; 
Ludwig et al., 1985) there is little evidence of impairment of the immune 
system in the peripheral blood of breast cancer patients. The immunological 
competence of the draining lymph nodes, therefore, represents an interesting 
and important area of study for both those who are involved with the 
management of breast cancer patients and those interested in the assessment of 
the role of the lymphoid tissue. In this respect, an important issue is whether 
an impairment of the immune response occurs in patients with metastatic 
spread to the axillary nodes.
The very early observation, as assessed by histological examination of 
the lymph nodes draining mammary carcinoma has been the observed alteration 
observed of the micro-architecture (Hamlin, 1968; Tsakraldides et al., 1974) of 
the nodes. As described in the more recent study of Eremin et al. (1980) and 
in agreement with some earlier studies (Black & Speer, 1958; Anatassiades & 
Pryce, 1966) alterations of lymphocyte subsets were described. Lymph nodes 
with a normal or increased T and/or B lymphocyte compartment were found to 
have a low incidence of nodal tumour spread (Eremin et al., 1980). On the 
other hand, hypocellularity of the T- or B-cell dependent areas was associated 
with a significant increase in metastatic invasion (Eremin et al., 1980). Using 
T cell resetting techniques for cell surface marker study, Heidenreich et al. 
(1979) found no significant difference between tumour free and metastatic 
lymph nodes of breast cancer patients. However, Tsakraklidesef al. (1975) 
had earlier found a significant difference between the two groups of nodes, 
with lymph nodes with disease metastatic to them having a higher percent of B 
cells and a lower percent of T cells than the nodes that did not have metastatic 
disease. In two more recent studies employing Mabs and flow cytometry, both 
the phenotypic and the activation markers were determined. In the study of 
Morton et al. (1986), regional lymph nodes from stage I patients, were found 
to contain a higher proportion of helper/inducer T cells which dropped 
significantly in stage II patients. Elevated levels of B cells, HLA DR- 
expressing activated Th and Tc cells and natural killer (NK) cells were found in 
stage II lymph nodes when compared to stage I. The second study on nodes 
regional to human melanoma (Farzad et al., 1990) showed a significant 
decrease in CD4+ T cells with a corresponding increase in CD8+ cells in stage 
II nodes compared to those from stage I.
1.2.11. Overall view
It therefore appears that there are alterations both in terms of the 
phenotype and the activation state of the lymphocytes in tumour draining 
nodes. The progression of the disease and the growth of metastasis may have 
an effect on the immunocompetence of the lymphocytes in the nodes. But with 
very litde work done on quantification of the lymphocytic population in the 
nodes and since the role of the node itself in breast cancer is still unclear, the 
precise nature of the impairment of the immune response is not yet elucidated. 
No studies have asked whether the presence of tumour cells within the nodes 
regional to breast cancer has any effect on the lymphocyte subpopulations. 
The only study to date (Farzad et al. ,1990), involved nodes regional to 
human melanoma from stage II patients and found that the presence of tumour 
within a node was associated with extreme variability in the number of CD3+ T 
cells, with some patients having very low values. This is the only report in 
which nodes invaded with tumour has been studied by flow cytometry. 
Although two studies involving breast cancer have been reported (Morton et 
al., 1986; Whitford et al., 1992b), these used nodes from stage I patients and 
uninvolved nodes from stage II patients, neither having direct contact with 
tumour.
There is a potential two way interaction in the node. One can examine 
the tumour cells to see if they are manifesting new features which may help 
them to escape immune detection. Conversely one can look at the lymphocytes 
themselves and ask how they have responded to invasion by epithelial cells, 
themselves foreign in a lymph node, which may or may not also bear foreign 
antigens. Assessment of the effect of metastasis on the immune function of the
regional nodes has obvious relevance to the surgical management of breast 
cancer patients.
1.3. Breast cancer-associated antigens: Alteration of 
surface carbohydrate structures
1.3.1. Breast cancer-associated antigens defined by monoclonal 
antibodies
During the early 1980s, there was much optimism about murine 
hybridoma-derived monoclonal antibodies (Mabs) in defining tumour-specific 
antigens. Several Mabs have been described that are reactive with human 
mammary carcinomas. These antibodies have generally been raised by two 
methods, using either breast tumour cell lines and extracts of breast carcinoma 
metastases or by using membranes from milk fat globule as immunogen. 
Antibodies with a preferential reaction with breast cancer tissue have a potential 
value in immunohistopathology as diagnostic tools and antigens that are 
secreted or shed may be useful in the development of serum assay and in the 
radio-immunodetection of metastases. It, however, became evident that 
although these Mabs are reactive against breast tumour cells, most of them also 
react with normal breast tissue, other normal tissues and other tumours 
(Colcher et al., 1981). A particular problem with the use of antibodies to 
detect tumour-associated antigens is that the methodology of Mab generation 
relies on the immune response of animals as it is unethical to hyperimmunise a 
human. Any component foreign to the animal will elicit a response and as 
such, a highly dominant antigen will tend to mask other more tumour-specific 
antigen which are more likely to be of value.
An alternative was the immortalisation of human B cell response to a 
tumour by developing human Mabs using lymphocytes from blood or lymph 
nodes (Section 1.2.2.1). But this attempt was even more disappointing as the 
antibodies were polyspecific and of little use in diagnosis or therapy (Campbell
et al., 1987). The murine Mabs, although not being tumour-specific, have 
been shown, at least in some cases, to have preferential reaction with breast 
tissues (Reviewed by Tjandra & McKenzie, 1988). This has led to the 
identification of a few breast cancer-associated antigens and a general 
awareness of the alteration in the carbohydrate structures on the cell surface.
1.3.1.1. Mucin molecules and anti-HMFG antibodies
The dominant cell in breast cancers expresses both the epithelial 
keratins and the mucin molecules expressed by the lumenal or secretory 
epithelial cells in the normal gland (Taylor-Papadimitriou, 1987). Mucins are 
characterised as large glycoproteins, containing 50-60% carbohydrate in which 
the sugar side chains are O-linked to serines and threonines through the sugar 
N-acetyl-galactosamine. In an attempt to generate immunological reagents for 
the identification of differentiation markers specific for breast epithelial tumour 
cells, a large number of antibodies have been developed which react with the 
mucins expressed by normal and malignant mammary epithelial cells. While 
some of these antibodies demonstrate a relative specificity for malignant breast 
tumour cells, other Mabs do not differentiate between normal and cancerous 
tissues. The related characteristics of these antibodies indicate that the 
antibodies recognise an antigen of normal epithelial cellular origin, which 
appear to represent a family of mucin molecules. The mucin molecules are 
very immunogenic in mice and the antibodies generated in these studies have 
put into focus the mucin molecules as a tumour-associated breast antigen. 
Many of these antibodies were raised against the human milk fat globule 
(HMFG) membranes, which are surface membranes that surround milk 
triacylglycerol droplets secreted from mammary epithelial cells (reviewed by 
Patton & Keenon, 1975). Antibodies raised against the HMFG mucin also
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react with components expressed by normal and malignant breast epithelial 
cells. Conversely, antibodies raised against carcinoma cells can react with the 
mucin produced by the lactating mammary gland. Although the exact nature of 
the epitopes recognised by these antibodies have not been determined, the 
components appear to be O-linked glycoproteins of Mr > 400,000 (Tjandra & 
McKenzie, 1988). One such mucin component found in the membrane of 
HMFG and also in human milk has been variously termed PAS-O (Shimizu & 
Yamauchi, 1982), EMA (Ormerod et al., 1983), NPG (Ceriani et al., 1983) 
and MAM 6 (Hilkens et al., 1984). Two most widely used Mabs in this class 
are HMFG-1 and HMFG-2, raised by immunising mice with the HMFG 
membrane and cultured human milk cells (Taylor-Papadimitriou et al., 1981). 
HMFG-1, which is highly reactive with the milk mucin, appears to recognise 
an epitope on the fully processed mucin, a characteristic of normal 
differentiation (Wilkinson et al., 1984). In tumours, the size of the component 
carrying the antigenic determinant differs among tumours and with HMFG-2, 
the components can differ over a range from 80,000 to 400,000 (Burchell et 
al., 1983). Griffiths et al. (1987) generated second-generation antibodies 
using the purified HMFG-2 reactive components and only reported the 
immunological complexity of the large components. Two of their antibodies 
showed cross-reaction with a smaller glycoprotein of Mr 68,000, which was 
found in breast cancer cell extracts. Using HMFG-1 affinity chromatography 
followed by treatment with hydrogen fluoride to remove all O-linked sugars, 
Burchell et al. (1987) isolated the mucin core protein of a similar size (Mr 
68,000) which carried epitopes for HMFG-1 and HMFG-2. Although similar 
in size, the deglycosylated milk core protein is however, a different molecule 
from the glycoprotein detected by the second generation antibody (Griffiths et 
al., 1987).
Mab (SM-3) was directed against the mucin core polypeptide and found 
to react with 47 of 50 (91%) breast cancers studied, while not staining normal 
tissues and HMFG-2- positive benign lesions. An unexpected finding was that 
both HMFG-1 and HMFG-2 which react with the milk mucin also showed a 
positive reaction with the extensively carbohydrate stripped mucin molecule. 
This suggests that the reaction of HMFG antibodies with the mucin molecule 
includes not only the carbohydrate portion but a part of the core protein 
component as well. Moreover, the SM-3 epitope appears to be masked by 
oligosaccharide moieties in normal cells but gets exposed, perhaps due to 
aberrant glycosylation, in malignant cells.
A second Mab with a relative specificity for breast cancer tissue is H23. 
This antibody was generated by immunisation with purified human MMTV- 
the retroviral-like particles released from a breast cancer cell line (T47D) 
(Keydar et al., 1989). It is reactive with a glycoprotein of Mr 68,000 and it is 
not known whether this glycoprotein is coded by viral genes. In a survey of 
532 breast cancer tissues, the H23-reactive antigen was detectable in 91% of 
the tested paraffin-embedded tissue sections and in all of 29 metastatic tissues 
(Keydar et al., 1989).
cDNA clones coding for the core protein of the milk mucin now termed 
Polymorphic Epithelial Mucin (PEM) and recognised by SM-3 have recently 
been isolated and the amino acid sequence fully determined (Gendler et al., 
1988 and 1990). From such sequence data, individual-specific genetic 
polymorphism in the core protein PEM have been reported and the protein 
found to contain varying numbers of a tandem repeat element comprising of 20 
amino acids. The various Mabs (DF3, HMFG-1, HMFG-2, SM-3, and H23) 
all recognise an epitope found within this tandem repeat but differ regarding 
their immunoreactivities with breast tissue (Siddiqui et al., 1988; Gendler et
al., 1988). While HMFG-1 and HMFG-2 do not distinguish between normal 
and malignant breast tumours, the SM-3 and H23 Mabs are relatively tumour- 
specific. Recently, Wreschner et al. (1990) isolated and characterised cDNAs 
which code for the mucin protein core. Complete sequence analysis in this 
study reveal the complexity of the epithelial antigen with the existence of 
multiple forms of the antigen. It is of interest that the mucin gene is located on 
chromosome 1 (Taylor-Papadimitriou, 1987) in a region where alterations in 
breast cancer have been reported in high frequency (Section 1.4.1; Section 
1.4.2.3.4).
Many more related Mabs have been generated, like the Mam 6 
antibodies raised against HMFG (Hilkens et al., 1984) and the NCRC 
antibody (Ellis et al., 1984), which although raised against a breast carcinoma 
metastasis detects high MW glycoproteins similar to those recognised by the 
anti-HMFG antibodies. The exact nature of the epitopes these Mabs recognise 
still remains unidentified and as such the epitope which is exposed in breast 
cancers is yet to be characterised. These studies, however, show that 
glycoproteins are altered in breast cancer and some of these alterations are 
tumour-associated. The reactivity of these Mabs also highlights a particular 
common problem related to the generation of murine Mabs and used to detect 
tumour-specific antigens. It is clear that the mucin molecules are highly 
immunogenic in mice and as such it is not surprising that all these Mabs, 
although raised against different immunogens, react with the same high MW 
glycoprotein. No matter what the immunogen, be it breast tumour tissue or 
established cell lines, the antibodies generated turned out to be directed against 
the same class of molecules- the mucins. It is likely that the mouse response 
against the highly immunogenic mucin molecule takes precedence over other 
more specific tumour antigens. This perhaps explains the poor specificity of
some of the antibodies. The likelihood of these Mabs being used to diagnose 
or in the therapy of breast cancer, therefore, appear not to be too promising.
1.3.1.2. Tumour-associated glycoprotein 72 (TAG-72)
The TAG-72 antigen is defined by Mabs B72.3 and CG49 (Colcher et 
al., 1981; Thor et al., 1986; Muraro et al., 1988). Mab B72.3 was generated 
using membrane-enriched extracts of a breast tumour metastasis to the liver as 
immunogen (Golcher, et al., 1981). The antigen reactive with this antibody 
was shown to be a high molecular weight glycoprotein complex of 
approximately 220,000 to 400,000 and is termed tumour-associated 
glycoprotein 72 (TAG-72). Studies employing radioimmunoassay and 
immunohistochemistiy have revealed that B72.3 reacts with approximately 50 
% of breast carcinomas (Nuti et al., 1982) and 85% of colon carcinomas 
(Stragmignoni et al., 1983) tested but with no reactivity with normal human 
tissues. Analysis of TAG-72 carried out by Johnson et al. (1986) suggests 
that it is a mucin-like molecule.
1.3.1.3. O ther breast cancer-associated glycoproteins identified 
by monoclonal antibodies
A number of other antibodies have also been generated using human 
breast carcinoma tissues or cellular fraction from breast cancer cell lines as 
immunogen. All of them react with breast cancer-associated glycoproteins, 
which remain uncharacterised. These Mabs appear not to react with the normal 
breast tissue although, cross reacting with a limited number of normal tissues.
One such Mab is 83D4, which was generated by immunisation with cell 
suspensions from a paraffin block of human breast carcinoma tissue (Pancino 
et al., 1990). The antibody showed reactivity with breast cancer tissue in 
paraffin and frozen sections and with other carcinomas including ovarian and 
colonic carcinomas. It showed no reactivity with normal breast epithelium or 
HMFG membranes or skimmed milk, although reacting with a limited number 
of other normal tissues which include colon, stomach and endometrium. 
Recently, Pancino et al. (1991) reported the purification and characterisation of 
a 83D4 reactive antigen, which was expressed in breast cancer but not in 
normal breast. The antigen appears to be a high MW glycoprotein (apparent 
Mr: 300-400 to over 1000 x 103) and the epitope recognised by the antibody 
involves carbohydrate but not sialic acid. In an ELISA assay the purified 
antigen was found not to display reactivity for HMFG-1 antibody, but bound 
two other Mabs, CC49 and B72.3, which define a tumour associated 
glycoprotein TAG-72. Competition radioimmunoassays distinguished the 
83D4 defined epitope from those recognised by the other two Mabs and it thus 
appears that these antibodies identifies antigens which are part of the same 
family of carcinoma associated glycoproteins. A few other B series antibodies 
have been developed and they are all directed to uncharacterised high MW 
glycoproteins (Schlom et al., 1984).
1.3.2. Tumour-associated antigens as markers of prognosis in 
breast cancer patients
I.3.2.I. Serum tumour marker and prognosis
Markers in the sera of cancer patients are much sought after due to the 
ease of collection of blood and more importantly in the continuous monitoring
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of the progress of the disease, which also has the potential for the early 
detection of metastases or recurrences. Most of the earlier serum markers were 
the traditional 'broad spectrum' tumour markers, like the oncofetal 
glycoproteins carcinoembryogenic antigen (CEA) and Tissue polypeptide 
antigen (TPA), both with very little usefulness. In later years, increasing 
numbers of carcinoma-associated (CA) markers were identified. Of these CA 
15.3 has been relatively more widely assessed as a breast tumour marker.
CA 15.3 has been found to be more specific and appears to be more sensitive 
than CEA (Gion et al., 1991). The antigen is defined by two different 
antibodies, DF3, which was raised against a membrane fraction of breast 
carcinoma cell line (Hilkens et al., 1984), and 115 Ds, raised against antigens 
of HMFG membranes (Kufe et al., 1984). Although Gion et al. (1991) lately 
reported a significant relationships between CA 15.3 preoperative serum level 
and tumour size and number of positive nodes, in previously published papers 
serum CA15.3 levels in breast cancer patients were studied anecdotically and 
results are conflicting ( Pons-Anicet et al., 1987; Schmidt-Rhode et al., 1987; 
Safi et al., 1987). There are reports of preliminary studies involving other CA 
markers detected in the sera of breast cancer patients. CA 549 has been 
reported to be of promise in advanced disease (Bray et al., 1987) and another 
marker termed MCA (mucin-like carcinoma-associated antigen) (Bombardieri 
et al., 1989) has shown high sensitivity in preliminary trials being of value in 
assessing metastatic spread (Miserez et al., 1991). While another breast CA 
antigen called mammary serum antigen (MSA) have been found to be more 
sensitive than the markers, CA 15.3 and CEA (Stacker et al., 1988; Sacks et 
al., 1987).
I.3.2.2. Anti-HMFG and related Mabs and prognosis
HMFG and related antibodies have been used more widely in assessing 
prognosis in breast cancer patients. But these studies have also produced 
conflicting results. Wilkinson et al. (1984) concluded that the HMFG-1 
antibody could be useful as a prognostic indicator, while Berry et al. (1985) 
could find no relationship between the extent of staining with HMFG-1 and 
HMFG-2 and survival. Ellis et al. (1985,1987) using the antibody NCRC 11 
reported a clear relationship between immunoreactivity of carcinomas and the 
clinical course of the disease. But Angus et al. (1986) found no significant 
relationship with prognosis and NCRC 11 staining. In the more recent study 
of Walker (1990), the three above antibodies and four of the Mam 6 series 
were applied to 115 stage I and II paraffin-embedded breast tissues to assess 
their value as prognostic indicator. In a follow-up of 36 months, only NCRC 
11 staining showed a relationship to development of recurrent disease and 
overall survival, but this was not an independent prognostic indicator above 
that provided by histological grade. It was, therefore, concluded that for short­
term prognosis, none of these markers can give independent prognostic 
information.
Although some of these Mabs generated against surface antigens 
associated with breast cancer appear to be promising in clinical applications 
(Reviewed by Tjandra & McKenzie, 1988), they appear to be of litde use in the 
management of cancer patients. None of these Mabs detect tumour-specific 
antigens and they are all directed against ill-defined epitopes. The antibodies 
however, reveal that alteration in the oligosaccharide moieties of surface 
glycoproteins occur. Increased reactivity of some of these antibodies with 
breast carcinomas suggest that such alteration lead to unmasking of certain
epitopes. Very little information is available concerning the exact nature of 
these epitopes. There is a need for the characterisation of these glycoproteins 
especially since the Mab-defined surface antigens appear to be high MW 
glycoproteins. A number of studies have examined the nature of carbohydrates 
associated with surface glycoproteins on tumour cells.
1.3.3. Expression and alteration of blood group antigens in 
human cancer
The earliest chemical evidence indicating the occurence of aberrant 
glycosylation in human cancer was the changes in blood groups (Reviewed by 
Hakomori, 1989). Changes in blood group antigens in terms of incompatible 
expression of A or B determinants, or the reduction of A or B determinants 
were observed. Related to the change of blood group antigens in human 
cancer, a large quantity of several fucose-containing glycolipids was found to 
be accumulated in various types of human adenocarcinomas, some of which 
were subsequently identified as the Lewis (Le) antigens (Hakomori et al., 
1967). The backbone structure (Gal(3l-3GlcNAcpl-3Gal) of these Le 
antigens represents the major carrier for the blood group ABH determinants. 
Le and Le related antigens represent the lacto-series antigens whose epitopes 
are defined by a large number of Mabs directed against various human tumours 
and are expressed in both glycolipids and glycoproteins. Some of these 
antigens like the Lex antigen have been found to be associated with mucin- 
type glycoprotein or with embryogenic antigen, carcinoembryogenic antigen 
(CEA).
A second group represents the core structure of O-linked glycans and 
includes the T (Thomsen-Friedenreich), Tn and sialyl Tn antigens. These
antigens are the components of alpha sialoglycophorin (glycophorin A), which 
is an important constituent of the membrane of erythrocytes and is responsible 
for the antigenic determinants of the MN blood group system (Springer & 
Desai, 1985). Sialoglycoprotein bears two cryptic antigenic determinants, T 
and Tn, and removal of sialic acid of sialoglycoprotein uncovers the T antigen 
(Gaipi-3GalNAcal- O-Ser/Thr) and this can possibly occur due to the action 
of bacterial neuraminidase following bacterial infection (Roxby et al., 1987). 
Moreover, anti-T and anti-Tn antibodies have been found in all individuals and 
are believed to be due to a response against intestinal organisms carrying 
related antigens. Removal of the penultimate galactose residue reveals the Tn 
antigen, first discovered by Moreau and co-workers on untreated 
polyagglutinable RBCs in a patient with haemolytic anaemia (Springer, 1989). 
The expression of Tn corresponds to exposure of N-acetyl-D-galactosamine 
residues O-glycosidically linked to serine or threonine.
Tn expression has been reported in a few cases of malignant or 
premalignant haemopoietic disorders. A somatic mutation at the gene locus of 
two enzymes, P-l-3-D-galactosyl transferase and a-2-6-N-acetylneuraminyl 
transferase have been implicated with Tn expression (Springer & Desai, 1985). 
Mabs have been used to detect both T and Tn antigens in human cancers, 
including breast cancer. Using human anti-Tn antibodies, Springer et al. 
(1985, 1989) found immunoreactive Tn epitopes in greater than 90% of 69 
primary breast carcinomas but absent in benign breast tumours. High density 
of Tn epitopes on breast, lung and urinary bladder cancers have been related to 
poor prognosis (Springer, 1984; Coon et al., 1985; Springer et al., 1985; 
Nishiyama et al.t 1987). With GalNAc as its terminal residue, the Tn antigen 
can be detected by the reactivity of the lectin Helix pomatia and other Gal NAc 
lectins (Section 1.3.5). This led Springer (1989) to propose that Tn might be
the biological marker associated with metastatic potential in breast cancer 
patients (Section 1.3.5.2).
Kurosaka et al. (1987) and Kjeldsen et al. (1988) established Mabs that 
were reactive with various types of human cancer. The epitope was identified 
as sialyl Tn (NeuAca2 - 6GalNAcal - R) and found to be highly expressed in 
gastric, colonic, and pancreatic cancer, but less in liver and breast cancer. In 
contrast to Tn and sialyl Tn antigens, although the T antigen is often expressed 
in cases of cancer the nature of tumour-associated T antigen is still unknown. 
Longenecker et al. (1987) reported that Mabs directed against the p- 
disaccharide (Galpl - 3GalNAc) exhibits cancer-associated activity but not 
those reactive with the a- anomeric configuration. Another Mab against Gal-A 
(Galpl - 3GalNAcal - 3Gal) sequence did not react with any tumour tissue 
(Clausen et al., 1987).
1.3.4. Glycosylation in tumour cells
The proportion of carbohydrates covalently linked to the plasma 
membrane of eukaryotic cells ranges from 2 and 10% of plasma membrane 
weight (Smets & Van Beek, 1984). Most of this carbohydrate makes up 
components of glycoproteins, in which the carbohydrate is linked to proteins, 
and glycolipids, in which the carbohydrate is linked to ceramide. The 
membrane glycoproteins, which contain at least 80% of all surface-located 
carbohydrate, act as transport systems, signal-transducing agents, antigens and 
receptors. As antigens and receptors, the glycoproteins play an important role 
in tumorigenesis. Numerous studies now reveal that the carbohydrate 
structures are altered in human malignant tumours.
1.3.4.1. Structure of glycoproteins
Glycoproteins are proteins to which carbohydrates are covalently 
bonded through glycosidic bonds. The linkage is either N-glycosidic via the 
amide nitrogen of an asparagine residue or O-glycosidic via the hydroxyl of 
serine, threonine, hydroxylysine or hydroxyproline. For the sake of 
convenience, glycoproteins are often differentiated from proteoglycans (eg. 
cartilage proteoglycan), which are a subclass of glycoproteins with distinctive 
features of carbohydrate structure and found in animal connective tissues 
(Beeley, 1985). A common structural characteristic of proteoglycans is that 
they contain linear polysaccharide chains which have a repeating unit 
containing an amino sugar derivative, which are often uronic acid or sulphate 
substituents. These carbohydrate chains are known as glycosaminoglycans. 
Glycoproteins and proteoglycans make up an overwhelming majority of 
extracellular proteins, which include the secreted glycoproteins, the mucins, 
serum, structural and the membrane glycoproteins.
I.3.4.2. O-linked glycoproteins
In comparison to N-linked glycoproteins, relatively little is known 
about the carbohydrates of carcinoma associated mucins or the sequence of 
events involved in glycosylation of the core protein. Events during addition of 
O-linked carbohydrates to proteins are not well established. The only common 
structural element in O-linked sugar chains is the GalNAc attached to the 
hydroxyl group of threonine or serine , which is also the first step in the 
biosynthesis of O-linked oligosaccharides. There is evidence for initiation of 
O-linked oligosaccharide synthesis occurring early (Strous, 1979; Cummings 
et al., 1983; Jokinen et al., 1985), late (Hanover et al., 1982; Roth, 1984) and
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continuously (Spielman et al., 1987) in the biosynthetic pathways of different 
proteins. Following initiation, chains may be elongated, usually proceeding 
first with the addition of galactose to give Gaipi - 3GalNAc.
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Figure 1.3.1. Structures of the major types of N-linked sugar chains of 
glycoproteins.
I.3.4.3. N-Iinked glycoproteins
Many secretory and membrane proteins are glycoproteins carrying N- 
linked oligosaccharides. Studies of these oligosaccharide sequences have 
revealed three fundamental types of structures: high mannose, hybrid and 
complex (Fig. 1.3.1) (Komfeld & Komfeld, 1985). They all share the 
common core structure Man al-3(Man al-6)Man pl-4GlcNAc pi-4GlcNAc- 
Asn, but differ in their outer branches. It is particularly the substitutions of
sialic acids, fucose and galactose at the termini of these oligosaccharide 
sequences and the variable presence of fucose linked 1-6 at the core GlcNAc 
which appear to be important events in malignancy (Foster, 1990). The 
majority of complex-type oligosaccharides in human epithelia contain between 
two and four outer branches and although a similar branched structures also 
occur in malignant tissues, some unique types of branching have recently been 
reported.
I.3.4.4. Biosynthesis and processing of N-linked glycoproteins
Biosynthesis of N-linked glycoproteins of the complex type proceeds 
via the high-mannose intermediate. Prior to glycosylation, N-linked 
oligosaccharide moieties are initially built on an activated lipid-carrier, dolichol 
phosphate. Upon phosphorylation, the dolichol moiety sequentially acquires 
the various monosaccharides starting with the transfer of a single N-GlcNAc 
residue (Parodi & Leloir, 1979). Addition of another N-GlcNA<v9inannose 
and 3 glucose residue units follow sequentially (Li et al., 1978) leading to the 
precursor structure GlC3Man9GlcNAc2 - The complete precursor-type 
oligosaccharide structure is then transferred to the nascent polypeptide chain, 
the acceptor site of which is a specific tripeptide sequence consisting of Asp-X- 
Thr/Ser, X being any amino acid except Asp/Pro (Marshall, 1972).
Processing of N-linked oligosaccharides involves a complex series of 
trimming reactions in which glucose and mannose residues are sequentially 
removed (Reviewed by Komfeld & Komfeld, 1985). The processing which 
takes place in the endoplasmic reticulum (ER) involves trimming glucosidases 
and mannosidases which remove 3 glucose residues and 1 mannose residue. 
After transport of the glycoproteins into the Golgi compartment, mannosidase I
removes 3 additional Man residues. The sequential actions of pl-2 GlcNac 
transferase I , mannosidase II and pi-2GlcNAc transferase II produce a 
biantennary structure. At this point, GlcNAc transferases IV and V can initiate 
pl-4 and pl-6 linked antennae respectively (Gleeson & Schachter, 1983). 
Finally terminal sugars such as N-GlcNAc, galactose, sialic acid, and fucose 
are added to the branched structure which results in the conversion of the high- 
mannose structure to a glycan of the complex type.
The biosynthetic and processing pathways afford potential sites at 
which malignancy-linked alterations may occur. There are now a number of 
accounts of alteration of the carbohydrate structure on the surface of malignant 
cells.
I.3.4.5. Alteration in Asn-linked oligosaccharide structures in 
cancer
Cellular transformation has been shown to be associated with 
modification in the composition, content and distribution of cell surface 
oligosaccharides of glycoproteins (Skutelsky et al., 1988). As the protein- 
bound carbohydrates are synthesised during a complex interplay of enzymes in 
which carbohydrate residues are sequentially added and removed and which 
leads to the generation of intermediate structures of varying composition, it is 
possible that cancer-related surface changes may be generated along this route. 
There is now considerable evidence that malignant transformation is 
accompanied by changes in the oligosaccharide structures of glycoproteins. 
One of the more common alterations in transformed cells is the presence of 
larger N-linked oligosaccharides (Smets & Van Beek, 1984; Santer & Glick, 
1979; Warren et al., 1978). This alteration has been widely observed in rodent
tumour cells transformed by activated H-ras, v-src oncogenes (Santer et al., 
1984; Dennis et al., 1989) and by DNA tumour viruses (Yamashita et al., 
1983; Pierce & Arango, ,1986). The increased size has been attributed to 
increased sialylation and more recently to increased -GlcNAcpl-6Manocl- 
6ManP~ branching of complex-type oligosaccharides. The increased pi-6 
branching is due to an increased GlcNAc-transferase V in malignant cells 
(Yamashita et al., 1985). In addition, increased pi-6 branching of complex- 
type oligosaccharides in a transfected mouse mammary cell line has been 
shown to be related to invasiveness and metastatic potential (Dennis et al., 
1987). In addition, somatic mutations and drugs which inhibit N-linked 
processing and reduce sialylation or branching of complex-type 
oligosaccharides were found to severely reduce the metastatic potential of 
human melanoma and B16 melanoma cells (Dennis, 1986a; 1986b; Finne et 
al., 1982; Ishikawa et al., 1988; Humphries et al., 1986). These studies reveal 
that the oligosaccharides are required for metastasis to occur and therefore, 
their increased presence or alterations in primary tumours may be diagnostic of 
metastatic disease. The plant lectin (Section 1.3.5) leukoagglutinin (L-PHA), 
which has high affinity for galactose and the pi-6 linked antenna in tri- and 
tetra-antennary structures., has proved useful for the detection of P1-6 branched 
complex-type oligosaccharides in malignant cells (Dennis et al., 1987). 
Fernandes et al. (1991) performed histochemical analysis with L-PHA on 
paraffin sections of human breast and colon tissues. The study revealed that 
pl-6 branched N-linked oligosaccharides are consistently increased in 
carcinomas of human breast and colon and that the level of L-PHA staining 
correlates with tumour progression in the breast and with metastatic disease in 
the colon. Although ductal epithelial cells in normal and benign tissue showed 
weak to moderate staining, strong staining was also observed in lymphoid and 
endothelial cells.
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1.3.5. The use of lectins in studying altered glycosylation in 
tumour cells
I.3.5.I. Lectins
Lectins are sugar-binding proteins and glycoproteins of non-immune 
origin. The agglutinating property of lectins were first reported by H. 
Stillmark when he observed that the Ricin extract agglutinated erythrocytes and 
hence the name 'haemagglutinins' and 'phytohaemagglutinins' (Sharon & Lis, 
1989). Years later the lectin PHA (phytohaemagglutinin) was found to act as a 
mitogen for lymphocytes. In addition to their agglutinating and mitogenic 
property, the high affinity and specificity of the lectins for certain carbohydrate 
residues has led to their use as probes to give information about the location, 
abundance and function of
TABLE 1.3.1. Lectins and their specificity
Lectin Sugar specificity
Arachis hypogea (Peanut) D-Galactose
Concanavalin A, Canavalia ensiformis (Jack bean) D-Mannose, D-Glucose
Dolichos biflorus (Horse gram)
Helix pomatia (snail)
Lotus tetragonolobus I, II & m  (asparagus 
or winged pea)
Triticum vulgaris (Wheat germ)
Ulex europeaus (UEA I, gorse)
N-Acetyl-D-Galactosamine
N-Acetyl-D-Galactosamine
L-Fucose
N-Acetyl-D-glucosamine
L-Fucose
glycoconjugates at the cell surface. Lectins possess certain very useful 
properties; they are multivalent and their interactions with oligosaccharides are 
specific and reversible and as they are not internalised they make a good probe 
for detecting carbohydrate structures on the cell surface (Beeley, 1985). Quite 
a number of lectins with differing specificity have been isolated from a wide 
range of plant and animal sources (Table 1.3.1) and are available commercially 
in a highly purified form.
I.3.5.2. Lectin binding in primary breast cancers
The availability of fluorescently-labelled lectins with differing 
specificity from various sources has made possible in recent years the use of a 
number of lectins in the study of carbohydrate expression on tissues from 
breast cancer patients. These studies have employed histochemical analysis on 
primary paraffin tissue or frozen sections from breast cancer patients to detect 
differences in carbohydrate expression. A number of such studies have now 
shown that such differences between normal and malignant cell can be of 
prognostic significance. There is however, disagreement between 
investigators.
The most widely studied and one of the earliest lectin to be used, 
peanut agglutinin (PNA) lectin, was used on human breast carcinomas as the 
binding sites for the lectin in rat were found to be hormone-dependent. In 
erythrocytes, the lectin binds to a component of the MN blood group antigen 
known as the T antigen (Thomsen-Friedenreich antigen), which is exposed 
only after desialation by neuraminidase. Binding of the lectin was also found 
to be a constant feature of normal human breast tissue, once sections have been 
treated with neuraminidase (Walker, 1984a). In breast carcinomas, positive
staining for PNA was associated with tumour differentiation (Walker, 1985), 
although the study by Bocker et al. (1984) disagrees. No significant 
correlation was, however, observed with hormone receptor content (Stanley et 
al., 1986, Walker et al., 1985; Dansey et al., 1988).
Binding to Concanavalin A (Con A), which has specificity for D-Glc or 
D-Man, has been implicated in the progression of the disease in breast cancer 
patients (Furmanski et al., 1981). The study employed a haemadsorption 
assay, in which human erythrocytes treated with various concentrations of Con 
A were incubated with the test mammary epithelial cells isolated from cultures 
of primary breast cancers. Con A reactivity of the tumours was classified as 
high or low with the Con A half-maximum value defined as the concentration 
of Con A at which approximately 50% of the test cells adsorbed erythrocytes. 
With a follow-up of about 22 months, the study showed that patients with 
high-reactivity tumours were at a significantly greater risk of early recurrence 
than those with low-reactivity tumours. There was no correlation with any of 
the pathological parameters. However, in an immunohistochemical analysis on 
paraffin-embedded tissues Dansey et al. (1988) reported that Con A reactivity 
was negative in normal breast tissue, whereas positive Con A staining of 
primary tissues was related to stage and disease-free survival in patients 
followed for 41 months. The relationship with disease-free survival was not 
independent but related to the stage of the disease as found in a multivariate 
analysis.
Both wheat germ agglutinin (WGA) and Ulex europeaus (UEA I) 
binding have also been studied to detect changes in carbohydrate expression in 
malignant breast tissues. Walker (1984b) reported a significant correlation 
between decreased WGA reactivity and the presence of lymph node metastasis. 
However, other studies reported either no differences in WGA binding to
breast carcinomas with, or without, axillary lymph node metastasis (Khan & 
Baumal, 1985) or a lack of correlation between WGA binding and the clinical 
outcome of the patients (Dansey et al., 1988). UEA I, with specificity for L- 
Fucose residues showed variable binding to normal breast epithelial cells as 
well as malignant breast epithelium (Walker, 1984c). Fenlon et al. (1987) 
found UEA I staining not to be related to any of the prognostic factors but 
significant relationships were shown with disease-free interval and length of 
survival. A greater cell staining proportion being related to earlier local 
recurrence and shorter survival.
The most extensive study regarding the Helix pomatia lectin (HPA), 
which has specificity for N-Acetyl-D-Galactosamine residues, has been carried 
out by Brooks and Leathern (1991). In their initial pilot study, a strong 
correlation was observed between HP A binding to primary tumour and the 
presence of axillary lymph node metastases (Leathern et al., 1984; Leathern et 
al., 1985). In a histochemical analysis of paraffin-embedded sections of 
primary tumours from 179 breast cancer patients and with a follow-up of 20 
years, HPA binding was found to be related to long-term prognosis (Leathern 
& Brooks, 1987). The study indicated that HPA positive tumours are more 
likely to have metastasised locally and to distant sites, that is patients with HPA 
positive tumours have shorter disease-free and overall survival times. This has 
been confirmed in a follow-up study involving 373 primary breast cancers. It 
further showed a strong association between HPA binding and presence of 
lymph node metastases, but no association with tumour size, histological grade 
or S-phase fraction (Brooks & Leathern, 1991). Although in the initial report 
significant differences between premenopausal and postmenopausal patients 
were observed, no association was observed between HPA staining and patient 
age in the later report. The relationship between HPA binding and lymph node
stage, local recurrence and survival has also been reported by other workers 
(Fenlon et al., 1987; Fukutomi et al., 1989).
There are also a limited number of reports of studies involving other 
lectins like Lotus tetragonolobus and Dolichos biflorus. But the binding of 
these lectins to fixed breast tissues has been found to be unsuitable, probably 
due to denaturation of binding sites or due to the solubility of the glycosylated 
substances in acqueous fixatives (Walker, 1984a) and as such of little use in 
retrospective studies. This highlights a particular problem with histochemical 
studies and the use of paraffinised tissues. Most of the above studies were 
done retrospectively and as such were carried out on paraffin sections of 
formalin-fixed, paraffin-embedded tissues. Fixation of tissues has the 
potential of altering the binding site if not denaturing it. In assessing the effect 
of fixation on lectin binding, Walker (1984a) reported that not all lectins gave 
consistent results and for some pretreatment with enzymes was a prerequisite, 
while still others were unreliable with fixed tissues when compared to frozen 
tissues. For lectins like soy bean agglutinin and Ulex europeaus, 
trypsinization of formalin-fixed tissue was a prerequisite and additionally soy 
bean agglutinin and Dolichos biflorus, both specific for N-GalNAc, showed 
binding patterns which vary between specimens and often between themselves. 
Similar problems was also reported for the lectin Lotus tetragonolobus. 
Moreover, histochemical analysis involves the determination of the extent of 
lectin binding by a simple visual assessment, often involving identification of 
subtle differences in staining intensity classified as moderate and strong. Such 
differences are often apparent only in an overall impression when multiple 
areas of tissues are scanned. This problem was encountered by Dansey et al. 
(1988) in assessing differences in binding patterns of PNA and WGA to 
normal and neoplastic breast tissues. These studies, however, provide 
important clues that there exist alteration on the carbohydrate structures of
breast tumour cells and although these structures are still not completely 
understood, recent evidences suggest that carbohydrates may play an important 
role as adhesion molecules and as such in the metastatic spread of the disease 
(Section 1.1.6.6).
1.3.5.3. Lectin-binding in primary breast cancers and their 
metastases
That tumour cell surface glycoconjugates play a pivotal role in the 
specific homing of metastases has been shown with the metastatic spread of 
mouse and rat melanoma cells (Fidler, 1973; Nicolson & Custead, 1982). 
Moreover, differences in cell surface carbohydrates have been demonstrated 
with animal tumours selected for high and low metastatic sublines (Altevogt et 
al., 1983; Mmura & Nicolson, 1984; Steck & Nicolson, 1983). Studies using 
lectins afford a useful method for studying alteration in carbohydrate structures 
associated with malignancy in breast cancer. All of these reports involve 
retrospective analysis of primary tumours. There is therefore, a need for a 
prospective study using preferably fresh tissues. In the case of the lectin HPA 
considerable evidence indicate that HPA recognises a glycoprotein that is 
associated with metastasis. It would be interesting to compare carbohydrate 
expression on primary tumours and their metastases in the same patient. Very 
few studies have analysed metastatic tissues for carbohydrate expression and 
only in a recent report Krogerus and Anderson (1990) analysed carbohydrate 
expression on both primary tumours and their metastases from the same 18 
breast cancer patients. In a histochemical analysis of paraffinised tissues and 
using a panel of seven fluorochrome-labeled lectins, the study reported that 
although the basic staining pattern of axillary lymph node metastases was 
similar that of the primary tumour, there was several quantitative and
qualitative differences. Compared with lymph node metastases, primary 
tumours were found to display a pattern of lectin-binding specificities that was 
more diversified in terms of both the extent of staining and reactivity with 
different lectins. In a small number of cases, in which distant metastases were 
also analysed, the distant metastases were found to be more restricted and 
displayed a generally uniform reactivity when compared to both nodes and the 
primary tumour. The study concluded that selected subclones with 
glycosylation patterns different from most of the nonmetastatic cells in the 
primary tumour invade lymph nodes and that further selection occurs for 
distant metastases. More similar studies are needed to define the surface 
carbohydrate structure associated with metastatic potential in breast cancer. A 
useful design of study would be is to analyse by flow cytometry lectin binding 
to fresh tissues from both primary tumour and axillary lymph node metastasis 
from the same patient. Flow cytometry would be advantageous in various 
aspects (Chapter 4, Section 4.9) as histochemical analysis is plagued with 
various technical difficulties.
1.4. DNA analysis of tumour cells
It is believed that during the progression of tumours, cancerous cells 
accumulate increasing genetic alterations that are generated by random, somatic 
mutational events (Nowell, 1976; Nowell, 1986). During this period of 
genetic instability and under host selective pressures, which are both immune 
and non-immune in nature, the tumour may progress to a highly malignant 
phenotype (Cifone & Fidler, 1981; Nicolson, 1987). This has lead researchers 
to assess both chromosomal abnormality, in terms of karyotype analysis, DNA 
content, and overexpression of oncogenes or gene loss, and the proliferation of 
tumour cells, in terms of its cell cycle. DNA analyses have not only revealed 
that solid tumours frequently have high proliferation rate, but that they also 
frequently have gross chromosomal abnormalities (Section 1.4.3). Detection 
of such abnormalities is important as they can be related to prognosis in 
patients and, as such, make possible characterisation of tumours with higher 
malignant capability.
The analysis of DNA of a tumour can be performed at various levels - 
by cytogenetics, molecular biology, cytophotometry and flow cytometry. 
Molecular biological analysis generally involves the use of oncogene probes 
which allows the detection of abnormalities of defined chromosomal loci 
(Section 1.4.2.). Additionally multi-locus recombinant DNA probes can be 
used to detect restriction fragment length polymorphism (RFLP), which has 
led to the detection of gene loss (Section I.4.2.3.). Cytogenetic analysis and 
more recently DNA flow cytometric analysis allow detection of DNA 
abnormality on a much larger scale. Cytogenetic analysis has been used to 
provide invaluable information in certain malignancies and DNA flow 
cytometry provides information on both the DNA content and the fraction of 
cells in the DNA synthesis phase (SPF) of a tumour. DNA abnormality
assessments may at times be hampered by technological constraints and while 
each of these techniques has some advantages over the other, the growing use 
of flow cytometry in breast cancer is quite apparent.
1.4.1. Cytogenetic (chromosomal) analysis in breast cancer
Initially, the clues that tumours can have detectable genetic alterations 
came from the analysis of tumour cell chromosomes. In a chromosomal or 
karyotypic analysis, single cell suspension from a tumour is exposed to a 
mitotic inhibitor (eg. colcemid), swelled in a hypotonic solution and fixed, and 
then the chromosomes are spread on glass slides. Alkylating fluorochromes 
(eg. quinacrine mustard) and histochemical stains (eg. Giemsa) are used to 
produce multiple characteristic bands which can be identified on the metaphase 
chromosomes (Caspersson et al., 1970). Recent refinements have improved 
resolution and have allowed enhanced identification of chromosomal 
rearrangements in the cells (Verma & Dosik, 1982). Abnormalities detected by 
chromosomal analysis include those in chromosome 1 and 11 of breast 
carcinoma cell lines (Cruciger et al., 1976; Satya-Prakash et al., 1981). 
Thereafter, a number of studies on both direct preparations and from primary 
cultures of breast tumour cells confirmed the structural involvement of 
chromosome 1 (Kovacs, 1981; Zhang et al., 1989; Bello & Rey, 1989. There 
are also reports of aberrations involving chromosomes 11 (Bello & Rey, 1989; 
Ferti-Passantonopoulou & Panani, 1991), 3, and 6 (Bello & Rey, 1989; Ferti- 
Passantonopoulou & Panani, 1987). Ferti-Passantonopoulou & Panani (1991) 
additionally reported the consistent involvement of band 1 lq23-24 and of band 
lip  15. Further involvement of the loss of chromosomes 8, 13, and 16 have 
also been reported (Rodgers et al., 1984; Hill et al., 1987). These cytogenetic 
studies were performed on a small number of cells from a small patient sample
and showed multiple complex rearrangements, which include both 
translocations and deletions. However, no consistent cytogenetically 
detectable chromosome abnormality has been shown to be associated with 
breast cancer.
Although it is possible to identify the nature of rearrangement in terms 
of translocation and deletion and the chromosomal arm responsible for the 
aberration in leukemia and retinoblastoma, the application of such an analysis 
on solid tumours like breast cancer poses difficult problems (Reviewed by 
Sandberg et al., 1988). The major problem is the scarcity of analysable 
chromosome spreads obtained from breast tumours. In primary cell cultures of 
breast tumours, only a minority of cells is mitotic and only a few of these 
mitoses can be analysed (Rodgers et al., 1984). This makes it necessary to 
rely on tumour cell culture, which may not be successful in all cases or may 
lead to overgrowth by normal diploid cells. Moreover, the dominant cells 
following prolonged culture may not necessarily represent the major clone in 
the tumour in vivo and generally cultured cells have extensive chromosomal 
anomalies. It is, therefore, not surprising that breast cancer has not yet been 
associated with any unique karyotypic change. In studies where it was 
possible to analyse cultured well-characterised primary breast tumour cells, 
karyotypic changes were surprisingly reported to be rare and the cells were 
predominantly diploid (Wolman et al., 1985; Zhang et al., 1989; Smith et al., 
1985). In contrast, effusion metastases were found to be aneuploid (Smith et 
al., 1985). Although the study of Smith et al. (1985) showed that the diploid 
cells retained their malignant phenotype, these cell cultures clearly represented 
only a subpopulation of the original tumours. The requirement for culture of 
tumour cells prior to analysis and the generally experienced inability to 
propagate aneuploid cells severely limits the applicability of the technique and
this is especially so as about 63% of human breast tumours are aneuploid 
(Frierson et al., 1991).
1.4.2. Oncogenes or tumour suppressor genes in breast cancer: 
A molecular biological analysis of tumour DNA
1.4.2.1 Background
Oncogenes are derived by alterations of normal genes, proto­
oncogenes, such that they are activated (Reviewed by Spandidos & Anderson, 
1989). Cellular proto-oncogenes code for proteins which are important in 
controlling growth and differentiation of cells but which become irreversibly 
and permanently expressed in tumour cells. In some cases, overexpression of 
the normal cellular proto-oncogene as a consequence of loss of regulatory 
control is sufficient to cause cell transformation. In others, the gene product 
itself carries a mutation and codes for a slightly altered protein. Most 
characterised oncogenes appear to encode proteins with diverse functions, e.g. 
some encode growth factors, growth factor receptors, signal transducing 
factors, or nuclear proteins controlling the gene expression and the cell cycle 
(Anderson & Spandidos, 1988). Their function at the molecular level is, 
however, unknown.
Tumour suppressor genes ("anti-oncogenes") share the property that 
their expression inhibits the cancer phenotype and whose inactivation or 
deletion is a step in tumour formation.
1.4.2.2. Oncogenes implicated in breast cancer
I.4.2.2.I. Methodology
Many oncogenes have been implicated in breast cancer, but only a 
small group have been regularly reported by a wide variety of labs. In most 
cases, these reports have been of gene amplification or overexpression. There 
are various methods of obtaining evidence. Molecular biological analysis 
involves extraction of DNA from a piece of tumour which may well contain 
normal cells (including infiltrating lymphocytes) and examine the Southern 
blotting profiles of oncogene probes. Pathological, in situ hybridisation, and 
immunocytochemical assays are conducted on a thin tissue slice which may be 
unrepresentative of the tumour but which preserves the original architecture of 
the tumour. Such methods can therefore be used to identify individual cells 
within the tumour and exclude any cells in the sample which are clearly 
normal.
Amplification/ overexpression may be further classified:
(i) That a proto-oncogene is amplified in the tumour as evidenced by Southern 
(DNA probes detecting genomic DNA) blotting of restriction fragments of 
tumour DNA.
(ii) That a proto-oncogene is rearranged or mutated in the tumour DNA.
(iii) That a tumour contains elevated levels of proto-oncogene messenger RNA 
as evidenced by Northern (DNA probes detecting mRNA) blotting, or 
cytochemical blotting (" in situ hybridisation") of mRNA populations.
(iv) That the oncogene product is inappropriately expressed in tumours to give 
excess protein.
Oncogenes which have clearly been associated with breast cancer by some of 
these methods are shown in Table 1.4.1.
Table 1.4.1. Oncogenes implicated in breast cancer.
Oncogene Human
chromosome
location
Possible 
function of 
gene product
Size and 
location
Possible alteration 
in breast cancer
myc 8q24 Gene
expression 
or cell cycle 
control
439 amino acids 
Nuclear
Amplification
(occasional
alteration)
H-ras l lp l4 GTP binding 
protein
189 amino acids 
Inner membrane
Overexpression 
Gene depletion
erb -B-2 
(neu)
17q21 Receptor 1260 amino acids Amplification 
Transmembrane Overexpression
hst and 
int -2
llq l3 Growth
factors
206 and 220 
amino acids 
Secreted
Amplification
I.4.2.2.2. c- m y c
The oncogene myc was first identified as the transforming element of 
avian myelocytomatosis virus-29 (Bister et al., 1977) and subsequently the 
homologous sequences in man were identified. In man, there are three related 
myc proto-oncogenes. N-myc is amplified and expressed in human 
neuroblastomas (Schwab et al., 1983) while L-myc is amplified in lung 
cancers (Nau et al., 1985). c-myc, which is encoded by chromosome 8q24, 
contains three exons of which only exons 2 and 3 contain the protein coding 
sequence. The c-myc protein product is a 439 or 454 amino acid nuclear DNA 
binding phosphoprotein with a short half life. The precise function of this 
protein is unclear, but it is thought to work in collaboration with other nuclear
proteins (Cole, 1991) and could be involved in the regulation of transcription 
of other genes important for cell growth regulation.
The deregulation of the c-myc proto-oncogene has been observed by 
three different mechanisms. Adjacent retroviral insertion causes activation in 
avian bursal lymphomas (Hayward et al., 1981), whereas, in human and 
murine leukemias and lymphomas, it may be activated by chromosome 
translocation (Adams et al., 1983; reviewed by Cole, 1991). In Burkitt’s 
lymphoma, chromosomal translocation juxtapose the myc gene on 
chromosome 8 to one of the immunoglobulin loci, either on chromosome 14, 
or chromosome 2, or chromosome 22. Consequently, the constant feature 
displayed by all Burkitt's lymphomas is that the myc gene on the derivative 
chromosome is expressed constitutively whereas that on the normal 
chromosome 8 is transcriptionally silent. Finally, amplification of the 
oncogene may occur and this has been reported in several types of human 
tumour (reviewed by Alitalo & Schwab, 1986).
c-myc amplification in breast cancer has been reported by several 
workers. In a study of 121 human primary breast carcinomas, Escot et al. 
(1986) observed a 2 to 15-fold amplification in 32% of the samples analysed. 
Tavassoli et al. (1989) reported a similar range of amplification (3-15 fold) in a 
sample of 52 breast tumours and in addition, found a significant correlation 
between amplification of the oncogene and histological grade in these tumours. 
Correlation between c-myc amplification and poor short-term prognosis was 
reported by Varley et al. (1987a), who reported levels of amplification of 2-10 
fold. Mariani-Constantini et al. (1988) studied the transcription of the c-myc 
proto-oncogene by RNA:RNA in situ hybridisation in the same 18 primary 
breast carcinomas which were previously examined by Escot et al. (1986) for 
gene amplification. They found high levels of hybridisation in four of seven
tumours with strong amplification of the gene. But two of nine cases which 
had an apparently normal c-myc locus also showed high levels of 
hybridisation.
There are few reports of alterations in c-myc gene in breast cancer. 
Escot et al. (1986) reported rearranged c-myc in only 5 samples, representing 
a mere 4% of the total cases studied. One patient with a particularly aggressive 
tumour was reported to have a deletion in exon 3 by Varley et al. (1987b).
I.4.2.2.3. H-rtfs
H-ras oncogene was first identified in transforming DNA from the 
human EJ bladder carcinoma and shown to be the cellular homologue of the ras 
H gene of Harvey sarcoma virus (Der et al., 1982; Parada et al., 1982; Santos 
et al., 1982). There is a family of ras oncogenes which also includes K-ras 
(the proto-oncogene corresponding to Kirsten sarcoma virus) and N-ras 
(identified in neuroblastomas). These members of the ras gene family are 
similar in that they encode a protein of Mr 21,000 in four exons (Lemione, 
1990). The H-ras gene is situated at chromosome location 1 lp l4  and encodes 
a protein of 189 amino acids. All known ras proteins are GTP binding 
proteins with substantial homology to the normal cellular G proteins which are 
known to act as regulatory elements in signal transduction systems (Barbacid, 
1987).
Ras activation is commonly by point mutation leading to single amino 
acid differences from the normal cellular proto-oncogene sequence. In human 
tumours studied, amino acid substitutions have been found to occur at specific 
positions, viz., 12, 13 and 61. Substitution of the normal glycine residue at
position 12 with any other amino acid except proline causes oncogenic 
activation and in the EJ bladder carcinoma, where the glycine is altered to 
valine, such a change is sufficient to cause transforming activity (Seeburg et 
al., 1984). A similar situation is observed for the glycine residue at position 
13 although a few substitution like Ser 13, may not be transforming (Bos et 
al., 1985). The result of the point mutation is an increase in the effective 
binding of GTP to the protein, thus maintaining it in a more highly activated 
state (Barbacid, 1987; Bos, 1989).
Apart from human cervical cancer, gene amplification is considered to 
be an infrequent mechanism of ras activation in most other tumours (Yokota et 
al., 1986). Three groups have, however, reported the loss of one of the two c- 
H-ras alleles in about 25% of breast cancers (Theillet et al., 1986; Ali et al., 
1987; Mackay et al., 1988). These studies also found a good correlation with 
histological grade, with more than 74% of tumours with c-H-ras allele loss 
being grade 3 (Theillet et al., 1986; Ali et al., 1987). There have also been 
studies showing that the ras protein is overexpressed (Horan-Hand et al., 
1984; De Bortoli et al., 1985) without gene amplification. The significance of 
these results is not clear, moreover, these reports were based on early 
immunocytochemical studies where it is possible that the specificity of the 
antibodies was not as high as anticipated.
1 .4 .2 .2 .4 . erb B
The erb B gene was originally identified in avian erythroblastosis virus 
as a cellular gene which had the capacity to induce avian leukemias (Fung et 
al., 1983). On subsequent analysis, it became apparent that the virus had led 
to the expression of a truncated form of a cellular proto-oncogene which was
the gene encoding the Epidermal Growth Factor Receptor (EGFR). EGFR is a 
transmembrane glycoprotein of Mr 170,000 and is found on many epithelial 
cell types, including breast epithelial cells. EGFR binds transforming growth 
factor a  (TGF-a) resulting in a growth stimulatory effect similar to that 
observed with EGF (Reviewed by Carpenter, 1987). The receptor has a 
cysteine-rich extracellular domain, which binds EGF and TGF-a, a 
transmembrane domain and an intracellular domain which contains a tyrosine 
specific protein kinase. The kinase is activated upon binding of EGF to the 
receptor, which is normally quiescent, but acts as a tyrosine kinase when the 
extracellular domain makes contact with its ligand and this leads to a signalling 
cascade. The truncation in v-erb B is such that the extracellular (N terminal) 
domain of the protein is lost but the transmembrane and internal domains are 
present. The erb B protein, therefore, lacks the extracellular domain and is not 
sensitive to EGF and the intracellular domain is permanently activated. It has, 
however, been shown that over-expression of the normal EGF receptor gene 
itself is sufficient to confer an EGF-dependent transformed phenotype on 
NIH/3T3 cells (Di Fiore et al., 1987a).
This is a case where the oncogene encodes only part of a normal 
cellular gene, which is known to be expressed in both breast cancer and normal 
breast epithelial cells. It is, therefore, difficult to devise antibody probes to 
indicate abnormal expression. There is no evidence that this gene is amplified 
in breast cancer. There are, however, reports of amplification of the normal 
proto-oncogene (EGF receptor) (Liberman et a l , 1985). Amplification of the 
EGFR gene accompanied by elevated levels of mRNA and protein have been 
reported in only about 3% of the primary carcinomas studied (Ro et al., 1988; 
Lacroix, 1989). Several groups (Harris et al., 1989; Sainsbury et al., 1987, 
Nicholson et al., 1988) have also obtained data showing that the expression of 
EGF receptor is a relevant factor in breast cancer prognosis ( Section 1.1.4.3).
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I.4.2.2.5. c-erb B-2 (neu,  HER-2)
The erb B-2 oncogene was originally identified as a result of 
transfection studies in which NIH-3T3 cells were transformed with DNA from 
chemically induced rat neuroglioblastomas (Shih et al.., 1981). Two groups 
working independendy, subsequently identified erb B-like genes, which they 
called c-erb B-2 and HER-2 respectively (Coussens et al., 1985; Semba et al., 
1985). In the same year, a third group reported amplification of an erb B-like 
gene in a single mammary carcinoma (King et al., 1985). All three of these are 
the same gene, which was shown to be the human homologue of the rat erb B- 
2 gene and the protein has substantial homology (45%) with the EGF 
receptor, particularly in the tyrosine kinase domain (82% homology) 
(Schechter et al., 1984). Cells transfected with the gene, however, showed no 
response to EGF.
Although closely related to it, the erb B-2 gene is distinct from the 
EGFR gene (Schechter et al., 1985). It is encoded on human chromosome 
17q21, whereas the EGFR gene is located at chromosome 7pll-p l3 . The 
protein encoded by the erb B-2 gene is 1260 amino acids long with Mr 
185,000, as compared to Mr 170,000 of the EGFR gene product. Like the 
EGFR, the erb B-2 protein has an extracellular domain, a transmembrane 
domain that includes two cysteine-rich repeat clusters, and an intracellular 
domain with tyrosine kinase activity. The ligand for the erb B-2 protein is as 
yet unknown, although a candidate ligand has recendy been identified (Lupu et 
al., 1990). A factor of Mr 30,000 (gp30) secreted by cells from a human 
breast cancer cell line (MDA-MB-231) was found to interact direcdy with both 
EGFR and the erb B-2 transmembrane protein In two cell lines that 
overexpress erb B-2, tyrosine phosphorylation was induced only by gp30 but
not by EGF. Although the role of gp30 in the growth and development of 
normal and malignant cells remains unresolved, it is of interest that the ligand 
specifically inhibited the growth of cells that overexpressed erb B-2.
erb B-2 can transform cells in two ways. Over-expression of the 
normal cellular proto-oncogene, c-erb B-2 is sufficient to transform NIH-3T3 
cells and, unlike, the erb B (EGFR) gene, the transformation is not dependent 
on exogenous growth factors (Di Fiore et al., 1987b). Gene amplification 
results in elevated levels of expression of both erb B-2 mRNA and protein 
(Venter et al., 1987; van de Vijver et al., 1988). The oncogene itself may carry 
a point mutation; valine at position 664 in the transmembrane region being 
replaced by glutamic acid. This leads to increased tyrosine kinase activity, 
probably through receptor dimerisation (Weiner et al., 1989).
The erb B-2 oncogene has been extensively studied in breast cancer 
since the report of Slamon et al. (1987), suggesting that its amplification 
correlated with poor prognosis. A large number of studies have now been 
published involving both erb B-2 gene and protein amplification in human 
primary breast tumours. The reported gene amplification rates range from 10 
to 46%, with an overall average of 20% (Clark & McGuire, 1991). Variability 
in these reports probably reflects differences in patient groups, the samples 
used for DNA analysis, paraffin-embedded as opposed to frozen or fresh, and 
the fact that the tumour samples from which DNA is prepared often contain 
normal vascular, stromal or inflammatory cells in addition to malignant cells. 
Although studies in general have shown good correlation between gene 
amplification and relative expression of both RNA and protein (Slamon et al., 
1989; Borresen et al., 1990), there are also reports of a significant percentage 
of tumours with a single copy of the gene that overexpress the protein product 
(Iglehart et al., 1990; Hanna et al., 1990; Tandon et al., 1989). As such,
measurement of protein expression may be a better guide to whether erb B-2 is 
involved in breast cancer (Clark & McGuire, 1991).
Although the potential site of mutation lies in the transmembrane 
domain, a feature of this onco-protein expression in breast tumours is that 
generally the normal erb B-2 protein is overexpressed. Immunohistochemical 
analysis or Western immunoblotting, therefore, involves a record of 
differences in the intensity of staining. In most of the studies, 
immunocytochemical analyses with polyclonal antibodies, specific for the erb 
B-2 protein and not cross-reacting with EGFR, have been used and often 
groups of investigators have used the same anti-serum from the same source. 
Several groups of investigators (Lovekin et a l , 1991; Winstanley et al., 1991; 
Gullick et al., 1991; O’Reilly et al., 1991), using one such anti-serum (21N- 
directed to peptides 1243-1255) reported overexpression in about 20% of 
breast tumours, which is similar to that reported for gene amplification. Using 
both polyclonal and monoclonal erb B-2 protein antibodies, membrane or 
cytoplasmic staining has been found to correlate with erb B-2 amplification 
(Venter et al., 1987; van de Vijver et al., 1988; Berger et al., 1988).
Most of the studies have also correlated erb B-2 amplification with 
prognosis in patients. In general, patients with node-positive disease have 
greater frequency of amplification than patients with node-negative disease. 
Although the original study reported by Slamon et al. (1987) and some of the 
more recent studies (Tandon et al., 1989; Borg et al., 1991; May et al., 1990) 
showed a positive association between erb B-2 expression and the number of 
invaded lymph nodes, this has not been generally reproducible. Van de Vijver 
et al. (1988) found large cells of comedo type in situ carcinomas were 
associated with more intense erb B-2 staining. None of the recently published 
papers report any significant relationship with nodal status. But the association
with histological grade has been consistently reported (Garcia et al., 1989; Paik 
et al., 1990; Wright et al., 1989; Parkes et al., 1990) although, investigators 
vary in their reports of the level of significance. A few studies also report that 
erb B-2 expressing tumours are generally larger in size (van de Vijver et al., 
1988; Borg et al., 1991) and negatively associated with steroid receptor status 
(Borg et al., 1991; Tandon et al., 1989) but others have failed to confirm this 
(Zhou et al., 1989; Slamon et al., 1987).
Although widely investigated, reports regarding the correlations 
between erb B-2 amplification and clinical outcome of breast cancer patients 
differ considerably. The patients groups included in these studies are variable 
and in some analyses are restricted to node positive and in others to node 
negative patients. Using a monoclonal antibody to stain erb B-2 protein, Van 
de Vijver et al. (1988) reported no significant correlation between erb B-2 
expression and disease free survival or overall survival after adjustment for 
tumour size. While Thor et al. (1989), studying overexpression of erb B-2 
with a Mab (TA1), which interacts with the extracellular domain of the protein, 
reported clinical significance in certain patient subpopulations only. In general, 
however, a significant prognostic effect of erb B-2 in terms of survival and 
recurrence has been reported in a larger number of studies compared to the 
reports of those studies which show no, or only a limited, prognostic effect 
(Perren, 1991). In a more recent study (Clark & McGuire, 1991), erb B-2 
oncogene amplification in breast cancer has been reported to be of marginal 
utility as a prognostic factor in indicating clinical outcome. Correlation with 
either disease-free or overall survival was marginally significant for node 
positive patients only, but was not retained in multivariate analyses. In 
contrast, in the analysis of Gullick et al. (1991), who combined the results of 
three relatively small studies and thus improved the total number of cases, erb 
B-2 protein overexpression was found to be significantly associated with both
recurrence and survival and which has also been confirmed in a multivariate 
analysis. This association was observed for breast cancer patients with 
involved and uninvolved nodes. As more studies with higher patient number 
are analysed, a clearer relationship will perhaps appear. At present, however, 
it is unclear which antibody preparation, method of tissue fixation, 
immunocytochemical reagents or schemes for immunohistochemical scoring is 
most useful.
1.4.2.2.6. Hst and int -2
Hst and int-2 are members of the Fibroblast Growth Factor (FGF) 
family of genes. The hst gene, also known as kFGF and as int -5 and now 
assigned the name HSTF1, for heparin-binding secretory transforming factor, 
was originally isolated by gene transfer experiments with DNA from human 
stomach cancers and Kaposi's sarcoma (Delli Bovi et al., 1987; Taira et al., 
1987). int- 2 is a proto-oncogene originally identified as being adjacent to one 
of the integration sites of the proviral DNA of mouse Mammary Tumour virus 
(MMTV) (Nusse & Varmus, 1982). Hst and int- 2 in man, are both located 
on chromosome llq l3  (Yoshida et al., 1988). Activation of both genes is by 
transcriptional deregulation giving overexpression of the normal gene product. 
The product of the hst gene is 206 amino acids long and that of the int -2 is 
220 amino acids long. They have sequence homology to basic and acidic FGF 
but, significantly, unlike the FGF genes, they carry a signal sequence which 
allows them to be secreted efficiently. Although the function of the gene 
product is not known, normal expression of int -2 is thought to be restricted to 
defined stages of embryonic development (Wilkinson et al., 1988) and 
transfection with int- 2 constructs in cell lines has led to a small but 
reproducible changes in cell morphology and growth rate (Van de Vijver &
Nusse, 1991). A receptor specific for the int- 2 protein has not yet been 
identified.
Hst and int -2 have been reported to be co-amplified in stomach cancer 
(Yoshida et al., 1988). In breast cancer, the degree of gene amplification is 
low, and is not paralleled by expression of the gene (Fantl et al., 1989). 
Varley et al. (1988) reported an amplification of int- 2 sequences ranging from 
2- to 20- fold in 23% of the studied 40 primary breast carcinomas, while Zhou 
et al. (1988) reported amplification in only 9% (9 out of 46) of the primary 
tumours. Other workers also report similar modest amplifications of int -2 
DNA in human breast cancers (Lidereau et al., 1988). In addition to reporting 
co-amplification of int -2 and hst in about 20% of primary tumours, Fantl et 
al. (1989) observed no significant correlation with any histopathological 
factors. Moreover, they also concluded that amplification of int- 2 and hst 
genes is not accompanied by marked overexpression. Co-amplification was 
also observed by Ali et al. (1989) and Theillet et al. (1989a; 1989b). Theillet et 
al. (1989a) also reported a correlation between RNA expression and gene 
amplification in the case of hst but not of int- 2, while Ali et al. (1989) found 
a significant association between int- 2 amplification and subsequent 
development of metastasis or local recurrence. In addition to amplification, 
Varley et al. (1988) have reported that the int -2 gene is altered in several 
amplified tumours with loss of an EcoRl site. In most of the tumours with 
int - 2 amplification, adjacent genes including the oncogenes hst and bcl-1 are 
co-amplified (Lidereau, et al., 1988; Yoshida et al., 1988). As int -2 and hst 
genes are not expressed in normal breast tissue, it is perhaps not surprising that 
they are not activated by amplification in human breast tumours.
1.4.2.2.7, Other oncogenes implicated in breast cancer
There are a small number of reports of other oncogenes being amplified 
or expressed in breast cancer. In some cases, the oncogenes are co-amplified 
with the more commonly reported oncogenes. One such gene, c-erb A, the 
gene for the thyroid hormone receptor, is on chromosome 17q21 and therefore 
often amplified with erb B-2 (Tavassoli et al., 1989).
I.4.2.3. Tumour suppressor genes ("Anti-oncogenes")
I.4.2.3.I. Introduction
In many human tumours, including breast cancer, there is now 
increasing evidence that a loss of specific chromosomal regions play an 
important role in tumour development. Such deletions usually involve only 
one of the two parental chromosomes present in normal cells. These allelic 
losses have been interpreted as evidence that the regions affected contain anti­
oncogenes or tumour-suppressor genes. The gene products of the tumour- 
suppressor genes are believed to normally regulate growth and differentiation 
in a negative fashion and thus indirectly suppress neoplastic development 
(Knudson, 1985). In tumours, therefore, loss of a tumour-suppressor gene 
leads to a loss of the natural control of cellular growth. The most extensively 
characterised is the Rb (retinoblastoma) gene, encoded by human chromosome 
13ql4. The Rb product is a phosphorylated protein which binds to DNA, but 
its function is not known (DeCaprio et al., 1989). In recent years, there has 
been a general awareness of the role of p53 as a tumour-suppressor gene in 
solid tumours, including breast cancer.
I.4.2.3.2. Methodology
It is now well established that when malignant cells are fused with 
diploid fibroblast of the same species, random chromosome loss with the 
acquisition of malignancy may occur in hybrid cells and as such it has been 
possible to correlate the loss of particular chromosomes with malignancy 
(Stanbridge, 1986). Karyotypic analysis to detect gene loss would then be 
required to detect the involvement of a tumour-suppressor gene. Although 
chromosomal losses in tumours were first detected cytogenetically, more 
recently, probes that detect restriction fragment length polymorphisms (RFLP) 
have been used to determine whether one of the two parental alleles is lost 
specifically in tumour DNA. In RFLP analysis, tumour and peripheral blood 
DNA are compared to show allele loss in the tumour, which in turn may 
represent the involvement of a tumour suppressor gene. All such studies relate 
to Southern blotting of DNA samples extracted from the tumour and, as with 
the proto-oncogene studies these cannot take account of normal cells such as 
fibroblasts or lymphocytes within the sample. Thus, allele loss is generally 
defined to occur when the density of various bands is reduced, rather than 
abolished, in comparison to the same bands from peripheral blood lymphocyte 
DNA from the same patient. In the case of anti-oncogenes like p53 the protein 
product is also identified by immunocytochemistry.
I.4.2.3.3. The p53 tumour suppressor gene
The p53 gene is located on human chromosome 17pl3 and encodes a 
protein of 393 amino acids. Like the Rb gene, it is a nuclear protein and was 
first discovered by immunoprecipitation with antisera from animals bearing
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SV40 induced tumours (Linzer & Levine, 1979; Lane & Crawford, 1979). 
Initially p53 was regarded as a nuclear oncogene and expression of p53 was 
shown to immortalise primary cells (Jenkins et al., 1984) while mutation of 
p53 would enhance its transforming activity (Jenkins et al., 1985). Recent 
findings however, indicate that p53 may actually be a tumour suppressor gene. 
p53 sequences have been found to be lost or inactivated in a number of 
malignancies and that the presence of wild-type p53 could suppress 
transformation of cells by other oncogenes (Finlay et al., 1989). The precise 
role of p53 is not clear but it has been suggested to interfere with the cell cycle 
(Reviewed by Levine et al., 1991). Introduction of the wild-type gene or 
cDNA into a transformed cell in culture stops cell growth (Baker et al., 1990) 
at the G1 phase of the cell cycle (Section 1.4.3.1), possibly by regulating 
transcription of genes that effect the passage from late G1 to S phase.
The p53 gene has been examined in a wide variety of primary tumours. 
Mutations in and/or reduction of heterozygosity of the p53 gene locus appear to 
be very frequent in many human tumours, including breast cancer. p53 gene 
has been most extensively studied in colon carcinomas, where more than 75% 
of carcinomas show a loss of a large portion of chromosome 17p (Vogelstein 
et al., 1988; Delattre et al., 1989). Similar losses have also been reported for 
breast tumours (Mackay et al., 1988; Devilee et al., 1989). In approximately 
65% of informative cases, a region (pl3.3) on the short arm of chromosome 
17, where p53 is located, has been reported to be lost in breast cancers 
(MacKay et al., 1988; Devilee et al., 1989). It has been suggested in a model 
for colorectal tumorigenesis (Fearon & Vogelstein, 1990), that the tumour may 
develop through loss of one allele and subsequently the other through point 
mutation, which gives rise to overexpression of an altered protein. The 
mutated protein is unable to exert the control function of the normal wild type 
protein. Like those in the H-ras oncogene, mutations in p53 appear at "hot
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spots" on the encoding gene, with residues such as 175, 248 and 273 being 
particularly significant (Levine et al., 1991). This complex data has only been 
rationalised by the proposition that the mutation of p53 on one allele, confers 
selective growth advantage on the cell even though the other allele expresses 
the normal wild type gene (Fearon & Vogelstein, 1990).
Study on p53 gene generally involves the examination of human 
tumours for loss of sequences and immunohistochemical analysis for gene 
expression. In assessing gene expression, advantage is taken of the fact that 
the wild-type p53 gene product has a short half life and low intracellular 
concentration, whereas most mutant forms appear to have a much longer half 
life and a high intracellular concentration. The identification of p53 in primary 
tumours by antibodies is possible if considerable quantity is present and, 
therefore, taken to indicate that the gene has been altered. In the case of breast 
cancer, loss of p53 allele, or overexpression of the mutated protein have been 
reported. Both Bartek et al. (1990) and Cattoretti et al. (1988), using 
immunocytochemical methods found the protein to be expressed in about 50% 
of human breast tumours. In the study of Cattoretti et al. (1988), the choice of 
antibody used was important as one antibody detected mutant proteins in more 
tumours than the other. In the more recent study of Varley et al. (1991), both 
loss of heterozygosity and p53 protein expression were examined. 86% of 
breast tumours exhibited either p53 expression or loss of heterozygosity with 
only a smaller percentage of their samples being positive for both. They also 
found three patients positive for p53 expression but negative for loss of 
heterozygosity where mutations in the p53 gene could be mapped by PCR.
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I.4.2.3.4. O ther possible tum our suppressor genes in breast 
cancer
There is now evidence that additional tumour-suppressor genes may be 
involved in breast cancer. Loss of heterozygosity has been reported for several 
loci in breast cancer and these are tabulated below (Table 1.4.2.). In some of 
these cases the actual gene involved has not been identified. The region on 
chromosome 11 is involved in about 20% of the cases studied. The deletions 
often involve the c-Ha-ras gene and always involve the region between the p- 
globin and parathyroid hormone loci on the short arm of chromosome 11 (Ali 
etal., 1987).
Table 1.4.2. Loss of heterozygosity (LOH) and oncogenes and tumour 
suppressor genes in breast cancer.
LOH
(chromosomal
location)
Possible oncogenes or 
tumour suppressor genes 
in that area
References
iq Unspecified Chen et al., 1989
lp Unspecified Genuardi et al., 1989
3p21 c-erb A Ali et al., 1989
lip Hras Ali etal., 1987; Mackay 
et al., 1988.
13q Rb Lundberg et al., 1987; 
Lee et al., 1988; Sato et 
al., 1990.
16q Unspecified Sato et al., 1990.
17pl3 p53 Mackay et al., 1988; 
Cropp et al., 1990; 
Varley etal., 1991.
18q DCC (Deleted in Colon 
Cancer)
Cropp et al., 1990; 
Devilee et al., 1991
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In the recent study of Sato et al. (1990), who used a panel of 39 RFLP 
markers to determine allele loss in 79 primary breast tumours, at least four 
tumour suppressor genes were identified on chromosomes 13q, 16q, and 17p 
(a suppressor gene in addition to p53 was implicated). Moreover, a group of 
tumours with loss of both 13q and 17p showed more malignant 
histopathological features, while another group with loss of 17p presented with 
frequent lymph node metastasis. This suggest that multiple allele losses are 
involved in breast cancer and it is possible that the cumulative effect of these 
losses contribute to a more malignant phenotype.
I.4.2.4. Genes controlling metastatic behaviour
Regulation of the metastatic process, which develops late in tumour 
progression, has been presumed to result from the activation or repression of a 
number of specific genes (Nicolson, 1988). It is therefore, of obvious 
importance to attempt to identify specific genes which are related to the 
metastatic process. Ideally, identification of alterations at various stages of 
tumour formation is the ultimate aim of such a study. This approach was 
applied successfully on colorectal tumours such that it was possible to 
construct a model for tumour development in which a number of genetic 
alterations were identified (Fearon & Vogelstein, 1990). It was however, 
found that the progressive accumulation of these changes, rather than the order 
suggested in the model, was most important in the development of colorectal 
tumour. It has been possible to construct a model for tumorigenesis in the case 
of colorectal tumour, because unlike the situation in most other common 
human tumours, colorectal tumours of various stages of development can be 
obtained for study. Genetic elements involved with metastatic spread can also
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be identified by comparing primary and secondary growths. Such a study 
involving breast cancer was carried out by Iglehart et al. (1990). To determine 
whether alterations in erb B-2 is an early event, the investigators examined 
gene amplification and expression in both the in situ and invasive tumour 
cells, in different stages of the tumour and compared primary and lymph node 
metastases. erb B-2 alterations were found to be present in all clinical stages 
and in both the in situ as well as the infiltrating component. Moreover, the 
gene copy number in lymph node metastasis was identical or within 2-fold of 
the copy number in the primary tumour. Based on these findings the 
investigators concluded that erb B-2 alterations are selected for early and may 
be important in the initiation of certain mammary cancers. This lends support 
to the report of Borg et al. (1991) that erb B-2 activity is related to increased 
tumour growth but not directly to metastasising ability. Although other 
oncogenes like ras have been shown in transfection studies to transform a cell 
line into one with metastatic capability, such oncogenes are infrequently 
implicated in breast cancer. One other approach in detecting novel genes which 
may modulate invasion and metastasis is to utilise differential screening of 
cDNA libraries. The objective here is to detect cDNA clones corresponding to 
mRNAs which differ in abundance between related cell populations, for 
example between cell lines of metastatic and non-metastatic behaviour. 
Applying such an approach on related low and high metastatic potential murine 
K-1735 melanoma cell lines, Steeg et al. (1988) identified a novel gene, nm23, 
whose mRNA levels were 10-fold higher in low metastatic potential lines than 
in high metastatic potential lines. Subsequently, lack of nm23 expression in 
human breast cancers was found to be associated with lymph node metastases 
(Bevilacqua et al., 1989b). An nm23 protein of Mr 17,000 has been identified 
in both murine and human cells. The biochemical functions of the protein are 
currently unknown but its homology (75%) to the Drosophila awd gene 
(abnormal wing discs) suggests that it may participate in normal development.
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Steeg & Liotta (1990), using antibodies raised against peptides corresponding 
to the N-terminus of the protein, showed that the situation at the protein level 
mirrors that occuring at the mRNA level. Recently, Leone et al. (1991) 
transfected a murine nm23 expression construct into highly metastatic murine 
melanoma cells and demonstrated the suppressive effect of nm23 on several 
aspects of the cancer process, including tumour metastasis. This identifies 
nm23 as a metastasis suppressor gene, the first of its kind to be detected in 
breast cancer. With time it is likely that more of such genes will be identified.
I.4.2.5. The extent to which known oncogene products can 
elicit an immune response.
Although the genetic alterations associated with breast cancer are still a 
subject of further research, a few specific genetic elements and their products 
have been implicated with the disease (eg. p53, erb B-2). An interesting 
aspect of this feature would be to relate the existing known genetic alterations 
with both the malignant nature of a tumour and the immune response in breast 
cancer patients. With respect to immunity against cancer, a mutated onco­
protein is likely to induce a response. Identification of such tumour-associated 
antigens against which there is a likelihood of a response is important in the 
design of therapeutic strategies.
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Figure 1.4.1. Oncogenes and tumour suppressor genes implicated in 
breast cancer.
I.4.2.5.I. Oncogene induced tumours and the immune response
Advances in the field of immunology has provided a better 
understanding of the nature of the immune response in human and molecular 
genetics has made it possible to identify specific genetic alterations in a tumour. 
It is now possible to rationalise the possible basis for immune response to 
tumours. The great majority of human tumours are of unknown origin. Any 
immune response may relate to the extent to which oncogene products as have 
been characterised are "foreign". Thus during tumour progression any change 
in a cellular protein, whether on the surface or inside a cell, makes it a potential 
target for immune recognition. Even if the coding sequence has been altered 
by even one amino acid (as occurs in H-ras and p53), there is ample classical 
evidence that the immune system has the capacity to detect it. In this context, it 
may be relevant to note that where analysis has been more detailed (Varley et 
al., 1991), point mutations in coding regions are detected. Thus all oncogenes 
are potential targets for the immune response.
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1.4.2.5.2. B or T cell responses
A B cell (antibody) response is only of value if the relevant antigen is 
expressed outside the cell or on the surface. Thus h s t , int- 2, neu or DCC 
could potentially elicit such a response is they were sufficiendy different from 
the normal gene product. The vast majority of oncogene products, including 
those known to carry mutations such as p53, are expressed within the cell 
(Figure 1.4.1.) and consequently can only elicit a T lymphocyte immune 
response. T lymphocytes can detect peptides derived from foreign proteins 
inside the cell if they are presented on the appropriate Class I (Townsend, 
1989) or Class IIMHC antigens (Grey et al., 1989; Unanue et al., 1989). No 
study to date has related the immune response to gene amplification, gene loss, 
or gene activation.
1.4.2.5.3. Variation between patients
Immune responses initiated by oncogenes or chromosome loss will 
also be affected by the MHC antigens borne by the tumour bearing patient. 
The human population is outbred and no two individuals have the same 
capacity to present antigenic peptides to T cells. Thus, the ability to mount a 
response against a particular antigen will also be determined by the ability of a 
patient’s MHC molecules to present the antigen.
In consequence the nature of human tumours such as breast cancer 
together with the interpersonal variation of the immune response suggests that 
there will be wide patient variability. Homogeneity in tumour phenotype or 
immune response cannot necessarily be anticipated, in fact tumours are known 
to be heterogenous in their expression of antigens. An additional feature of a
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tumour that is relevant to the generation of a response is that many tumours 
lose the expression of some or all of their MHC class I determinants (Section 
1.1.6.5.1). Using monoclonal antibodies to detect class I antigens, several 
studies have shown the loss of class I expression in many human tumours 
which include colorectal cancer (Lopez-Nevot et al., 1989; Momburg et al., 
1986; Momburg & Koch, 1989; Smith et al., 1989), skin melanoma (Brocker 
et al., 1984) and breast cancer (Perez et al., 1986; Goepel et al., 1991; 
Whitford et al., 1992a). Additionally, Perez et al. (1986) and Whitford et al. 
(1992a) reported that both MHC class I and class II are variably expressed. 
Tumour cells lacking MHC class I determinants are protected from cytotoxic T- 
cell attack with respect to any determinant (Bodmer, 1987). An interesting 
study design would be to relate all these parameters with specific genetic 
changes in a tumour and to determine how such changes affect the immune 
response in a breast cancer patient.
109
1.4.3. Analysis of cell cycle and DNA content (Ploidy) in 
breast cancer.
As described in Section 1.4.1, karyotype analyses in breast cancer are 
limited by technical factors. Many groups have, therefore, focussed on other 
means of analysing the abnormalities in the DNA and the growth rate of a 
tumour. Various methods have now been developed to investigate the two 
distinct but related parameters- cell cycle analysis, in which the 
proliferation rate is determined and ploidy analysis, which determines the 
DNA content of a tumour. Most of these techniques determine either of the 
two parameters, while DNA flow cytometry allows the determination of both 
parameters.
1.4.3.1. Analysis of the cell cycle
1.4.3.1.1. Phases of the cell cycle
In any growing cell population, there is a sequence of events which 
ultimately leads to cell duplication. Two identifiable events that can be used to 
characterise the cell cycle are the mitotic cell division and DNA synthesis. As 
shown in Fig 1.4.2., the period of mitosis is represented by M and the period 
of DNA synthesis is S. Go cells are in the resting phase, while the phases G1 
and G2 are gaps between the phases M and S, and S and M, respectively. G1 
and G2 have been termed gaps due to the absence, until recently, of knowledge 
of any markers in these areas (Adams, 1990).
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Figure 1.4.2. The phases in the cell cycle.
I.4.3.I.2. Control of the cell cycle
The period of time cells spend in various phases of the cell cycle is 
variable and depends on the type of tissue and culture conditions for cells in 
culture. For some cell populations, such as lymphocytes in the human 
peripheral blood or cells in sub-optimal culture conditions, the majority of cells 
are generally in the quiescent phase (Go) and are said to be 'out of cycle1. 
These cells require a stimulus (antigenic or mitogenic stimulation in the case of 
lymphocytes) to initiate their re-entry into the cycle. Generally a single 
restricting point in G1 regulates their entry (Pardee, 1974) and the cells then 
moves through the different phases of the cycle (Fig 1.4.1), and following 
mitosis enter a second round of the cycle. Data from various sources 
including those for breast cancer cells (McGuire & Dressier, 1985) suggest that 
the duration of G1 phase can be highly variable. Entry of cells into the G1 
phase initiates the cell cycle, and is followed by DNA synthesis during S 
phase. The cells then proceed towards M phase. In the case of at least some 
tumours, unlike the quiescent lymphocytes, a commonly observed feature is
111
Cyclin
destruction
cdc2
active
CYCLIN
Tyrosine phosphatase
Cyclin
cdc 2
i nactive
cdc2
r
CYCLIN
L _ J
inactive
Tyrosine kinase
©
cdc 2
CYCLIN
inactive
Figure 1.4.3. Cycle of the cdc2 subunit (P= protein phosphorylation).
the high proportion of cells in the proliferating phases of S and G2/M. 
Moreover, the cell cycle profile, i.e. the distribution of cells in the different 
phases, of breast cancer cells is not only different from the normal counterpart 
but also dramatically different from one patient to another.
Although, a loss of control of the cell cycle in cancer is evident, very 
little is known concerning the regulation of the cell cycle. The ordered 
sequence of events in the cell cycle suggest that the two crucialpointsof control 
lies at the transition between G2 and M phases and at Gl, a point at which cells 
are commited to division. Recently, a universal mechanism common to all 
eukaryotic cells controlling the onset of M-phase (reviewed by Nurse, 1990) 
has been proposed. Central to this mechanism is the protein kinase p34 (Mr
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34,000), which was first identified as the product of the cdc 2/ cdc 28 gene in 
yeast mutants and is believed to function both at the onset of S-phase 
(Mendenhall et al., 1987) and at mitosis (Nurse, 1990). The p34cdc2 kinase 
phosphorylates key proteins which leads to the events in M-phase. A second 
class of protein, the cyclins ( Moreno et al., 1989), forms a complex with and 
activates the p34cdc2 kinase, whose high activity maintains the cell in the M- 
phase. The binding of the cyclin initiates covalent modification of p34cdc2 
(Fig. 1.4.3.). The phosphorylation of p34cdc2 on tyrosine 15 keeps its kinase 
activity turned off, and activation of p34cdc2 is associated with 
dephosphorylation at tyrosine 15 (Hunt, T. 1991). The cyclin joining is 
required for activation both to get the cdc2 into the correct phosphorylation 
state and to provide a companion subunit for the kinase. The process by which 
p34cdc2 kinase is inactivated is not understood but a possible way of exit from 
mitosis could occur via cyclin degradation, which would disrupt the p34 cyclin 
complex and thereby inactivate the kinase. The timing of mitosis, as in the 
case of fission yeast, is determined by a regulatory gene network which 
includes two further putative protein kinases (nim 1, wee 1), and the cdc 25 
gene, which encodes a phosphoprotein (Mr 80,000) (Moreno et al., 1990) 
believed to be involved with the cell cycle timing of p34 kinase activation and 
thus of the mitotic onset.
The initiation of S phase also involves the p34 kinase and the G1 
cyclins, which appear in G1 and are degraded as cells enter S phase. The 
budding yeast G1 cyclins, first discovered by their essential role at the decision 
point at the G1 to S transition known as Start (Reviewed by Nasmyth, 1990), 
represent a class of regulatory proteins that are made and involved in the G1 
phase of the cell cycle. It appears that there is a positive feedback loop in 
which the G1 cyclins activate transcription of their genes, CLN1 and CLN2 
subset, by activating, in concert with cdc 28, the genes SW14 and SW16,
which are required for Start (North, 1991). Recently, a candidate for a human 
G1 cyclin has been described. Motokura and co-workers (1991) have 
succeeded in isolating a cDNA of a putative oncogene, PRAD1, which appears 
to encode a polypeptide that is a member of the cell-cycle regulating cyclin 
family. Interestingly, PRAD1 has been found to be overexpressed in a subset 
of parathyroid tumours, in which a chromosomal rearrangement fused the 
PRAD1 gene to the parathyroid hormone gene. PRAD1 has also been 
implicated in non-parathyroid tumours, which includes breast and squamous 
cell carcinomas (Lammie, et al., 1991).
Deregulated expression of other cyclins may also be involved in 
abnormal cell proliferation. Moreover, potential substrates of p34/cdc2 kinase 
include p60/c-src, the large T antigen of simian virus 40, and the tumour 
suppressor gene product p53 (Hunter, 1991). It is likely that mutations in cell 
cycle regulators cooperate with other mutations that activate proto-oncogenes 
or inactivate growth suppressor genes (Hunter & Pines, 1991) and together 
contribute toward the multistep process of tumourigenesis.
I.4.3.I.3. Cell cycle analysis of breast tumours
Although the regulatory mechanism of the cell cycle is gradually being 
unravelled, cell cycle analyses of breast tumours have been extensively 
studied. Several methods have been devised to quantify the distribution of 
cells in the various phases of the cell cycle (reviewed by Visscher et al., 1990a; 
Quinn & Wright, 1990) and such measurements have been related to the 
biological behaviour of the cell. Early investigators, using crude estimates of 
gross doubling times based on radiographic observations or chest wall 
recurrences (Pearlman, 1976), observed large variations in growth rates among
individual tumours. More recent methods have greatly improved the 
assessment. Among the techniques that allow the assessment of only the 
kinetic measurements are the Thymidine Labelling Index, Bromodeoxyuridine 
and Ki-67.
i) Thymidine Labelling Index (TLI)
TLI, which is a measure of the percentage of tumour cells in the DNA 
synthetic S phase, involves incubation of unfixed viable, thin slices of tumour 
tissue with radioactive-labeled thymidine. The thymidine is incorporated into 
cells synthesising DNA and these cells are quantitated by counting radiolabeled 
nuclei in autoradiographs. This technique was first applied to breast cancer by 
Johnson & Bond (1961) who demonstrated increased TLI in fibroadenoma. 
Higher TLI values have been shown to be associated with larger and locally 
advanced primary tumours (Meyer et al., 1986). However, no significant 
correlation between TLI and regional status was observed (Visscher et al., 
1990a). Two studies also compared primary tumours and corresponding 
metastasis (Meyer et al., 1986; Tubiana et al., 1981), but observed no 
significant differences in their TLI values. In these same studies and that of 
Silvestrini et al. (1985), histological grade was significantly correlated with 
TLI values, which were found to be higher in premenopausal and younger 
patients. With respect to outcome of the disease following mastectomy, both 
the study of Meyer et al (1986) and of Tubiana et al (1981) demonstrated a 
significant association between high TLI and early relapse. Moreover, the 
prognostic significance of TLI has been shown to be independent of stage 
(Meyer et al., 1986). From the practical point of view, the use of TLI has 
several limitations as an indicator of tumour proliferative activity. It is a 
laborious and a technically difficult method. It requires careful preparation of 
the slices which have to be thin enough to allow maximum thymidine
permeation. This is then followed by counting of hundreds of nuclei and the 
fact that the uptake of thymidine is affected by incubation conditions makes 
comparability between observers difficult. Moreover, slices prepared from 
tumours may not be true representative of the larger mass as most tumours are 
known to be heterogenous.
ii) Bromodeoxyuridine
Being a pyrimidine analogue, bromodeoxyuridine (BrdU) is readily 
incorporated into cells synthesising DNA and enhances cell sensitivity to X- 
rays. It can thus, be used to measure S phase labelling index and has also been 
used widely in radiotherapy regimes for human malignant tumours. More 
recently, use has been made of monoclonal antibodies to BrdU (Gratzner, 
1982; Morstyn et al., 1983) and the proliferation of cancer cells assessed by 
immunocytochemical techniques or by flow cytometry. Due to instant 
immunofluorometric detection and being non-isotopic, the method has 
advantages over TLI. Moreover, by infusing BudR prior to sampling, the 
method can also be used for in vivo kinetic studies (Wilson et al., 1988). 
Extensive assessment of cell proliferation as judged by BrdU has not been 
performed. Although studies on gastric carcinoma shows association between 
labelling index and stage of the tumours (Kikuyama et al. , 1988), there is very 
little data concerning breast cancer. Recently, Remvikos et al. (1991) used 
flow cytometry to assess simultaneously both S-phase fraction and BrdU 
incorporation on fine needle aspirates samples from breast cancer patients. The 
study found good correlation between BrdU labeling index and SPFs 
measured on samples taken from the same patient.
11 6
iii) Ki-67
Among the Mabs to be used to recognise antigens associated with cell 
proliferation, Ki-67 has been increasingly used in histopathology. The mouse 
antibody Ki-67 produced by Gerdes et al . (1983), reacts with a nuclear 
antigen expressed on all human proliferating cells. This antigen, recently 
shown to be a component of the nuclear matrix (Verheijen et al., 1988; 
Verheijen et al., 1989) is expressed preferentially during late G l, S, G2 and M 
phases of the cell cycle. Cells in the Go phase consistently lack the antigen 
(Gerdes et al., 1983; Gerdes et al., 1984) and thus, the Ki-67 labelling index is 
an indicator of the growth fraction in human neoplasms. The growth fraction 
is determined using immunohistological methods on frozen tissue sections or 
by flow cytometry on cell suspension. However, the use of the antibody in 
breast cancer has not been very encouraging. In the study of van Dierendonck 
et al. (1989) on the breast cancer cell line MCF-7, it was shown that compared 
to growth fraction estimation by BUdR, Ki-67 fractions were invariably 
higher. In addition, the study pointed out that Ki-67 fractions may not always 
be a reliable indicator of growth fractions, as under sub-optimal conditions 
non-proliferating cells may retain the antigen for a considerable period of time. 
Lelle er al. (1987) found increased Ki-67 positive cells in node-positive breast 
and Isola et al. (1990) revealed Ki-67 staining to be significantly higher in 
DNA aneuploid tumours. However, in the study of Lelle et al. (1987), the 
positivity was found to decrease with increasing numbers of positive nodes. 
Other workers (Barnard et al., 1987; Bouzebar et al., 1989) only observed a 
poor correlation between Ki-67 staining and other pathological parameters. 
Walker & Camplejohn (1988) compared Ki-67 reactivity of breast carcinomas 
with histological grade and found that although the presence of nuclear staining
was associated with a poorer grade, the extent of staining did not correlate with 
grade.
I.4.3.2. Measurement of DNA content
The terminology of 'ploidy' or the DNA content was defined in 
cytogenetics, with normal human somatic cells with 46 chromosomes referred 
to as diploid (Tijo & Levan, 1956), while a cell with fewer or more than 46 
chromosomes is described as aneuploid, and a cell with a balanced gain or loss 
of chromosomes or with structural rearrangement but with 46 chromosomes, is 
pseudodiploid (Friedlander et al., 1984). The term aneuploidy is reserved for 
chromosomal studies, and DNA aneuploidy is used for flow cytometric data.
Although the Feulgen-Schiff technique has been used in earlier studies, 
currently the preferred technique for the quantitative measurements of cellular 
DNA involves the use of fluorescent dyes which bind directly to DNA. The 
procedure relies on the stoichiometric binding of the dyes to DNA such that the 
degree of stain is directly proportional to the amount of DNA present. The 
DNA content of individual cells is then assessed either by static cytometry or, 
by flow cytometry.
14.3.2.1. Measurement of DNA content by static cytometry
In static cytometry, stained cells are visualised microscopically and the 
amount of DNA bound dye is determined directly by absorption or fluorimetric 
methods. Histological sections of formalin fixed tissue or fixed smear of 
sections from tumours can be analysed using this procedure. Lymphocytes 
and normal epithelial cells present in the tissue section which complicate flow
cytometric analysis, can be easily visualised and are used as a normal diploid 
control. Studies that have utilised this technique in assessing the DNA content 
in breast cancer patients showed a strong relationship between DNA content 
and recurrence-free survival (Fallenius et al., 1988; Auer et al., 1980a) and to 
tumour size and ER level (von Rosen et al., 1989). However, data acquisition 
by static cytometry is relatively slow and measurement of DNA content is 
usually restricted to several hundred cells in any one sample. Moreover, the 
resolution of the technique is poor compared to those obtained from flow 
cytometric analysis and the technique has lost favour to the latter method.
I.4.3.3. Flow cytometric DNA analysis
In contrast to the above described techniques, flow cytometric (FCM) 
DNA analysis provides dual information. The technique gives information on 
both the nuclear content (DNA ploidy), which is frequently abnormal in breast 
tumours, and the S phase fraction (SPF), which is the measure of the 
proliferative rate of a growing cell population. A statistically meaningful 
number of cells, usually 10,000 and greater, can be measured in a short time 
and with the technique being automated, the ease of measurement being one 
strong point of the method. Either nuclei or intact cells from tumour tissues are 
stained with DNA specific dyes (such as propidium iodide) and the end result 
of a computer analysis produces a DNA histogram, from which both ploidy 
and the S phase content and the proliferative activity (S+G2M) can be 
determined. Ploidy is expressed in terms of DNA index, which allows 
comparability between observers, while the S phase can be determined 
manually or with the use of a computerised analysis programme. Although in 
FCM DNA analysis one can employ either nuclear suspensions or intact cell 
suspensions obtained from various sources (fresh tissue, unfixed frozen
tissue, ethanol- or formalin-fixed cells, and formalin-fixed paraffin-embedded 
tissue) there are clearly differences in the quality and the nature of information 
acquired. Retrospective analysis with clinical follow-up, and selection of a 
large number of cases predefined by clinical factors can be done on archival 
tissue kept frozen or embedded in paraffin. Although a few studies that have 
compared ploidy results from formalin-fixed, paraffin-embedded cells with that 
from fresh cells show good agreement (Frierson, 1988; Kallioniemi, 1988a; 
Owainati et al., 1987), the quality of DNA histograms obtained from 
deparaffinised tissue is relatively poor. Samples from deparaffinised tissue 
contain a large amount of debris, which compromises the sensitivity of 
detection of abnormal DNA content and in a greater number of specimens, 
calculation of SPF is not possible (Visscher et al., 1990a). Frozen tissue can 
be used for both prospective and retrospective studies, while with fresh tissues 
only a prospective study is possible. It is technically easier to extract nuclei 
from frozen or fresh tissue specimens and the DNA histograms produced are 
of a much higher quality.
A number of studies have been done to assess the potential of DNA 
FCM as a prognostic indicator. These studies have now shown that DNA 
ploidy and SPF data are of prognostic value in patients with breast cancer. 
Both these FCM parameters have been correlated with histopathological factors 
and in retrospective studies, the clinical outcome of the patients with respect to 
the DNA content and the SPF of their tumours have been assessed.
1.4.3.3.1. Correlation of DNA content (ploidy) with
histopathological factors
A universal finding finding in all the studies that assessed the ploidy of 
primary tumours is the presence of a substantial proportion of aneuploid cells 
in a high percentage of breast cancer patients. Taking into account the 56 
publications, reviewed by Frierson (1991), 63% of breast neoplasms were 
DNA aneuploid, the precise figure ranging between 53 and 75%. The 
biological role and the mechanism underlying DNA abnormality at this level is 
not known. Correlation with histopathological factors, however, showed that 
DNA ploidy has prognostic relevance.
There are conflicting reports concerning the association between DNA 
aneuploidy and lymph node involvement in breast cancer. DNA aneuploidy 
has been found to be significantly related to lymph node involvement 
(Eskelinen, et al., 1989; Toikkanen et al., 1989; Hedley et al., 1984). 
However, others have found such association not to be statistically significant 
(Visscher et al., 1990a; Moran et a l, 1984; Horsfall et al., 1986; Thorud et al., 
1986; McDivitt et al., 1986; O'Reilly et al., 1990). Studies employing a larger 
series of patients (Hedley et al., 1987; Ewers et al., 1984; Dressier et al., 
1988) observed only a weak correlation between DNA content and staging 
parameters. In studies that found a statistical correlation between size and 
ploidy, larger tumours were noted more often to be aneuploid (Dowle, et al., 
1987; Ewers et al., 1984; Thorud et al., 1986; Visscher et al., 1990a).
DNA content correlates significantly with histopathological tumour 
grade and in this the agreement between workers is highly consistent 
(Toikkanen et al., 1989; O'Reilly et al., 1990; Thorud et al., 1986; Moran et
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al., 1984; Kute et al., 1985; Kallioniemi et al., 1987; Feichter et al., 1988; 
Dowle et al., 1987; Hedley et al., 1987; McDivitt et al., 1986; Visscher et al., 
1990a). An association between tumour ploidy and steroid receptor status has 
also been shown (Moran et al., 1984; Dressier et al., 1988; Olszewski et al., 
1981; Horsfall et al., 1986), with aneuploid tumours tending to be receptor 
negative. It is perhaps relevant to point out that oestrogen receptor-negative 
tumours are more poorly differentiated compared to oestrogen-positive 
tumours (McCarty et al., 1980). The relationship of ploidy to hormone status 
is perhaps an effect of the strong association between ploidy and tumour grade.
I.4.3.3.2. FCM analysis of SPF
In a FCM DNA histogram, S phase cells (SPF) represent the area 
between Go/Gl and G2/M peaks (Fig 1.4.4). Although some of the cells may 
be arrested in SPF (So), SPF in non-synchronised tumour populations 
accurately reflect cellular proliferation (Visscher et al., 1990a). The relative 
area of the DNA histogram is calculated by making use of mathematical 
models.
122
No.
of
cells
Reference 
Chick RBC
Cell
C ycle
Fluorescence Intensity  
Relative DNA content
Figure 1.4.4. Flow cytometric analysis of the cell cycle.
Calculation of SPF is, however, difficult because of the lack of a 
theoretically-based demarcation between G1 and S phase and that between S 
phase and G2 phase. The calculation can be attempted manually by assigning 
markers to discriminate the S phase or with the use of a rectangular model 
described by Baisch et al. (1982) or more easily with the use of computerised 
analysis programmes like the Sum of Broadened Rectangluar (SOBR) model 
(Becton Dickinson). Manual calculation involves placing of markers to define 
the phases in the cycle (Fig 1.4.4).
Discrimination of S phase is difficult and it is more of a choice of the 
researcher and therefore, will give rise to inter-observer variation. Although 
computerised models make the calculation a very simple matter, these models 
are based on assumptions about the phases of the cell cycle, and at times the 
analysis may differ with the choice of the model. In addition, in many 
tumours, the presence of aneuploid populations overlapping with the diploid 
population or with contaminating non-tumour diploid cells, makes the precise 
discrimination of S phase cells impossible. A further problem associated with
SPF calculation is the presence of debris, probably representing DNA 
fragments, which can give rise to background and thus, a higher SPF than the 
true situation. Background DNA staining can be particularly prominent in 
nuclei extracted from paraffin-embedded tissues, while fresh tissues are 
certainly the best choice. Recently, it has been shown that background noise 
can be managed in calculating SPF by exponential background subtracting 
(Visscher et al., 1990b) and computerised analysis programmes have also been 
developed which can assess SPF even in cases where there are overlapping of 
peaks. Ideally, a substantial improvement can be the use of an antibody 
specific for the tumour cells.
The difficulty is assessing SPF is evident from the reported success of 
various investigators in calculating SPF, the values ranging from 55 to 100% 
(Visscher et al., 1990a). The SPF, as reported in the literature for breast 
tumours range from 1 to 30%, with a mean between 8% (McDivitt et al., 1986) 
and 15.7 % (Coulson et al., 1984).
I.4.4.3.3. Correlation of SPF with histopathological factors
The most significant finding concerning SPF determination by FCM is 
that aneuploid tumours from breast cancer patients have a higher SPF than 
diploid tumours. A point to make here is that in diploid cases, the true nature 
of the cell population has not been determined and that in some cases at least, 
the diploid cells or a proportion of them constitute non-cycling stromal and 
even lymphocytic cells, which can often make up a good percentage of the total 
population (Whitford et al., 1990), with a low SPF. This, again, would 
require the use of tumour-specific markers to correctly identify the cells within 
the diploid population. In general, however, the large number of studies 
support the general consensus that aneuploidy is associated with a higher SPF.
As with ploidy, most of the studies find higher SPF to be associated 
with poorer histopathlogical features. Dressier et al. (1988) found a 
significantly higher mean SPF in axillary node positive diploid tumours than in 
node-negative diploid tumours. This difference, however, was not present 
among aneuploid tumours. Hedley et al. (1987) found only a weak association 
between regional nodal status and SPF. Relationship with grade was highly 
significant (Hedley et al., 1987; McDivitt et al., 1986; Feichter et al., 1988; 
Moran et al., 1984; Kallioniemi et al., 1987; Olszewski et al., 1981). High 
SPF in breast cancer is also related to oestrogen and progesterone- negative 
status (Hedley et al., 1987; Moran et al., 1984; Dressier et al., 1988; 
Olszewski et al., 1981).
I.4.3.3.4. DNA ploidy and SPF and prognosis in breast cancer
Employing retrospective and follow-up studies, several investigators 
have analysed the results of DNA content and SPF and compared them with 
the clinical outcome of breast cancer patients. Two parameters, relapse or 
disease-free survival (DFS) and overall survival have been assessed in follow- 
up studies. The period of follow-up used, however, varies between 
observers. Most of the studies having a follow-up from 5 to 8 years, with 
only Toikkanen et al. (1989) having a follow-up as long as 25 years. The 
finding from these investigations are however, relatively consistent.
In the earlier study of Kallioniemi et al. (1987), the overall 8-year 
survival rate of patients with diploid tumours was 74%, compared to 51% in 
aneuploid cases. The difference was statistically significant and was found to 
apply to both node-negative and node-positive patients. Moreover, in a
multivariate analysis, DNA ploidy emerged as a significant independent 
prognostic indicator. In a later study (Kallioniemi et al., 1988b), the same 
group of workers, combined DNA index with SPF, and reported that in 
patients with diploid tumours and low SPF, prognosis was especially 
favourable. O'Reilly et al. (1990), employing the same follow-up period, 
however, found that only SPF but not ploidy was associated with the clinical 
course of the patients. Even this significance was lost in a multivariate 
analysis, when histological grade was included. The other report that failed to 
observe any significance of FCM studies with prognosis, was that of Dowle et 
al. (1987), who observed that the significant advantage of diploid tumours 
were lost on a longer-term follow-up of 84 months. Studies employing much 
longer follow-up times (Eskelinen et al., 1989; Toikkanen et al., 1989) provide 
evidence to indicate that FCM studies can be of importance in predicting the 
outcome of patients. The mean follow-up in the study of Eskelinen et al. was 
12.4 years and DNA aneuploidy showed a significant association with 
decreased survival. 33 percent of patients with diploid tumours and 65% with 
aneuploid tumours died during the follow-up. High SPF were also associated 
with distant metastases or death. The follow-up period of about 25 years used 
by Toikkanen et al. (1989) is the highest so far reported. This study found that 
although survival rate of patients with diploid tumours was better, the ploidy 
significance held only in node-negative patients, while SPF were equally 
important for both node-negative and node-positive patients. Moreover, SPF 
was also found to have a prognostic value independent of other parameters.
That SPF may be a parameter of greater biological importance than 
ploidy have been implicated (Visscher et al., 1990a) and in the study of Stal et 
al. (1989), only SPF was found to be a predictor of disease recurrence. Clark 
et al. (1989), however, found that SPF was important only in cases of diploid 
tumours. In an attempt to identify a sub-group with poorer prognosis within
node-negative patients, Clark et al. (1989) found that DFS at 5 years were 
significantly lower for patients with diploid tumours and with aneuploid 
tumours SPF were not an additional significant predictor. This is perhaps a 
reflection of the fact that aneuploid tumours have been found to be associated 
with high SPF. The study of Clark et al. (1989) also showed that breast 
cancer patients can be divided into 3 groups in terms of decreasing DFS: i) 
Diploid with low SPF; ii) Aneuploid tumours, irrespective of SPF; and iii) 
Diploid with high SPF. The DFS rates found for the three groups being 90, 
74 and 70 % respectively. Although the follow-up in the Clark et al. (1989) 
study was only 5 years, it is consistent with the findings reported in studies 
with longer follow-up time and perhaps, summarises the relationship between 
ploidy and SPF and patient outcome, that is, breast cancer patients with 
diploid, low SPF tumours have a good prognosis. This then indicates that 
both aneuploidy and high SPF are associated with aggressive nature in breast 
cancer.
I.4.3.3.5. FCM DNA studies on primary and metastatic tissue 
from the same patient
The present knowledge of abnormality in tumours has been related to 
known prognostic indicators or, in some of the studies, to the outcome of the 
disease. Such studies have shown that DNA FCM data provide information 
pertinent to the behaviour of tumours in breast cancer patients. The precise 
relationship between the abnormality detected by FCM and the prognosis of 
patients, although reported to be significant in some studies, is not clearly 
understood. In breast cancer, the clinical outcome depends largely on the 
development of distant metastases and their biological aggressiveness and 
therefore, the characterisation of metastases is also relevant. Although
extensive DNA analyses of primary tumours from breast cancer patients have 
been undertaken, these were carried out principally to assess the potential of 
DNA flow cytometry as a prognostic indicator and were involved with the 
DNA ploidy and SPF of the primary tumours alone. Very little attention has 
been directed towards examining the direct relationship between metastatic 
potential and DNA ploidy and as such in comparing the ploidy in metastases 
with that in the primary tumour. In breast cancer surgical practice, the 
availability of invaded lymph nodes along with the primary tumour from the 
same patient makes them an excellent candidate for the study of aneuploid cells 
and their ability to invade lymph nodes. There are, however, only a few 
reports in breast cancer where lymph node metastases were analysed by DNA 
FCM, along with the primary tumour from the same patient.
In the few studies carried out involving breast cancer, a high degree of 
concordance between metastases and autologous primary tumours has been 
reported by most, but not all investigators. In the earlier study of Auer et al. 
(1980b), who used static cytophotometry and Olszewski et al. (1982), who 
used flow cytometry and studied only aneuploid tumours, the DI of primary 
tumours were found to be identical to those of lymph node metastases. This 
constancy with respect to ploidy, DI and SPF have also been reported in two 
later studies (Feichter et al., 1989; Beerman et al., 1991). However, these 
studies also report DNA profile differences between primary tumours and 
lymph node metastases in a small number of cases. Feichter et al. (1989) 
reported agreement of DI between the two tissues in 61 out of 80 cases, while 
SPF showed less consistency with only 62% displaying similar percentages of 
SPF. Additionally, the study reported that diploid tumours and their 
metastases revealed more consistency than aneuploid tumours. Altered kinetics 
have also been reported by Olszewski et al. (1982), who reported a significant 
reduction of SPF in the metastases of tumours with a positive content of
oestrogen receptors. Differences in the ploidy of primary tumours and lymph 
node metastases in only a small number of cases have also been observed by 
Beerman et al. (1991) and in agreement with other studies they found that 
lymph node metastases could be both diploid and aneuploid suggesting that 
diploid primary tumours can give rise to aneuploid metastatic tumours and vice 
versa. Although the authors in these studies concluded that ploidy is a 
generally stable phenomenon which is established early in the development of 
the primary tumour, their reports do show that in a small number of cases, 
compared to the primary tumour a lymph node metastasis can have a different 
DNA profile. The greatest extent of changes in the ploidy between primary 
and metastases have been reported by Hitchcock et al. (1989). In a study of 36 
breast cancer patients, they found that 44% of metastases to the ovary and 
axillary lymph nodes had a ploidy different from the corresponding primary 
sites. Along with grade, reactivity for CEA and to NCRC-11, which detects a 
surface glycoprotein (Section 1.3.1.1), the report concluded that changes in 
ploidy in a metastasis is not unidirectional and is not related to the ploidy status 
of the primary. Unlike the previous observation, this suggests that changes in 
ploidy and other variables may occur after metastasis. In this context, an 
important issue is whether aneuploidy itself or a specific aneuploid 
subpopulation has a higher metastatic potential. As only a small number of 
studies have been done it is not clear whether a tumour is stable in terms of its 
DNA profile, and although heterogeneity in terms of ploidy of the primary 
tumour have been reported (Hitchcock et al., 1989; Beerman et al., 1991), 
there is no direct evidence to indicate that the development of clones with 
metastatic potential is related to the DNA profile of a tumour.
An important point to make here is that tumour cells analysed for DNA 
flow cytometry are extracted from a slice of an excised tumour mass which 
contains in addition to epithelial breast tumours, surrounding tissue which
comprise both normal epithelial cells and non-epithelial stromal, fibroblast and 
lymphocytic cells. The proportion of these cells relative to epithelial tumour 
cells, which are the object of study, can affect both the determination of ploidy 
and the measurement of SPF. Apart from the study of Feichter et al. (1989) 
which attempted to remove contaminating lymphocytes by centrifugation, in 
none of the other studies were the true identity of the diploid population known 
and, in cases where the lymph node metastases were reported to be diploid, the 
population observed may have been lymphocytes. That aneuploid cells in 
metastases can go undetected due to the presence of lymphocytes was 
explained by Tribukait (1987), who observed a diploid metastasis in cases 
where the primary tumour was aneuploid in 30% of bladder carcinomas 
examined. Moreover, it is also possible that aneuploid populations in tumours 
designated diploid may have been gone unnoticed simply because the 
aneuploid cells made up only a small percentage of the total cell population 
under study. There is therefore, a need for further analysis of both primary 
tumours and metastases in breast cancer by DNA flow cytometry with the help 
of a methodology which would allow discrimination of a tumour cell from its 
normal counterpart or simply from contaminating cells like fibroblasts and 
lymphocytes.
I.4.3.3.6. Multiparametric FCM DNA analysis
The presence of contaminating cells, both epithelial and non-epithelial 
normal cells, is a major problem often encountered in analysing cell 
suspensions from a solid tumour like breast cancer. Although in a 
histochemical analysis such cells can be easily recognised, it is not so in FCM 
DNA analysis, in which such contaminants make both the assessment of 
ploidy and the measurement of SPF inaccurate. In a study of ploidy or SPF of
primary tumours and their corresponding metastases, this is an issue that needs 
to be resolved. Ideally, a tumour specific antigen is what one would prefer in 
order to sort this problem, but surface expression heterogeneity and the 
absence of any known breast tumour-specific antigen makes this impractical. 
Unlike haemaopoietic tumours, breast tumour cells cannot be distinguished in 
terms of their intrinsic light scatter properties, which reflect cell size and 
granularity (Section 2.2.1.4).
Recently, Zarbo et al. (1989), described the use of a multiparametric 
DNA analysis using dual-labelled intact cells. Use was made of the epithelial 
tissue-specific, cytokeratin-antibody, which has been previously employed in 
the FCM analysis of urothelial (Feitz et al., 1985; Smeets et al., 1987) and 
colonic carcinoma (Crissman et al., 1988). With this technique, specific gating 
on cytokeratin-positive epithelial cells was possible. Non-staining stromal, 
fibroblast and lymphocytic cells were therefore, excluded from the analysis and 
this greatly refined the detection of both aneuploidy and the calculation of SPF 
of primary tumours. Employing this technique in a later study of breast 
carcinomas, Visscher et al. (1990b) found that both aneuploidy and SPF was 
significantly related to accepted histopathologic and hormonal factors in the 
identification of high risk patient populations. The investigators concluded 
that the use of multiparametric analysis with cytokeratin gating significantly 
refines the biologic relevance of FCM data. Although this technique was 
performed mainly on primary tissues, it holds the prospect of being used to 
analyse primary tumours and lymph node metastases taken from the same 
patient. This method would allow the true identification of ploidy status of 
both primary and metastatic cells and therefore, a clearer understanding of the 
relationship between FCM data and metastatic potential.
I.4.3.3.7. Aneuploidy, oncogenes and tumour suppressor genes
It is evident that in breast cancer, there are both alterations at specific 
gene level as reported in terms of gene amplification or loss and genetic 
alterations on a much larger scale as observed in terms of tumour ploidy. Of 
the most widely studied oncogene erb B-2 alterations have been detected in 
only about 20% of breast tumours, whereas aneuploid data indicates that the 
genome of >60% of tumour cells is highly abnormal. There is obviously a 
requirement that the area of gene amplification or loss be related to the ploidy 
of the original tumour. Only in a few of the recent studies have investigators 
also reported ploidy status of breast tumours for which gene amplification has 
been studied. Studying erb B-2 amplification, Borg et al. (1991) found that 
aneuploid, but not diploid, tumours with gene amplification were more 
aggressive. In an earlier study, Tavassoli et al. (1989) also reported that the 
tumours with erb B-2 and myc amplification were aneuploid. Correlation 
between erb B-2 protein expression and DNA Index have also been reported 
by Baak et al. (1991), while Bacus et al. (1990) found that tumours that 
overexpress the erb B-2 protein have tetraploid DNA content. It is important to 
point out that in all of these studies DNA ploidy and gene amplification or 
protein overexpression were determined on the same tumour specimen but not 
on the same tumour cell. With respect to protein overexpression, a direct 
correlation between the two features can perhaps be best established in a dual­
parameter flow cytometric analysis. Lately it has been shown that both cellular 
integrity and erb B-2 antigen reactivity were preserved in cells and tissues 
following fixation in ethanol and thereby, allowed a dual parameter analysis 
(Kelsten et al., 1990).
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1.4.4. DNA fingerprint analysis of tumour DNA
It appears that mutations in several genes may affect the control of 
growth and malignant capability of a breast tumour. Not only is there an 
alteration at a specific site on a chromosome but that several of such sites are 
affected before a highly malignant clone of tumour appears. In breast cancer, 
where oncogenes or tumour suppressor genes have been implicated such 
studies were carried out simply because the specified gene was found to be 
affected in another cancer type or in an experimental cell line or animal models. 
There are clearly more such sites involved yet unidentified. Therefore, 
determination of the total extent of alterations on all chromosomes rather than 
losses on individual chromosomes might more accurately measure the level of 
genetic change and perhaps would be useful for assessing prognosis. To 
record all the major changes in a tumour a battery of DNA probes representing 
different loci have to be used.
An alternative approach only recently developed is the use of DNA 
fingerprinting analysis for screening human tumour DNA. The DNA 
fingerprint technique makes use of the existence of multiple hypervariable 
tandem repetitive sequences (or minisatellites) that are dispersed throughout the 
genome and are largely polymorphic due to allelic variation in repeat copy 
number (Jeffreys et al., 1985). Minisatellite probes consisting of the core 
sequences present on the majority of human chromosomes rather than on a 
single chromosome provide a set of genetic markers that have been found to be 
of value in detecting changes in tumour DNA (Thein et al., 1987; Fey et al., 
1988). This technique was first tested on a small number of tumours of 
various human cancers (Thein et al, 1987) and later applied on gastrointestinal 
(Fey et al., 1988) and ovarian cancers (Boltz et al., 1990, Saito et a l, 1991).
The investigators showed that DNA fingerprint analysis can be applied on 
human tumours to detect deletion or reduction in intensity of a band suggesting 
loss of heterozygosity, increased intensification of single bands and the 
appearance of novel DNA fragments. A similar study can be carried out to 
analyse breast tumours to detect changes during progression and metastasis. 
Primary and lymph node metastasis can be compared from the same breast 
cancer patients to detect changes which would reflect alterations associated 
with metastasis.
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1.5. Aim of study
This study has been designed to assess different parameters in relation 
to metastasis to the lymph node in breast cancer patients. In order to do this, 
primary tumours and lymph node samples, both normal and with metastasis, 
were obtained from the same patient undergoing surgery for breast cancer.
The parameters studied include (i) immunological responses in the 
tumour-draining lymph nodes, (ii) carbohydrate expression at the tumour cell 
surface, and at the DNA level, (iii) the DNA content by flow cytometry and 
(iv) DNA fingerprinting with multi-locus satellite DNA probes.
The immunological responses of the lymph nodes were assessed by 
studying both phenotypic markers and activation status of lymphocytes by 
flow cytometry. The effect of metastasis on lymph node immunological 
responses was assessed by examining both tumour-free and tumour-invaded 
nodes taken from the same patient.
Cell surface carbohydrate expression was studied by flow cytometric 
analysis of lectin binding. The expression of lectin-binding marker was also 
assessed in metastatic cells in the lymph nodes.
FCM DNA analysis was used to assess DNA content. Using a 
cytokeratin-antibody, a dual-parameter flow cytometric analysis was found to 
be useful in assessing DNA ploidy of both primary tumours and lymph node 
metastases.
Four different DNA satellite probes were used in DNA fingerprinting 
analyses. Fingerprints from tumour DNA was compared with peripheral blood
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from the same patient to determine changes in terms of band loss, appearance 
of new bands and changes in hybridisation intensity.
The prognostic value of these parameters were assessed by comparison 
with histopathological data and tested in a statistical test. Finally, in a group of 
patients, the different parameters have been interrelated in an attempt to assess 
their overall value in providing additional information.
The use of flow cytometry and fresh tissues provided a relatively non- 
subjective analyses of antibody- or lectin-stained intact cells.
CHAPTER 2 
M aterials and M ethods
2.1. Materials
All chemicals used in this study were supplied by Sigma Chemical 
Company or BDH Chemicals, both of Poole, Dorset, England. These 
chemicals were of the highest grade available. All plasticware were from 
Sterilin Ltd., Feltham, England.
2.1.1. Tumour cell and lymphocyte preparation.
RPMI-1640 (Gibco Ltd., Paisley, Scotland)
Penicillin/Streptomycin (Gibco Ltd., Paisley, Scotland)
Dimethyl sulfoxide (DMSO) (BDH Chemicals Ltd., Poole)
FCS (Imperial Laboratories, Andover, Hants.)
Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) 
Collagenase (Worthington Biochemical Corp.)
2.1.2. Reagents for tissue culture media
RPMI-1640 (Gibco, Paisley)
Penicillin/Streptomycin (Gibco, Paisley)
FCS (Imperial Laboratories, Andover, Hants.)
2.1.3. Antibodies
Except for those listed below, all antibodies were purchased from 
Becton Dickinson, Cowley, Oxford and Dakkopatts A/S. These antibodies 
were either conjugated to FITC or PE (Table 2.1).
Sheep anti-mouse Ig-FITC conjugated (whole antibody) (Amersham 
International pic, Bucks.)
Rabbit F(ab)2 anti-human IgG(y chain)-FlTC (Dakkopatts)
2.1.4. Lectins
All fluorescently-labelled and biotinylated lectins were obtained from 
Sigma Chemical Co.
Streptavidin-PE to label biotinylated lectins was from Becton 
Dickinson, Cowley, Oxford.
2.1.5. General Buffers
PBS (phosphate buffered saline), pH 7.4:
170 mM NaCl; 3.4 mM KC1; 10 mM Na2HP0 4 ; 1.8 mM KH2PO4 .
Sheath fluid, pH 7.2 (FACScan fluid):
1.3 mM NaCl; 0.02 mM KC1; 20 mM LiCl, 15 mM KH2P04,
10 mM Na2HP04, lOmM EDTA.
2.1.6. Solutions for DNA flow cytometric analysis
These solutions were prepared as described by Vindel<{>v et al. (1983). 
Citrate buffer, pH 7.6: 250 mM Sucrose, 40 mM trisodium citrate, 
2H20; 5 % (v/v) DMSO.
Stock solution , pH 7.6 : 3.4 mM Trisodium citrate, 2H20 ; 0.1% 
(v/v) Nonidet P40; 1.5 mM Spermine tetrahydrochloride; 0.5 mM Tris.
Solution A: Trypsin (15 mg, TO 134, Sigma Chemical Co.) dissolved in 
500 ml stock solution, pH 7.6.
Solution B: Trypsin inhibitor (250 mg, T9253, Sigma Chemical Co.) 
and Ribonuclease A (50 mg, R4875, Sigma Chemical Co.) dissolved in 500 
ml stock solution, pH 7.6.
Solution C: Propidium iodide (208 mg) and spermine tetrachloride (580 
mg, Sigma Chemical Co.) dissolved in 500 ml stock solution, pH 7.6.
Solution C was protected against light with tinfoil and all these 
solutions were aliquoted and stored in plastic tubes at -70 °C.
2.1.7. Solutions and buffers used in DNA manipulations
2.1.7.1. Extraction of DNA from primary tumours, lymph 
nodes and PBL
Nuclei lysis buffer: lOmM Tris-HCl, 400 mM NaCl, 2 mM
Na2EDTA, pH 8.2.
10% SDS.
Proteinase K (Boehringer Mannheim, West Germany) solution: 1 
mg/ml in 1% SDS, 2 mM Na2EDTA.
Saturated NaCl (approximately 6M)
TE buffer, pH 8.0: 10 mM Tris-HCl, 1 mM Na2EDTA.
TE buffer, pH 7.4: 10 mM Tris-HCl, 1 mM Na2EDTA
2.1.7.2. Plasmid DNA preparation
Solution I: 50 mM glucose, 25 mM Tris, pH 8, 10 mM EDTA, pH
7.5, 2 mg/ml lysosyme (fresh).
Solution II: 0.2 N NaOH, 1% SDS.
Solution IH: 5M K-acetate, pH 4.8 (60 ml 5M K-acetate + 11.5 ml 
acetic acid, and the volume made to 100 ml with water).
2.1.7.3. Transformation buffers
TSB (Transformation & storage buffer): L broth (pH 6.1) containing 
10% PEG, 5% DMSO and 20 mM Mg++ (10 mM MgCl2 + 10 mM MgS04). 
50 mM CaCl2,.
2.1.8. Bacterial media and reagents
Reagents for bacterial media were from Difco Laboratories, Detroit, 
Michigan.
L-broth (500 ml): bacto-tryptone 5g, yeast extract 2.5g, NaCl 5g, 
pH 7.4.
H plates (per 1): 8g NaCl, lOg bacto-tryptone, 15g bacto-agar, pH 7.5
Top agar (per 1): 8g NaCl, lOg bacto-tryptone, 7g bacto-agar, 
pH 7.5.
X-Gal (5-bromo-4-chloro-3 indolyl-(3-D-galactoside) plates: 40 p.1 of 
2% X-Gal in dimethyl formamide and 40 |il 100 mM IPTG (Isopropyl 
thiogalactoside) added to ampicillin-containing (100 jig/ml) agar plates.
2 x TY broth (per 1): 16g tryptone, lOg yeast extract, 5g NaCl, 
pH 7.4.
2.1.9. Bacteria
All bacterial strains used as hosts were generously provided by Dr. 
M.L.M. Anderson, Dept, of Biochemistry, University of Glasgow.
E. coli strain DS941 rec F"143, proA7, str31, thrl,leu6, tsx33, intl2, 
his4, argE3, galK2, aral4, supE44,xyll5,lacI,lac ZAM15.
E. coli strain JM101 supE, thi-1, A(lac-proAB), [F, traD36, proAB, 
lac<lZAM15], X'-
Phage strain MV1190 A(lac-pro), thi, supE, A(srl - recA), TnlO (tet^), 
F',traD36, proAB.
2.1.10. Agarose gel electrophoresis
Electrophoresis grade agarose was from BRL, Paisley.
Tris-borate (TBE) buffer : 89mM Tris-borate, pH 8.3, ImM EDTA, 
0.2 pg/ml ethidium bromide.
Tris-acetate (TAE) buffer: 40mM Tris-acetate, pH 7.8, ImM EDTA, 
0.2 (ig/ml ethidium bromide.
Gel Loading buffer: 10 mM Tris-HCl, pH 7.2, 1 mM EDTA, 0.25% 
bromophenol blue, 20% Ficoll (Type 40), 10 fig/ml ethidium bromide.
2.1.11. Purification of probe DNA
Purification of DNA fragments (representing each of the DNA probes) 
from acetate gels was carried out using a Geneclean II kit from BIO 101 Inc. 
La Jolla, California.
2.1.12. Restriction enzymes and DNA standards
All restriction enzymes were obtained from Gibco BRL (UK), Paisley, 
and Pharmacia LKB Biotech., Uppsala, Sweden.
Standard DNA markers X DNA-Hind III, and 
c|)-X174 DNA-Hae El were from Gibco BRL (UK). The sizes are as follows: 
Hind IDA 23.7, 9.5, 6.6, 4.3, 2.3, 2.1, 0.6 kb 
Hae III/<|)X 1.3, 1.08, 0.87, 0.6, 0.3, 0.28, 0.27, 0.23 kb.
2.1.13. Satellite probes
Plasmid DNA (100 ng in 100 pi Tris buffer) containing multi-locus 
minisatellite probes 33.6 (in pUC18) and 33.15 (in pUC19) were purchased 
from Cellmark Diagnostics, Abingdon, Oxfordshire.
Recombinant phage containing 228S (13 pg, 5 pi of 2.6 pg/pl) and 
216S (2 x 5 pi from a single plaque in TE buffer) satellite DNAs in phage M13 
were generously provided by Dr L. Burgoyne, The Flinders University of 
South Australia, Australia. These were treated as stock and were diluted 1:500 
for use in transformation (Seection 2.2.4.3.5).
2.1.14. Nick Translation
DNA probes were radiolabelled using the nick translation kit (code N 
5000) from Amersham pic.
2.1.15. Pre-hybridisation buffer
Both pre-hybridisation buffer and hybridisation solution were prepared 
according to Anderson & Young (1985).
Solution A: 50 ml deionised formamide;
25 ml 20 x SSC (SSC is 0.15M NaCl, 0.015M 
trisodium citrate, pH 7.0);
5 ml 100 x Denhardt's solution (100 x Denhardt’s 
solution contains 2% Ficoll (mol. wt. 400 000), 2% polyvinyl pyrrolidone 
(mol. wt. 400 000) and 2% bovine serum albumin):
5 ml 1M sodium phosphate buffer, pH 6.8 (25.5 ml of 
1M NaH2P04 and 24.5 ml of 1M Na2HP04);
0.5 ml 20% SDS
volume adjusted to 95.5 ml with water.
Solution B: 2 ml sonicated salmon sperm DNA at 5 mg/ml;
denatured in a boiling water bath for 5 min. and then
quenched in ice.
Solution B was added to solution A and volume made to 100 ml with
water.
2.1.16. Hybridisation solution
All solutions were prepared as in pre-hybridisation buffer.
Solution A: 50 ml deionised formamide;
25 ml 20 x SSC;
1 ml 100 x Denhardt’s solution;
2 ml 1 M sodium phosphate buffer, pH 6.8; 
lm l 20% SDS;
lOg dextran sulphate (mol. wt. 500 000)
Volume adjusted to 95.5 ml.
Solution B: 2 ml sonicated DNA (5 mg/ml)
Denatured in a boiling water bath for 5 min. and then quenched in ice. 
Solution B added to solution A and volume made to 100 ml with water.
2.1.17. Radiochemicals and autoradiography
[a-32p]-deoxycytidine triphosphate (3000 Ci/mmol in acqueous 
solution at 10 mCi/ml) was obtained from Amersham International pic., 
Amersham, Bucks.
[a-35s]-ATP (600 mCi/mmol) used in sequencing was also from 
Amersham.
Kodak X-OMAT S film was used for autoradiography.
2.2. Methods
2.2.1. Sample preparation for immunological analysis
2.2.1.1. Patient samples
Samples of ipsilateral axillary lymph nodes and peripheral blood were 
obtained from 26 patients undergoing breast cancer surgery at the Western 
Infirmary, Glasgow. Twelve of these patients had stage II breast cancer (with 
nodal metastasis- Section 1.1.5.2), while the other 14 had stage I. For stage I 
(without metastasis) patients, specimen of one half of nodes were aseptically 
sampled. For the study of tumour invaded versus tumour free lymph nodes in 
stage II patients, one half of a lymph node invaded with tumour and one half of 
a node half free of tumour from the same patient were separately aseptically 
sampled. The other halves of these nodes were sent to Pathology for routine 
histological examination. Histopathological reports confirmed that the lymph 
nodes initially assessed by the surgeon had been correctly allocated in terms of 
invasion status.
The age of the patients ranged from 43 to 85 with a mean of 57. All 
but one patients were subsequently found by histopathological examination to 
have ductal infiltrating carcinoma of the breast. The one exception as found by 
histopathology was lobular breast carcinoma. None of these patients had 
received preoperative cytotoxic, endocrine or radiotherapy.
2.2.1.2 Harvesting of cells
Lymph node lymphocytes (LNL)
The aseptically obtained lymph nodes were processed immediately in 
order to avoid alteration in membrane receptor expression. The cells were 
released by teasing them apart with a scalpel and needle. The lymphocytes 
were isolated from the lymph node cell suspension by layering the cell
suspension over an equal volume of Ficoll Hypaque. After centrifugation at 
500 g for 20 min, the lymphocytes were isolated from the interface by careful 
pipetting. The lymphocytes were then washed in RPMI-1640 medium, 
resuspended in a freezing mixture consisting of 90% heat-inactivated foetal calf 
serum (FCS) and 10% DMSO and finally stored in liquid nitrogen until they 
could be analysed. The recovery of lymphocytes from the lymph nodes was 
quite variable as also reported by Whitford et al. (1992b). The number of 
lymphocytes recovered from tumour invaded nodes were found to vary from 
greater than 107 to 4 x 106. Low recovery of lymphocytes was also found in 
cases of some nodes which were small but otherwise tumour free. On two 
occasions, no attempt was made to isolate lymphocytes from the cell 
suspension by Ficoll Hypaque density centrifugation as the lymph node 
appeared to be replaced by tumour cells to a great extent. A previous attempt to 
do so with a grossly tumour invaded half lymph node had resulted in the loss 
of the lymphocyte layer. Therefore, in order to treat samples from invaded and 
tumour free lymph nodes in an identical manner, the cell suspensions from 
both pairs of nodes were washed twice in RPMI and resuspended in freezing 
mixture before storing in liquid nitrogen.
Peripheral Blood Lymphocytes (PBL)
Peripheral venous blood were also obtained from each of the patient on 
the day of surgery. 10 ml of blood, collected in potassium EDTA tubes was 
gently layered over 10 ml of Ficoll Hypaque and centrifuged for 20 min at 
500g. The lymphocytes were obtained by carefully pipetting the layer at the 
interface. The cells were washed in RPMI-1640, resuspended in freezing 
mixture and finally stored in liquid nitrogen.
2.2.1.3 Lymphocyte preparation for flow cytometry
Cell samples kept frozen in liquid nitrogen were quickly thawed in a 
water bath at 37°C, to avoid damage by ice crystal formation within the cells. 
The cells were washed twice in filtered PBS and resuspended at a cell density 
of approximately 2 x 107 cells per ml. 50 jil of this cell suspension was placed 
into flow cytometry tubes (Falcon 2052) and monoclonal antibodies (MAbs) to 
specific phenotypic and activation markers on the lymphocytic cell membrane 
were then added. The full panel of combinations of MAbs in Table 2.1 was 
used with each lymphocyte preparation from lymph nodes and peripheral 
blood. After addition of the antibodies, the content of the tubes were mixed on 
a vortex briefly and the tubes were incubated on ice for 20 min. The incubation 
was carried out in the dark to prevent bleaching of the fluorochromes and to 
avoid capping and internalisation of the antibody/antigen complexes, 0.02% 
w/v sodium azide was added and the tubes kept on ice. The cells were next 
washed and resuspended in filtered PBS. Propidium iodide to a final 
concentration of 2 |ig/ml was then added to each tube to allow the identification 
and exclusion of dead cells from the analysis. Data on 5000 live cells were 
then acquired on a Becton Dickinson FACScan flow cytometer.
TABLE 2.1. Flow cytometric examination of monoclonal antibody defined
phenotypic and activation markers of human lymphocytes.
Antibody 1 Antibody 2 Predominant
reactivity
IgGl-FITC IgG2a-PE Control
Leucogate
Anti-CD45-FTTC Anti-CD14-PE Differential staining of 
leukocyte subpopulations 
(lymphocytes, monocytes, 
neutrophils)
Anti-Leu4-F1TC
Anti-Leu3a-FITC
Anti-Leu 3a-PE 
Anti-Leu 3a-PE 
Anti-Leu 2a-PE 
Anti-Leu 2a-PE 
Anti-Leu 12-PE
Anti-Leu 12-PE T-lymphocytes,
B-lymphocytes
Anti-Leu2a-PE CD4+ Helper T cells,
CD8+ Suppressor/cytotoxic 
T cells
Anti-HLA DR-FITC
Anti-CD25-FTTC
HLA DR-FITC
Anti-CD25-FTTC
Rabbit F(ab)2 
anti-human
IgG(y chain)-FTTC
Activated CD4+ 
Helper T cells
IL2-receptor on 
CD4+ Helper T cells
Activated CD8+ 
cytotoxic T cells
IL2-receptor on 
CD8+ cytotoxic T cells
surface IgG- 
expressing
CD19+B cell
2.2.1.4 Flow cytometry of lymphocytes
All lymphocyte samples were acquired on the FACS can with two 
acquisition gates operative. This involves exclusion of dead cells and the use 
of scatter gate to collect only the lymphocyte population.
Live gate
P l -n o n -s ta in in g  
in ta c t  c e l l s
P l - s t a in in g  
dead c e l l s
No. of  
c e l l s
F luorescence  2
Fig. 2.1. Pi-gating to exclude cells with breached membranes.
Exclusion of dead cells
An advantage with flow cytometry is that it allows exclusion of dead 
cells. Using PI, it is possible to segregate live cells with intact membrane from 
dead cells with breached membrane. PI binds to DNA but cannot to do so in 
the case of cells with intact membrane thus all non-staining PI cells represent 
live cells. These non-staining cells can be preferentially selected in flow 
cytometry by using a live selection gate (PI gate, Fig. 2.1). This is particularly 
important in studies involving antibodies to surface markers as these antibodies 
can bind to irrelevant intracellular antigens if the cell membrane is breached 
(Section 4.8).
Scatter gate to collect lymphocytes
Forward and side scatter of laser light reflect the size and granularity of 
of cells respectively and these properties can be used to differentiate between 
lymphocytes, monocytes and neutrophils (Fig. 2.2). Simultaneous with this 
and using the cocktail Leucogate antibodies (Table 2.1), these leucocyte 
subpopulations can be differentially stained with antibodies and therefore can 
be identified as distinct cell populations on FL1 versus FL2 plot (Fig. 2.2B). 
By drawing a gate around the lymphocyte population and as shown in Fig 
2.2C & 2.2D, it is possible to exclude the other cell types and the collected data 
can be confined only on lymphocytes.
In this study, all analyses of lymphocytes were carried out with both 
the Pl-gate and the lymphocyte scatter gate operative. The data presented here 
is therefore, on live lymphocytes only.
Analysis gate and assessment of positive cells
To exclude non-specific binding, all assessment of cells positive for a 
phenotypic or activation marker is based on markers set on the control sample, 
which was stained with irrelevant antibodies of matched isotype (Table 2.1). 
The proportion of cells positive for the phenotypic markers were analysed 
using four quadrant analysis. The quadrants were set on the control sample 
such that at least 95% of these cells fell within quadrant 3 (Fig. 2.3). The 
proportions of positive cells falling in each quadrants were identified on the 
basis of the fluorescence channel and the relative percentages of these cells 
measured on the computer using the FACScan software. Activation markers 
were measured by isolating the cell population under study on FL2 (using a 
PE-labelled antibody) and the percentage of these cells positive for a given
Figure 2.2. Flow cytometric analysis of lymphocytes.
A. The forward (FSC, cell size) and side (SSC, cell granularity) scatter 
properties of leucocytes allow them to be differentiated in a dual-parameter dot 
plot. This is shown here for a lysed whole blood preparation.
Green colour represents lymphocytes, blue is monocytes, red is granulocytes, 
and yellow represents cellualr debris.
B. The above sub-populations of blood cells stained differentially with the 
leucogate antibodies (Table 2.1) and identified as distinct cell populations on 
FL1 (FITC-staining) and FL2 (PE-staining) plot.
C. Lymphocytes gated on FSC versus SSC. In this case, the instrument has 
been set so as not to acquire cellular debris.
D. The efficiency of the lymphocyte gate is shown upon staining with 
leucogate antibody.

Figure 2.3. Phenotypic analysis of lymphocytes from breast cancer patients
A. The control sample. The cells have been stained with irrelevant antibodies 
to exclude non-specific binding. This is done by setting a four-quadrant 
analysis marker such that at least 95% of these cells fell within quadrant 3 (the 
origin). All analyses is then based on the marker set on the control sample.
B. Lymph node lymphocytes stained with anti-Leu 4-FITC and anti-Leu 12- 
PE to assesss the proportions of T and B lymphocytes respectively.
C. Phenotypic proportions of T cell subsets. CD8+ T cells on quadrant 1 
(FITC-stained) and CD4+ T cells on quadrant 4 (PE-stained).
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Figure 2.4. Analysis of activation marker expression.
A. Dot-plot display of anti-CD19 (FL2) and anti-IgG staining (FL1). The 
distinct doubly-stained IgG+ B cells show up on quadrant 2.
B. The proportion of cells expressing an activation marker (in this case IgG 
expression on CD 19+ cells) is analysed by isolating the particular population 
on FL2 (phenotype staining).
C. On a histogram on FL1, the proportion og IgG+ B cells is assessed by 
placing a marker, the position of which is based on the control sample.
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activation marker (FITC-labelled) were then measured on a histogram on FL1. 
This is illustrated in Fig. 2.4, which shows the measurement of IgG+ B cells.
2.2.2. Sample preparation and flow cytometric analysis of 
lectin binding
2.2.2.I. Patient samples
32 primary tumour samples, half lymph node samples from 12 lymph 
node metastases and 8 non-involved lymph nodes were obtained breast cancer 
patients immediately after surgery at the Western Infirmary, Glasgow. Tissue 
samples were sliced and the tumour and lymph node cells were spilled by 
extensive chopping with a scalpel blade and washed in RPMI-1640. The cells 
were then centrifuged for 5 minutes at 300g. Spilled cells were epithelial in 
morphology and marker staining with monoclonal antibody to HMFG 2. All 
samples were analysed for lectin binding on the day the tissues were collected, 
as freezing and thawing resulted in considerable cell death.
The spillage technique for cell preparation was suitable for flow 
cytometry as it provided a clean suspension of single cells with very little cell 
aggregate and debris. Both spilled cells and preparation obtained from 
collagenase-treated samples have been found to show similar staining for both 
HPA and Con A (Alam et al., 1990).
Table 2.2. Ingredients for complete growth medium (50 ml).
Heat inactivated Dextran charcoal coated FCS 1.5 ml
Insulin 5 |ig/ml
Hydrocortisone (Cortisol) 6 x 10'5 mM
EGF 0.1 |ig/ml
Ethanolamine 0.1 mM
Phosphoethanolamine 0.1 mM
Transferrin 5 (ig/ml
Prolactin 1 (ig/ml
Prostaglandin El 2.5 x 10'5 mM
Penicillin/Streptomycin 1.0 ml
Fusidic acid 5 |ig/ml
RPMI-1640 44.0 ml
The ingredients are added together and then filter sterilised into the RPMI 
medium. FCS is inactivated at 56 °C for 30 min.
2.2.2.2. Sample preparation of normal breast cells
A sample preparation from reduction mammaplasty served as the 
source of normal breast tissue. Cells from this tissue sample were cultured by 
the method of Wolman et al. (1985). The tissue sample was sliced and treated 
with collagenase (15 mg) at 37 °C overnight. After washing in RPMI-1640 
medium, the cells were seeded in two 25 cm tissue culture flasks containing the 
complete growth medium (Table 2.2). Three weeks later considerable growth 
of breast epithelial tissue was observed in one of the flasks. Cells were 
removed with brief trypsin treatment and assessed for MHC class I antigens to
ensure that cell surface proteins had not been damaged by this treatment. A 
single cell suspension from this culture was prepared by passing the cells 
through a 21G needle (Becton Dickinson).
2.2.2.3. Flow cytometric analysis of lectin binding
FITC-conjugated HPA and biotinylated succinyl Con A lectins were 
used at a concentration of 1 jug/ml and the staining was carried out as described 
by Alam et al. (1990). Both tumour and lymph node samples were 
disaggregated immediately after resection into single cell suspensions by 
mechanical mincing with scalpel blades in a petti dish containing RPMI-1640 
medium. Spilled cells from primary tumours and lymph nodes were washed 
twice in PBS and resuspended at a cell density of approximately 2 x 107 cells 
per ml. 50 pi of this cell suspension was then incubated with 100 pi of the 
lectin solution on ice for 30 minutes in the dark and then washed twice in PBS. 
Cell suspensions treated with biotinylated Con A were further labelled with 
streptavidin-PE solution by adding 10 pi of streptavidin-PE solution per test 
and then incubated for 20 minutes. All stained cells were washed in PBS and 
finally resuspended in 500 pi PBS. 10 pi of PI were added to give a final 
concentration of 2 pg/ml before acquisition to provide live/dead discrimination.
Controls were included with each batch of tissue processed to give 
autofluorescence of tumour cells. 10,000 events per test were acquired for 
each tumour samples and 5000 events per test for each lymph node samples. 
All samples were collected with a live gate to exclude dead cells as described in 
Section 2.2.1.4. For both primary tumours and lymph node metastases, a live 
scatter gate on FSC scatter versus SSC scatter was used to exclude the 
lymphocytes and as such to restrict the analysis to tumour cells alone (Fig. 
2.5). This scatter gate was essential with the cell suspension from lymph 
nodes as it invariably contained a high percentage of lymphocytes. Near
absence (< 5%) of lymphocytes in the acquired lymph node samples was 
confirmed using the leucogate antibody.
The specificity of the lectins were assessed by sugar inhibition test. 
The appropriate sugar (0.1M) was added to a separate tube which was 
otherwise treated as above.
2.2.2.4. Fluorescence microscopy
For examination of lectin binding by fluorescence microscopy, tumour 
cell suspensions were stained as described for flow cytometry (Section 
2.2.2.3) except that the lectins were used at a concentration of 10 pg/ml. 
Stained cells were then applied to multispot microscopic slides, which were 
previously washed with ethanol and air dried. The slides were examined in a 
Leitz Qrthoplan fluorescent microscope.
Figure 2.5. Analysis of tumour cells for lectin binding.
a) Dual parameter dot-plot display of FSC and SSC of lymph node 
lymphocytes.
b) Scatter plot of a cell suspension from a lymph node, showing the gate 
drawn to exclude lymphocytes.
All surface marker analysis of tumour cells ( from both primary tumours and 
lymph node metastases) were carried out using this gate.
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2.2.3. Flow cytometric DNA analysis
2.2.3.1. Patient samples
Fresh, primary tumour and axillary lymph node samples were obtained 
from 57 consecutive patients undergoing definitive surgery for breast 
carcinoma in the Western Infirmary, Glasgow. 31 of these patients had 
metastasis in their lymph nodes while the remaining 26 lymph nodes were free 
of tumour. Involvement of lymph nodes was confirmed by histological 
examination of matching halves of nodes sent to pathology.
2.2.3.2. Sample preparation from primary tumours and lymph 
nodes ;
Cell suspensions from both primary tumours and lymph nodes were 
prepared by mechanical disaggregation as described in Section 2.2.2.3. The 
cells were washed and resuspended in citrate buffer at a cell density of 5 x 105 
cells per test.
2.2.3.3. Preparation of nuclei
Nuclei for flow cytometric DNA analysis were prepared and stained 
according to the method of Vindelov et al. (1983). This involved the treatment 
of the cell suspension with solution A (trypsin, Section 2.1.6) and the contents 
were mixed by inverting the tube. The suspension was incubated for 10 
minutes at room temperature, during which the tube was inverted five or six 
times. This was followed by a further 10 minutes incubation with solution B 
(trypsin inhibitor and RNAse, Section 2.1.6) and again the solutions were 
mixed by inversion of the tube. Finally, the cells were stained with PI by 
adding ice-cold solution C (Section 2.1.6) which also contained spermine
All samples were analysed twice to assess DNA ploidy. The CV (coefficient of 
variation) of the aneuploid peaks (Go/Gl) of tumour cells ranged from 2.0 to 7.0. Any 
sample with an aneuploid peak showing a CV greater than 10 was not included in the 
study.
tetrachloride. At this stage the tubes were incubated in the dark at 0 °C until 
analysed 15-60 minutes later.
Chicken red blood cells (CRBC) were stained identically in a separate 
tube and then added to an amount no more than 10% of the total acquisition. 
CRBC peak served as internal standard and was set at FL2 channel 24-26. 
PBL were also available from each patient and these were stained and analysed 
separately with each sample being evaluated for DNA content
2.2.3.4. DNA analysis by flow cytometry
10,000 nuclei were acquired per sample on a FACScan flow cytometer 
(Becton Dickinson) and as described in Alam et al. (1992b). DNA content was 
confirmed to be diploid if the Go/Gl peak of blood lymphocytes was 
superimposable with that of the tumour sample. Any additional peak was 
considered aneuploid if the suspected aneuploid G0/G1 peak contained at least 
20% of the total sample events and the corresponding G2/M peak was also 
detectable. This was done to ensure that the detected peak was well above 
background and was clearly representative of a distinct population. The DNA 
index (DI), which is a measure of aneuploidy, is calculated as the ratio of the 
peak channel number of the aneuploid G0/G1 peak to the peak channel number 
of the diploid G0/G1 peak.
2.2.3.5. Measurement of SPF
Various alternatives were available for the measurement of SPF of 
primary tumours. Two computer-run models for SPFmeasurement, the 
Polynomial model and the SOBR (Sum of broadened rectangles) model were 
available with the DNA software. Alternatively, SPF can also be assessed by 
placing markers manually to define the SPF region and then the percentage of 
cells under the region can be calculated on the computer.
Table 2.3. Calculation of SPF using the computer-run polynomial model, 
sum of broadened rectangles model (SOBR) and manually by placing markers.
Tumour Method SPF
Diploid Polynomial 7%
SOBR 2%
Manual 2.04%
Aneuploid Polynomial 7%
SOBR 6%
Manual 3.3%
Both the models were unsuitable in cases where there was overlapping 
of peaks. The SOBR model offered more flexibility, while the polynomial 
model was highly restricted to well-defined single cell populations. The 
limitation of SOBR was observed in tumours with high SPF and G2/M cells. 
In these cases, SPF could not be calculated as the histogram did not fit the 
model. It was also observed that the two model at times gave different values 
for SPF (Table 2.3).
In the light of these difficulties, the computer-run program was not 
used in assessing SPF of primary tumours. The measurement of SPF was 
carried out by placing markers manually. SPF were measured for all diploid 
tumours and for a limited number of aneuploid tumours, 9 cases where there 
was no complication from overlapping peaks and in 4 tumours, where the 
diploid population was gated out using CK-antibody. The manual 
measurement of SPF was carried out as described by Visscher et al. (1990b) 
and is illustrated in Fig. 2.6. It shows that S-phase has been defined by 
assuming that both Go/Gl and G2/M are gaussian distribution. Markers are
160
Figure 2.6. Manual SPF determination.
Distribution limits are set with markers to define the S-phase (A). This is done 
by assuming that both Go/Gl and G2/M peaks are gaussian distribution. The 
region within the S-phase is calculated on the computer (B). Next, a separate 
distribution region range for background fluorescence is also set. Background 
events are then substracted from the total events found in the S-phase to give 
the true SPF (C).
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also set to assess background and this is substracted from the S-phase region. 
The background was at times found to be variable and appears to depend on 
the quality of the preparation. Its substraction, therefore, gives the true relative 
proportion of cells in the S-phase.
2.2.3.6. Dual parameter DNA flow cytometry with PI and CK 
staining
It was important to exclude non-epithelial cell components, which 
includes leukocytes, stromal fibroblasts and endothelial cells, from both 
primary tumour and lymph node metastases. This was achieved in a multi- 
parametric two-colour FCM analysis using an FITC-labelled antibody to CK 
(CAM 5.2-FITC). The CAM 5.2 monoclonal antibody detects CK8, CK18, 
and CK19, which are CK peptides consistently present in all layers of normal 
and malignant mammary epithelium (Moll et al., 1982; Moll et al., 1988; 
Ramaekers et a/., 1984). Gating for CK positivity allowed DNA analysis to be 
restricted to epithelial cells and this allowed both the determination of the true 
identity of diploid cells in primary tumours and also to determine the ploidy of 
small proportions of tumour cells in lymph node metastases.
Cell suspensions from both primary tumours and lymph nodes were 
fixed in ethanol according to the method of Zarbo et al. (1989). 12 paired 
primary tumours and lymph node samples from the same breast cancer patients 
were spilled as described above in Section 2.2.2.3. The washed cells were 
resuspended in 1 ml of RPMI-1640 plus 1 ml of FCS. 6 ml of cold 70% 
ethanol was then added slowly, dropwise, while vortexing, to give a final 
ethanol concentration of 50%. Ethanol fixation preserved the antigenicity of 
cytoplasmic and surface markers while at the same time creating access for 
nuclear DNA dye (PI) penetration (Zarbo et al., 1989). Ethanol-fixed cells 
were then washed twice and resuspended in PBS.
The efficiency of ethanol-permeabilisation may be tested by staining of ethanol-treated 
cells with anti-CK antibody. These stained cells may then be counted by fluorescence 
microscopy.
Staining of the cells were carried out according to the method of Zarbo 
et al. (1989) and as described in Alam et al. (1992b) a directly labelled anti- 
CK-FITC antibody (Becton Dickinson) was used. Cells were first treated with 
anti-CK-antibody, incubated on ice and kept in the dark for 20 minutes. After 
two washes in PBS, 1 ml of PI (0.05 mg/ml) and 100 pi of RNAse (1 mg/ml) 
were added to the sample in each tube and incubated at room temperature for 
30 minutes prior to analysis on FACScan. Cells stained with FITC-mouse 
IgG of irrelevant specifcity served as a green fluorescence negative control, 
while those treated with PBS was used as an autofluorescence control.
2.2.3.7. Dual-parameter analysis using a CK+ gate
Gating for CK-positive (CK+) cells and analysis of a DNA histogram 
is illustrated in Fig 2.7 and 2.8. CK+ cells were identified during analysis by 
comparing single-parameter FL1 (green) intensity to negative controls. Next a 
gate was drawn on FL1 (CK-FITC) versus FL2 (PI stain) to include only the 
cells positive for CK (Fig. 2.8). DNA profile analysis (FL2 parameter) was 
pereformed as described above. When primary tumours were analysed for 
CK+ cells, diploid peaks were always reduced and in some cases (Fig. 2.8) to 
a negligible level.
2.2.3.8. Sensitivity test of the dual-param eter DNA analysis.
Sensitivity tests of the dual-parameter analysis using CK was 
performed using a breast tumour cell line (ZR-75). ZR-75 cells are CK+ and 
aneuploid with a DI of 1.65. To determine the limit of detection of CK+ cells, 
ZR-75 cells were mixed with human PBL at following proportions: 30% of 
total cells, 5% of total cells, 3% of total cells, 1% of total cells, and 0% of total 
cells (PBL alone). Ethanol fixation, staining and analysis of CK+ cells was 
carried out as described above in Section 2.2.3.6. and 223.1.
Figure 2.7. Multiparametric flow cytometric DNA analysis 
Ethanol-fixed intact breast tumour cells were labeled with anti-cytokeratin- 
FITC and then stained with PI for DNA.
A. FL1 versus FL2 dot-plot showing CK-positive (green population) tumour 
cells and CK-negative population (red).
B. FSC versus FL1 plot showing CK-positive (green) tumour cells and CK- 
negative lymphocytes (red).
C. Single-parameter DNA histogram showing CK-negative and CK-positive 
cell populations having diploid (red) and aneuploid (green) DNA content 
respectively.
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Figure 2.8. Dual-parameter gating for CK-positive cells.
A. The reaction of the anti-CK antibody with tumour cells (unshaded area) 
overlaid on the reaction with lymphocytes (shaded area).
B. A flow cytometric "gate" (area within box) drawn on the plot of FLI 
(green-CK+) and FL2 (red-PI) to analyse the ploidy status of CK+ cells only.
C. An ungated DNA histogram of a primary tumour showing a diploid 
population (d) and an aneuploid population (a= Go/Gl peak, G2/M peak).
D. A CK-gated histogram of the same tumour showing CK+ epithelial cells. 
The diploid peak (d), representing non-epithelial cells, has been largely gated 
out.
d= diploid; a= aneuploid; G2/M= G2/M peak of the aneuploid population.
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2.2.3.9. Growth of cells from primary breast tumours
4 primary breast tumours were put into short-term culture. Tissue 
slices were mechanically disaggregated as described in Section 2.2.2.1 and 
culture of these cells were carried out as described in Section 2.2.2.2.
2.2.4. DNA fingerprinting of primary tumours and lymph node 
metastases
2.2.4.1. Extraction of DNA
High MW DNA from primary tumours, lymph nodes and PBL from 20 
breast cancer patients was extracted according to the method of Miller et al. 
(1988). This involved twice washing spilled tumour, lymph node cells and 
PBL from the same patient in PBS. About 1 x 106 cells were resuspended in 1 
ml of nuclei lysis buffer. To this 66 pi of 10% SDS were added with gentle 
mixing, then 167 pi proteinase K solution was added. The cell extract was 
incubated overnight at 37 °C with gentle shaking and then decanted into Falcon 
tubes and 0.33 ml of saturated NaCl was added. The contents were mixed for 
15 secs by shaking the tube fairly vigorously. Next the tube was centrifuged at 
800g for 6 min. The supernatant was removed carefully and the DNA was 
precipitated by adding exactly 2 volume of ethanol at room temperature. 
Strands of DNA were then spooled and transferred to an Eppendorf tube and 
washed in 70% ethanol. The DNA precipitate was dried briefly under vacuum 
and then allowed to resuspend in 200 pi TE buffer by incubating the tube at 
37 °C. Finally, the DNA solution was transfered into a collodian sac 
(Sartorius) and dialysed overnight against TE buffer at 4 °C.
DNA extracted by this method was of high MW and gave a yield 
ranging from 25 to 50 pg per lxlO6 cells. The 260/280 ratio was generally 
about 1.9.
2.2.4.2. Satellite DNA probes
Minisatellite probes 33.6 and 33.15 were obtained as inserts cloned 
into stable plasmid vectors pUC18 and pUC19 respectively and were removed 
by EcoRI-Hind ID digestion. The inserts 33.6 and 33.15 are of sizes 0.72kb 
and 0.60 kb respectively (Jeffreys et al., 1985). The recombinant plasmids 
were transformed into an appropriate host and from bulk growth of these cells 
the insert DNA was excised from purified plasmid DNA on gels. Finally insert 
DNAs were purified. This is described in Section 2.2.4.2.I.
Multi-locus satellite probes 216S and 228S were inserts obtained from 
recombinant M13 phage DNA. The inserts were subcloned into a more 
convenient plasmid vector and recovered in large amounts. The amplification 
and purification of these DNA satellite inserts are described in Section 2.2.4.3.
2.2.4.3. Amplification and purification of minisatellite 
sequences 33.6 and 33.15
2.2.4.3.I. Transformation of host E.coli cells
E.coli strains JM101 and DS941 were found to be suitable hosts for 
plasmids carying DNA probes 33.6 and 33.15 respectively in that they 
reproducibly yielded inserts of correct size.
Host cells were grown overnight in L-broth at 37 °C. These were then 
subcultured into pre-warmed L-broth, shaken at 37 °G and allowed to grow to 
the early log phase (2-4 x 107 cells/ml).
Transformation was carried out by the method of Chung & Miller 
(1988). The bacterial cells were harvested by centrifugation (lOOOg for 10 
mins at 4 °C) and resuspended in 1/10th volume of transformation and storage 
buffer (TSB) at 4 °C, and incubated on ice for approximately 10 mins. For
transformation, 0.1 ml aliquots of the cells were pipetted into cold sterile tubes 
and mixed with 100 pg of plasmid DNA. The tubes were then put on ice for 5- 
30 mins. Next, 0.9 ml TSB containing 20 mM glucose was added and the 
cells incubated at 37 °C with shaking for 60 mins. Finally, 0.1 ml of these 
cells were plated on ampicillin-containing (100 pg/ml) agar plates and grown 
overnight at 37 °C. Control plates with and without ampicillin were also set 
up. While there was no growth in the negative controls (nontransformed cells 
in the presence of ampicillin), colonies of transformants appeared for each 
recombinant plasmids.
2.2.4.3.2. Plasmid mini-prep
It is important to test a number of transformants to check that they 
contain the full length probe fragment, especially as the cloned repetitive DNA 
may be unstable. DNA prepared by a mini-prep method is suitable for this 
purpose. Three colonies were picked from both 33.6- and 33.15-plasmid 
containing hosts and grown in 1 ml of ampicillin-containing L broth in an 
Eppendorf tube with good aeration. The protocol of Bimboim & Doly (19 ) 
for a plasmid mini-prep was followed. Overnight cultures of bacterial cells 
were pelleted by centrifuging for 15 secs. All medium was removed and the 
pellet was resuspended in 100 pi solution I (Section 2.1.7.2) by vortexing and 
kept at room temperature for 5 mins. 200 pi of solution II (Section 2.1.7.2) 
was added and mixed by rocking tube sharply. After incubation on ice for 5 
mins, 150 pi of precooled solution III (Section 2.1.7.2) was added and the 
contents of the tube mixed by gently inverting the tube. Following incubation 
on ice for 5 mins, the tube was spun in a microfuge for 1 min. The 
supernatant was carefully removed, transfered to a fresh tube and washed with 
500 pi 70% ethanol. The tube was spun for 1 min and the supernatant 
carefully removed. The plasmid pellet was dried briefly under vacuum and 
resuspended in 25-30 pi TE buffer by vortexing for 5 min.
2.2.4.3.3. Restriction digestion and electrophoretic analysis of 
digests
2-3 pi aliquots from the mini-prep were digested with enzymes EcoRI 
and Hind El according to the manufacturer’s instructions. The enzymes were 
used at 5-10 units per reaction (usually 0.5 pl/reaction) and the reaction was 
usually carried out in a total volume of 20 pi at 37 °C for 45 min. After which 
1 pi of boiled RNAse (0.5 pg/pl) was added to each tube and incubated at 37 
°C for 15 mins. Standard DNA markers were heated to 68-72 °C for 5 min 
and quenched on ice to disrupt the hydrogen-bonding of the lambda DNA 
cohesive ends. Finally, 1 pi 0.4M EDTA and 2 pi loading buffer was added to 
each 20 pi digest and the digested DNA fragments were separated by 
electrophoresis in a 1% agarose gel containing TBE buffer and ethidium 
bromide (0.2 pg/ml). Gel electrophoresis was carried out as described in 
Sambrook et al. (1989). Gels were run at approximately 100 volts until the 
bromophenol blue dye front was near the bottom of the gel. Polaroid 
photographs were taken under uv light with an orange filter. Both the 0.72 kb 
(33.6 insert) fragment and the 0.6 kb (33.15 insert) fragments were detected 
(Fig.2.9) and it was, therefore, adjudged that the the plasmid was stable in that 
particular host.
2.2.4.3.4. Bulk preparation of plasmid DNA carrying DNA 
iinsertsi 33.6 and 33.15
Bulk DNA preparations were made from recombinants in suitable 
hosts. Colonies were picked from plates into 10 ml L broth containing 
ampicillin (100 pg/ml) and incubated at 37 °C with shaking overnight. These 
cells were subcultured by transferring the culture to 500 ml L broth plus 
ampicillin in 2 liter indented flasks and incubated overnight with shaking. The 
cells were then pelleted by centrifuging at 5000g for 5 min at 4 °C. The
Figure 2.9. Isolation of mini-satellite sequences 33.6 and 33.15. 
Electrophoresis of EcoRI + Hind IE digested recombinant plasmid DNA show 
0.72 kb and 0.6 kb inserts representing minisatellite sequences 33.6 and 33.15 
respectively. U represents undigested plasmid DNA. The first three digested 
lanes (from left) are plasmid DNA extracted from DS941 and the last three 
lanes (from left) are from JM101 strains.
ST represents standard DNA markers.
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supemantant was decanted and the buckets were wiped well to remove as 
much of medium as possible. The pellet was gently resuspended in 18 ml 
solution I (Section 2.1.7.2) and incubated at 0 °C for 30 mins. 40 ml of 
solution II (Section 2.1.7.2) was then added and the contents were swirled 
gently before incubating on ice for 5 mins. Next, 20 ml of cold solution m  
(Section 2.1.7.2) was added and the contents mixed gently and incubated on 
ice for 15-60 mins. The suspension was then centrifuged at 9000g for 5 mins 
at 4 °C. The supernatant was poured through gauze into a measuring cylinder 
to remove floating clumps. 0.6 volumes isopropanol was then added to the 
supernatant and left at room temperature for 15 mins. After centrifuging at 
9000g for 10 mins at room temperature, the supernatant was drained well and 
the pellet resuspended in 5 ml of 50 mM Tris-HCl, pH 8,10 mM EDTA.
For equilibrium centrifugation in CsCl-ethidium bromide gradients, it is 
necessary to adjust the refractive index of the plasmid DNA-CsCl solution. 
Solid CsCl and 0.5 ml of ethidium bromide (10 mg/ml) were added to the 
DNA solution. The refractive index (RI) of each DNA preparation was 
adjusted using a sodium lamp reffactometer to 1.3902. The DNA solutions 
were then transfered to ultracentrifuge tubes and the tubes were accurately 
balanced by layering paraffin oil on top. The tubes were then centrifuged at 
100,000g for 40 hr at 25 °C in a Beckman L7 ultracentrifuge. The ethidium 
bromide staining lower plasmid bands (supercoiled DNA) were visible without 
use of uv light, while RNA was pelleted.
The top layer was carefully pipetted out and the lower plasmid band 
was carefully removed. This was then extracted with n-butanol saturated with 
TE (10 mM Tris, pH 8, 1 mM EDTA) at least 5 times or until all traces of 
ethidium bromide were removed. 2 volumes of water was added and mixed 
well, followed by the addition of 2.2 volumes of ethanol and the contents were 
mixed well. The plasmid DNA solution was left overnight at -20 °C. The 
DNA was then pelleted by centrifuging at 14000g for 10 mins at 4 °C. The
supernatant was decanted and the pellet resuspended in 3 ml TE buffer. 1.5 ml 
7.5M ammonium acetate was then added and the contents mixed well. This 
was followed by the addition of 10 ml of ethanol and the contents again mixed 
and incubated overnight at -20 °C. The supernatant was drained completely 
after centrifuging at 14000g for 10 mins. The tube was then rinsed in 70 % 
ethanol and centrifuged again at 14000g for 10 mins and decanted and drained 
completely. Finally, the pellet was dried briefly under vacuum and 
resuspended in 0.5 ml TE buffer.
2.2.4.3.5. Gene-clean purification of DNA sequences 33.6 and
33.15
In order to use the DNA satellites as probes for DNA fingerprinting, it 
was necessary to excise and purify each of the inserts from the vectors carrying 
them. Purification of the satellite inserts were carried out using the Gene-clean 
purification kit. 150 pg each of plasmid DNA with insert 33.6 and 33.15 were 
digested with EcoRI and Hind III according to the manufacture’s instructions 
and as described in the previous section. The digested DNA fragments were 
then separated by electrophoresis on 1% agarose gel in TAE. The 0.72 kb 
fragment and the 0.60 kb fragment representing satellite DNA 33.6 and 33.5 
respectively were excised from the gel with a sterile scalpel blade. The excised 
bands were then purified using the Geneclean II kit and following the 
manufacturer's instructions. The excised bands were weighed and cut into 
small cubes and 3 volumes of Nal stock solution was added and the tube 
incubated for 5 mins at 45 to 55 °C  to dissolve the agarose. Then an 
appropriate amount of Glassmilk suspension (5 jllI of Glassmilk suspension to 
solutions containing 5 pg DNA and an additional 1 pi for each 0.5 fig of DNA 
above 5 pg) was added and the contents incubated for 5 mins to allow DNA to 
adsorb to the glass milk. The glassmilk/DNA complex was then pelleted by 
centrifuging for 5 seconds. The supernatant was removed and set aside and
the pellet washed 3 times with NaCl/ethanol/water wash (New Wash). 
Finally, the DNA was eluted by incubating in 2 x 15 pi TE buffer for 5 min at 
50 °C. The final recovery of DNA probes is shown in Table 2.4. Aliquots of 
purified satellite DNAs were run on a agarose gel and their sizes verified (Fig. 
2 .11)
2.2.4.4. Purification of satellite DNA sequences 216S and 228S
2.2.4.4.1. Tranformation of E. coli with phage DNA carrying 
216S and 228S inserts
From the supplied recombinant M l3 phage DNA, it was necessary to 
grow up bulk stock of the insert DNA. Preparation of competent host cells for 
transformation with phage DNA containing 216S and 228S inserts was carried 
out using the CaCl2 method (Dagert & Ehrlich, 1979) as the Chung & Miller 
(1988) method failed to produce any transformants. Dried recombinant phage 
DNA containing 216S insert was provided as 2 x 5pl from a single plaque, 
while there were 13 pg of phage DNA carrying 228S insert (5 pi of 2.6 
pg/pl). The dried probe DNAs were resuspended in 10 pi of TE buffer (stock 
DNA). E. coli strains MV1190 and JM101 were grown overnight by shaking 
in 2 x TY medium at 37 OC. 0.5 ml of bacterial cultures were transferred to 
flasks containing 50 ml 2 x TY media and allowed to grow to log phase at 37 
°C. 40 ml of the cell cultures were pelleted by centrifuging at 5000g for 10 
mins at 4 °C. The remaining cells were used as non-competent cells to provide 
background to plaque formation. The supernatant was gently decanted and the 
cells were resuspended gently in 1/2 volume of cold, sterile 50 mM CaCl2 and 
kept on ice for 20 mins. The cells were spun down at 5000g at 4 °C and 
resuspended a second time in 1/16th volume of cold, sterile 50 mM CaCl2. To 
0.3 ml of these transformation competent cells were added 1 pi (from a stock 
diluted 500 x in TE bufer) of 216S and 228S DNA and the cells were
incubated on ice for 30 mins. The cells were then heat treated at 42 °C for 2 
mins, after which 100 pi of respective non-competent bacterial cells were 
added to each tube. To these cells 3 ml of warm top agar was added, mixed 
gently and poured on H plates. Control cultures without probe DNA and those 
with non-competent cells were also plated. All plates were incubated overnight 
at 37 °C. Plaques were observed for both DNA probes and in both JM101 
and MV1190 cells. With JM101 as host cells, there were fewer but well 
separated plaques while numerous plaques all over the plates were observed 
with MV1190.
2.2.4.4.2. Growth of 216S and 228S "plaques"
Plaques were picked from both JM101 and MV1190 plates using a 
sterile micropipette and inoculated into a bijoux containing 2 x TY medium and 
grown overnight at 37 °C with good aeration. Cells were pelleted and a 
plasmid mini-prep of both DNA probes were prepared as described in Section
2.2.4.2.I. The DNA was digested with EcoRI-Hind III and the fragments 
separated by agarose gel electrophoresis as described above. The fragment 
sizes of 210 bp and 330 bp representing DNA probes 216S and 228S 
respectively were observed in the plasmid DNA isolated from both transformed 
JM101 and MV1190. The 216S and 228S inserts were excised and purified 
using the gene-clean purification kit as described above in Section 2.2.4.2.2.
2.2.4.4.3. Subcloning of 216S and 228S inserts
It was desirable to subclone inserts 216S and 228S from recombinant 
M13 into a more suitable plasmids from which the inserts could be more easily 
isolated in bulk. The DNA inserts 216S and 228S isolated from M l3 
recombinants in JM101 and MV1190 were subcloned into vector pTZ18U. 
pTZ18U plasmids provided a stable vector in both strains of E. coli. These 
plasmids have a polylinker region and contain ampicillin resistance genes
which can be used in transformant selection. Screening of host transformants 
is made easier as the plasmids also have the lac Z gene, so that in the presence 
of IPTG and X-gal, non-recombinant clones will produce active p- 
galactosidase, thus producing blue colonies. But when DNA is inserted in the 
lac Z gene, no active p-galactosidase is produced, and these clones will be 
white.
216S (0.21 kb) and 228S (0.33 kb) fragments (10 ng DNA) were 
ligated to EcoRI/Hind III pTZ18U plasmids in presence of Tris HC1, MgCl2 . 
The fragments were incubated at 16 °C overnight in a 10 pi reaction mixture 
containing 2 pi buffer (2 pi of 5x) and 1 unit DNA ligase enzyme. To monitor 
that the enzymes and buffers were functional a control was set up; Hind HI cut 
X DNA was incubated with and without ligase enzyme. After incubation, 
ligated and unligated samples were run on a gel against markers to check if the 
ligation had worked.
2.2.4.4.4. Transformation with pTZ18U plasmids ligated with 
216S and 228S DNA
E. coli JM101 and DS941 cells were made competent for 
transformation with CaCl2 as described above (Section 2.2.4.5). 3 pi of 
216S- and 228S- ligated plasmid DNA (10 ng/pl) were used to transform 200 
pi of competent JM101 cells and the transformation was carried out by the 
CaC12 method (Section 2.2.4.4.1). 100 pi of transformed cells per plate were 
spread on X gal/IPTG plates containing ampicillin (100 pg/pl) and the plates 
incubated overnight at 37 °C. Transformant white colonies in DS941 and 
JM101 for each for the two inserts were detected.
Transformant colonies were picked from all plates (both JM101 and 
DS941) and streaked on to ampicillin containing plates and incubated overnight 
at 37 °C. Growth of ampicillin-resistant cells were observed with all colonies 
picked. These cells were restreaked a second time and the stability of the
Figure 2.10. Isolation of satellite sequences 216S and 228S. 
Electrophoresis of EcoRI + Hind m  digested (D) recombinant plasmid DNA 
show 0.21 kb and 0.33 kb inserts representing minisatellite sequences 216S 
and 228S respectively. D represents undigested plasmid DNA. The first D 
lane and the last D lane (from left) are plasmid DNA extracted from DS941 
and the remaining lanes represent plasmid extracted from JM101 strains.
ST represents standard DNA markers.
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transformants was checked. Mini-prep DNA was digested with EcoRI+Hind 
HI and electrophoresed on agarose gel. The 210 bp band of probe 216S and 
330 bp band of probe 228S were detected (Fig. 2.10).
2.2.4.4.5. Gene clean purifications of DNA fragments 216S 
and 228S
Plasmid DNA containing 216S and 228S inserts were extracted from 
bulk cultures of 500 ml of recombinant cells as described for probes 33.6 and 
33.15. 150 pg of plasmid DNAs were digested with EcoRI+Hind III and the 
satellite DNA fragments were excised and purified using the geneclean kit as 
described above. The final recovery of the satellite DNAs is listed in Table 2.4. 
Aliquots of purified satellite DNA were run on a gel and the sizes verified 
(Fig.2.11).
Table 2.4. Recovery of satellite DNA probes after geneclean purification.
Probe Insert size 
(in base pairs)
Amount of insert 
recovered
recovery*
(as % of expected)
33.6 720 22.5 pg 56
33.15 600 30 Hg 86
216S 210 6|xg 65
228S 330 12 Hg 69
^Recovery after gene-clean purification of excised satellite inserts from 150 pg 
of plasmid DNA.
Figure 2.11. Gene clean purified satellite DNA sequences 33.6 (0.72 kb),
33.15 (0.6 kb), 228S (0.33 kb) and 216S (0.21 kb).
ST represents standard DNA markers.
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2.2.4.5. Sequencing of satellite DNA
The purification of satellite DNAs involved a number of manipulations 
which then generated recombinant plasmids carrying the desired sequences. 
This is evident in the case of satellites 216S and 228S, which were originally 
inserts in M l3 phage and were finally isolated as pTZ18U recombinants. 
Nucleotide base sequences for all the isolated DNA satellites were therefore 
analysed to check the conformity of the isolated sequences with those of the 
reported sequences.
2.2.4.5.I. Sequencing reaction
Purified plasmid DNAs carrying the desired satellite DNAs were used 
for sequencing. 3 pg of plasmid DNA in 9 pi of TE buffer was denatured by 
adding 1 pi of 2M NaOH and incubating for 15 min at 37 °C. To anneal the 
sequencing primer (Universal & Reverse) to the denatured template 10 pmoles 
(1 pi of a lOpM stock) of primer was added and briefly vortexed prior to 
neutralisation of the NaOH with 3M potassium acetate (3 pi). The DNA was 
then ethanol precipitated (75 pi) overnight at -20 °C. Following centrifugation 
in a microfuge for 10 min, the pellet was washed with 100 pi of 75% ethanol 
and finally dried under vacuum.
A commercial "Sequenase" kit (USB) was used for sequencing and the 
reaction carried out according to manufacturer's instructions.
Sequenase buffer 5x: 200 mM Tris HC1, pH 7.5; 100 mM MgCl2‘, 250 
mMNaCl.
Labelling mix: 15 M dITP; 7.5 M dCTP; 7.5 M dTTP
Enzyme dilution buffer: 10 mM Tris HC1, pH 7.5; 5 mM DTT; 0.5 
mg/ml BSA.
Stop solution: 95% formamide; 2 mM EDTA; 0.05% EDTA; 0.05% 
bromophenol blue; 0.05% xylene cyanol FF.
2.2.4.5.2. Annealing mixture
Annealing reaction was carried out in a 10 pi mixture containing 7 pi 
DNA (denatured), 2 pi sequencing buffer and 1 pi of primer. The mixture was 
heated at 65 °C for 2 min and then slowly cooled to less than 35 °G. While 
the mixture was cooling, tubes were labelled and filled with 2.5 pi of each 
termination mixture. 4 termination tubes (dATP, dGTP, dCTP, dTTP) were 
set up for each sample to be sequenced. Labelling mix was diluted 1:4 (6 pi 
mix + 24 pi water) and enough of Sequenase (3 pi + 21 pi ice cold TE) was 
diluted 1:7 for all templates. The sets of 4 termination tubes were prewarmed 
in 37 °C water bath.
2.2.4.5.3. Labelling reaction
To annealed DNA mixture (10 pi) was added lp l DTT (0.1M), 2 pi 
diluted labelling mix, 0.5 pi [35S]-dATP and 2 pi diluted Sequenase. The 
contents were mixed and incubated at room temperature for 5 min.
2.2.4.5.4. Termination reaction
3.5 ml of labelling reaction was transferred to each termination tube 
(A,G,C,T), the contents were mixed and incubation at 37 °G was continued 
for another 5 min. Finally the reaction was stopped by adding 4 pi stop 
solution.
Scrupulously clean glass plates were taped together on three sides. A 
50 ml urea/acrylamide gel was prepared. The gel was pre-run for 3 min to 
warm before loading samples. All samples were heated to 90 °C for 15 min 
and then 3 pi were immediately loaded on to the gel. Gels were run at 4 mA 
and 1.4 kV constant power. Two sets of gels were run for each sample: a 
short gel run for 3 h to allow the first dye, bromophenol blue (runs at 18 
nucleotides) to reach the bottom of the gel, and a long gel was run for for 6 h 
which allows both dye fronts to run off the gel (dye xylene cyanol runs at 70 
nucleotides). After the run was complete glass plates were prized apart and the 
gel washed in 10% glacial acetic acid, 10% methanol for 10 min. This 
treatment allows urea to diffuse out and fixes the DNA in the gel. A dampened 
piece of Whatman 3MM paper was then placed over it and the gel transferred 
on to the paper. The gel was then covered in Saran wrap and dried in a gel- 
dryer for 1-1.5 h. The gels were finally autoradiographed for 1-4 days at room 
temperature.
2.2.4.5.5. Sequence analysis
Sequences were analysed from both the short 3h and the long 6h gels 
and overlapping sequences from both these gels were linked where possible. 
All sequences were analysed and compared to those in the EMBL database. 
Complete sequences for satellite DNAs 216S and 228S were available from 
Fowler et al. (1988) and Fowler et al., (1987) respectively. Sequences for 
minisatellites 33.6 and 33.15 were obtained from a computer search and then 
compared on the computer. For all 4 analysed satellite sequences good 
alignments with reported sequences were observed. Nucleotide base 
sequences for satellite 228S and 216S are shown in Fig. 2.12. The computer 
print-out of analysed sequences and its alignment with the reported sequences 
are given in Fig. 2.13a and 2.13b.
Figure 2.12. Sequencing of satellite DNA 228S and 216S.
The sequencing was carried out as described in Section 2.2.4.5. The figure 
shows the 3-hr gel.
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Figure 2.13a. Sequencing data on satellite DNA 228S.
The nucleotide base sequences as obtained in this study was compared with 
sequence data obtained from EMBL database
1  ............................. GGAATGGAATGGAATGGAATGGAATGGAATGGA 3 3
II I I I I I I I ! II I I I I I I I I I I I I I I I I I I I I I 
1 ACGGTCGACTGATCCCCGGAATGGAATGGAATGGAATGGAATGGAATGGA 5 0
3 4  ATGGATTCAACCCGAATGGAATGGAAAGGAATGGAATAAACCCGAGTGGA 8 3  
I I I M I i l l M l l l l l l l l M I I M I I M M I I M M M M I I M I M M
5 1  ATGGATTCAACCCGAATGGAATGGAAAGGAATGGAATAAACCCGAGTGGA 1 0 0
8 4  ATGGGATGGAATGGAGTGGAATGGAATGTAATGGAAGGGAATGGTACGGA 1 3 3  
I I I I I I I II I I I I I I I ! ! II I ! I I I ! I I I I I I I I I I I I I I I I I I I I I I I I 
1 0 1  ATGGGATGGAATGGAGTGGAATGGAATGTAATGGAAGGGAATGGTACGGA 1 5 0
1 3 4  ATGGAATGGAATGGAACTAAATGAAATGGAATGGAATGGAATGGAATGGA 1 8 3  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I 
1 5 1  ATGGAATGGAATGGAACTAAATGAAATGGAATGGAATGGAATGGAATGGA 2 0 0  '
1 8 4  ATGGAATGGAATGGAATGAACCCGTGTGCAATTGAATGGAATCGAATGGA 2 3 3  
I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I  
2 0 1  ATGGAATGGAATGGAATGAACCCGTGTGCAATTGAATGGAATCGAATGGA 2 5 0
2 3 4  ATGGAATGCCAATGGAATGGATTCA CTAG. ATGGAATGGAA GGAATGGAA 2 8 2  
l l l l l l l l l  I I  I I I I  I I  I I  I I I I I I N I  l l l l l l l l l l l  I I I  I N I  
2 5 1  ATGGAATGC AATGGAATGGATTCAACTAGAATGGAATGGAAAGGA TGGA 3 0 0
2 8 3  TCAACC AGTGGAATGGCAATGGCATGGAATGGAATCGAATGGAATGCAGT 3 3 2  
I M i l  l l l l l l l l l l l  I I I  l l l l l l l l l  l l l l l l  I I I  I I  I I I 
3 0 1  TGAACCGAGTGGAATGGC. ATGCCATGGAATG. AATCGA TGGAATGC. . . 3 4 4
Figure 2.13b. Sequencing data on satellite DNA 216S.
The nucleotide base sequences as obtained in this study was compared with 
sequence data obtained from EMBL database
1  GTTTCATAGCTTCTATCTCGAAAGGAAAGTTCAACTCTGTGAGTTGAATG 5 0
M i l l
1  ......................       GAATG 5
5 1  CAAGCATCACAAAGAAGTTTCTGAGAATGCTTCTGTTTAGCTTTCCTGTG 1 0 0  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
6 CAAGCATCACAAAGAAGTTTCTGAGAATGCTTCTGTTTAGCTTTCCTGTG 5 5
1 0 1  AAGATTCTCCCGTTTCCAACGAAATCTTCAAAATAGGTCCAAATATCC.A 1 4 9  
l l l l l l l l l l l l l f l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I 
5 6  AAGATTCTCCCGTTTCCAACGAAATCTTCAAAATAGGTCCAAATATCCAA 1 0 5
1 5 0  CTTGCAGATTCCACACAAGAGTGATTGGAAACTGCTCTTGAAAGGAACCT 1 9 9  
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  
1 0 6  CTTGCAGATTCCACACAAGAGTGATTGGAAACTGCTCTTGAAAGGAACCT 1 5 5
2 0 0  CACTCTGTGAG ..............   2 1 0
I I  I N I
1 5 6  TCAACTCTGAGCCGAATGCCAATCATCACAAGGAAGGTTCTGGGAATTCC 2 0 5
2.2.4.6. Digestion of genomic DNA from primary tumours, 
lymph nodes and PBL
Approximately 10 pg of genomic DNA were digested with the 
appropriate DNA restriction endonuclease. Hinf I was used for probing with 
33.6 and 33.15 satellites ( Jeffreys et al., 1985; Fey et al., 1988; Boltz et al., 
1990) and Taq I for probing with 216S and 228S satellites (Boltz et al., 1990). 
Restriction digestion was carried out under conditions recommended by the 
manufacturer (Pharmacia LKB).
The extent of digestion was tested on 0.4 |ig aliquots from each sample 
by electrophoresis on a 1% agarose gel. After digestion was judged complete, 
5pg DNA was electrophoresed on a 20 cm long 1% agarose gel till the 
bromophenol blue dye had run off the gel. DNA samples from PBL, primary 
tumour and lymph node were run in neighbouring lanes in the above order for 
each patient. Standard DNA markers were loaded on the extreme left and right 
lanes of the gel. All gels were photographed with a ruler with markings in 
centimeters placed alongside.
2.2.4.7. Southern Blotting
Southern blotting of the electrophoresed DNA was carried out using the 
standard capillary transfer method (Southern, 1975) and as described in 
Sambrook et al. (1989). The DNA was transferred on to Hybond-N nylon 
membranes (Amersham pic). Covalent attachment of DNA to the membrane 
was carried out by placing the membrane under uv light for 5 mins.
2.2.4.8. Radioactive labelling of DNA probes
All DNA probes and standard DNA were radioactively labelled with 
[a-32P]-deoxycytidine triphosphate using the nick-translation kit from 
Amersham pic. The labelling was carried out according to the manufacturer's 
instruction. This involved incubation of 1-2 |ig of satellite DNA with buffer, 
a-32p_dCTP (10jiCi/|il), and enzyme solution and incubated at 15 °C for 2 h. 
The reaction was stopped by adding 10 mM EDTA, 1% SDS and un­
incorporated nucleotide was removed by gel filtration through agarose A 1.5 
(Bio-Rad). The specific activity of the DNA probes ranged from 2 to 4 x 107 
c.p.m./pg.
2.2.4.9. Hybridisation with radiolabelled probes
Heat-denatured radiolabelled probes were hybridised to the Southern 
blots in the presence of formamide as described Anderson & Young (1985).
2.2.4.9.I. Pre-hybridisation
The filters were wetted evenly in 1% Triton X-100 and blotted gently 
with Whatman 3MM paper to remove excess liquid. Each filter was placed in a 
separate bag. 10 ml of prewarmed (37 °C) pre-hybridisation buffer (prepared 
as described in Section 2.1.15) was added and the bags heat-sealed. The 
filters were incubated overnight at 37 °C with shaking.
2.2.4.9.2. Hybridisation
Radiolabelled satellite DNA probes were mixed with radiolabelled 
marker DNA at a ratio of 50:1 cpm and placed in a boiling water bath for 5 min 
to denature the double-stranded DNA. After which the probes were quenched 
in ice and added to pre-warmed hybridisation buffer (prepared as described in 
Section 2.1.15). Pre-hybridisation buffer was removed from each bag by 
cutting a comer open and 8-10 ml of radiolabelled probes were added to each 
bag to give a probe concentration of 106 c.p.m./ml. Hybridisation was at 37 
OC for 12-18 h.
2.2.4.9.3. W ashing
The hybridisation buffer was removed from each bag and the filters 
were immersed in 200 ml of 2 x SSC, 0.1% SDS at room temperature. Filters 
were rinsed 4-5 times for 5 min in this solution. Next, the filters were shaken 
in 400 ml 0.1 x SSC, 0.1% SDS at 55 °C for lh. This was repeated twice. 
Finally, the filters were blotted to remove excess liquid and placed in a fresh 
bag and exposed to Kodak X-Omat S film with intensifying screens at -80 °C. 
All filters were exposed for a short time, which was usually overnight, and for 
a longer exposure which varied from 4 days to a week.
2.2.4.9.4. Reprobing of filters
All filters with Hinf I-digested DNA were first hybridised with DNA 
probe 33.15 followed by probe 33.6. Similarly, filters with Taq I-digested 
DNA were first hybridised with DNA probe 228S and then with probe 216S.
Filters were stripped of the first probe by heating in 0.01 x SSC, 0.1% SDS at 
85-90 °C for lh. The filters were then blotted dry and autoradiographed to 
ensure that no traces of the first probe remained before the second probe was 
applied.
2.2.5. Statistical analysis
Non-parametric statistical tests have been used to compare different 
groups of patients and to assess the association between different parameters. 
With the exception of chi-square test, all statistical analysis have been carried 
out using the Statworks software. Significance is taken at the level of 5%. In 
most cases, p values were derived on the computer. For cases with small n 
values, probability Tables have been consulted and in which case p values are 
given as either < than or > than the given value.
When comparing tumour-free and invaded lymph nodes from the same 
patient, Wilcoxon signed rank test was used. This same test was used when 
comparing HPA binding cells in lymph node metastases and autologous 
primary tumours.
When comparing groups of unrelated patients, stage I versus stage II, 
diploid versus aneuploid, the Mann Whitney U test was used. This same test 
was also used when comparing HPA binding between stage I and stage II 
patients.
All correlations have been assessed with the Spearman correlation test. 
This includes correlation of both tumour-free and invaded lymph nodes with 
peripheral blood lymphocytes from the same patient and the correlation 
between HPA binding in primary tumour and lymph node metastases.
All frequency tables have been analysed by the chi-square test with 
Yates correction. Both the chi-square (%2) statistic and the p value derived 
from the Table are given.
2.2.6. Histopathology and ER status
Histopathological and ER content data were available as a result of 
routine clinical practice carried out at Western Infirmary. Tumour grade, 
which was assessed by the method of Bloom & Richardson (1957) and the 
number of lymph nodes invaded out of the total nodes examined were assessed 
by a pathologist at the Western Infirmary. Pathological examination was 
carried out on one half of the same nodes that were examined in this study.
ER content of primary tumours were determined by the ligand binding 
method (Leake etal., 1981).
3. The effect of metastasis on the immune function of 
the axillary lymph nodes.
It is apparent (Section 1.2) that the immune response within human 
patients is highly variable and may be influenced not only by the 
immunological status of the patient but also by the oncogene complement of the 
tumour. Tumour draining lymph nodes in breast cancer patients represent a 
site where malignant cells may be recognised by the host immune system and 
additionally metastatic cells invading the nodes may adversely affect the 
response. In consequence, the general phenotype and activation state of the 
lymphocytes in the nodes may be found altered. As such, the comparison 
likely to be most relevant is of two axillary lymph nodes, one invaded and one 
tumour-free, both obtained at the same time from the same patient. However, 
to test the hypothesis that any breast tumour affects the nodal response at long 
range so that stage I patients are able to remain in that state because they have 
kept the tumour from invading, it is also useful to compare stage I derived 
nodes with both invaded and tumour-free nodes from stage II patients. This 
section describes pilot studies addressing such questions.
The methodology of lymphocyte staining and gating is described in 
Section 2.2.1.3 & 2.2.1.4.
3.1. Phenotypic markers
3.1.1. T and B lymphocytes
From the results in Table 3.1, it can be seen that the mean proportions 
of T and B lymphocytes in tumour-free and invaded nodes from stage II 
patients were similar. The proportions of CD3+ T cells in tumour invaded 
nodes (mean 45.7%) were only slightly lower compared to those in tumour
TABLE 3.1. Distribution of phenotypic markers on lymphocytes from 
tumour invaded and tumour free lymph nodes of stage II breast cancer patients 
and from lymph nodes in stage I breast cancer patients.
Phenotypic STAGE II 
Marker Tumour Tumour 
Invaded Free 
(n=12) (n=12)
STAGE I 
(n=14)
Statistical
Significance+
CD3 (%T cells) 45.7+/-4.6 49.7+A4.8 51.5+/-3.0
a) N.S.
b) N.S.
c) N.S.
CD19 (% B cells) 41.6+/-6.0 41.0+/-4.35 36.4+/-3.2
a) N.S.
b) N.S.
c) N.S.
CD8
(%CD8+T cells)
14.4+/-2.4
(12.3+/-8.4)*
7.9+/-1.0 
(7.4+/-3.3)
8.9+/-0.8
(9.5+/-3.0)
a) p= 0.002 
b) 0.05>p<0.1 
c) N.S.
CD4
(% CD4+T cells]
a) p= 0.003
32.0+/-3.3 41.1+/-3.8 42.1+/-3.3 b) N.S.
> (29.5+/-11.5)* (40.5+/-13.0) (40.5+/-12.3) c) N.S.
CD4/CD8
RATIO
2.9+/-0.5 
(2.05+/-1.7)
5.8+/-0.7
(5.3+/-2.2)
6.0+/-1.4 
(4.8+/-5.1)*
a) p= 0.001
b) N.S.
c) N.S.
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
* values in bracket represents median +/- standard deviation (SD). Median 
values and SD are cited for all cases where a distribution appeared to be 
skewed (marked with asterisk).
+ Statistical test used: Wilcoxon signed rank test, when comparing tumour 
invaded and tumour free nodes from the same patient; Mann Whitney U test, 
when comparing independent samples of stage I and stage II patients (Methods 
and Materials, Section 2). Statistical significance is taken at a p value equal to 
or < 0.05. Only significant p values and those with p<0.1 are given. N.S. is 
not significant.
a) is tumour invaded versus tumour free stage II lymph nodes; b) is tumour 
invaded stage II versus stage I nodes; and c) is tumour free stage II versus 
stage I nodes.
free nodes (49.7%). While the proportions of CD 19+ B cells were similar in 
both node types in stage II patients, there were slighdy fewer CD3+ T cells and 
more CD 19+ B cells in stage II invaded nodes in comparison to nodes from 
stage I patients. None of these differences were, however, statistically 
significant. When comparing tumour-free nodes with invaded nodes in the 
same stage II patient (Fig. 3.1a & 3.1b), differences were observed more with 
respect to B cells than T cells, then again this was in some but not all patients. 
There was, however, no consistent trend for T or B lymphocytes to be higher 
or lower in the two nodal groups (Fig. 3.1a & 3.1b).
The major differences with respect to the proportion of B and T 
lymphocytes were observed when stage II patients were compared with each 
other. Here again, patient variability was greater with respect to B cells than 
with T cells (Fig. 3.1a, 3.1b). A few patients were found to have very low 
levels of B cells (Fig. 3.1b) and in this, patient 2 was notable in having less 
than 10% of B cells and over 80% T cells.
3.1.2. T cell subsets
Analysis of T cell subsets showed differences between tumour-invaded 
and tumour-free nodes. The mean percentage of CD8+ suppressor/cytotoxic T 
cells in tumour invaded nodes (14.4%) was higher when compared with 
tumour free nodes (7.9%) of matched stage II patients (Table 3.1). This 
difference was statistically significant (p=0.002). The distribution in the 
invaded nodes was, however, skewed (median 12.3%) with only three patients 
having greater than 20% of CD8+ T cells (Fig. 3.3a). In the remaining cases,
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Figure 3.1a. CD3+ T cells in tumour-free (un) and invaded (inv) lymph 
nodes within the same stage II patients.
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Figure 3.1b. CD 19+ B cells in tumour-free (un) and invaded (inv) lymph
nodes within the same stage II patients.
the differences in the proportion of CD8+ T cells were much smaller. 
Conversely, the CD4+ helper T cells in the stage II invaded nodes were 
decreased (32%) in comparison with tumour free stage II nodes (41.1%) 
(p=0.003). Figures 3.2a and 3.2b show the differences in CD4+ and CD8+ T 
cells within the same stage II patients. Although the majority of invaded 
nodes had higher CD8+ cells, the difference between the two groups was 
smaller when compared to the differences observed with CD4+ T cells (Fig. 
3.2b).
The alterations in the T cell subsets within individual stage II patients 
however, did not reach statistical significance when invaded nodes from stage 
II and tumour free nodes from unrelated stage I patients were compared (Table
3.1). The mean proportions of both CD8+ and CD4+ cells in stage I patients 
were the same as those for tumour-free nodes in stage II patients. The 
distribution of CD8+ cells varied highly in the invaded nodes compared to both 
tumour-free nodes in the same patient and unrelated stage I patients (Fig 3.3a). 
Variations in the proportion of CD4+ T cells were observed in all three groups 
(Fig. 3.3b), but invaded nodes had lower values of this T cell subset compared 
to the other two groups.
3.1.3. CD4+/CD8+ Ratio
In consequence of the above differences, the CD4/CD8 ratio was 
significandy different in the comparison between invaded nodes from the same 
stage II patients (p=0.001). Although the median value of this ratio in invaded 
nodes (2.0) was 2 fold lower in comparison to stage I patients (4.8), this 
difference failed to reach statistical significance (Table 3.1).
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Figure 3.2a. CD8+ T cells in tumour-free (UN) and invaded (INV) lymph 
nodes within the same stage II patients.
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Figure 3.2b. CD4+ T cells in tumour-free (UN) and invaded (INV) lymph
nodes within the same stage II patients.
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Figure 3.3a. Distribution of CD8+ T cells in tumour invaded (1), tumour 
free (2), and stage I (3) lymph node lymphocytes from breast cancer patients.
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Figure 3.3b. Distribution of CD4+ T cells in tumour invaded (1), tumour 
free (2), and stage I (3) lymph node lymphocytes from breast cancer patients.
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Figure 3.4a. CD4+/CD8+ ratio in tumour-free (UN) and invaded (INV) 
lymph nodes within the same stage II patients.
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Figure 3.4b. Distribution of CD4/CD8 ratio in tumour invaded (1), tumour 
free (2), and stage I (3) lymph node lymphocytes from breast cancer patients.
The CD4/CD8 data are further examined in Figures 3.4a and 3.4b. Inspection 
of the data shows extensive patient variability. In some patients, there was 
both a depression of the proportion of CD4+ cells and an increase in CD8+ T 
cells with cases where the difference in values reached 2 fold. There were, 
however, also cases where the difference in the ratio was contributed by 
changes in only one of the T cell subsets. The depression of the CD4+ 
population in the tumour invaded nodes was, however, more pronounced and 
more consistently observed (Fig 3.2b). Figure 3.4b shows the precise 
distribution of the proportion of CD4+ and CD8+ T cells in invaded and 
tumour free nodes. The CD4/CD8 ratios for the invaded nodes were within a 
relatively tight range of 1.1 to 5.42 compared to the higher range of 1.15 to 
9.16 for tumour free nodes.
3.2. Activation markers
Table 3.2 summarises the expression of the activation markers HLA 
DR and IL-2 receptor (Tac) on T cells and slgG on B cells. With the exception 
of slgG on B cells, no significant differences in terms of expression of any of 
these markers were observed. However, slight differences did occur in some 
cases.
3.2.1. HLA DR
In all cases the percentage of CD8+ cells bearing HLA DR was higher 
than HLA DR-expressing CD4+ cells. The proportion of HLA DR+ T cells 
was slightly higher in invaded nodes with a mean value of 69.9% compared to 
64.8% in tumour free nodes (Table 3.2). The mean proportions of these HLA
T A B L E  3.2. Distribution of activation markers on lymphocytes from 
tumour invaded and tumour free lymph nodes in stage II breast cancer patients 
and from lymph nodes in stage I breast cancer patients.
Activation
Marker
STAGE II 
Tumour Tumour 
Invaded Free 
(n=12) (n=12)
STAGEI 
(n=14)
Statistical+
Significance
HLA DR on 
T cells 69.9+/-5.8 64.8+/-6.7 73.2+/-8.9
a) N.S.
b) N.S.
c) N.S.
HLA DR on 
CD8+T cells 42.4+/-4.8 42.9+/-3.6 48.1+/-6.0
a) N.S.
b) N.S.
c) N.S.
HLA DR on 
CD4+T cells 28.5+/-3.3 25.4+/-3.4 32.7+/-4.1
a) N.S.
b) N.S.
c) N.S.
Tacon 
T cells 44.9+/-3.9 37.7+7-3.5 45.3+/-6.3
a) N.S.
b) N.S.
c) N.S.
Tac on 
CD8+T cells 19.6+/-2.6
(20.2+/-9.2)
a) N.S.
15.7+/-3.1 16.4+/-3.2 b) N.S. 
(12.7+/-10.8)* (12.8+/-11.5)* c) N.S.
Tacon 
CD4+T cells 24.0+/-3.4 21.9+/-2.2 28.8+/-3.6
a) N.S.
b) N.S.
c) N.S.
slgG on 
B cells 34.6+/-4.1 
(33.2+/-14.0)
27.6+/-2.6
(30.8+/-8.9)
25.8+/-6.6
(18.0+/-24.6)*
a) p<0.05
b) 0.02<p<0.05
c)0.05<p<0.1
Values represent mean % +/- standard error of lymphocytes expressing the 
phenotypic marker.
* values in bracket represents median +/- standard deviation (SD). Median 
values and SD are cited for all cases where a distribution appeared to be 
skewed (marked with asterisk).
+ Statistical test used: Wilcoxon signed rank test, when comparing tumour 
invaded and tumour free nodes from the same patient; Mann Whitney U test, 
when comparing independent samples of stage I and stage II patients (Methods 
and Materials, Section 2). Statistical significance is taken at a p value equal to 
or < 0.05. Only significant p values and those with p< 0.1 are given. N.S. is 
not significant.
a) is tumour invaded versus tumour free stage II lymph nodes; b) is tumour 
invaded stage II versus stage I nodes; and c) is tumour free stage n  versus 
stage I nodes.
DR+ cells were not significantly different between autologous nodes from 
stage II patients or in comparison between stage I and stage II patients. This 
was also true for T cell subsets, and although in some cases there was a 
slightly higher proportion of HLA DR+ T cells in invaded nodes when 
compared to tumour-free nodes, there were also cases where the reverse was 
true (Fig. 3.5a & 3.5b). Thus, no general trend was apparent.
3.2.2 Interleukin-2 receptor (Tac)
In all the three groups of nodes analysed, there was a higher percentage 
of Tac-expressing CD4+ T cells than CD8+ T cells (Table 3.2). The mean 
percentage of Tac+ T cells in stage II tumour invaded nodes (44.9%) was 
higher than in stage II tumour free nodes (35.3%) but similar to stage I nodes. 
Although CD8+ population from invaded nodes (median 20.2%) expressed the 
marker on a slightly higher proportion of cells when compared to tumour free 
nodes (median 12.7%), the difference was not statistically significant (Table
3.2). Patient variability was high, with some cases of higher percentages in 
invaded nodes and others with the reverse (Fig.3.6a & 3.6b). Moreover, in a 
few patients, the expression of this marker was markedly low (Fig. 3.6b).
3.2.3 Surface Immunoglobulin G (slgG)
The percentage of slgG-expressing B cells in tumour invaded nodes 
(median 33.2%) was slightly higher in comparison to tumour-free nodes 
(median 30.8%) and about 2 fold higher in comparison to stage I nodes 
(median 18%). The small difference between tumour-free and invaded nodes 
reached statistical significance (p<0.05). The distribution of stage I nodes
It is important to point out that IgG-expressing B cells as detected in this study, may 
also reflect the presence of cytophilic antibodies. These antibodies would bind to the 
Fc receptors and as such would be included in the IgG+ population. This may be 
tested in two ways-
i) a control may be set up in which lymphocytes may be stained with anti-kappa-FTTC 
and anti-lambda-PE antibodies. In a dual-parameter analysis, the cytophilic antibodies 
would show up as double positive as opposed to single-stained B cells expressing 
specific IgG (either kappa or lambda).
ii) IgG+ B cells may be stripped of their surface immunoglobulin (and cytophilic 
antibodies) by treating with papain and then put into culture to allow regeneration of 
slgG.
(mean 25.8%, median 18%) was skewed (Fig. 3.7b) and the difference 
between stage I and tumour-invaded stage II nodes from unrelated patients also 
reached statistical significance ( p< 0.05; Table 3.2).
A notable feature of IgG-expression was that the differences between 
invaded and tumour-free nodes were often strong in a few patients. A 
representative example where the invaded node had a considerably higher 
proportion of slg-bearing B cells than the tumour free nodes is shown in Fig 
3.8.
3.3 Correlation with peripheral blood lymphocytes (PBL)
PBL from breast cancer patients have fewer CD4+ T cells and a higher 
proportion of CD8+ T cells than those from LNL (Whitford et al., 1992b). A 
strong positive correlation with CD4+ T cells and an inverse relation with 
CD8+ T cells was found in lymphocytes from these sources. To determine 
whether alterations observed in the invaded nodes also reflect similar changes 
in the cell populations from PBL, lymphocytes from these sources from the 
same patient were compared in a correlation test.
In this study, comparison of the phenotypic markers and slgG 
expression between tumour-invaded nodes and those from the PBL from the 
same patient (Table 3.3) revealed no significant correlation, either positive or 
negative. This suggests that the peripheral blood reflects neither the depression 
of CD4+ cells nor the elevation of the CD8+ T cells observed in tumour 
invaded nodes. Similarly, slgG expression, which was found in only a small 
number of cells (Fig 3.8), was not reflected in B lymphocytes from peripheral 
blood.
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Figure 3.5a HLA DR expressing CD4+ T cells in tumour free (UN) and 
invaded (INV) lymph nodes
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Figure 3.5b HLA DR-expressing CD8+ T cells in tumour free (UN) and
invaded (INV) lymph nodes within the same stage II patients.
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Figure 3.6a. Tac-expressing CD4+ T cells in tumour free (UN) and 
invaded (INV) lymph nodes within the same stage II patients.
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Figure 3.6b. Tac-expressing CD8+ T cells in tumour free (UN) and
invaded (INV) lymph nodes within the same stage II patients.
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Figure 3.7a. IgG-expressing B cells in tumour free (un) and invaded 
(inv) lymph nodes within the same stage II patients.
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Figure 3.7b. Distribution of IgG-expressing B cells in tumour invaded (1),
tumour free (2), and stage I (3) lymph node lymphocytes from breast cancer
patients.
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Figure 3.8. slgG-expressing B cells (CD 19+) in lymphocytes from 
peripheral blood (A), tumour-free (B), and invaded (C) lymph nodes from the 
same breast cancer patient.
Such strong differences between invaded and tumour-free nodes were 
observed in some stage II patients.
Anti-CD 19 staining is plotted on FL2 and anti-IgG staining is on FL1.
% IgG+CD19+cells: PBL-0.6; tumour-free nodes-8.1; 
tumour-invaded nodes- 33.5.
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TABLE 3.3. Correlation of phenotypic marker on lymphocytes from
lymph node (LNL) and peripheral blood (PBL) of stage II breast cancer
patients.
Phenotypic/
Activation
Marker
LNL-
Tumour
Invaded
(n=12)
LNL-
Tumour
Free
(n=12)
PBL
(n=12)
Spearman
Correlation*
CD8 14.4+/-2.4 7.9+/-1.0 26.9+/-3.5 a) N.S.
b) N.S.
CD4 32.0+/-3.3 41.1+/-3.8 35.6+/-3.0 a) N.S.
b) N.S.
CD4/CD8
RATIO
2.9+/-0.5 5.6+/-0.7 1.6+/-0.3 a) N.S.
b) N.S.
slgG on 
B cells
34.6+/-4.1 27.6+/-2.6 3.95+/- 0.88 a) N.S.
b) N.S.
* a) is tumour invaded nodes versus PBL; b) is tumour free nodes versus 
PBL.
values represent mean % +/- standard error of lymphocytic subset expressing 
the phenotypic marker.
3.4 Comparison of two invaded lymph nodes from the same 
stage II patient and two (by definition) non invaded lymph nodes 
from the same stage I patient.
This study was undertaken to find out whether lymph nodes operate 
independently within an individual. In stage I patients, a necessary control is 
to test two anatomically independent lymph nodes in each other. In stage II 
patients, it is necessary to find whether tumour invasion causes the same 
changes in both cases. Technically, the latter is difficult as the precise degree of 
tumour invasion is difficult to judge and therefore a matched pair from the 
same patient is not readily obtained. However, the status of the selected lymph 
nodes were verified by histopathology.
Comparisons of the phenotype and activation state of 
lymphocytes from two tumour invaded nodes within a single stage II patient 
and two tumour free nodes within a single stage I patient were peformed (Table 
3.4). The two tumour free nodes from a stage I patient were similar in all 
respect with good conformity between the CD4/CD8 ratio and in the proportion 
of cells expressing the activation markers. The similarities between the two 
invaded nodes from the stage II patient were much less. The relatively lower 
value of CD4+ T cells and the slight elevation of CD8+ T cells in node A gave 
a CD4/CD8 ratio for this node similar to the mean value for the invaded nodes 
given in Table 3.1. But node B had a much higher CD4+ population and a 
CD4/CD8 ratio which was more similar to the tumour free nodes. Likewise, 
with respect to activation markers, node B had a higher proportion of HLA DR 
expressing T cells, but the two nodes showed better conformity with respect to 
Tac expression. Although the proportions of B cells were similar in all of 
these nodes, there was a higher percentage of IgG+ B cells in the invaded
T A B L E  3.4. Comparison of the phenotype and activation state of 
lymphocytes isolated from two invaded lymph nodes removed from a stage II 
and two tumour free nodes from a stage I breast cancer patient.
PHENOTYPIC/ TUMOUR INVADED TUMOUR FREE
ACTIVATION NODE A NODEB NODE A NODEB
MARKER % % % %
CD3+ 59.0 71.5 64.6 70.6
CD 19+ 22.5 16.8 28.8 21.5
CD8+ 11.5 9.6 7.3 7.8
CD4+ 46.2 62.1 55.4 62.1
CD4+/CD8+ 4.0 6.4 7.5 8.0
HLA DR+CD8+ 13.8 27.6 27.7 26.4
HLA DR+CD4+ 8.7 19.8 14.6 14.5
TAC+CD8+ 17.3 22.4 12.6 10.3
TAC+CD4+ 14.6 18.7 26.2 22.5
IgG+ CD 19+ 15.3 15.9 9.0 7.6
nodes and in this respect both node A and B in the invaded group had almost 
identical proportions of these activated cells.
This data, therefore, suggest that the presence of tumour cells within a 
node may have variable effects, while tumour free nodes in a patient are similar 
with respect to the phenotypic and activation markers. It should, however, be 
emphasised that only a single pair of these nodes was analysed.
3.6. D iscussion
Axillary lymph nodes in breast cancer patients may be an important site 
for mediating immune responses to tumours. As these nodes primarily drain 
the breast, they are ideally situated to encounter tumour cells and, as such, 
tumour antigen recognition leading to host-mediated immune response can 
occur. At the same time, however, metastatic tumour cells invading the nodes 
can adversely influence the lymphocytes within such nodes. An analysis of the 
phenotype and the activation states of lymphocytes within lymph nodes from 
patients with metastatic breast cancer can reflect the nature of the response and 
may also determine the outcome of the tumour-host interaction.
Only a few studies have analysed lymph node lymphocytes from breast 
cancer patients by flow cytometry (Morton et al., 1986; Whitford et al., 
1992b). Although nodes from both stage I and stage II patients were analysed 
in the above studies, nodes free of tumour were preferred and grossly invaded 
nodes were omitted. Moreover, these studies compared nodes in groups with 
respect to the stage of the disease and no study has compared nodes within the 
same patient. In this study, phenotypic and activation markers on lymphocytes 
from a tumour-free and an invaded node taken from the same stage II patient 
(with metastasis) was analysed by flow cytometry. Furthermore, the two 
groups of nodes were compared to lymph node lymphocytes from patients 
without metastasis (stage I).
Results described in this section reveal that in some breast cancer 
patients, differences in the proportion of T cell subsets and activated B cells 
exist between nodes that are invaded and those that are not. Notable but not 
significant differences were also observed between invaded nodes and stage I 
nodes, while the phenotype and the activation states of lymphocytes from
tumour-free nodes from both stage I and stage II patients were found to be 
similar. The mean proportions of T and B lymphocytes were similar in both 
invaded and tumour-free stage II nodes, but there were more B cells in stage II 
patients. The lymph node is the major site of the B lymphocyte population and 
elevation of B cells in stage II patients was also observed by Morton et al. 
(1986). The proportion of T cells in invaded nodes although varying among 
patients was not significantly lower when compared to those in tumour-free 
nodes. Lower proportions of T cells in invaded nodes from melanoma patients 
has been reported by Farzad et al. (1990).
There were, however, notable differences in the proportion of T cell 
subsets and the most significant difference between tumour-free and invaded 
nodes was observed with the CD4+/CD8+ ratio. In invaded nodes, this ratio 
was reduced to less than half that of tumour-free nodes. The reduction in 
CD4+/CD8+ ratio was due to an increase in CD8+ T cells and a decrease in the 
CD4+ population. Similar alterations in the CD4 and CD8 populations have 
been reported for stage II breast cancer (Morton et al., 1986) and melanoma 
(Farzad et al., 1990) patients. However, in the study of melanoma patients, 
the significant depression of CD4+ cells was observed in both tumour-free and 
invaded nodes and while CD8+ cells were higher in both these nodes, only the 
tumour-free nodes were significantly higher than stage I nodes. In this study, 
the T cell subsets in stage I nodes were found to be similar to tumour-free 
nodes, suggesting that only the presence of tumour cells in the nodes affects 
the T cell subsets such that the CD4+/CD8+ ratio drops in invaded nodes. It 
must be pointed out that with the exception of three patients, the increase in 
CD8+ T cells was small and was not always accompanied by a decrease in 
CD4+ cells in the same patient. The decrease in the proportion of CD4+ T 
cells in invaded nodes was, however, more pronounced and showed more 
variability among patients. It is of interest to note here that lymphocytes that
infiltrate tumours (TILs) have been found to comprise predominantly of CD8+ 
T cells (Whitford et al., 1990; Durie et al., 1990) and the increase in the same 
phenotype in invaded nodes is perhaps suggestive, in both cases, of activated 
cytotoxic cells in close proximity to their target cells.
The expression of the activation marker HLA DR was similar in both 
tumour-free and invaded nodes and was not significantly different from stage I 
nodes. This is in contrary to the finding of Whitford et al. (1992b), who 
found the expression on CD8+ T cells to be related to stage, and Morton et al. 
(1986), who reported higher proportions of HLA DR-expressing CD4+ and 
CD8+ T cells in stage II patients. However, in agreement with all other 
reports, this marker was found to be expressed on higher numbers of CD 8+ 
than CD4+ T cells. In contrast, the IL-2 receptor (Tac) was present on twice 
as many CD4+ than CD8+ cells in lymphocytes from all three sources. It is 
not known whether this reflects any functional difference in the expression of 
the receptor on these T cell subsets or if this is a reflection of the activated state 
of the respective cells. In general, the percentage of Tac-expressing T cells 
were slightly higher in invaded nodes when compared to tumour-free nodes, 
while being similar to stage I nodes. The proportions of T cells expressing Tac 
were, thus lower in tumour-free nodes compared to invaded nodes, but these 
differences were not statistically significant. IL-2 receptor as a activation 
marker, however, should be interpreted with caution. Although an increased 
expression of the receptor indicates an activated state of a T cell, lack of the 
receptor does not necessarily suggest an inactive state as the receptor is known 
to undergo down-regulation following binding of its ligand (Duprez et al., 
1988).
The proportion of B cells was not only higher in stage II nodes but the 
mean percentage of slgG-expressing B cells in invaded nodes were higher than
stage I nodes. The difference between invaded and tumour-free nodes within 
the same stage II patient was also statistically significant. In the other study to 
assess this marker but which did not include invaded nodes, no significant 
difference was observed with stage (Whitford et al., 1992b). However, in this 
study an interesting feature of IgG-expression in lymph node lymphocytes was 
that in some patients, compared to tumour-free nodes there was a considerably 
higher numbers of these activated B cells in invaded nodes. The expression of 
slgG on B cells marks the onset of a mature humoral response. It is thus 
probable that in some of the invaded nodes, showing high percentage of IgG+ 
B cells, the presence of tumour cells provide adequate antigens for this 
secondary B cell response.
A characteristic feature observed with respect to both the phenotype and 
activation marker expression by lymph node lymphocytes from breast cancer 
patients is patient variability. This variability was more often observed in the 
case of invaded nodes than tumour-free nodes. This may reflect both the 
capability of host-immunity and the oncogenic or antigenic complement of the 
tumour. A parameter that could be related with host response is the 
differentiation state of the tumour as assessed in terms of histological grade. 
But as only 12 patients were studied and as there was a bias for grade 3 
tumours, no relationship could be determined between any of the changes 
observed with the grade of the primary tumour. In addition to variation among 
patients it is likely that variation may also exist within a patient, such that 
variation is also observed among nodes of the same status in the same patient. 
Analysis of two invaded and two tumour-free nodes suggest that while 
tumour-free nodes were similar, the presence of tumour cells within a node 
may exert varying influences. This probably reflects differences in the degree 
of involvement by the tumour cells.
Taken together, these results suggest that the presence of metastatic 
tumour cells in a lymph node can cause specific alterations of the phenotype of 
the T cells and the activated state of the B cells in a proportion of the patient. 
While certain cell populations are being activated others appear not to be 
proliferating or perhaps are being actively suppressed. In effect, such 
alterations in the lymphocytic populations reflect the presence of metastatic 
cells and may be important elements in the metastatic process.
CHAPTER 4
FCM analysis of cell surface  
c a r b o h y d r a t e s
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4. FCM analysis of cell surface carbohydrates in
breast cancer
Surface carbohydrate structures and their alterations in human breast 
cancer have been studied with the intention of identifying both tumour- 
associated changes and structures related to metastatic spread. Recent evidence 
suggests that in the role of adhesion molecules, surface glycoproteins may be 
involved in the metastatic spread of cancer (Section 1.1.6.6). In breast cancer, 
alterations in cell surface carbohydrate expression have been detected using 
lectins and in a number of studies such differences have been shown to be of 
prognostic significance (Section 1.3.5). Most of these studies were 
histochemical analysis and have been performed on paraffin sections of 
primary tumours.
This section presents data on a FCM analysis of lectin binding to both 
primary and lymph node metastases from breast cancer patients. Recognising 
the evident limitations of histochemical analysis and the use of paraffinised 
tissue, fresh samples were used and the extent of staining has been quantified 
in a well-defined manner. Two fluorescently-labelled lectins, Concanavalin A 
(Con A) and Helix pomatia (HPA), which were found to show detectable 
changes in binding to breast tumours, have been used to assess the value of 
lectin binding to a large number of live cells (10,000) from fresh breast 
cancers. Reactivity to both these lectins has been previously reported to be 
related to malignancy in breast cancer (Leathern & Brooks, 1987; Dansey et 
al., 1988; Furmanski et al., 1981). Although these studies analysed primary 
tumours, metastatic tissues have not been analysed. In this study, metastatic 
cells from axillary lymph node metastases have also been analysed for their 
binding to these lectins. Data presented here shows that HPA binds to a 
surface molecule present on tumour cells with higher malignant potential.
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4.1. Quantification of fluorescence intensity by Flow cytometry
The methodology of staining and analysis of lectin binding on gated 
tumour cells have been described in Section 2.2.2. A gated analysis of breast 
tumour cells was necessary as tumour cells frequently have a substantial 
percentage of infiltrating lymphocytes (Whitford et al., 1990). At the 
concentration of lectins used, lymphocytes were, however, found not to bind 
HPA and showed only low-intensity binding to Con A (Alam et a l, 1990).
In general, the binding of both HPA and Con A to both malignant and 
normal breast epithelial cells could be categorised into two groups - a low- 
intensity binding and a high-intensity binding cell population (Figure 4.1). 
Cell populations showing fluorescence intensity 10 times brighter than the 
autofluorescence were taken to be the low-intensity binding group and the 
high-intensity binding group showed a fluorescence intensity which was 100 
times brighter. It was the percentage of cells in the high binding group that 
varied with each specimen analysed and the extent of which could be correlated 
with clinicopathological factors. Henceforth, both HPA and Con A binding 
refers to these populations of these cells showing high intensity binding to the 
lectins.
4.2. High-intensity lectin binding cells in normal breast tissue
Binding to cells from normal breast tissue (a reduction mammaplasty 
sample, Section 2.2.2.2) was observed for both HPA and Con A. However, 
the proportion of high-intensity HPA-binding cells in the normal breast 
epithelial tissue was markedly lower (18%) in comparison to high Con A 
binding cells (39%). These values were considered to assign cut-off points
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Figure 4.1. Markers set to define regions of unbound cells, low intensity 
and high intensity binding of the tumour cells to the lectins.
II EBB
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when relating lectin binding to clinicopathological features.
4.3. Con A binding to primary breast tumours
Although high-intensity Con A binding cells were detected in primary 
breast tumours, the proportion of these cells were quite variable with one 
tumour not having any of these cells and a few tumours having greater than 
80% of these cells. The values ranged from 0 to 96%, with a mean of 38.5 +/- 
5.5%. The mean is similar to the percentage of high-intensity Con A binding 
cells detected in normal breast cells (39%).
When correlating Con A binding with histopathological factors, it was 
necessary to assign a cut-off value to distinguish tumours with higher 
percentage of high-intensity Con A binding cells from those with lower 
proportions of these cells. The cut-off value >40% was found to be most 
informative in relating Con A binding and henceforth tumours with >40% of 
these cells will be termed Con A positive.
Of the 32 primary tumours analysed, 14 were positive for Con A 
binding. The relationship between Con A binding and various 
clinicopathological factors is shown in Table 4.1. Although a higher number 
of Con A positive tumours had metastasised to the nodes, the difference was 
not statistically significant. As with lymph node involvement, no correlation 
was observed between Con A binding and either tumour grade or ER status.
Table 4.1. Clinicopathological features of breast cancer patients and their 
relation to HPA and Con A binding.
Clinicopathological
features
Total Positive HPA Positive Con A
All patients 32 17 (53%) 14 (44%)
Node involvement:
invaded 16 13 (81%) 9 (56%)
non-invaded 16 4 (25%) 5 (31%)
Histological grade:
I 4 0 1 (25%)
n 14 7 (50%) 6 (43%)
m 14 10(71%) 7 (50%)
Oestrogen receptor: 
ER+ve
(>20 fmol/mg protein) 14 6 (43%) 6 (43%)
ER-ve
(<20 fmol/mg protein) 11 10 (91%) 5(45.5%)
ER receptor (25 cases) data were not available for all patients.
HPA positive tumours have > 20% of cells showing high-intensity binding. 
Con A positive tumours have > 40% of cells showing high-intensity binding. 
Some of the tumours were positive for both lectins (9 cases), some were 
negative for both (10 cases), while a few others (13 cases) were positive for 
only one lectin.
4.4. HPA binding to primary breast tumours
Among the 32 primary tumours analysed, there was much variation in 
the proportion of cells showing high-intensity HPA binding. The values 
ranged from 0 to 83%, with a mean of 28.74 +/- 4.5%. This mean is higher 
than the proportion of high HPA cells observed for normal breast cells.
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As with Con A binding, HPA positive tumours have been defined as 
those having >20% of high-intensity HPA binding cells. Of the various cut­
off points assessed >20% offered the most informative cut-off value, 
especially when related to grade and node involvement.
4.5. Correlation of HPA binding with clinicopathological 
features
Of the total 32 primary tumours, 53% (17 cases) were designated HPA 
positive (Table 4.1). Correlation of positive HPA binding with 
clinicopathological factors revealed that there was strong correlations with 
lymph node involvement and ER status.
Lymph node involvement
As shown in Table 4.2, a significant positive correlation was observed 
between HPA binding and lymph node involvement (p<0.01). 81.25% 
(13/16) of tumours with invaded nodes were HPA positive, while only 25% 
(4/16) of HPA positive tumours were without nodal metastasis. Such a 
difference was also observed when stage I and stage H tumours were 
compared with respect to the presence of high-intensity HPA binding cells (p=
0.019). Among tumours with lymph node metastasis (stage II), the proportion 
of cells with high-intensity HPA binding ranged from 0.4 to 83% (Fig. 4.2), 
with a mean of 39.1 +/- 6.2%. Such HPA binding cells in tumours without 
metastasis (stage I) were also widely distributed (Fig. 4.2), ranging from 0.0 
to 67%, but with a two-fold lower mean value (18.3 +/- 5.6%).
Table 4.2. Correlation of HPA binding to lymph node involvement.
Histopathology of 
lymph node
HPA
positive
(n=17)
HPA
negative
(n=15)
Statistical 
significance 
(Chi-square test)
Invaded 13 3
Non-invaded 4 12
%2= 8.03, D.F.= 1
p<0.01
HPA postive tumours have been taken as those with >20% of cells showing 
high-intensity HPA binding.
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Figure 4.2. Distribution of HPA binding cells in primary tumours with 
metastasis (2) and without metastasis (1).
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Table 4.3. Positive HPA binding related to tumour grade and lymph node 
involvement.
Histopathology of Grade I Grade II Grade IH
lymph node (n=4) (n=14) (n=14)
Invaded (n=16) 0/2 3/4 10/10
Non-invaded (n=16) 0/2 4/10 0/4
Values represent number of HPA positive tumours/total.
Tumour grade
The number of HPA positive tumours and their histological grade, as 
assessed by the method of Bloom & Richardson (1957), is shown in Table
4.1. None of the 4 grade I tumours were positive for high HPA binding. 
However, there was a marked increase in the number of positive HPA tumours 
in the grade II and III tumours, with grade III tumours showing a higher 
incidence (71%) of HPA binding when compared with grade II tumours 
(50%). There were, therefore, marked differences between HPA binding to 
grade I tumours and tumours of higher grade (II and m ) but these differences 
are statistically not significant.
The relationship between HPA binding and lymph node involvement 
and tumour grade is further examined in Table 4.3. Since HPA binding related 
significantly to lymph node involvement, it was examined to see how node 
involvement and tumour grade related to HPA binding when considered 
together. With grade II and III tumours, node involvement appear to relate
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with HPA binding irrespective of grade, since with the exception of one all the 
grade II and HI tumours with invaded nodes were positive for HPA binding. 
In contrast, only 4 of the grade II tumours and none of the grade IE tumours 
without metastasis were positive for HPA binding. This relationship, 
however, does not hold with grade I tumours. None of the grade I tumours, 
whether with metastasis or not, were positive for HPA binding, suggesting 
that HPA binding correlates with lymph node involvement only with tumours 
of higher grade (II and El). The small number of grade I tumours should, 
however, be noted.
Table 4.4. Correlation of HPA binding to oestrogen (ER) receptor status of 
primary breast tumours.
ER+ve 
(n= 14)
ER -ve 
(n= 11)
Statistical 
significance 
(Chi-square test)
HPA +ve 6 10 %2= 4.26, D.F =1
p<0.05
HPA -ve 8 1
HPA +ve tumours have >20% cells showing high-intensity binding. ER status 
cut-off point is 20 fmol/mg protein.
Oestrogen receptor (ER) status
ER data was available for 25 of these patients and this has been also 
been correlated with HPA binding (Table 4.4). 91% (10/11) of ER -ve 
tumours were found to be HPA positive while among ER +ve tumours about
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43% (6/14) were HPA positive. This association between ER status and HPA 
binding was statistically significant (p<0.05).
4.6. Relationship between HPA binding and Con A binding in 
primary tumours: a dual-label analysis.
Figure 4.3 illustrates examples of a dual-label analysis of HPA and 
Con A binding to breast tumours. This was attempted to see if HPA binding 
cells were also positive for Con A binding. Plot f is the profile of the normal 
breast tissue, having a small proportion of doubly-labelled (quadrant 2, plot f, 
Figure 4.3) and HPA binding cells (18%), while the rest of the cells bound 
exclusively to Con A (quadrant 1, plot f). Though each tumour displayed a 
characteristic profile of HP A/Con A binding cell distribution, roughly 4 distinct 
features appeared when all the analysed samples were considered. 3 tumour 
samples showed binding patterns consistent with Plot b, where the tumours 
had >70% cells which bound exclusively to HPA (quadrant 4, plot b) and all 
of these samples were from grade III tumours with invaded node. If the 4 
tumours which were positive for HPA binding are excluded, plot e appears to 
be representative of tumours without nodal metastasis, which included all the 4 
grade I tumours as well as some grade II and III tumours. Another group with 
a higher intensity of Con A binding (not shown) could also be included in the 
plot e group. Plots c and d include tumours of grade II and III and stage I 
tumours which were high on HPA binding. There was, therefore, no 
consistent positive or negative correlation between HPA binding and Con A 
binding.
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Figure 4.3. Dual-label analysis of HPA and Con A binding to breast 
tumour cells.
a, is a control sample;
b, is representative of grade n, node-positive tumours. 3 samples showed 
binding patterns consistent with this profile. >70% tumour cells showed 
exclusive HPA binding in all these samples.
c, and d, represents patterns observed with most of the higher grade (II and 
IE) tumours with invaded nodes.
e, represents tumours without lymph node metastasis.
f, is the profile for the normal breast epithelial tissue as cultured from a 
reduction mammaplasty sample.
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4.7. HPA binding to tumour cells from invaded lymph nodes
In the same group of patients in whom primary tumours were analysed, 
lymph node samples were also available from all pateints without metastasis 
and from 12 of these patients with metastasis. The methodology for staining 
and gating for tumour cells in lymph nodes is decribed in Section 2.2.2.
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Figure 4.4. Correlation of HPA binding to tumour cells in invaded lymph 
nodes with autologous primary tumours.
In an attempt to see if high binding HPA cells could also be detected in 
invaded lymph nodes, spilled cells from all available lymph nodes were 
analysed for binding to HPA. For subsequent correlation with histopathology, 
only nodes which were invaded and for which tumour samples were also 
available were chosen. It is of interest to note that all non-invaded node 
samples were negative for HPA binding.
2 2 5
There were 12 invaded lymph node samples available for analysis and 
for each of these node samples corresponding autologous primary tumour 
samples were also analysed. As shown in Fig. 4.4, there was a strong 
positive correlation between percentage HPA binding cells in lymph nodes and 
those in autologous primary tumours (p= 0.001). The proportion of HPA 
binding cells in invaded lymph nodes were, however, less than those observed 
for the primary tumours. In lymph nodes, HPA binding cells ranged from 0.7 
to 38.0%, with a mean of 16.5 +/- 3.7%. This mean is less than that observed 
for primary tumours (39.1%). It should, however, be pointed out here that 
about 5% of lymphocytes were collected within the tumour gate (Section 
2.2.2.3) and as the number of tumour cells present in a nodal metastasis was 
variable only 5000 events were acquired for lymph node samples, compared to
10,000 events for primary tumours.
Table 4.5. HPA binding in tumour cells (non-lymphocytes) from invaded 
lymph nodes and autologous primary tumours.
HPA positive/total
% examined nodes
invaded Lymph node Primary tumour
<50 4/7 5/7
>50 5/5 5/5
In breast cancer, both the number of invaded nodes and the total 
number of nodes examined vary with each patient. To further assess the 
relationship between HPA binding tumour cells in invaded lymph nodes with
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those in primary tumours, the number of nodes invaded and the number of 
nodes examined were taken into consideration. All the cases with invaded 
nodes were grouped into having either less than 50% or greater than 50% of 
examined nodes invaded. The relatively lower cut-off value of 10% (compared 
to 20% for primary tumours) was found to be informative in defining HPA 
positivity in tumour cells in invaded lymph nodes. As shown in Table 4.5, all 
the samples (5/5) with >50% of examined nodes invaded were positive for 
HPA binding in cells from the lymph nodes, whereas samples with <50% of 
invaded nodes showed a lower incidence (4/7) of positive HPA binding.
4.8. Examination of lectin binding by fluorescence microscopy
It was of interest to examine the nature of the lectin binding to the 
tumour cells as this information cannot be obtained from a flow cytometric 
(FCM) analysis. By visualising the sample direcdy it is possible to determine 
whether the staining is uniform or localised in certain areas. Fresh primary 
breast tumour cells were stained for examination by fluorescence microscopy 
as described in Section 2.2.2.4. A 10-fold higher concentration of the lectin 
(10 pg/ml) than that used for FCM analysis was used to visualise the staining.
Figure 4.5 shows the staining pattern of lectin-stained (FITC- 
conjugated) primary tumour cells under both bright field examination and 
fluorescent microscopy. It is apparent that only a small population of the cells 
stain, and that in this case the brightly staining cells are largely the ones which 
have poorly defined membrane structure. With this respect, FCM analysis 
affords an advantage as the "Pi-gating" methodology allows exclusion of cells 
with breached membrane (Section 2.2.1.4) and therefore, the FCM analysis 
described above can be taken to define binding of the lectins to surface
Figure 4.5. Examination of lectin binding by fluorescence microscopy.
In A, tumour cells are observed under a bright field (x 25) and in B, the same 
cells stained with FTTC-labelled Con A are observed under a dark field (x 25).
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Figure 4.6. Microscopic examination (x 40) of breast tumour cells stained 
with A) FITC-Con A and B) FITC-HPA.
These photomicrographs show the surface staining pattern of tumour cells.
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molecules on cells with intact membranes. Exclusion of dead cells is 
particularly important for a lectin which has a wide binding specificity and may 
stain intracellular sugars irrelevant to the metastatic potential of the tumour.
On the few cells which were more clearly intact, the membrane staining 
in the cases of HPA and Con A was highly variable, sometimes uniform and 
sometimes polarised to sections of the membrane (Fig. 4.6).
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4.9. Discussion
From the results described in this section, it is apparent that HPA 
binding defines an N-acetyl galactosamine-containing cell surface marker on 
breast tumours which is associated with metastasis to lymph nodes. Tumour 
cells that express this HPA marker were also found in lymph node metastasis 
and the strong correlation between HPA binding in primary tumour and their 
corresponding lymph nodes further substantiates the conclusion that HPA 
binding represents a phenotypic marker of metastatic potential. The bulk of 
this data has been published (Alam et al., 1990).
This study also demonstrates the use of flow cytometry as an effective 
technique in detecting differences in lectin binding in spilled cells from fresh 
breast cancer tissues. In all previous studies involving lectins, histochemical 
analysis was performed on paraffin sections of formalin-fixed tissues and the 
extent of lectin binding was determined by a simple visual assessment. 
Histochemical analysis suffers from a number of limitations and not all lectins 
give consistent results when fixed tissues are used (Walker, 1984a). 
Additionally, it is difficult to quantitate fluorescence intensity and as observed 
by Dansey et al. (1988) this can be highly subjective (Section 1.3.5.2). In 
this study, therefore, fresh tissues have been used and the use of flow 
cytometry demonstrated some distinct advantages of the technique. A large 
number of cells per samples have been analysed (10,000 for primary tumours,
5,000 for lymph node metastases). Moreover, the use of "Pi-gating" has 
effectively allowed the exclusion of dead cells from the analysis. This is 
particularly important in assessing lectin binding as breached membranes can 
expose irrelevant intracellular sugars. Finally, the extent of lectin binding has 
been expressed in a defined quantitative fashion, thereby allowing the
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percentage of positive cells to be readily determined. However, it must be 
pointed out that with flow cytometry, the nature of staining cannot be 
determined and as only free cells are studied, the normal architecture of the 
tissue is lost.
The data in this study show a significant correlation between HPA 
binding and lymph node involvement (p<0.01). This association appeared to 
be related to tumours of higher grade (Grade II and III). Although only 4 
Grade I tumours were available, all these tumours were found to be negative 
for HPA binding, irrespective of their nodal status. There were more HPA 
positive tumours in the grade III group compared to grade II, but the 
relationship was statistically not significant. HPA positive tumours were also 
more likely to be ER negative (p< 0.05). In the recently reported follow-up 
study of Brooks & Leathern (1991), the strong association between HPA 
binding and the presence of lymph node metastasis has been confirmed. In 
this and other studies, HPA binding was not only related to lymph node stage, 
but also to local recurrence and survival ( Brooks & Leathern, 1991; Fenlon et 
al.t 1987; Fukutomi et al., 1989). HPA binding, however, has been found 
not to relate to either tumour grade (Brooks & Leathern, 1991; Fenlon et al., 
1987) or ER status (Fenlon etal., 1987).
No correlation with any of the histopathological features was observed 
with Con A binding. Although Dansey et al. (1988) have reported no Con A 
binding to normal breast epithelial tissue, significant positive binding (39%) 
was observed in this study. It must, however, be added that normal breast 
tissue in this study was cultured from a reduction mammaplasty sample.
In this study, the binding of Con A and HPA were also directly 
compared in a simultaneous dual-label flow cytometric analysis. Although a
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few characteristic features of lectin binding were observed, in general each 
tumour behaved individually and no consistent pattern could therefore, be 
recognised.
Tumour cells in invaded lymph nodes were analysed by gating out the 
bulk of the lymphocytes, which were invariably present in large numbers but 
were found not to show any high-intensity binding to HPA. Although lymph 
node metastases also showed abnormal HPA binding, there were fewer of 
these cells in the nodes when compared to the primary tumour. However, the 
invaded nodes reflected the binding of the lectin in the primary tumours and a 
strong positive correlation was observed between HPA binding in primary 
tumours and those in tumour cells from lymph node metastasis in the same 
patient (P=0.001). In only one recent study has lectin binding been studied in 
metastatic tissues from breast cancer patients (Krogerus & Anderson, 1990). 
Using a panel of lectins, which also included HPA, the study reported that 
while primary tumours were heterogeneous in their reactivity to lectins, lymph 
node metastases from the same patient showed a more restricted reactivity. 
This was suggested to indicate the presence of selected clones of primary 
tumour cells in the lymph node metastasis. A further implication of this is that 
carbohydrate structures detected by lectin binding can identify clones of tumour 
cells with higher metastatic potential. The presence of a percentage of cells 
with high-intensity binding to HPA observed in this study can then, be 
considered as a subpopulation of tumour cells with higher metastatic potential. 
In lymph nodes invaded with tumours, the presence of these HPA binding 
cells, therefore, provides further evidence of HPA being a surface marker of 
metastatic potential.
CHAPTER 5
DNA analysis of primary tumours  
and lymph node metastases
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5.1 Flow cytometric (FCM) DNA analysis of primary 
tumours and lymph node metastases from breast cancer 
patients
A number of studies have now shown that in breast cancer patients, 
high SPF and abnormality in the DNA content of breast tumours correlate with 
poor prognosis (Section 1.4.3). These studies reveal that ploidy, which is 
abnormal in about 65% of breast tumours, and SPF reflect important 
aggressive features of a primary breast tumour. However, little is known 
about the true biology of aneuploid cells, especially whether these cells have a 
higher metastatic potential. As in the past and also described in this section, 
growth of aneuploid cells in culture has been difficult and as such 
characterisation of aneuploid breast tumour cells in terms of surface markers 
and oncogene expression has not been possible. The majority of FCM DNA 
studies have focussed on primary tumours and were carried out principally to 
assess the potential of DNA flow cytometry as a prognostic indicator. Very 
little attention has so far been directed towards comparing the ploidy in 
metastases with that of the primary tumour. Lymph node metastasis remain the 
most important indicator of the tumour's biological aggressiveness and the 
availability of invaded lymph nodes together with the primary tumour from the 
same patient makes it possible to conduct a simultaneous comparative DNA 
analysis of the two tissues.
This section describes data from a FCM DNA analysis of primary 
tumours and its correlation with histopathological factors. In addition, it also 
describes a comparative study between the DNA profiles of fresh primary 
tumours and metastatic cells from the axillary nodes of the same patients. The 
principal aim of the study was to investigate whether metastatic population in 
invaded nodes included the cells with grossly abnormal DNA. Detection of the
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tumour DNA profiles in the node has generally been difficult because of the 
comparatively small number of metastatic tumour cells present. In this study, 
therefore, using an antibody against cytokeratin, a dual-parameter FCM DNA 
analysis was performed. This allowed study of true epithelial cells in the 
primary tumours while in the lymph nodes, small proportions of tumour cells 
which normally go undetected were analysed for their DNA ploidy.
5.1.1. Ploidy status of primary tumours and its correlation with 
histopathological features
The study initially involved the determination of DNA ploidy status of 
primary tumours from breast cancer patients. Samples from 57 primary 
tumours were suitable for analysis. 63% (36) of these were aneuploid and the 
remaining 21 cases (37%) were diploid. The majority of aneuploid tumours 
(31/36) were hyperdiploid (1.0<DI<1.9) with a single aneuploid peak. One 
tumour was classified hypodiploid (DIcl.O) and 4 were multiploid, having 
two aneuploid stemlines in addition to the normal diploid peak. The DNA 
index (DI) of the hyperdiploid tumours ranged from 1.2 to 2.95, median 1.7. 
In most tumours, a diploid peak was always present in addition to the 
aneuploid peak. However, in 2 tumours no diploid peak was detectable and 
the DNA histogram showed a single aneuploid population for both these cases. 
Representative examples of DNA profiles of primary breast tumours is shown 
in Fig. 5.1.
Each primary tumour appeared to be characteristically different from the 
other and this is reflected in the distribution of their DI shown in Fig. 5.2. In 
general, the distribution is bimodal with peaks in the diploid region and the 
hyperdiploid region of DI 1.7.
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Figure 5.1. Representative examples of DNA histograms of primary breast 
tumours.
I. A diploid tumour;
n. Aneuploid tumour with a predominantly aneuploid population (A).
III. Aneuploid tumour with both diploid (D) and aneuploid populations (A). 
In this tumour the proportion of diploid cells is much greater than the aneuploid 
cells.
IV. Aneuploid tumour with both diploid (D) and aneuploid populations (A).
V. Multiploid tumour with two aneuploid peaks (Al & A2). A2 peak appear 
as a shoulder to the main Al peak.
VI. Multiploid tumour with more distinct aneuploid peaks, Al and A2.
c represents chicken RBC. In aneuploid tumours, G2/M cells of the aneuploid 
population is marked.
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Figure 5.2. Distribution of DNA Index (DI) in all 57 cases of breast cancer 
analysed by DNA flow cytometry.
Lymph node involvement (Stage II)
DNA ploidy correlated significandy with lymph node involvement 
(p<0.01). In 80.6% (25/31) of the patients with invaded nodes, the primary 
tumours were aneuploid (Table 5.1). But it should be noted that among the 
patients with non-invaded nodes, a substantial percentage (11/26; 42%) of the 
tumours was also aneuploid (Table 5.1). At the same time, 30.5% (11/36) of 
patients with aneuploid tumours were without metastasis in their nodes.
Tumour grade
Although the correlation of ploidy with tumour histological grade failed 
to reach statistical significance (0.5<p<0.1), a trend indicating that poorly 
differentiated tumours are more likely to be aneuploid than diploid was 
observed (Table 5.2). As there were only 3 grade I tumours in the total
Table 5.1. DNA ploidy of primary tumours and lymph node status of 57 
patients with breast cancer.
Histopathology of FCM DNA analysis
lymph node Aneuploid
(n=36)
Diploid
(n=21)
Statistical 
Significance 
(Gu-square test)
Invaded 25 6
X2 = 7.36, D.F.=1
Non-invaded 11 15 p < 0.01
Table 5.2. DNA ploidy and histological tumour grade of 57 primary breast 
tumours.
Histological FCM DNA analysis *Statistical
Grade of Aneuploid Diploid Significance
differentiation (n= 36) (n = 21) (Chi-square test)
I (Well) 1 2 X2 = 2.88, D.F.= 1 
0.05< p <0.1
II (Moderate) 15 13
DI (Poor) 20 6
*As only 3 grade I tumours were available for analysis, grade I and grade II 
tumours were grouped and compared with grade DI in the chi-square test.
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Table 5.3. DNA ploidy and Oestrogen receptor (ER) status of 44 breast 
cancer patients.
ER status FCM DNA analysis ^Statistical
Aneuploid Diploid Significance
(n= 27) (n = 17) (Chi-square test)
ER-ve 
(<20 fmol/mg
protein)
14 2
x2 = 5.6, D.F.=1
p < 0.02
ER +ve 
(>20 fmol/mg 
protein)
13 15
samples analysed, the differences observed are between grade II and grade III 
tumours.
ER status
The ER content data was available for 44 of the 57 primary tumours. 
The ER status was compared with the ploidy status of these patients (Table 
5.3). Of the diploid tumours, 15/17 (88%) were ER positive compared with 
13/27 (48%) of aneuploid tumours. There was thus a strong trend for diploid 
tumours to be ER positive, and this was found to be statistically significant 
(p < 0.02). However, it should be noted that among aneuploid tumours, 
almost equal number of tumours were ER+ve and ER-ve.
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5.1.2. S phase fraction (SPF) of primary tumours
The methodology of SPF measurement is described in Methods and 
Materials (Section 2.2.3.5). Aneuploid tumours were analysed for their SPF 
only in cases (9 tumours) where there were no overlapping peaks from the 
diploid stemlines and in 4 cases in a gated analysis of CK+ single cell 
population (Section 3.3.5.1). The SPF of diploid tumours ranged from 0.65 
to 12.0%, while those of aneuploid tumours ranged from 7.0% to 25%. The 
distribution of SPF differed significantly (P= 0.001) between diploid and 
aneuploid tumours, with means of 3.5+/-0.69 and 8.6+/-1.3 percent, 
respectively.
As SPF could be determined only for a selected number of patients 
with aneuploid tumours, no attempt was made to relate SPF of primary 
tumours with histopathological prognostic parameters.
5.1.3. DNA ploidy of primary breast tumours in short-term  
culture
4 primary breast tumours, of which 3 were aneuploid and one diploid, 
were put into short-term culture as described in Section 2. DNA ploidy of the 
tumours both prior to and after culture were compared. Of the 3 aneuploid 
primary tumours all but one culture gave rise to epithelial cells. That one 
culture comprised only of colonies of fibroblast cells. DNA ploidy analysis 
revealed that both from the diploid and the aneuploid primary tumour cells, a 
single population of cells with diploid DNA content grew in culture. Fig 5.3a
Figure 5.3a. FCM DNA analysis of breast tumour cells before (A) and after 
short-term culture (B).
From these 3 tumour samples, it was possible to grow epithelial cells as 
opposed to one sample which morphologically resembled fibroblasts.
While tumour from patient A was diploid, both patient K and T had aneuploid 
tumours. Cells that came out in culture were all diploid (B).
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shows the DNA histograms of these samples both before and after culture. 
Although only a small number of primary tumours were put into culture, the 
results suggest that while the culture condition allows growth of diploid 
tumour cells, it is unable to propagate aneuploid cells. It is interesting to note 
that as with many established cell lines, the breast cell line ZR-75 was found to 
be aneuploid, while the cultured normal breast cells from the reduction 
mammaplasty sample were diploid (Figure 5.3b).
5.1.4. Single-parameter ploidy studies on invaded lymph node 
and tumour samples from the same patients
The distribution of DNA indices of all primary tumours with invaded 
nodes is shown in Figure 5.4. The distribution of DI over such a wide range 
suggests that there is considerable differences between patients with respect to 
their DNA ploidy but within a patient, the majority of tumour cells carry the 
same amount of DNA. In addition, the wide range of DI suggests that the 
metastatic capability is not inherent in any aneuploid cell population with a 
specific DI.
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Figure 5.4. Distribution of DNA Index (DI) in 31 breast cancer patients 
with lymph node metastasis (Stage II).
As primary tumours with aneuploid DNA are likely to be more 
aggressive than those with diploid DNA, a relevant question is whether it is 
possible to detect metastatic tumour cells in lymph nodes and if so, then to 
determine the ploidy of these metastatic cells. Using a single-parameter 
analysis no aneuploid cells were detected in lymph nodes, whether invaded or 
not, from patients with diploid tumours. This suggests that at least with 
diploid tumours, the ploidy status of primary tumours is maintained after 
metastasis. This apparently did not hold for aneuploid tumours. Within the 25 
invaded lymph nodes from patients with aneuploid primary tumours, an 
aneuploid peak was detected in only 6 cases. However, the DI of the 
aneuploid peak in all these lymph node metastases were identical to the DI of 
the primary tumours. Figure 5.5 shows two such cases. In these cases the 
nodes were grossly invaded by tumour cells and as such tumour cells were 
detectable. It can, however, be seen in Fig. 5.5 that proportion of tumour cells 
in a lymph node can vary considerably.
Figure 5.5. DNA content of primary tumours (A) and associated heavily 
tumour invaded lymph node metastases (B) from two breast cancer patients. 
The two examples cited here represent cases where the lymph nodes were 
grossly invaded and aneuploid peaks (a) were detected in a single parameter 
DNA analysis.
c= chicken red blood cells; d= diploid Go/Gl peak; a= aneuploid Go/Gl peak; 
G2/M= G2/M peak of the aneuploid population.
A. Primary tumour B. Lymph nod© m©tastasis
Figure 5.6. Single-parameter DNA profiles of two patients presenting with 
double primary tumours.
In patient A, the aneuploid population in the invaded right node has a DI of 
1.75, identical to that in the primary tumour. The left tumour has a different 
aneuploid population (DI=1.6) and no aneuploid population can be detected in 
the left tumour-free node.
Patient B, with both primary tumours on the same side, had a diploid tumour 
(not shown) and an aneuploid tumour as shown (DI= 1.6). The aneuploid 
peak can be seen in the invaded lymph node.
The CV of the aneuploid Go/Gl peaks are:
Patient A, right tumour- 3.7 
Patient A, right lymph node- 2.6 
Patient A, left tumour- 2.8 
Patient A, left lymph node- 2.4 
Patient B, primary tumour- 6.1 
Patient B, lymph node- 5.4
Patient A:
Right tumour Right lymph node
© ©■
G2/M
50 150 250200250 50 100 150
Left tumour Left lymph node
G2/M d(G2/M)
250150 250 15050 100 50
Patient B:
Primary tumour Lymph node
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5.1.5. Single-parameter DNA ploidy analysis of double primary 
tumours and their corresponding lymph nodes within the same 
patient
In the course of this study two patients presented with rare double 
primary tumours. In both cases, only one of these appeared to have 
metastasised. In the case of Patient A , who had bilateral carcinoma, both right 
and left tumour samples and the corresponding lymph nodes were available for 
DNA analysis. Histopathology revealed both tumours to be poorly 
differentiated (Grade m ) infiltrating carcinoma. DNA analysis revealed both 
tumours to be aneuploid but with differing DI (Patient A, Figure 5.6). The 
DNA histogram of lymph node cells from the right,which was invaded, 
showed aneuploid cells with DI identical to the right primary. Although the left 
tumour was aneuploid, no aneuploid population was detected in the left lymph 
node, which on histopathological examination was found to be tumour free. 
Comparison of the DNA histograms of the two tumours reveal that it is likely 
that the left tumour represents a second primary and not a secondary deposit of 
the right primary tumour.
The second double primary, Patient B, presented with two distinct 
primary tumours on the same side. Tumour specimens from the two regions 
and lymph nodes were analysed (Patient B, Figure 5.6). Histological 
evaluation, which revealed carcinoma of Grade II, was possible in only the 
larger of the two tumours. The smaller tumour was diploid, wheras the 
invaded lymph node had a detectable aneuploid peak with DI identical to the 
larger, presumably primary tumour (Figure 5.6).
Ploidy analysis in these patients with double primaries reveal that 
within a patient, two tumours can have different ploidy and that they may differ
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in their ability to metastasise. In the lymph node, cells from only one of these 
tumours were apparently present as the ploidy matched with only one of the 
primary tumours. In addition to the difference between being diploid or 
aneuploid, there also appears to be a distinct difference between aneuploid 
tumours in terms of their aggressive nature.
5.1.6. Dual-parameter FCM DNA analysis of primary tumours 
and their corresponding lymph nodes from the same patient
Although detected in a relatively small number of cases, the above 
results indicate that invaded lymph nodes harbour aneuploid tumour cells 
which appear identical to a subpopulation of cells within the corresponding 
primary tumour with respect to their DNA content. However, aneuploid cells 
were detected in only 24% (6/25) of the analysed lymph nodes with aneuploid 
primary tumours. As diploid populations were almost always detected in 
aneuploid tumours, this could reflect the presence of a substantial malignant 
diploid population from which terminally differentiated and essentially 
harmless aneuploid cells evolve. However, an alternative explanation is that it 
reflects the low sensitivity of detection of DNA peaks from small numbers of 
highly aggressive aneuploid cells, effectively swamped by the large dilutional 
effect caused by the inevitable presence of lymphocytes in the node 
preparation. To resolve this matter it was, therefore, necessary to exclude 
lymphocytes from lymph nodes. With respect to the primary tumour, it is not 
known whether the diploid cells in such tumours represent epithelial cells, in 
which case they could be both normal and/or tumour cells, or whether they 
represent non-epithelial cells from the surrounding tissues. It is highly relevant 
to add here that often large number of lymphocytes infiltrate breast tumours 
and as such are also a potential candidate for the diploid population. Thus as
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for the lymph node, in the case of the primary tumour too, it is necessary to 
correctly establish that the diploid peak is contributed by epithelial tumour cells 
and not by contaminating stromal and inflammatory cells. This has been 
accomplished in a dual-parameter DNA FCM analysis.
5.1.7. Dual staining of tumour cells with anti-cytokeratin (CK) 
antibody and propidium iodide (PI)
Contaminating lymphocytes from the lymph node and non-epithelial 
cells from the primary tumour were excluded in a dual-parameter DNA analysis 
using CK staining. When primary tumours were analysed for CK and PI 
staining, diploid peaks were always reduced, sometimes to a negligible level 
(Section 2.2.3.7, Fig 2.9). In the lymph node, the sensitivity of the analysis 
could be exploited by restricting the analysis to invading tumour cells and 
thereby the assessment of whether invading cells in the lymph node are diploid
and/or aneuploid was possible. Moreover, it improved detection in one lymph
/
node metastasis, where an aneuploid peak which was undetectable was 
subsequently made visible by gating for CK+ cells.
The sensitivity of CK+ gating was tested in a mixing experiment as 
described in Section 2.2.3.8. The sensitivity was high enough to detect as low 
as 5% of tumour cells in involved lymph nodes, allowing a 20 fold 
enrichment. As shown in Fig.5.7, the position of the aneuploid peak remained 
the same at all concentrations of tumour cell and was identical to that of the 
tumour cells alone. When 5% of tumour cells were present, both the Go/Gl 
and the G2/M peaks were clearly visible above the background, while below 
5% (Fig 5.7, C), although the Go/Gl peak was still detectable, the G2/M peak 
was not.
Figure 5.7. Sensitivity test of the dual-parameter DNA analysis in detecting 
CK+ cells.
Breast tumour cell line (ZR-75), which are aneuploid with a DI= 1.65, were 
mixed in varying proportions with human blood lymphocytes.
A- 30% ZR-75 cells; B- 5% ZR-75 cells; C- 3% ZR-75 cells of total cells; and 
D-lymphocytes alone.
I is scatter plot with the analysis gate, II is ungated DNA histogram, and III is 
gated (CK+) DNA histogram.
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5.1.8. Dual-parameter FCM DNA analysis of primary tumours 
and their corresponding lymph node metastases
Twelve paired primary tumours and lymph nodes from the same 
patients were selected to determine the ploidy of the CK+ primary tumour cells 
and their corresponding lymph nodes were analysed to detect the ploidy of the 
invading tumour cell population (CK+). The results are summarised in Table
5.4.
In tumour-free lymph nodes, CK+ cells were absent (Table 5.4 ) and 
the diploid cells in the ungated histogram clearly represented lymphocytes. 
This was true whether the primary tumour was diploid or aneuploid.
Comparison of CK+ gated primary tumours and lymph node 
metastases in the same patient reveal that aneuploid tumour cells differ in their 
metastatic capability and where a tumour was multiploid, there was evidence to 
suggest that there is selective metastasis of a subpopulation of aneuploid cells 
(Table 5.4). Three such cases are detailed in Fig. 5.8.
In patient 1, although both aneuploid and diploid cells were present in 
the primary tumour, only aneuploid cells were detected in the lymph node 
metastasis and they had a DI identical to the aneuploid cells in the primary 
tumour. The invaded lymph node in patient 2 revealed a single aneuploid peak 
with a DI identical to peak a2 of the primary tumour. In patient 3, an aneuploid 
peak with DI similar to the shoulder (a2 in Fig. 5.8) in the main aneuploid peak 
of the primary tumour was detected in the lymph node. An additional peak 
(a3, DI= 2.7) which was not detectable in the tumour also appeared in the 
lymph node histogram.
TABLE 5.4. Results from Dual-parameter DNA analysis of CK-gated 
paired primary tumour and lymph node from the same patient
Patient Histopathology Ploidy and DI of CK+ve cell population 
No. of lymph node Tumour Lymph node
1 Invaded Diploid & Aneuploid 
DI=1.0+1.7
Aneuploid
DI=1.7
2 Invaded Diploid & Aneuploid 
DI= 1.0+1.45 +1.8
Aneuploid
DI=1.8
3 Invaded Diploid & Aneuploid 
DI=1.0+1.6+1.8
Aneuploid 
DI= 1.85+2.7
4 Invaded Diploid
DI=1.0
Diploid
DI=1.0
5 Invaded Aneuploid 
DI= 1.3
Aneuploid 
DI= 1.3
6 Invaded Diploid & Aneuploid 
DI= 1.0+ 1.4
Aneuploid 
DI= 1.4
7 Invaded Diploid 
DI= 1.0
Diploid 
DI= 1.0
8 Non-invaded Diploid 
DI= 1.0
None
9 Non-invaded Aneuploid 
DI= 2.2
None
10 Non-invaded Aneuploid
DI=1.6
None
11 Non-invaded Aneuploid
DI=1.8
None
12 Non-invaded Diploid
DI=1.0
None
The presence of CK+ve diploid cells in both the primary tumour and 
lymph node metastases from Patients 4 and 7 suggests that diploid cells are as 
potentially metastatic as the aneuploid cells (Table 5.4).
Figure 5.8. CK+ gated and ungated DNA profiles of 3 lymph node 
metastases together with their primary tumours.
In patient 1, the diploid peak of the primary tumour was not represented in the 
lymph node following CK+ gating and the DI of the aneuploid population in 
the node matches the DI (1.7) of the aneuploid population in the primary 
tumour.
In patient 2, the aneuploid peak in the node is detected only after CK+ gating 
and represents the smaller of the two aneuploid peaks (a2, DI= 1.8) seen in the 
tumour.
In patient 3, two aneuploid peaks appear in the node after CK+ gating. Peak 
a2 (DI= 1.85) has a DI close to a2 peak in the primary tumour (DI= 1.8), 
whereas a3 (DI= 2.7) was not detected either in the ungated node or in the 
primary tumour.
Patient 1
G2/MG2/M
G2/M
2501500 50.
Patient 2
100 1505050 150 250
d(G2/M)
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5.1.9. Discussion
This study presents data involving FCM DNA analysis of primary 
tumours and their corresponding lymph node metastases derived from the same 
breast cancer patient. Analysis of 57 primary tumours revealed that 63% of 
these breast tumours were aneuploid. This is in agreement with all previous 
reports (Frierson, 1991). Although abnormal in DNA content, these tumours 
appear to be characteristically different from one another and this was evident 
in the wide spread in the distribution of DNA indices in primary tumours 
whether or not the patient had metastasis. Correlation with histopathological 
prognostic factors revealed that aneuploid tumours are more likely to be poorly 
differentiated, and behave more aggressively with respect to metastasis to 
axillary lymph nodes. Presence of aneuploidy was found to be significantly 
related to lymph node metastasis. However, it is important to point out that a 
good percentage of patients (42%) without metastasis also had aneuploid 
tumours. This probably explains the conflicting reports in the literature 
concerning the relationship between DNA aneuploidy and lymph node 
involvement (Section 1.4.3.3.1). In studies where a larger number of patients 
were employed, the relationships observed were weak (Dressier et al., 1988; 
Hedley et al., 1984; Ewers et al., 1984). Correlation with grade showed a 
trend suggesting that tumours of higher grade are more likely to be aneuploid. 
This relationship failed to reach statistical significance, presumably as there 
were not enough grade 1 tumours available for analysis. Almost all workers 
have reported a significant association between tumour ploidy and the 
differentiation state of the tumour (Section 1.4.3.3.1). Association between 
tumour ploidy and steroid receptors has also been reported by other workers 
(Dressier et al., 1988; Moran et al., 1984; Horsfall et al., 1986; Olszewski et 
al., 1981).
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Assessment of SPF poses certain problems as discussed in Section
I.4.4.3.3. As the available computer models (Section 2) were not reliable for 
assessing SPF of aneuploid populations with high SPF, the percentage of cells 
in the S phase was determined by placing markers to define S-phase and 
assuming that both Go/Gl and G2/M peaks are a Gaussian distribution 
(Section 2). This made assessment of SPF possible in only cases where there 
were no complications from overlapping peaks and where the tumours were 
diploid. No correlation was, therefore, attempted between tumour SPF and 
histological prognostic factors. However, in agreement with other reports, 
aneuploid tumours were found to be significantly higher in SPF compared to 
diploid tumours. Recent findings identify both aneuploidy and high SPF to be 
related to bad prognosis in breast cancer patients (Toikkanen et al., 1989; 
Eskelinen et al., 1989; Clark etal., 1989).
It is generally assumed that only a subpopulation of tumour cells have 
the capacity to metastasise and it is possible that the generation of such 
populations occur as a result of abnormalities in the DNA. However, there is 
no direct evidence to indicate that clonal development of cells with a higher 
metastatic potential is related to the DNA profile of a tumour and the biological 
events leading to the generation of aneuploid tumours is not clear. From the 
ploidy analysis of primary tumours presented in this section, it is evident that 
some aneuploid tumours are likely to be more aggressive than others and a 
tumour can have both a diploid and an aneuploid population. It is, therefore, 
relevant to determine the ploidy of secondary deposits in lymph nodes. With 
the evident difficulty in assessing SPF, this study focussed on DNA ploidy 
determination of primaiy tumours and comparing them with those of metastatic 
cells in the lymph nodes of the same patient. Only a few studies have 
compared primary tumours and metastases by DNA FCM in breast cancer 
patients. Although these studies report a high degree of concordance between
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the ploidy of the two tissues (Feichter et al., 1989; Beerman et al., 1991), there 
are also reports of discordance in a substantial proportion of cases (Hitchcock 
et al., 1989). All these studies employed single parameter DNA analysis and 
Feichter et al. (1989), who attempted to remove contaminating lymphocytes 
from the tumour cell suspension, reported that in some cases the ploidy and 
SPF of primary tumours can differ from metastatic cells. In this study attempts 
were made to determine whether the metastatic population in invaded nodes 
included the cells with grossly abnormal DNA. Using a single-parameter DNA 
analysis the detection of aneuploid cells in lymph node metastases was a rare 
event (only 6 cases out of 25). However, in a dual-parameter DNA analysis, 
which involved the use of a directly labelled antibody to cytokeratin, it was 
possible to detect subpopulations of aneuploid cells in the lymph node. 
Results described in this section suggest that these cells are capable of 
metastasis and indeed that within these cells, certain further sub-populations 
are capable of preferential metastasis.
The use of a CK antibody to differentiate epithelial cells from other cell 
types in both tumour and node samples confers a significant advantage. It is 
possible to analyse the ploidy status of the tumour cells alone and this becomes 
important when they form a small percentage of the cells under analysis. In the 
lymph node where there are extensive numbers of lymphocytes, this is of 
particular value. However, the primary tumour may also contain as much as 
50% lymphocytes (Whitford et al., 1990) in addition to stromal and other cell 
types and therefore this antibody will be of use in the flow cytometric analysis 
of tumour markers.
Although the refined technique of multi-parameter FCM DNA 
analysis, first described by Zarbo et al. (1989), has previously been used to 
study primary breast tumours (Visscher et al., 1990b), no study has used it to
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analyse primary and secondary deposits in the same breast cancer patient. 
Results from such a comparative analysis described in this study provides 
evidence to suggest that although diploid tumours can be found in lymph node 
metastases where the primary tumour was itself diploid, this is not the only cell 
population to invade lymph nodes in breast cancer patients. In multiploid 
tumours, double primaries and in tumours consisting of both diploid and 
aneuploid populations, only a subpopulation of these cells comprises the 
secondary deposits in lymph nodes. The DNA analysis performed in this 
study provided several noteworthy observations. Firstly, in 4 cases diploid 
peaks, although present in the primary tumour, were absent in nodes. 
Secondly, in cases of multiploid primary tumours, preferential appearance of a 
single aneuploid peak of higher DI was observed. Thirdly, there are the 
examples of the bilateral carcinoma patient and the patient with two tumours on 
the same breast. They show that even in the same patient two tumours may 
have different ploidy and since one of the bilateral tumours metastasised and 
the other did not, this raises the question of the relationship between metastatic 
potential and aneuploidy. These observations suggest that with respect to 
DNA content some of the primary tumours contain a heterogeneous population 
of cells with differing metastatic capability and that the subpopulation detected 
in the lymph node represent tumour cells of higher metastatic potential. 
Alternatively, the fact that only a subpopulation of tumour cells proliferate in 
the lymph nodes of some breast cancer patients suggests the possibility of a 
local inhibitory effect of the lymph node on tumour cell proliferation. Such an 
effect has been suggested by Olszewski et al. (1982), who observed a 
significant reduction of S-phase cells in lymph node metastases compared to 
those in primary tumours of the same patient. In all of these patients, the 
primary tumours were oestrogen receptor-positive.
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Although in lymph node metastases only a subpopulation of tumour 
cells were detected, the observed peak had a DI identical to that in the primary 
tumour. The high degree of concordance between primary tumours and their 
metastases have led previous workers to suggest that ploidy is established early 
in tumour development and remains stable in the metastatic process. One 
invaded lymph node, in this study, was found not only to have an aneuploid 
peak similar to a subpopulation in the primary tumour, but also to have an 
additional peak not present in the primary tumour. Differences in ploidy and 
surface antigen expression in metastases have been reported by Hitchcock et al. 
(1989). This led them to suggest that changes in ploidy in a metastasis is not 
unidirectional and that changes in ploidy and other variables can occur after 
metastasis. In this study, at least in one nodal metastases such an event was 
found to occur.
Attempts to culture aneuploid tumour cells resulted in the growth of 
diploid cell population only. The restricted ability of current tissue culture 
methodology to propagate primary aneuploid tumour cells has been previously 
reported (Smith et al., 1985; Wolman et al., 1985). This, however, means 
that only rarely can a primary tumour or metastasis with abnormal ploidy be 
subjected to conventional cytogenetic analysis, internal labelling with isotope, 
or analysis for cell surface or enzyme markers. In effect, aneuploid cells are 
often assumed to be terminal cells resulting from the general disorganisation of 
tumour cell cycle control. Data described in this section suggest that despite 
their abnormal chromosome load, they are more than capable of either 
themselves metastasising or of constituting the bulk of metastatic deposits. 
The importance of this observation has recently been made more relevant by 
the observation that both amplification and overexpression of the erb B2 
oncogene was observed in tumours with abnormal DNA content (Tavassoli et 
al., 1989; Bacus etal., 1990; Baak etal., 1991).
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5.2. DNA fingerprint analyses of primary breast
tumour and lymph node metastases
As discussed in Section 1.4, mutations in several genes are probably 
involved in the generation of a highly malignant tumour. Most recent studies 
on breast cancer have focussed on detecting changes involving specific 
oncogenes. But it appears that there is a progression of events in the 
tumorigenesis pathway and it is the final accumulation of these events that 
triggers the metastatic state. Therefore, not only is the knowledge about 
specific activation of a proto-oncogene important but also the sequences of 
events preceding or leading to it are equally important. Moreover, there is the 
likelihood of the existence of more of yet unidentified oncogenes involved in 
this process.
In order to record these changes, therefore, a panel of DNA probes 
representing different loci have to be used. The recently established technique 
of DNA fingerprinting affords an alternative to this. Using minisatellite DNA 
probes, it is possible to detect simultaneously highly variable regions widely 
dispersed in the human genome. These repeat sequences provide individual- 
specific RFLP (Jeffreys et al., 1985) and therefore, any localised changes in 
tumour DNA which also include the satellite sequences can be detected by 
comparison with DNA from normal tissues. The advantage of the technique is 
that it can simultaneously detect changes in a number of chromosomal sites. 
DNA fingerprinting has been applied in a few preliminary studies on 
gastrointestinal and ovarian cancers and has been shown to detect loss and 
appearance of novel bands as well as changes in hybridisation intensity (Fey et 
al., 1988; Boltz etal., 1990; Saito etal., 1991).
This section describes results from such an approach on primary 
tumours and lymph node metastases from breast cancer patients. It is relevant 
to point out that as described in section 5.1, aneuploidy is a frequent event in 
breast cancer and in some patients the presence of aneuploid tumours is 
associated with metastasis. It is of much interest to determine whether 
aneuploidy in these patients is associated with any specific change in the 
tumour DNA. Changes observed in the DNA fingerprint pattern of primary 
tumours and lymph node metastases have, therefore, been compared with the 
ploidy status of the primary tumour.
Four satellite probes were used to obtain the DNA fingerprints. 
Minisatellites 33.6 and 33.15 detect sequences derived from approximately 30 
loci dispersed throughout the human genome (Jeffreys et al., 1985). The 
macro-satellite 228S is present on the majority of chromosomes and is 
predominantly centromeric in location (Boltz et al., 1990), while 216S is a 
satellite ID DNA probe which gives an invariant banding pattern (Boltz et al., 
1990). DNA satellites 33.6 and 33.15 were obtained as inserts in pUC18U 
and pUC19U recombinants respectively. These recombinant plasmids were, 
therefore, used to transform E. coli strains and the inserts were then isolated 
and purified from bulk growth of these cells. DNA probes 216S and 228S, 
which were originally in an inconvenient M l3 phage DNA, were subcloned 
into a stable pTZ18U vector and then isolated and purified from these 
recombinants. The cloning and purification of the DNA satellite sequences is 
described in Section 2.2.4.3 and 2.2.4.4. DNA from primary tumour, lymph 
node and peripheral blood samples from 13 breast cancer patients was 
extracted as described in Section 2.2.4.1. Digestion with restriction enzymes, 
gel electrophoresis, southern blotting and hybridisation with radioactive probes 
were carried out as described in Section 2.2.4.6.
The selection of patients was performed without prior knowledge of the 
histopathology and although DNA FCM analysis was previously undertaken 
on these cases, each sample was coded such that the fingerprint analysis could 
be performed as a blind test. To eliminate bias, interpretation of 
autoradiographs was also carried out independently by a second observer. 
Both patient histopathology and DNA ploidy data was consulted after the 
complete analysis had been recorded. Changes in DNA fingerprint pattern 
described below are based on comparison with DNA from PBL, which can be 
considered as constitutional DNA, from the same patient.
5.2.1. DNA fingerprint analyses using minisatellite probe 33.6
Using minisatellite probe 33.6, in most cases only 2 distinct bands 
were observed. Changes were detected between primary tumour and PBL for 
some but not all patients. These included both loss of a band and the 
appearance of a band which was not detected in PBL. Changes in intensity of 
hybridisation was difficult to assess as in some cases DNA loading was not 
uniform in all lanes. DNA loading was assessed by comparing 
autoradiographs with photographs of ethidium bromide stained gels. In 6 
cases, there were either no differences between primary tumour or lymph node 
when compared to PBL or in some cases the autoradiograph was 
uninterpretable. In the remaining 7 patients, both loss of bands and appearance 
of new bands were observed. The data is presented in Table 5.2.1.
The fingerprint patterns were different for each patient. A few common 
changes, for instance, the loss of bands 1.4 kb and 1.35 kb were observed in 
primary tumours. The loss of the 1.4kb band was also seen in two cases of 
lymph node metastasis (patient B5 and L ll). Appearance of band 1.3 kb in
Table 5.2.1. DNA fingerprint analyses of primary tumours and lymph node 
metastases from breast cancer patients using minisatellite probe 33.6.
Patient DNA
source
Changes in DNA fingerprint Lymph node 
status, Ploidy & 
Tumour gradeLoss of 
bands
New
bands
F3 PT 1.4kb 1.3kb without metastasis,
NLN identical to PBL diploid, grade I
B5 PT 1.4kb, 1.35kb 1.5kb, 1.45kb with metastasis,
LNM 1.4kb, 1.35kb 1.5kb, 1.45kb aneuploid, grade II
H6 PT 1.45kb, 1.35kb 1.4kb, 1.3kb with metastasis,
LNM 1.45kb 1.3kb,1.2kb aneuploid, grade III
M9 PT _ 1.2kb with metastasis,
aneuploid, grade III
DIO PT 1.25kb 1.3kb with metastasis,
LNM 1.25kb 1.3kb diploid, grade II
L ll PT 1.4kb 1.3kb, 1.2kb with metastasis
LNM 1.4kb 1.3kb, 1.2kb aneuploid, grade II
N12 PT 1.3kb with metastasis,
LNM 1.3kb diploid, grade II
PT=primary tumour, LNM=lymph node metastasis, NLN= normal lymph 
node. Differences observed are in comparison to PBL DNA from the same 
patient.
Band sizes were measured relative to marker DNAs.
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Figure 5.2.1. Autoradiograph of DNA samples from patients B5 and H6 
using minisatellite probe 33.6.
Peripheral blood (P), primary tumour (T) and lymph node metastasis (L) were 
digested with Hinf I and the southern blot filters were hybridised to 
radiolabelled probe 33.6. Both patient B5 and H6 had aneuploid tumours. 
The changes observed are marked with arrows. In patient B5, the 1.5kb and 
1.45kb bands are present in both T and L, while the 1.4kb and 1.35 kb bands 
observed in P, are absent. In patient H6, lymph node metastasis is different 
from primary tumour. Bands of different sizes appear in T (1.4kb, 1.3kb) and 
L (1.3kb, 1.2kb).
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Figure 5.2.2. Autoradiograph of DNA samples from patients L ll  and N12 
using minisatellite probe 33.6.
Peripheral blood (P), primary tumour (T) and lymph node metastasis (L) were 
digested with Hinf I and the southern blot filters were hybridised to 
radiolabelled probe 33.6. Patient LI 1 had aneuploid tumour, while the tumour 
from patient N12 was diploid. The changes observed are marked with arrows. 
In both L ll  and N12, the changes observed in the primary tumours are also 
seen in the metastases. In patient L ll , bands of 1.3kb and 1.2kb appear, 
while 1.4kb band in P, is absent from both T and L. In patient N12, the 1.3 
kb (not seen in P) bands appear in both T and L.
I
L11 N12
' P T L P TL ST Kb
primary tumours was also more commonly observed and in these cases a band 
of the same size was also detected in lymph node metastases from the same 
patient. In general, therefore, in cases where changes in the primary tumour 
were detected, similar changes were also seen in lymph node metastases (e.g., 
patient B5, L ll  & N12, Fig. 5.2.1 & Fig. 5.2.2). In one case, however, the 
fingerprint from the lymph node metastasis was found to be different from the 
primary tumour (patient H6, Fig. 5.2.1).
The changes observed did not correlate with the ploidy status of the 
primary tumour as changes in the fingerprint from both diploid and aneuploid 
tumours were observed. Although the changes in tumours were observed in 
majority for stage II patients, in one stage I patient changes in tumour 
fingerprint was also seen. There appears to be no relationship with tumour 
grade either, but this is only based on a small number of patients.
5.2.2. DNA fingerprint analyses using minisatellite probe 33.15
Using probe 33.15, autoradiographs from 6 patients could be 
interpreted. In the remaining cases it was difficult to interpret the fingerprint 
pattern as the bands were hazy. In 4 of the 6 cases, changes in the fingerprint 
pattern in both primary tumours and lymph node metastases were observed. 
The data is presented in Table 5.2.2. Numerous bands ranging from 15 to 20 
in number were clearly resolved in each DNA samples. In general, both loss 
of bands and appearance of new bands were observed. Here again, changes in 
hybridisation intensity could not be determined. With respect to band sizes, 
the changes observed with probe 33.15 were different from those seen with 
probe 33.6.
Table 5.2.2. DNA fingerprint analyses of primary tumours and lymph 
node metastases from breast cancer patients using minisatellite probe 33.15.
Changes in DNA fingerprint Lymph node 
status, Ploidy &
Patient DNA
source
Loss of 
bands
New
bands
Tumour grade
F3 PT - 1.9kb without metastasis, 
diploid, grade I
B5 PT, LNM identical pattern in both tissues* with metastasis 
aneuploid, grade II
H6 LNM 4.3kb,
2.25kb
3.7kb,
1.7kb
with metastasis, 
aneuploid, grade III
DIO PT 8kb with metastasis,
LNM - 8kb diploid, grade II
N12 PT - with metastasis,
LNM* 5.2kb 5kb diploid, grade II
PT=primary tumour, LNM=lymph node metastasis. Differences observed are 
in comparison to PBL DNA. Band sizes were measured relative to marker 
DNAs.
*In these cases, the PBL DNA was uninteipretable, and only PT and LNM 
could be compared.
Unlike probe 33.6, in each of the primary tumours where changes were 
observed the band sizes differed in each patients. Thus, no common changes 
could be identified. The highest number of changes were observed in 
thelymph node metastasis (LNM) of patient H6. Compared to PBL, DNA 
from this node showed loss of two bands and the appearance of two new 
bands (Table 5.2.2; Fig 5.2.3). Although the fingerprint of primary tumour 
(PT) DNA could not be interpreted in this patient, it is of interest to note that 
with probe 33.6, the DNA from LNM was different from the PT.
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As with probe 33.6, changes observed with probe 33.15 did not 
correlate with the ploidy status of the primary tumour. Changes observed in 
the primary tumours were not restricted to stage II patients as in one stage I 
patient changes in primary the tumour was observed. Although the final 
analysis was possible in only a small number of patients, the observed changes 
were not restricted to tumours of any particular histological grade.
5.2.3. DNA fingerprint analysis using macrosatellite probe 228S
With probe 228S, the observed bands were often diffuse and the 
fingerprint patterns were identical in all samples (Fig. 5.2.4). Thus no 
changes in either primary tumour or lymph node metastasis could be detected 
with this probe.
5.2.4. DNA fingerprint analysis using macrosatellite probe 216S
With probe 216S, no differences were observed in the majority of 
cases and all such samples gave an identical banding pattern (Fig. 5.2.5). 
However, in two stage II patients (H4 and H6), changes in both primary 
tumour and LNM were observed (Table 5.2.3). In patient H4 both loss of 
bands and appearance of new bands in PT and LNM were of similar sizes 
(Fig. 5.2.5). Likewise in patient H6, the loss of a 7.1 kb band was observed 
in both tissues. In this case, however, changes in hybridisation intensity could 
be interpreted. A 1.3kb band in the PT of patient H6 was more intense than 
both LNM and PBL.
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Figure 5.2.3. Autoradiograph of DNA samples from patients B5 and H6 
using minisatellite probe 33.15.
Peripheral blood (P), primary tumour (T) and lymph node metastasis (L) were 
digested with Hinf I and the southern blot filters were hybridised to 
radiolabelled probe 33.6. Both patient B5 and H6 had aneuploid tumours. In 
patient B5, the primary tumour and lymph node metastases show identical 
fingerprint patterns. The PBL from this patient could not be interpreted and as 
such it could not be determined whether there were any specific changes in 
these tumour cells. In patient H6, the T lane is uninterpretable but the lymph 
node metastasis (L) show numerous changes when compared to PBL (P). 
Some of the observed changes in L are marked with arrows (loss of 2.25kb 
band; appearance of 3.7 kb and 1.7 kb bands).
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Figure 5.2.4. Autoradiograph of DNA samples from 4 breast cancer 
patients using satellite probe 228S.
Peripheral blood (P), primary tumour (T) and lymph node (L) samples were 
digested with Taq I and the southern blot filters were hybridised to 
radiolabelled probe 228S. With probe 228S no change in the fingerprint was 
observed.
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Table 5.2.3. Changes detected in DNA fingerprint of primary tumours and 
lymph node metastasis from 2 breast cancer patients using minisatellite probe 
216S.
Patient DNA 
source
Changes in DNA fingerprint Lymph node 
status & Ploidy 
of PTLoss of 
bands
New Change in 
bands intensity*
H4 PT, LNM 5.8kb, 4.3kb, with metastasis,
3.7kb 2.7kb aneuploid, grade n
H6 PT 7.1kb 1.3kb with metastasis,
(PT>LN,PBL) aneuploid, grade IH
LNM 7.1kb -
PT=primary tumour, LNM=lymph node metastasis, 0=no differences 
observed. Only cases where differences with PBL DNA were observed are 
shown here. For all other cases, both PT and LNM DNA was 
indistinguishable from PBL DNA (Fig. 5.2.5).
^changes in hybrisation intensity is recorded as greater (>) or less (<).
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Figure 5.2.5. Autoradiograph of DNA samples from 4 breast cancer 
patients using satellite probe 216S.
Peripheral blood (P), primary tumour (T) and lymph node (L) samples were 
digested with Taq I and the southern blot filters were hybridised to 
radiolabelled probe 216S. In the majority of cases and as shown here for 
patient F3 and B5 no change in the fingerprint between the DNA from the three 
sources was observed. Changes were observed in patient H4 and H6, both 
having aneuploid tumours. In the case of patient H6, the loss of a 7.1kb band 
was observed in both tumour and lymph node metastasis, while a 1.3kb band 
was more intense in the T. Similar changes in both tumour and lymph node 
metastasis were observed in the case of patient H4 (loss of 5.8kb & 3.7kb; 
new bands of sizes 4.3kb & 2.7kb).
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5.2.5. Discussion
DNA fingerprint analysis provides a useful new approach in which 
changes in tumour DNA can be studied. The advantage of the technique is that 
changes at several chromosomal sites can be simultaneously detected. 
Moreover, it is also possible to repeatedly use several mini-satellite probes on 
the same filter and this increases the chance of detecting a change. In this 
study, DNA from both primary tumours and lymph node metastases have been 
compared with DNA from peripheral blood lymphocytes from the same 
patient. Samples from both stage I and stage II breast cancer patients have 
been analysed using 4 different probes. The changes observed were found not 
to be associated with the ploidy of the primary tumour. In both aneuploid and 
diploid tumours changes in DNA pattern were observed. Although only a 
small number of tumours were analysed, it appears that changes in fingerprint 
were not restricted to tumours of any histological grade.
Four different probes have been used for hybridisation and the DNA 
fingerprint patterns were found to depend on the satellite probe used. Most of 
the changes observed were with probes 33.6 and 33.15. As these two probes 
detect DNA fragments derived from different sets of loci (Jeffreys et al., 
1986), probing of the same filter with 33.15 followed with 33.6 provided 
additional information. Hybridisation with probe 228S produced hazy bands 
and in all cases no differences could be detected. Boltz et al. (1990), however, 
have reported detectable changes in ovarian tumours with 228S, although the 
number of changes detected were less than those obtained with probe 33.15. 
As also reported by Boltz et al. (1990), the hybridisation pattern with 216S 
was invariant in the majority of cases. However, in two instances in this 
study, changes in both the primary tumour and lymph node metastasis were 
observed. Changes in tumour fingerprint with probe 216S in a small number
of cases have also been reported by Boltz et al. (1990). As has been shown 
for ovarian and gastrointestinal cancers, it thus, appears that the DNA 
fingerprint probes 33.15 and 33.6 can be used to detect changes in breast 
tumours. Only 4 primary breast tumours were previously analysed by Thein et 
al. (1987) and only shifts in hybridisation intensity were observed in two of 
these cases. Although in one case changes in the hybridisation intensity of a 
band was detected with probe 216S, this was difficult to assess in this study as 
DNA loading was often not uniform. With probe 33.15, some 15 to 20 bands 
were resolvable, which is similar to the number of bands reported by other 
workers (Fey et al., 1988), while only 2 distinct bands were observed with 
probe 33.6. Although the two probes were hybridised and washed under 
identical conditions (Section 2.2.4.9), this probably reflect differences in 
washing conditions used in this study as compared to other studies.
Although the changes detected in the fingerprint pattern appear not to be 
related with aneuploidy, differences were observed in both the primary 
tumours and lymph node metastases. In both primary tumours and lymph 
node metastases, loss of bands and the appearance of new bands were 
observed. The fingerprint patterns were highly patient-specific and with probe 
33.15 the observed changes in a patient did not match with any of the other 
patients. However, with probe 33.6, band loss of 1.4kb and a new band of 
1.3kb were found to be common changes. In general, where changes in 
primary tumours were detected, there was also changes in LNM. These 
changes when detected in the primary tumour were also present identically in 
lymph node metastases. However, for one patient (H6), tumour DNA from 
the two tissues were found to differ when probed with 33.6. This probably 
suggest that in this case further alterations may have occurred following 
metastasis or alternatively, it might reflect changes in the growth characteristics 
of subpopulations of tumour cells (Fey et al., 1988), for instance dormant cells
which grow rapidly in metastases (Alexander, 1985). Differences in DNA 
fingerprints of primary tumours and metastasis have also been reported for 
gastric cancers (Fey et al., 1988). It is of interest to point out here that FCM 
DNA analysis of lymph node metastasis has also revealed in one case the 
probable existence of an aneuploid population of cells which was not detected 
in the primary tumour (Section 5.1).
It is necessary to be cautious in assessing the implication of the changes 
observed with DNA fingerprinting. Firstly, although the minisatellites used as 
probes in this study detect sequences derived from a number of different loci, 
this represent only a fraction of the genome. Secondly, changes in DNA 
methylation have been shown to occur in colorectal cancer (Goelz et al., 1985) 
and these changes may alter Hinf I cleavage sites. However, using Alu I and 
Hae III, Thein et al. (1987) have reported that the changes observed with Hinf 
I were not due to tumour-specific DNA methylation changes. Finally, the 
number of samples analysed was low and then this was further restricted to 
cases where changes could be clearly inteipreted. Thus, these changes could 
not be tested statistically. However, in cases where changes could be detected, 
alterations in both primary tumour and lymph node metastases were observed. 
It appears this approach is likely to be fruitful when applied on a larger number 
of samples.
It is generally believed that loss of a band or decrease in intensity is 
suggestive of loss of heterozygosity. However, in DNA fingerprinting, 
mutation in a single base of an enzyme restriction site can generate differences 
in fingerprint pattern. Loss of bands were frequently observed and while no 
consistency was observed with probe 33.15, it appears that with probe 33.6 
the loss of 1.4kb band in primary tumours, which was also absent in LNM, 
could represent a more common occurrence in patients with metastasis.
Increased intensity of bands is probably related to localised amplification of 
DNA and this may be relevant as amplification of oncogenes in breast cancer 
have been reported (Section 1.4). This could not be assessed in this study as 
in most of the cases, changes in intensity could not be correcdy recorded.
The objective of this study was to detect abnormalities in tumour DNA 
and by comparing primary tumours and lymph node metastases to detect 
changes which might be related to metastatic potential. As the changes 
observed did not appear to relate with the tumour DNA content or with tumour 
grade, it is not clear whether these changes are related to the pathogenesis of 
the disease. The data presented here, however, show that DNA fingerprinting 
can be used to detect simultaneously several changes in breast tumours. A 
clear finding here is that there may be numerous alterations in the DNA of 
breast tumours. Any one of such alterations may not be important and the 
general belief is that the cumulative effect of these changes in specific genes 
may explain the aggressive behaviour of a metastatic tumour. The DNA 
fingerprinting approach used here complements the conventional method of 
using a single oncogene probe. The changes observed not only reflect the 
known DNA sequences, but also provide the possibilty of identifying new 
genes involved in breast cancer. Using this technique, it would be possible to 
obtain DNA hybridisation probes by isolating and cloning selected fragments 
obtained from breast cancer patients showing some specific alterations (for 
instance the loss of 1.4kb band detected in this study) in their DNA fingerprint 
pattern. This approach has proved fruitful in detecting chromosome 7 loss in 
myelodysplasia (Thein et al., 1988).
CHAPTER 6
DNA content, cell surface 
expression, and activation states 
of lymph node lymphocytes
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6. DNA content, cell surface expression, and 
activation states of lymph node lymphocytes.
It is evident from the results presented in previous sections, that both 
DNA aneuploidy and HPA binding are related to metastasis in breast cancer 
patients. HPA binding significantly correlated with lymph node metastasis 
(Section 4) and more than 60% of primary tumours were found to be 
aneuploid (Section 5.1). However, while primary tumours may have both 
diploid and aneuploid populations, dual-parameter analysis of lymph node 
metastases revealed that only a subpopulation of the primary tumour appears in 
these nodes. There is evidence to suggest that, with respect to DNA ploidy, 
breast tumours not only differ among patients, but also within the same 
tumour, so that only a subpopulation may possess a higher malignant 
capability. Since tumour cells in lymph node metastases were also found to 
show HPA binding, it is of much interest to determine whether there also 
exists a relationship between HPA binding and aneuploid DNA content. In 
this context, the relevant question to ask is whether tumours that are aneuploid 
also express HPA binding markers on their surface.
Results described in Section 3 suggest that at least in some patients, the 
presence of tumour cells can cause significant alterations in the lymphocyte 
populations from axillary lymph node metastases. Alterations both in T cell 
phenotype and the activation states of B cells were observed. It is therefore, 
also relevant to determine whether such alterations are related in any way to the 
DNA content of the primary tumour. Recent studies reveal that tumours that 
overexpress erb B-2 are likely to be aneuploid (Bacus et al., 1990; Tavassoli et 
al., 1989) and that such tumours are more aggressive (Borg et al., 1991). 
Expression of oncoproteins is likely to induce a host-mediated response,
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provided that the protein is recognised as foreign and in this respect, a mutated 
protein would be a likely candidate.
In this section, therefore, attempts have been made to relate aneuploidy 
with both HPA binding and phenotype and activation states of lymphocytes 
from lymph node metastases.
6.1. DNA aneuploidy and HPA binding
Ideally, a dual-colour analysis would have revealed whether in a breast 
tumour, the aneuploid cells also express HPA binding markers. However, 
such an attempt was unsuccessful, as HPA binding was found not to be stable 
after ethanol treatment, which is a prerequisite for PI staining for simultaneous 
DNA ploidy analysis. A dual-parameter analysis on the same tumour cells was 
therefore, not possible. Alternatively, a correlation of HPA staining with 
ploidy has been attempted on the same breast tumour samples.
In 28 tumour samples, data from both HPA binding and DNA ploidy 
was available. As shown in Table 6.1, among the HPA positive tumours, the 
majority (81%) were also aneuploid (13/16). However, the converse was not 
true. There were equal numbers of diploid and aneuploid tumours among 
HPA -ve tumours. There was no statistically significant association between 
HPA positivity and DNA ploidy (p>0.1). It, however, appears that HPA 
positivity may be of value in patients with aneuploid tumours. This is further 
examined in Table 6.2, in which stage (lymph node status) has been included 
to relate aneuploidy with HPA binding. The data shows that the majority of 
aneuploid tumours positive for HPA binding (12/14) have metastasised to the
lymph node. In contrast, the majority of aneuploid tumours negative for HPA 
binding (4/5) are without lymph node metastasis. This relationship, could not 
be examined in a statistical test. The number of stage I patients was only 5 and 
this reduced the frequency when patients were further put into subgroups (<5 
cases). However, the data does show that aneuploid tumours with metastatic 
capability are also positive for HPA binding.
Table 6.1. Relating DNA ploidy and HPA binding in breast cancer patients.
HPA +ve HPA -ve Statistical 
significance 
(Chi-square test)
Aneuploid 13 6 X2 = 1.8, D.F. 1
Diploid 3 6
N.S. (p > 0.1)
Table 6.2. DNA aneuploidy and HPA binding and their relation with lymph 
node metastasis (stage).
With metastasis Without metastasis
(Stage II) (Stage I)
Aneuploid, HPA +ve 12 1
Aneuploid, HPA -ve 2 4
6.2. Phenotype and activation states of lymph node lymphocytes
in patients with aneuploid primary tumours.
The phenotype and activation state of lymph node lymphocytes and 
DNA ploidy of autologous primary tumours from 15 breast cancer patients 
were analysed. All these patients had metastasis in their axillary lymph nodes 
(stage II). 9 of these primary tumours were aneuploid while the remaining 6 
were diploid. The data is presented in Table 6.3. There were no differences in 
terms of the phenotype of T cells. The CD4/CD8 ratio was more variable in 
patients with diploid tumours, ranging from 1.4 to 9.0, but the mean ratio was 
similar to those observed in patients with aneuploid tumours.
Significant diferences were observed in terms of the activation states of 
both T and B lymphocytes. However, Tac-expressing T cells were similar in 
both groups and this was true for both the CD8+ and CD4+ T cells. With 
respect to expression of the activation marker HLA DR on T cells, the 
differences observed beteween aneuploid and diploid tumours was statistically 
significant (p<0.05). This marker was expressed on a greater proportion of T 
cells in patients with aneuploid tumours (76.7%) than those with diploid 
tumours (42.7%). This difference was also maintained when expression of 
HLA DR was compared in T cell subsets. The proportions of HLA DR- 
expressing CD8+ and CD4+ T cells were lower in patients with diploid 
tumours (28.3 and 17.9% respectively). The mean proportions of these 
activated T cell subsets in patients with aneuploid tumours were 48.0 and 
32.4% for CD8+ and CD4+ cells respectively, which are similar to the mean 
values observed for stage II lymph nodes (Table 3.2, Section 3). Similarly,
Table 6.3. Distribution of phenotypic and activation markers in lymphocytes 
from lymph nodes of breast cancer patients with aneuploid and diploid primary 
tumours.
Phenotypic/
Activation
markers
Aneuploid
tumours
(n=9)
Diploid
tumours
(n=6)
Statistical
significance
CD4/CD8
ratio
3.2+/-0.4 
(3.3+/-1.2)
3.8+/-1.3 
(2.5+/-3.1)*
N.S.
HLA DR on 
T cells 76.7+/-7.5 42.7+/-7.0 0.01<p<0.05
HLA DR on 
CD8+ T cells 48.0+/-5.0 28.3+/- 4.5 0.01<p<0.05
HLA DR on 
CD4+T cells 32.4+/-4.5 17.9+/-1.8 0.01<p<0.05
Tac on T cells 39.2+/-5.6 33.9+/-2.4 N.S.
Tacon 
CD8+ T cells 16.8+/-3.8 19.4+/-3.4 N.S.
Tac on 
CD4+T cells 22.2+/-3.1 21.2+/-3.2 N.S.
IgG on 
B cells 34.3+/-4.0 22.6+1-3.3 p=0.05
Values represent mean percentage +/- standard error of lymphocytes 
expressing the phenotypic marker.
♦values in bracket represents median +/- standard deviation (SD). Median 
values and SD are cited for cases where a distribution appeared to be skewed 
(marked with asterisk).
+ Statistical test used: Mann Whitney U test was used in comparing patients 
with diploid and aneuploid tumours. Statistical significance is taken at a p 
value equal to or < 0.05. Only significant p values are given. N.S. is not 
significant
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the mean proportion of IgG-expressing B cells (34.3%) in patients with 
aneuploid tumours was also higher when compared to those in patients with 
diploid tumours (22.6%). This difference just reached statistical significance 
(p=0.05).
These results, therefore, suggest the possibility of the presence of 
some antigenic determinants in aneuploid tumours that are absent in diploid 
tumours. The activation states of both T and B cells suggest that the probable 
antigen(s) is likely to induce recognition by T cells and also to generate a B cell 
response.
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6.3. Discussion
In this section, aneuploidy of primary tumours has been related with 
both HPA staining and the activation status of lymph node lymphocytes. 
While the association with HPA staining was not statistically significant, 
aneuploid tumours were found to be positive for HPA staining in patients with 
lymph node metastasis. There was a significant association between DNA 
ploidy of primary tumours and the activation state of lymphocytes from lymph 
node metastasis.
Both DNA ploidy and HPA staining were found independently 
(described in Sections 5.1 and 4 respectively) to be related to lymph node 
metastasis. However, a good proportion of aneuploid primary tumours was 
also found to be without nodal metastasis. This suggest that aneuploidy does 
not represent an aggressive feature in all primary breast tumours. Results in 
this section show that lymph node metastasis was present in the majority of 
aneuploid tumours showing HPA positivity. It can, therefore, be concluded 
that HPA positivity in aneuploid tumours define that group of patients in 
whom aneuploidy represents an aggressive feature. It should, however, be 
pointed out that after selecting for aneuploid tumours, there was only a small 
number (6) of HPA negative tumours available. Both HPA staining and DNA 
ploidy have not been included in the same study previously, while Hitchcock 
etal. (1989), who compared surface antigen (NCRC-11, CEA) expression and 
DNA ploidy between primary and metastatic tissues, only recorded changes 
between the two tissues.
Alterations in the activation status of lymphocytes in lymph node 
metastasis was found to be significantly associated with the ploidy of the 
primary tumour. While no differences were observed in the phenotype of
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these lymphocytes when patients with aneuploid and diploid tumours were 
compared, aneuploidy was associated with both HLA DR and IgG-expression. 
In patients with aneuploid tumours, the percentage of cells expressing HLA 
DR on both CD8+ and CD4+ T cells were higher than those in patients with 
diploid tumours. Likewise IgG-expressing B cells were also higher in patients 
with aneuploid tumours. The mean values of these activated T and B cells 
were the same as those observed for stage II patients, suggesting that were 
fewer activated lymphocytes in the lymph nodes of patients with diploid 
tumours. Since only stage II patients were studied, it is not known whether 
lymph nodes in stage I patient would also show similar differences with 
respect to the ploidy of the primary tumour. It should be noted that in this 
study, no differences were observed in the activation states of lymphocytes 
between stage I and stage II patients, although in the study of Whitford et al. 
(1992b), which analysed a larger number of samples, and Morton et al. (1986) 
HLA DR expression was found to be higher in stage II patients.
Although a small number (15 samples) of lymph nodes were analysed, 
the data presented here suggest that aneuploid tumours probably express some 
antigenic determinant which is not present in diploid tumours. The activation 
states of the lymphocytes in these lymph nodes suggest that the antigen(s) 
probably induces the T cell populations and may also generate a B cell 
response. No differences were observed with Tac-expression, and it is 
difficult to interpret this as the IL-2 receptor can undergo internalisation and as 
such the loss of the receptor does not necessarily means an inactive state. Data 
for HLA DR expression, however, suggest that both the T cell subsets are in 
an activated state in patients with aneuploid tumours. In addition to the 
previous reports of increased HLA DR expression in stage II patients 
(Whitford et al., 1992b; Morton et al., 1986), the results described here shows 
that the expression of this T cell activation marker is higher in stage II patients
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who have aneuploid tumours. The implication of this finding is however, not 
clear as no specific oncogene or tumour antigen has been associated with 
aneuploid DNA content. In some of the studies, where oncogene and DNA 
ploidy have been analysed, gene amplification and protein overexpression of c- 
erb B-2 (Baak etal., 1991; Bacus et al., 1990; Borg et a l, 1991, Tavassoli et 
al., 1989) have been found to significantly correlate with DNA ploidy. 
Although in the study of Tavassoli et al., a large number of aneuploid tumours 
also showed myc amplification, the correlation was not significant. It needs 
to be established in a dual-colour analysis, whether aneuploid cells, indeed are 
also overexpressing these oncogenes.
A relationship that is also relevant but not studied here is that between 
the activation states of lymph node lymphocytes and HPA binding. Although 
the affinity of the lectin is for N-acetylgalactosamine residue, the precise 
marker that HPA binds to in breast tumours is not known and HPA binding 
remains an 'undefined biological marker" (Leathern & Brooks, 1987). 
Springer (1989) however, has proposed that the predominant structure 
recognised by HPA may be the Tn antigen. It is interesting to note that Tn, 
which is a close precursor of the M and N blood group antigens is believed to 
be a cell-adhesion molecule on tumour cell membranes (Springer, 1989). It is 
therefore, of interest to determine whether the HPA marker is antigenic in 
breast cancer patients.
CHAPTER 7 
G eneral D iscussion
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7. General Discussion
This study has focussed on various parameters which relate to the 
metastatic potential of breast tumours. In breast cancer, axillary lymph node 
metastasis is a frequent occurrence and is currently the most important 
prognostic indicator (Bloom & Richardson, 1970). The surgical practice at the 
Western Infirmary provided both primary tumour and lymph node specimens 
from each patient. Each aspect of this study has, therefore, involved 
measurement of different molecular parameters in relation to metastasis to the 
lymph node. Although a number of histopathological factors are in use to 
assess prognosis in breast cancer patients (Section 1.1.5.2), there is clearly a 
need to identify other parameters which would provide additional prognostic 
information. In this study, parameters both at the cell surface and at the DNA 
level have been analysed. Tumour cell characteristics studied here included 
carbohydrate expression at the cell surface level (Chapter 4), and at the DNA 
level, the DNA content by flow cytometry and alterations at multiple sites of 
the tumour DNA as determined by DNA fingerprinting (Chapter 5). In 
addition, the effect of metastasis on the lymphocyte populations in the lymph 
node has been studied (Chapter 3). The axillary lymph nodes are not only a 
site for secondary deposits of tumour cells but being a lymphoid tissue may 
also be involved in modulating the immune response (Section 1.2). This is 
particularly important in breast cancer, as in some patients there is clinical 
evidence to suggest that the lymph nodes may be involved in generating a host- 
mediated response against the disease (Crile, 1968; Crile, 1969; Fisher et al., 
1980). Finally, an attempt has been made to interrelate these parameters in a 
group of patients (Chapter 6).
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7.1. Flow cytometry
Flow cytometry (FCM) has been used both to analyse the lymphocyte 
populations and in studying tumours for their surface carbohydrate expression 
and DNA ploidy. While DNA FCM analysis provides new information, the 
use of this technique in the study of surface expression has certain advantages 
over the more commonly used technique of immunocytochemistry. Firstly, the 
instrument is computer-run and this makes it relatively objective. The task of 
assessing surface antigen expression or DNA analysis can be carried out in a 
very short time while the number of cells analysed can be as high as 10,000 
per sample. In this respect, immunocytochemistry is relatively subjective. 
Moreover, only a few hundred cells can possibly be analysed and as 
experienced with lectin binding to breast tumour cells, often the general 
impression of the binding can only be assessed after a number of a fields have 
been scanned (Dansey et al., 1988). In effect, it is a laborious and time- 
consuming process. In this study, using FCM it was possible to quantify the 
intensity of lectin binding and this allowed the percentage of positive cells to be 
readily determined. Secondly, dead cells could be excluded from the analysis 
by simply adding PI and using a live acquisition gate (Section 2.2.1.4). This 
operation is simple but very important as both lectins and Mabs to surface 
antigens can bind to irrelevant intracellular molecules. In contrast to most of 
the previous studies, fresh or carefully frozen single cell suspensions were 
used in this study and this ensured that the proportion of dead cells was 
relatively low. Finally, using FCM it was possible to perform a dual­
parameter analysis on intact lymphocytes from lymph nodes of breast cancer 
patients (Chapter 3). Lymphocyte populations were selected on the basis of 
their FSC (forward scatter) and SSC (side scatter) and cells stained 
simultaneously with FITC- and PE-labelled Mabs allowed the measurement of
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the relative proportions of lymphocyte subsets (Section 2.2.1.4). Dual-colour 
analysis also allowed the assessment of activation markers on a selected 
lymphocyte subset (Section 2.2.1.4). The five-parameter analysis operative in 
the flow cytometer was also found to be useful in analysing lectin binding to 
tumour cells in lymph node metastasis and in assessing DNA ploidy of 
metastatic cells in the nodes. Lymph nodes invariably contain a large number 
of lymphocytes and it was possible to exclude them during assessment of lectin 
binding by gating on FSC versus SSC (Section 2.2.2.3) while during DNA 
analysis, lymphocytes could be excluded on the basis of cytokeratin staining 
(Section 2.2.3.7). There are, however, a few limitations with flow cytometry. 
As only free cells are stained for analysis, the tumour tissue has to be 
completely disaggregated. This disrupts the normal architecture of the tissue 
and unlike histochemistry, it is not possible to observe the relationship between 
staining cells and the rest of the tissue.
7.2. Factors associated with metastasis in breast cancer patients 
7.2.1. A study of primary tumours and lymph node metastases
The various parameters assessed in this study have been found to be 
associated with metastasis to the lymph nodes in breast cancer. As is apparent 
throughout this thesis heterogeneity in breast tumours is a common finding and 
it is likely that such heterogeneity may represent populations of cells with 
differing metastatic potential, that is, populations of metastatic and non­
metastatic cells can pre-exist within the same tumour (Fidler & Kripke, 1977). 
It is generally believed that the progression of cancer proceeds through multiple 
alterations in the DNA and some of these may provide growth advantage or 
higher metastatic potential (Fearon & Vogelstein, 1990) to a subpopulation of
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tumour cells. In this respect a relevant question is whether cells with higher 
malignant potential have a distinct phenotype and whether there are any specific 
alterations in the tumour DNA which give rise to the malignant phenotype. A 
number of studies, the majority of which have concentrated on the primary 
tumour, have revealed that certain tumour characteristics, which involve both 
cell surface expression (Section 1.3) and tumour DNA (Section 1.4), are 
associated with metastatic potential. However, in assessing metastatic 
potential, while it is necessary to study primary tumours, it is also worthwhile 
to examine tumour cells from secondary deposits. Cells from metastases may 
comprise of a population of cells which are more aggressive and may only 
represent a subpopulation of cells in the primary tumour. In breast cancer, the 
availability of lymph nodes along with the primary tumour makes such a 
comparison possible. Therefore, by comparing primary tumours and lymph 
node metastases from the same breast cancer patient, it is possible to determine 
whether tumour cells that invade the node represent any specific sub­
population of the primary cells.
As demonstrated with FCM DNA analysis, assessment of primary 
tumours is generally representative of cells which make up the bulk of the 
tumour specimen and may also include contaminating normal cells (Chapter 4). 
In lymph node metastases, the detection of tumour cells is made difficult by the 
presence of lymphocytes in large number. These difficulties have been 
overcome in a dual-parameter flow cytometric analysis. Similarly, it was also 
possible to confine the measurement of lectin binding to tumour cells alone.
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7.2.2. Cell surface carbohydrate expression
At the cell surface, alterations in carbohydrate structures are well 
documented in breast cancer (Section 1.3). This has been highlighted both 
with the use of lectins and with Mabs reacting with breast tumour cells. 
Studies with murine Mabs directed against breast tumours have failed to reveal 
any well-characterised tumour-specific antigen but in most cases they appear to 
react with high MW glycoproteins, the most dominant of which are the mucins 
(Section 1.3.1.1). Although restricted in reactivity to carbohydrate residues, 
lectins can be used to detect alterations in carbohydrate expression. In a 
tumour, these lectin-reactive carbohydrate residues may represent exposed 
sugar residues due to alteration in oligosaccharide processing or 
overexpression of a surface marker. In this study, HPA binding, which was 
initially reported to be a marker of metastatic potential (Leathern & Brooks,
1990), was found to be significantly associated with lymph node metastasis 
(Chapter 4; Alam et al., 1990). Tumour cells that invade lymph nodes also 
express this marker and this correlated significantly with HPA binding in 
primary tumours. Thus the HPA marker may represent a metastatic 
phenotype. However, the particular molecule in breast tumour cells that HPA 
binds to is not known. A particular limitation in interpreting lectin binding 
being that since lectins are specific for a sugar residue, this sugar residue may 
be common to several glycoproteins present within the same cell. It is not, 
therefore, known whether the binding represents a number of markers which 
are all expressed together or it represents one particular marker which is being 
overexpressed. Although it has been proved that the combining groove of 
HPA reacts specifically with N-acetyl galactosamine, it is believed that the total 
combining site is considerably larger and complex formation involves 
interactions between surfaces and not sugar units per se and this reaction
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remains ill defined (Baker et al., 1983). Thus, minor variations in the 
composition of oligosaccharide chains, not necessarily involving the lectin- 
specific sugars, can also affect binding. At this stage, therefore, it may only be 
concluded that HPA binds to N-acetyl galactosamine-containing glycoproteins 
or proteoglycans that are expressed on tumour cells which have a higher 
metastatic potential.
7.2.3. DNA aneuploidy
A more frequently observed breast tumour characteristic is the 
abnormality in the DNA content. This has been widely studied and a universal 
finding is that more than 60% of breast tumours are aneuploid (Frierson et al., 
1991). In this study it was observed that although aneuploid tumours were 
more frequent in patients with metastasis, such tumours were also detected in 
patients without metastasis (Section 5.1). This was also evident in DNA 
fingerprinting of breast tumours, where changes in tumour DNA was observed 
in both tumours with and without metastasis (Section 5.2). However, it 
appears that among aneuploid tumours some are more aggressive than others. 
While most of the previous studies were on primary tumours, in this study 
lymph node metastases have also been analysed. Using an anti-cytokeratin 
antibody and employing a dual-parameter DNA analysis it was possible to 
exclude contaminating cells and the analysis could be restricted to epithelial 
cells alone. This is particularly important in lymph node metastases, which 
contain a large number of lymphocytes and as such contain tumour cells which 
may not be detected in a ploidy analysis. Using this technique it was possible 
to ask the question whether aneuploid cells have a higher metastatic potential in 
case of a primary tumour with both diploid and aneuploid cells. In general, 
both diploid and aneuploid tumours were detected in lymph node metastases
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suggesting that both tumour cell types can be metastatic. Although aneuploid 
tumour cells were detected in lymph nodes in cases, where the primary 
tumours were also aneuploid, it was observed that with multiploid tumours, a 
subpopulation of aneuploid cells appeared in lymph node metastases. This, 
therefore, implies that at least in some primary tumours, differences in DNA 
content may reflect differences in metastatic potential. An alternative 
explanation, however, could be that there might be a local inhibitory effect of 
the lymph nodes on the proliferation of some tumour cells such that only a 
subpopulation of them survive. In any case, this suggests that in some breast 
tumours there are differences in tumour cell populations with respect to DNA 
content.
A relevant question to ask here is whether there is a role of aneuploidy 
in respect of gene deletion and expression. The inability of aneuploid tumour 
cells to grow in culture had led to a belief that aneuploidy is perhaps a harmless 
feature of a cell's uncontrolled terminal growth with no inherent metastatic 
property. In this study it was also not possible to grow aneuploid cells and as 
such these cells could not be studied specifically (Section 5.1.3). But this only 
reflects the inability of the in vitro culture conditions to allow growth of 
aneuploid cells. The exact mechanism which leads to aneuploidy in a cell is 
not known. It is, however, possible to speculate that aneuploidy may increase 
the instability of a tumour cell and thus cause an increase in the rate of gene 
deletion and activation. This has not been examined as until very recently, 
researchers studying oncogenes in breast cancer were apparently not concerned 
with aneuploidy and no study attempted to correlate the two features. 
However, in a few recent studies the amplification and overexpression of the 
erb B2 oncogene was observed in breast tumours which were also aneuploid 
in their DNA content (Tavassoli et al., 1989; Bacus et al., 1990; Baak et al.,
1991). This supports the view that aneuploidy may be associated with gene
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overexpression and perhaps also deletion in breast tumours. In turn, some of 
these changes may be the precise events necessary to confer a higher metastatic 
potential on the tumour. Therefore, only those aneuploid tumours with the 
right genes activated and/or deleted will behave aggressively. To test this 
hypothesis, it is necessary to analyse both the relevant gene expression and 
DNA ploidy on the same breast tumour cells. This can be performed by 
employing a dual-parameter analysis similar to the one used to analyse CK+ 
epithelial cells and DNA ploidy.
With respect to surface expression, it appears that among aneuploid 
tumours HPA binding may identify a group of patients in whom aneuploidy 
represents an aggressive feature (Chapter 6). However, to confirm this 
association a much larger number of patients have to be analysed.
7.3. Metastasis and the immunological role of lymph nodes in 
breast cancer
The axillary lymph nodes that drain breast tumours not only represent a 
site for the secondary deposit of tumour cells but are also an attractive subject 
for the study of immune response against cancer (Section 1.2.9.2). With 
respect to breast cancer patients, it is most relevant to determine whether the 
axillary nodes are involved in mediating immunity against cancer and as such 
whether in some patients the absence of metastasis is the effect of such a 
response. The role of lymph nodes in mounting an immune response against 
breast cancer still remains controversial. Although not many studies have 
analysed lymphocytes from the nodes, some of the recent studies provide 
evidence to suggest that host-mediated immunity against breast cancer may 
occur at least in some patients (Section 1.2.9.2). HLA DR-expressing T cells
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and IgG-expressing B cells were found to predominate in the nodes of breast 
cancer patients (Morton et al., 1989, Whitford et al., 1992). Although both 
stage I and stage II patients were studied, only tumour-free nodes were 
analysed and as such the effect of metastasis on the immune function of the 
lymph nodes could not be assessed. This study involved the analysis of 
tumour-free and tumour-invaded lymph nodes from the same patient and these 
were then compared with lymph nodes from patients without metastasis 
(Chapter 3). Such analyses reflect the nature of the response and may also 
determine the outcome of the tumour-host interaction as encountered in lymph 
nodes.
The response in breast cancer patients was highly patient specific and 
the differences observed were often seen in only a proportion of patients. The 
analysis carried out in this study, therefore, reflect trends observed in 
comparing two groups of nodes in the same patient. The presence of 
metastatic tumour cells in a lymph node were found to cause specific alterations 
of the phenotype of the T cells and the activation state of the B cells. It appears 
that in some patients the presence of tumour cells provide antigens for a 
secondary B cell response. It is of interest that the alterations in the T cell 
subsets in the nodes reflect those observed in tumour infiltrating lymphocytes 
(TILs) (Section 1.2.9.1). As in the TILs, the CD8+ T cells were found to be 
in higher proportion in invaded nodes of some patients. Here again, close 
contact of the tumour cells in the nodes with CD8+ T cells may have caused 
proliferation of these cells. On the other hand, however, lower percentages of 
CD4+ T cells were also observed in invaded nodes. This reflects the 
complexity of the host-tumour interaction and it appears that while certain 
populations are being activated others appear not to be proliferating or are 
perhaps being suppressed. It is perhaps the final outcome of this interaction 
which determines whether the host response will be able to contain the tumour.
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This can only be established in a follow-up study where recurrences or 
survival in these patients may be used to assess the implication of a host- 
mediated anti-tumour response.
The variability between patients in terms of both the phenotype and the 
activation states of lymphocytes was highly notable. This probably reflects 
differences in host-immunity but on the other hand may also reflect the 
oncogenic or antigenic complement of the tumour. Due to the small number of 
patients studied it was not possible to assess if the alterations observed in 
lymph node lymphocytes were associated with the differentiation state (grade) 
of the tumours. However, it was possible to assess this with respect to the 
DNA content of the primary tumour. Both HLA DR expression on T cells and 
IgG-expression on B cells were found to be related to the ploidy of the primary 
tumour. It appears from this that there may be some antigenic determinants in 
aneuploid tumours that are absent in diploid tumours. This in turn would 
suggest that a putative oncoprotein, which is probably expressed in some 
aneuploid tumours, may be antigenic in mediating a host-mediated response. 
Therefore, it is necessary to determine whether any particular breast cancer- 
associated antigen/oncoprotein is involved in the observed response. For 
instance, p53 is known to carry mutations and the mutated protein reported to 
be expressed in 50% of breast tumours (Bartek et al., 1990; Cattoretti et al., 
1988). The p53 protein is expressed within the cell and can, therefore, elicit a 
T cell response. Although there are no reports of mutation in the c-erb B2 
gene, the other oncogene widely studied in breast cancer (Slamon et al., 1989; 
Borresen et al., 1990; Iglehart et al., 1990; Clark & McGuire, 1991), the gene 
product carries an extracellular domain and, therefore, theoretically could elicit 
a B cell response
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7.4. Surgical and clinical relevance
The treatment of breast cancer not only involves the removal of the 
cancer at the primary site but essentially it involves an attempt to arrest further 
spread of the disease. The once used Halsted radical mastectomy, which 
involved en-bloc removal of the breast and adjoining area, has been abondoned 
in favour of a much conservative approach. Nowadays, a simple mastectomy 
or even lumpectomy is performed followed by adjuvant therapy, which 
includes chemotherapy and loco-regional radiotherapy to the breast, axilla, or 
both. But there still remains much controversy in the surgical treatment of 
breast cancer. The controversy centres around treatment of axillary lymph 
nodes. Here surgeons have various options- a surgeon can choose to ignore 
the nodes, to sample only the lower nodes, or can make a complete axillary 
clearance. Nodal clearance is a skilled operation and is associated with 
significant potential morbidity and is therefore, only performed in large centres 
where the surgeons have regular experience in it. Surgeons who prefer not to 
perform a clearance probably have more faith in the Fisher Trial (Fisher et al., 
1980), which showed in a randomised trial that survival was not adversely 
affected in some patients in whom no axillary clearance was performed but 
who may be presumed to have had lymph node metastasis. Moreover, the 
survival rates for node positive patients randomised to receive either radical 
mastectomy alone or mastectomy without axillary dissection but with regional 
irradiation were equivalent at 10 years. The trial indicated that axillary 
clearance whether carried out early or only after clinical presentation does not 
affect survival in breast cancer patients. However, in counterarguments others 
point out that these trials were performed before the successful use of systemic 
adjuvant therapy has been established and as such the findings are not valid 
(Fentiman & Mansel, 1991). Accurate assessment of nodal status is believed 
to be important as a recently reported worldwide collaborative trial has shown
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that adjuvant chemo-endocrine therapy can significantly reduce both recurrence 
and death in breast cancer patients (Early Breast Cancer Trialists' Collaborative 
Group, 1992). Although both node-positive and node-negative patients were 
found to benefit from a combined chemo-endocrine therapy, the improvement 
in 10-year survival was twice as great for patients with nodal involvement. On 
the other hand, an additional feature that may be relevant here is the patient's 
lymph node response. If any of the breast cancer patients are responding to 
their cancer and since the response appears to be localised to the lymph nodes, 
then in this case removal of these nodes would definitely compromise the 
patient's ability to fight the disease.
The major implication of axillary clearance is that it allows accurate 
assessment of nodal status and lymph node metastasis remains the most 
important prognostic indicator. However, it must be pointed out that staging is 
not always accurate and 30% of stage I patients still die from their malignant 
disease (Bloom et al., 1970; Fisher et al., 1980). There is therefore, a need for 
identification of other biological features of breast tumours, features which 
might provide additional information and help in correctly assessing prognosis 
in breast cancer patients. Ideally, these features should be detectable pre- 
operatively, for instance on fine-needle aspirates. Although a few biological 
features have been identified, these are still at an investigational phase. Each 
aspect of this study has involved measurement of different molecular 
parameters in relation to metastasis to the node. Although these parameters 
need to be established in further studies involving a larger number of patients, 
it appears that these parameters may be of value as prognostic factors. Ideally, 
it should be possible to build up a database from each patient with all available 
information- stage, grade, ER status, lectin binding capacity, lymph node 
immunological responses, aneuploidy status and oncogene content. It might 
then be possible to make a logical correlation between a set or subset of these
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parameters and tumour metastasis in a substantial number of patients. This can 
perhaps be illustrated by two representative cases where some of these 
parameters were assessed (Table 7.1). Although both the tumours are 
aneuploid, the patients differ in their lymph node responses. Patient 1 appears 
to have a favourable response in the lymph node, more HLA DR+ T cells and 
and a higher percentage of IgG+ B cells. Patient 1 may, therefore, be regarded
Table 7.1. Data on lymph node response, DNA ploidy and histopathology 
for two breast cancer patients.
Patient 1 Parameter analysed Patient 2
9.5 %CD8+T cells 6.5
36.1 %CD4+T cells 31.0
3.8 CD4+/CD8+ ratio 4.7
70.0 % HLA DR+CD8+ cells 44.0
53.0 % HLA DR+CD4+ cells 18.5
46.0 % sIgG+ B cells 20
Aneuploid DNA ploidy Aneuploid
n Tumour grade m
without Nodal status with
metastasis metastasis
to have a good prognosis and this bears out in the tumour grade and the lymph 
node status. On the other hand, patient 2 is apparently responding poorly and 
the aneuploid primary tumour is more aggressive, which is reflected in tumour 
grade and lymph node status. Additional information may be gathered by 
assessing HPA binding capacity and oncogene content, and together these
2 9 8
would provide a more comprehensive assessment of the biological nature of 
the tumour and the patient's response to it. This illustration further implies that 
each patient may have to be treated individually as the cancer may be 
biologically different, at a different differentiation stage and moreover, the 
host-tumour interaction is likely to be patient-specific.
Technically, such an approach has two major problems-
(i) It requires a synthesis between the work of surgeons, pathologists, 
immunologists, biochemists, geneticists and finally a good computer database 
technologist to keep a datafile for each patient.
(ii) It requires more tissue than is currently available either from the primary or 
the node. Moreover, more representative material may be needed as primary 
tumours received in the clinical laboratory are heterogeneous in nature. For 
instance, the sample sent to pathology for grading may be different from that 
sent to biochemistry for ER analysis and different again from the sample sent 
to genetics for oncogene analysis.
If these problems can be resolved, it might then be feasible to analyse 
only the features relevant to the metastatic capacity of a primary breast tumour. 
There is clearly a lack of understanding of the true biology of breast cancer and 
further basic research in this field is much warranted.
CHAPTER 8 
R e f e r e n c e s
Aamdal, S., Bormer, O. & Jorgensen, O. (1984). Cancer, 54: 2525.
Acha-Orbea, H. & Palmer, E. (1991). Immunology Today, 12 (10): 356.
Acha-Orbea, Shakov, A.N., Scarpellino, L., Kolb, E., Muller, V., Vessaz- 
Shaw, A., Fuchs, R., Blochlinger, K., Rollini, P., Billotte, J., Sarafidou,
M., MacDonald, H.R. & Diggelmann, H. (1991). Nature, 350: 207.
Adams, R.L.P. (1990). "Cell culture for biochemists." Laboratory techniques 
in Biochemistry and Molecular Biology. Ed. R.H. Burdon & P.H. van 
Knippenberg. 2nd revised edition, Elsevier, Amsterdam, New York, Oxford.
Adams,J.,Gerondakis,S.,Webb,E.,Corcoran,L.M. & Cory,S. (1983). Proc. 
Natl. Acad.Sci. USA, 80: 1982.
Alam, S.M., Whitford, P., Cushley, W., George, W.D. & Campbell, A.M. 
(1990). Br. J. Cancer 62: 238.
Alam. S.M., Clark, J.S., Leech, V.,Whitford, P., George, W.D. & 
Campbell, A.M. (1992a). Immonology Letters, 31: 279.
Alam, S.M., Whitford, P., Cushley, W., George, W.D. & Campbell, A.M. 
(1992b). Eur. J. Cancer, (in press).
Alexander, P. (1985). Br. J. Cancer, 51: 453.
Ali, I.U., Lidereau, R., Callahan, R. (1989). J. Natl. Cancer Inst. 81:115.
Ali, I.U., Lidereau, R., Theillet, C. & Callahan, R. (1987). Science,
235: 185.
Alitalo, K. & Schwab, M. (1986). Adv. Cancer Res., 47: 235.
Altevogt, P., Fogel, M., Cheingsong-Popov, R., Dennis, D., Robinson, P. & 
Schirrmacher, V. (1983). Cancer Res., 43, 5138.
Anastassiades, O.T. & Pryce, D.M. (1966). Br. J. Cancer, 20: 239.
Anderson, D.C., Butcher, E.C., Gallatin, M., Rosen, S.K., Jishimoto, K., 
Lasky, L., Miyasaka, M., Scollay, R., Smith, C.W. & Haskard, D. (1991). 
Immunology Today, 12: 216.
Anderson, D.E. (1974). Cancer, 34:1090.
Anderson, M.L.M. & Spandidos, A.S. (1988). Anticancer Research, 8: 873.
Anderson, M.L.M. & Young, B.D. (1985). Quantitative Filter Hybridisation. 
In " Nucleic acid hybridisation. A practical approach." Ed. B.D. Hames & 
S.J. Higgins. IRL Press, Oxford, Washington DC.
Angus, B., Napier, J., Purvis, J. & others. (1986). J. Pathol., 149: 301.
Askensten, U. G., Von Rosen, A.K., Nilsson, R.S., & Auer, G.U., (1988). 
Adenocarcinomas. Cytometry, 10: 326.
Auer, G.U., Caspersson, T.O.& Wallgren, A.S. (1980a). Anal Quant Cytol., 
2: 161.
Auer, G.U., Arrhenius, E., Granberg, P-0 & Fox, C.H. (1980b). Europ. J. 
Cancer, 16: 273.
Baak, J.P.A., Chin, D., van Deist, P.J., Ortiz, R., Matze-Cok, P. & Bacus, 
S.S. (1991). Lab. Invest., 64: 215.
Bacus, S.S., Bacus, J.W.Slamon, D.J. & Press, M.F. (1990). Arch Pathol. 
Lab. Med., 114: 164.
Baisch, H., Beck, H-P., Christensen, I.J., Hartman, N.R., Fried, J., Dean, 
P.N., Gray, J.W., Jett, J.H., Johnston, D.A., White, R.A., Nicolini, C., 
Zeitz, S. & Watson, J.V. (1982). Cell Tissue Kinet., 15: 235.
Baker, S.J., Markowitz, S., Fearon, E.R., Wilson, J.K.U. & Vogelstein, B. 
(1990). Science, 249: 912.
Balch, C.M., Riley, L.B., Bae, Y.J., Salmeron, M.A., Platsoucas, C.D., von 
Eschenbach, A. & Itoh, K. (1990). Archives of Surgery, 125: 200.
Balch, C.M., Riley, L.B., Bae, Y.J., Salmreon, M.A., Platsoucas, C.D., von 
Eschenbach, A. & Itoh, K. (1990). Archives of surgery, 125: 200.
Barb acid,M. (1987) Ras genes. Ann.Rev.Biochem. 56 779.
Bard, D.S., Hamond, W.G. & Pilch, Y.H. (1969). Cancer Research, 29: 
1379-1384.
Barlogie, B., Raber, M.N., Schumann, J., Johnson, T.S., Drewinko, B., 
Swartzendruber, D.E., Gohde, W., Andreef, M., & Freireich, E. (1983). 
Cancer research, 43: 3982.
Barnard, N.J., Hall, P.A., Lemione, N.R.& Kadar, N. (1987). J. Pathol., 
152: 287.
Bartek,J.,Bartkova,J.,Vojtesek,B.,Staskova,Z.,Rejthar,A.,Kovarik„J., & 
Lane,D.P. (1990). IntJ.Cancer 46 839.
Barth, R.J., Dabforth, D.N., Venzon, D.J., Straus, K.L., d'Angelo, T., 
Merino, M.J. & Gerber, L. (1991). Arch. Surg., 126: 574.
Bartrop, R.W., Lazarus, L., Luckherst, E., Kiloh, L.G. & Penny, R.
(1977). Lancet, I: 834.
Beeley, J.G. (1985). Glycoproteins and Proteoglycans. In "Glycoprotein and 
Proteoglycan Techniques" Laboratory techniques in Biochemistry and 
Molecular Biology, Editors: R.H. Burdon & P.H. van Knippenberg,
Elsevier, Amsterdam, New York, Oxford.
Beerman, H., Kluin, M., Hermans, J., Velde, CJ.H.van de, & Comelisse, 
C.J. (1990). Int. J. Cancer. 45: 34.
Beerman, H., Smit, V.T.H.B.M., KLuin, P.M., Bonsing, B.A., Hermans, J. 
& Comelisse, C.J. (1991). Cytometry, 12: 147.
Belldegrun, A., Kasid, A., Uppenkamp, M., topalian, S.L. & Rosinberg,
S.A. (1989). J. Immunol., 142: 4520.
Belldegnin, A., Muul, L.M. & Rosenberg, S.A. (1988). Cancer Research, 
48: 206.
Bello, M.J. & Rey, J.A. (1989). Neoplasma, 36: 71.
Ben-Ezra, J. & Sheibani, K. (1987). Cancer, 59: 2037.
Benacerraf, B. (1981). Science, 212: 1229.
Berger, M.S., Locher, G.W., Saurer, S. & 4 others. (1988). Cancer Res., 
48: 1238.
Berry, N. Jones, D.B., Smallwood, J., Taylor, I., Kirkham, N. & Taylor- 
Papadimitriou, J. (1985). Br. J. Cancer, 51: 179.
Bevilacqua, M. P., Stengelin, S., Gimbrone, M.A. & Seed, B. (1989a). 
Science, 243: 1160.
Bevilacqua, G., Sobel, M.E., Liotta, L.A. & Steeg, P.S. (1989b). Cancer 
Research, 49: 5185.
Bilik, R., Mor, C., Hazaz, B. & Moroz, C. (1989). Cancer Immunol. 
Immunother.,
28: 143.
Bimboim, H.C. & Doly, J. (1979). Nucleic Acid Research, 7: 1513.
Bister,K. Hayman,M.J. & Vogt,P.K. (1977). Virology, 82: 431.
Bjorkman, P.J., Saper, M. A., Samraoui, B., & Bennet, W.S. (1987). 
Nature, 329: 506.
Black, M.M. & Speer, F.D. (1958). Surg. Gynaecol. Obst., 106: 163.
Black, M.M., Barclay, T.H.C. & Hankey, B.F. (1975). Cancer, 36: 2048.
Block, M.M., Barclay, T.H.C. & Hankey, BF. (1975). Cancer, 36: 2048.
Bloom, H.J.G. & Richardson, W.W. (1957). Brit. J. Cancer, 11: 359.
Bloom, H.J.G., Richardson, W.W. & Feild, J.R. (1970). Brit. Med. J., 3: 
181.
Bocker, W., Klaubert, A., Bahnsen, J., Schweikhart, G., Pollow, K., Mitze, 
M., Kreienberg, R., Beck, T. & Stegner, H.E. (1984). Virchows Arch 
(Pathol Anat). 403: 149.
Bodmer, (1991). Immunology, 30: 259.
Bodmer, W.F. (1987). J. Clin. Pathol. 27: 948.
Boltz, E.M., Harnett, P., Leary, J. Houghton, R., Kefford, R.F. & 
Friedlander, M.L. (1990). Br. J. Cancer, 62: 23.
Bombardieri, E., Gion, M., Mione, R., Dittadi, R., Bruscagnin, G. & 
Buraggi, G. (1989). Cancer, 63: 490.
Borg, A., Baldetrop, B., Femo, M., Killander, D., Olsson, H & Sigurdsson, 
H. (1991). Oncogene, 6: 137.
Borresen, A.-L., Ottestad, L., Gaustad, A., Andersen, T.I., Heikkila, R., 
Jahnsen, T., Tveit, K.M. & Nesland, J.M. (1990). Br.J. Cancer, 62: 585
Bos, J.L., Toksoz, D., Marshall, C.J., Verlaan-de-vries, M., Veeneman, G., 
van der Eb, A.J., van Boom, J.H., Janssen, J.W.G. & Steenvoorden,
A.C.M. (1985). Nature, 315:726.
Bos,J.L. (1989). Cancer Res ,49: 4682.
Bouzebar, N., Walker, K.J., Griffiths, K. & Others. (1989). Br. J. Cancer, 
59:943.
Boyle, P. & Leake, R. (1988). Breast Cancer Research & Treatment, 11: 91.
Bray, K.R., Koda, J.E., & Gaur, P.K. (1987). Cancer Research, 47: 5853.
Brocker, E.B., Suter, L., & Sorg, C. (1984). HLA-DR antigen expression in 
primary melanomas of the skin. J. Invest. Dermatol., 82:244.
Brooks, S.A. & Leathern, A.J.C. (1991). Lancet,
338: 71.
Brown, J.H., Jardetzky, T., Saper, M.A., Samraoui, B., Bjorkman, P.J. & 
Wiley, D.C. (1988). Nature, 332: 845.
Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., 
Millis, R. & Lamport, D. (1987). Cancer Res., 47: 5476.
Burchell, J.M., Durbin, H. & Taylor-Papadimitriou, J. (1983). J. Immunol., 
131: 508
Butcher, E.C. Scollay, R.G. & Weissman, I.L. (1979). J. Immunol., 123: 
1996.
Cairns, J. (1981). The origin of human cancers. Nature. 289: 353.
Camerini, D., James, S.P., Stamenkovic, I. & Seed, B. (1989). Nature,
342: 78.
Camerini, D., James, S.P., Stamenkovic, I., & Seed, B. (1989). Nature. 
342: 78.
Campbell, A.M. & Leake, R.E. (1990). The Cancer Journal, 3:40.
Campbell, A.M., Whitford, P. & Leake, R.E. (1987). Br. J. Cancer, 56: 
709.
Carpenter, G. (1987). Annu. Rev. Biochem, 56: 881.
Carroll, K.K. (1975). Cancer Research, 35: 3374.
Caspersson, T., Zech, L. & Johnson, C. (1970). Exp. Cell Res., 60: 315.
Cattoretti, G., Rilke, F., Andoreola, S., DfAmato, L. & Delia, D. (1988).
P53 expression in breast cancer. Int.J. Cancer, 41: 178.
Ceriani, R.L., Peterson, J.A., Lee, J.Y., Moncada, R. & Blank, E.W.
(1983). Som. Cell Genet. 9: 415.
Champion, H.R., Wallace, I.W.J. & Prescott, R.J. (1972). Brit. J. Cancer, 
26: 129.
Chen, L., Dollbaum, C. & Smith, H.S..(1989). Proc.Natl.Acad.Sci. USA, 
86: 7204.
Choi, Y., Kappler, J.W. & Marrack, P. (1991). Nature, 350: 203.
Chung, C.T. & Miller, R.H. (1988). Nucleic Acids Research, 16(6): 3580.
Cifone, M.A. & Fidler, I.J. (1981). Proc. Natl. Acad. Sci. USA., 78: 6949.
Clark, G.M. & McGuire, W.L.(1991). Cancer Research, 51: 944.
Clark, G.M., Dressier, L.G., Owens, M.A., Pounds, G., Oldaker, T., & 
McGuire, W.L. (1989). New Eng.J.Med. 320,627.
Clausen, H., Levery, S.B., Salyan, M.E.K., Nudelman, E.D., Stroud, M.R. 
& Hakomori, S. (1987). J. Biol. Chem., 262: 14228.
Clevers, H., Alarcon, B., Wileman, T. & Terhorst, C. (1988). Ann. Rev. 
Immunol., 6: 629.
Colcher, D., Horan Hand, P., Nuti, M. & Schlom, J. (1981). Proc. Nad. 
Acad. Sci. USA, 78: 3199.
Cole, M.D. (1991). Myc meets its Max. Cell, 65:715.
Coon, J.S., McCall, A., Miller, A.W. Ill, Farrow, G.M. & Weinstein, R.S.
(1985). Cancer 56: 797.
Comelisse, C.J., Van De Velde, C.J.H., Caspers, R.J.C., Moolenaar, A J. & 
Hermans, J. (1987). Cytometry 8, 225
Coulson, P.B., Thomthwaite, J.T., Woolley, T.W. (1984). Cancer 
Research, 44: 4187.
Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A. and 
Francke, U. (1985). Science 230:1132.
Crissman, J.D., Zarbo, R.J., Niebylski, c.D., Corbett, T. & Weaver, D. 
(1988). Mod. Pathol. 1:198.
Cropp, C.S., Lidereau, R., Campbell, G., Champene, M.H. & Callahan, R.
(1990). Proc.Natl.Acd.Sci.USA, 87:7737
Cruciger, Q.V.J., Pathak, S. & Gailleau, R. (1976). Cytogenet. Cell Genet. 
17:231.
Cummings, R.D., Kornfeld, S., Schneider, W.J., Hobgood, K.K., 
Tolleshaug, H., Brown, M.S. & Goldstein, J.L. (1983). J. Biol. Chem.
258: 15261.
Daar, A.S., Fuggle, S.V., Fabre, J.W., Ting, A. & Morris, P.J. (1984a). 
Transplantation, 38: 287.
Daar, A.S., Fuggle, S.V., Fabre, J.W., Ting, A. & Morris, PJ. (1984b). 
Transplantation, 38: 293.
Dagert, M. & Ehrlich, S.D. (1979). Gene 6: 23.
Damato, B.E., Campbell, A.M., McGuire, B.J., Lee, W.R. & Foulds, W.S. 
(1988). Br.J. Cancer, 58: 182.
Dansey, R., Murray, J., Ninin, D. & Bezwoda, W.R. (1988). Oncology,
45: 300.
Davey, F.R., Kurec, A.S., dock, N.L., Hubell, C. & Falen, S.W. (1984). 
Tissue Antigens, 24: 98.
Davis, M.M. & Bjorkman, P.J. (1988). Nature, 334: 395.
De Bortoli,M.E.,Abou-Issa,H., Haley,B.E. & Cho-Chung,Y.S. (1985). 
Biochem. Biophys.Res.Comm. 127 699.
DeCaprio, J.A., Ludlow,J.W., Lynch, D., Furukawa, Y., Griffin, J., 
Piwnica-Worms, H., Huang,C.M. & Livingstone,D.M. (1989). Cell 58 
1085.
Delattre, P., Olschwang, S., Law, D.J., Melot, T., Remvikos, Y., Salmon, 
R.J., Sastre, X., Validire, P., Feinberg, A.P. & Thomas, G. (1989). Lancet, 
2: 353.
Delides, G.S., Garas, G., Georgouli, G. (1982). Arch. Pathol. Lab. Med., 
106: 126.
Delli Bovi,P.,Curatola,A.M.,Kem,F.G.,Greco,A.,Ittman,M.,& Basilico,C. 
(1987). Cell, 50 729-737.
Dellides, G.S., Garas, G., Georgouli, G (1982). Arch. Pathol. Lab. Med., 
106: 126.
Dennis, J.W. (1986a). Cancer Res., 46: 4595.
Dennis, J.W. (1986b). Cancer Res., 46:5131.
Dennis, J.W., Kosh, K., Bryce, D.M. & Breitman, M. (1989). Oncogene,
4: 853.
Dennis, J.W., Laferte, S., Waghome, C., Breitman, M.L. & Kerbel, R.S.
(1987). Science 236: 582.
Der,C.J.,Krontiris,T.G., & Cooper,G.M. (1982). Proc.Natl.Acad.Sci.USA 
79 3637.
Devilee, P., van den Broek, M., Kuipers-Dijkshoom, N., Kolluri, R., Khan, 
P.M., Pearson, P.L. & Comelisse, C.J. (1989). Genomics, 5: 554.
Devilee,P.,vanVliet,M.,Kuipers-Dijkshoom,N.,Pearson,P.L.,& Comelisse, 
C.J. (1991). Oncogene 6: 311.
Di Fiore, P.P.,Pierce, J.H. ,Fleming,T.P., Hazan,R., Ullrich,A., King,C.R., 
Schlessinger,J. & Aaronson,S.A. (1987a). C ell, 51: 1063.
Di Fiore,P.P.,Pierce,J.H.,Kraus,M.H.,Segatto,0.,King,C.R. & 
Aaronson,S.A. (1987b). Science, 237: 178.
Donegan, W.L. Introduction to the History of Breast Cancer. In "Cancer of the 
Breast" by W.L. Donegan & J.S. Sprat, Third Edition, 1988, W.B. Saunders 
Company, Philadelphia.
Dowle, C.S., Owainti, A., Robbins, A & 4 others. (1987). Br. J. Surg., 74: 
133
Downward, J., Parker, P. & Waterfield, M.D. (1984). Nature, 311: 483.
Dressier, L.G., Seamer, L.C., Owens, M.A., Clark, G.M., McGuire, W.L.
(1988) Cancer 61: 420
Duffy, M.J. (1987). Eur. J. Cancer Clin. Oncol., 23: 583.
Duffy, M.J., OGrady, P., Devaney, D., O'Siorain, L., Fennelly, J.J. & 
Lijnen, H.J. (1988a). Cancer, 62: 531.
Duffy, M.J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J.J. & 
Lijnen, H.R. (1988b). Cancer Research, 48: 1348.
Duffy, M.J., Reilly, D., O'Sullivan, C., O’Higgins, N., Fennelly, J.J. & 
Andreasen, P. (1990). Cancer Research, 50: 6827.
Duprez, V., Comet, V. & Dautry-Varsat, A. (1988). J. Biol. Chem. 263: 
12860.
Durie, F.H., Campbell, A.M., Lee, W.R. & Damato, B.E. (1990). Invest. 
Opthalmol. Vis. Sci., 31: 178.
Dustin, M. L., Staunton, D.E., & Springer, T.A. (1988). Immunol. Today 9: 
213.
Dustin, M.L. & Springer, T.A. (1991). Ann. Rev. Immunol., 9: 27-66.
Dustin, M.L., & Springer, T.A. (1988). J. Cell Biol. 107: 321.
Dustin, M.L., Rothlein, R., Bhan, A. K., Dinarello, C.A., & Springer, T.A.
(1986). J. Immunol., 137: 245.
Early Breast Cancer Trialist's Collaborative Group (1992). Lancet, 339: 1- 
15, 71-85.
Edwards, D.P., Chamness, G.C. & McGuire, W.L. (1979). Biochim. 
Biophys. Acta., 560: 457.
Edwards, P.A.W. (1985). Br. J. Cancer, 51: 149.
Ellis, I.O., Bell, J., Todd, J.M. & others. (1987). Br. J. Cancer, 56: 295.
Ellis, I.O., Hinton, C.P., MacNay, J. & others. (1985). Br. Med. J., 290: 
881.
Ellis, I.O., Robins, R.A., Elston, C.W., Blarney, R.W. & Baldwin, R.W. 
(1984). Histopathology, 8: 501.
Eremin, O., Coombs, R.R.A. & Ashby, J. (1981). Br. J. Cancer, 44: 166.
Eremin, O., Coombs, R.R.A., Prospero, T.D. & Plumb, D. (1982). J. Natl. 
Cancer Inst., 69:1.
Eremin, O., Plumb, D. & Coombs, R.R.A. (1976). Int. Arch. Allergy Appl. 
Immunol. 52: 277.
Eremin, O., Roberts, P. Plumb, D. & Stephens, J.P. (1980). Br. J. Cancer, 
41: 62.
Escot, C.,Theillet, C.,Lidereau, R.,Syratos, F.,Champeme, M.,Gest, J. & 
Callahan, R. (1986). Proc.Natl.Acad,Sci.USA , 83 4834.
Eskelinen, M.J., Pajarinen, P., Collen, Y., Personen, E., Alhava, E., 
Kettunen, K., & Nordling, S. (1989). Br. J. Surg. 76: 830
Ewers, S-B, Langstrom, E., Baldetrop, B.& Killander, D. (1984).
Cytometry, 5: 408.
Fallenius, A.G., Franzen, S.A. & Auer, G.U. (1988). Cancer, 62: 521.
Fantl, V., Brookes, S., Smith, R., Casey, G., Barnes, D., Johnstone, G., 
Peters, G. & Dickson, C. (1989). Characterisation of the proto-oncogene int- 
2 and its potential for the diagnosis of human breast cancers. In "Molecular 
diagnostics of human cancer", Cold Spring Harbor Laboratory.
Farzad, Z., Cochran, A.J., McBride, W.H., Gray, J.D., Wong, V. &
Morton, D.L. (1990). Cancer Res., 50: 3585.
Fearon, E.R. & Vogelstein, B. (1990). Cell, 61: 759.
Feichter, G.E., Kaufmann, M., Muller, A., Haag, D., Eckhardt, R., & 
Goertder, K. (1989). Breast Cancer Research and Treatment, 13: 17.
Feichter, G.E., Mueller, A., Kaufman, M., & 6 others. (1988). Int. J. Cancer 
41: 823
Feitz, W.F.J., Beck, H.L.M., Smeets, A.W., Debruyne, F.M., Vooijs, G.P., 
Herman, C.J. & Ramaekers, F.C.S. (1985). Int. J. Cancer, 36: 349.
Fenlon, S., Ellis, I.O., Bell, J., Todd, J.H., Elston, C.W. & Blarney, R.W.
(1987). J. Pathol., 152: 169.
Fentiman, I.S. & Mansel, R.E. (1991). Lancet, 337: 221.
Fernandes, B., Sagman, U., Auger, M., Demetrio, M. & Dennis, J.W.
(1991). Cancer Research, 51: 718.
Ferti-Passantonopoulou, A. & Panani, A. (1987). Cancer Genet. Cytogenet. 
27: 289.
Ferti-Passantonopoulou, A., Panani, A.D. & Raptis, S. (1991). Cancer 
Genet. Cytogenet. 51: 183.
Fey, M.F., Wells, R.A., Wainscoat, J.S. & Thein, S.L. (1988). J. Clin. 
Invest. 82: 1532.
Fidler, I.J. (1973). Nature, 242: 148.
Fidler, J. & Kripke, M.L. (1977). Science, 197(4306): 893.
Finlay, C.A., Hinds, P.W. & Levine, A.J. (1989). Cell, 57 : 1083.
Finne, J., Burger, M.M. & Prieels, J.P. (1982). J. Cell Biol. 92: 277.
Fisher, B., Bauer, M., Marolese, R. et al. (1985). N. Eng. J. Med., 312: 
665.
Fisher, B., Bauer, M., Wickerham, L., Redmont, C.K. & Fisher, E.R.
(1983). Cancer, 52:1551.
Fisher, B., Redmont, C. & Fisher, E.R. (1980). Cancer, 46: 1009.
Fisher, B., Saffer, E.A. & Fisher, E.R. (1972). Cancer, 30: 1202.
Fisher, B., Slack, N.H.& Bross, I.D.J. (1969). Cancer, 24: 1071.
Fisher, E.R., Redmond, C. & Fisher, B. (1980). Pathol. Ann. 15: 239. 
Folkman, J. (1990). J. Natl. Cancer Inst., 82: 4.
Foster, C.S. (1990). Br. J. Cancer, 62: 57.
Fowler, C., Drinkwater, R., Burgoyne, L. & Skinner, J. (1987). Nucleic 
Acids Research, 15: 3929.
Fowler, C., Drinkwater, R., Skinner, J. & Burgoyne, L. (1988). Human 
Genetics, 79: 265.
Freidlander, H.T. (1984). J. Clin. Pathol, 37: 961.'
Friedlander, M.L., Hedley, D.W. & Taylor, I.W. (1984). J. Clin. Pathol. 
37: 961.
Frierson H.F., Jr. (1988). Hum. Pathol., 19:290.
Frierson, H.F. Jr.(1991). American J. Surg Path., 15(4): 358.
Fukutomi, T., Itabashi, M., Tsuane, S., Yamamoto, H., Nanasawa, T., 
Hiroto, T. (1989). J. Clin. Oncol., 19: 127-134.
Fung,Y.K.,Lewis,W.G.,Crittenden,L.B., & Kung,H.J. (1983). Cell , 33: 
357.
Furcht, L.T. (1986). Lab. Invest., 55: 505.
Furmanski, P., Kirkland,W.L., Gargala, T., Rich, M.A. & The breast cancer 
prognostic study clinical associates. (1981). Cancer Res., 41:4089.
Gallatin, W.M., Weissman, I.L. & Butcher, E.C. (1983). Nature, 304: 30.
Garcia, I., Dietrich, P., Aapro, M., Vauthier, G., Vadas, L. & Engel, E.
(1989). Cancer Res., 49: 6675.
Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J. & Burchell, J.
(1988). J. Biol. Chem., 263: 12820.
Gendler, S.J., Lancaster, C.A., Taylor-Papadimitriou, J. & others (1990). J. 
Biol. Chem., 266: 12286.
Gentile, J.M. & Flickinger, J.T. (1972). Surgery, Gynaecology & 
Obstetrics, 135: 69-73.
Genuardi, M., Tsihira, H., Anderson, D.E. & Saunders, G.F. (1989). Am. 
J. Hum. Genet., 45: 73.
Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U., Stein, H.
(1984). J. Immunol., 133: 1710.
Gerdes, J., Schwab, U., Lemke, H.& Stein, H. (1983). Int. J. Cancer, 31: 
13.
Ghosh, S., Campbell, A.M. (1987). Immonol. Today, 8: 74.
Gilchrist, K.W., Kalish, L., Gould, V.E. (1985). Breast Cancer Res. Treat. 
5: 3.
Gion, M., Mione, R., Nascimben, O., Valsecchi, M., Gatti, C., Leon, A. & 
Bruscagnin, G. (1991). Br. J. Cancer, 63: 809.
Gleeson, P. & Schachter, H. (1983). Journal of Biological Chemistry, 258: 
6161.
Goelz, S.E., Vogelstein, B., Hamilton, S.R. & Feinberg, A.P. (1985). 
Science, 228:187.
Goepel, J.R., Rees, R.C., Rogers, K., Stoddard, C.J., Thomas, W.E.G. & 
Sheperd, L. (1991). Br. J. Cancer, 64: 880.
Goodman, T. & LeFrancois, L. (1988). Nature, 333: 855.
Gratzner, H.G. (1982). Science, 218: 474. Br. J. Cancer, 39: 1.
Grey, H.M., Dmotz, S., Buus, S.& Sette, A. (1989). Studies on the nature 
of physiologically processed antigen and on the conformation of peptides 
required for interaction with MHC. Cold Spring Harbor Symp. Quant. Biol., 
54: 393.
Griffiths, A.B., Burchell, J., Gendler, S., Lewis, A., Blight, K., Tilly, R. & 
Taylor-Papadimitriou, J. (1987). Int. J. Cancer, 40:319.
Guillet, J.G., Lai, M.Z., Briner, T.J., Smith, J.A. & Gefter, M.L. (1986). 
Nature, 324: 260.
Gullick, W.J., Love, S.B., Wright, C.A., Barnes, D.M., Gusterson, B., 
Harris, A., & Altman, B. (1991). BritJ. Cancer, 63: 434.
Hakomori, S. (1989). Advances in Cancer Research, 52: 257.
Hamlin, I.M.E. (1968). Br. J. Cancer, 22: 383.
Hammerling, G.J. (1976). Transplantation Reviews, 30: 64.
Hanna, W., Kahn, H.J., Andrulis, I. & Pawson, T. (1990). Modem 
Pathol., 3: 455.
Hanover, J.A., Elting, J., Mintz, G.R. & Lennarz, W.J. (1982). J. Biol. 
Chem. 257: 10172.
Harris, A.L., Nicholson, S., Sainsbury, Neal, D., Smith, K., Famdon, J.R. 
& Wright, C. Epidermal growth factor receptor: A marker of early relapse in 
breast cancer and tumor stage progression in bladder cancer; interaactions with 
neu. (1989). In "Molecular Diagnostics of human cancer", Cold Spring 
Harbor Laboratory.
Hayakawa, K. & Hardy, R.R. (1988). Ann. Rev. Immunol., 6: 197.
Hayward,W.S., Neel,B.G. & Astrin,S.M. (1981). Nature, 290: 475.
Hedley, D.W., Rugg, C.A., Gelber, R.D. (1987). Cancer Res., 47: 4729.
Hedley, D.W., Rugg, C.A., Hg, A.B.P. & Taylor, I.W. (1984). Cancer 
Res., 44: 5395.
Heidenreich, W., Jagla, K., Schussler, J., Bomer, P., Dehnhard, F., Kalden, 
J.R., Leibold, W., Peter, H.H. & Deicher, H. (1979). Cancer, 43: 1308.
Heo, D.S., Whiteside, T.L., Johnson, J.T., Chen, K., Barnes, E.L. & 
Herberman, R.B. (1987). Cancer Res., 47: 6353.
Herzberg, V.L. & Smith, K.A. (1987). J. Immunol. 139: 998.
Hewitt, H.B., Blake, E.R. & Walder, A.S. (1976). British J. Cancer, 33: 
241.
Hilkens, J., Buijs, F., Hilgers, J. & 4 others. (1984). Int. J. Cancer, 34: 
197.
Hill, S.M., Rodgers, C.S., Hulten, M.A. (1987). Cancer Genet. Cytogenet. 
24: 45.
Hitchcock, A., Ellis, I.O., Robertson, J.F.R., Gilmour, A., Bell, J., Elston,
C.W. & Blarney, R.W. (1989). J. Pathol. 159: 129.
Horan-Hand,P.,Thor,A.,Wunderlich,D.,Muraro,R., Caruso,A. & Schlom,J.
(1984). Proc.Natl.Acad.Sci.USA, 81:5227.
Horsfall, D.J., Tilley, W.D., Orell, S.R., Marshall, V.R., Cant, E.L. (1986). 
Br. J. Cancer 53: 23.
Hsuan, J.J. (1989). British Medical Bulletin, 45(2): 425.
Humphrey, L.J., Humphrey, M.A., Singla, O. & Volenec, F.J. (1981). 
Annals of Surgery, 193: 574.
Humphrey, L.J., Humphrey, M.A., Singla, O. & Volenec, FJ. (1981). 
Annals of Surgery, 193: 574.
Humphries, M.J., Matsumoto, K., White, S.L. & Olden, K. (1986). Proc. 
Natl. Acad. Sci. USA, 83: 1752.
Hunt, T. (1991). Nature, 349: 100.
Hunter, R., Ferguson, D., Coplleson, W. (1975). Cancer, 36: 526.
Hunter, T. & Pines, J. Cyclins and Cancer. (1991). Cell, 66:1071.
Hunter, T. (1991). Cell, 64: 249.
Iglehart, J.D., Kraus, M.H., Lamgton, B.C., Huper, G., Kerns, B.J. & 
Marks, J.R. (1990). ICancer Research, 50: 6701.
Imam & Taylor, C.R. (1989). Br. J. Cancer, 59: 922.
Irimura, T. & Nicolson, G.L. (1984). Cancer Res., 44: 791.
Ishikawa, M., Dennis, J.W. & Kerbel, R.S. (1988). Cancer Res., 48: 665.
Isola, J.J., Helin, H.J., Helle, M.J., Kallioniemi, O-P. (1990). Cancer, 
65(5): 1180.
Itoh, K., Platsougas, C.D. & Balch, C.M. (1988). J. Expt. Med., 168: 
1419.
Janeway, C.A. (1988). Nature, 330: 804.
Janicke, F., Schmidt, M. Ulm, K., Gossner, W. & Graeff, H. (1989). 
Lancet, 2: 1049.
Jeffreys, A.J., Wilson, V. & Thein, S.L. (1985). Nature, 314: 67.
Jenkins, J.R., Rudge, K.& Currie, G.A. (1984). Nature, 312: 651.
Jenkins, J.R., Rudge, K., Chumakov, P. & Currie, G.A. (1985). Nature, 
317: 816.
Johnson, H.A. & Bond, V.P. (1961). Cancer, 14: 639.
Johnson, J.P., Stade, B.G., Holzman, B., Schwable, W. & Reithmuller, G.
(1989). Proc. Natl. Acad. Sci. USA., 86: 641.
Johnson, V.G., Schlom, J., Paterson, A.J., Bennet, J. Magnani, J.L. & 
Colcher, D. (1986). Cancer Res., 46: 850.
Johnston, G.I., Cook, R.G. & McEver, R.P. (1989). Cell, 56: 1033..
Jokinen, M., Andersson, L.C., & Gahmberg, C.G. (1985). J. Biol. Chem., 
260: 11314.
Kallioniemi, 0., Blanco, M.M., Alavaikko, M & 4 others. (1987). Br. J. 
Cancer 56: 637
Kallioniemi, O-P. (1988a). Cytometry, 9: 164.
Kallioniemi, O., Blanco, G., Alavaikko, M., Hietanen, T., Matilla, J., 
Lauslahti, K., Lehtinen, M. & Koivula, T. (1988b). Cancer 62: 2183
Kansas, G.S., Wood, G.S. & Engleman, E.G. (1985). J. Immunol., 134: 
3003.
Katz, D.H., Hamaoka, T. & Benacerraf, B. (1973). J.Exp. Med., 137: 
1405.
Kelsten, M.L., Berger, M.S., Maguire, H.C., Chianese, D.A., Heilman, 
M.E., Weiner, D.B. & Greene, M.I. (1990). Cytometry, 11: 522.
Keydar, I., Chou, C.S., Hareveni, M., Tsarfaty, I., Sahar, E., Selzer, G., 
Chaitchik, S. & Hizi, A. (1989). Proc. Nad. Acad. Sci. USA., 86: 1362.
Khan, H.J. & Baumal, L.R. (1985). Am. J. Pathol., 119: 420.
Khuri, N., Jotty, S.P. & Shibata, H.R. (1989). Canadian J. Surgery, 32:
23.
Kikuyama, S., Kubota, T., Watanabe, M., Ishibiki, K., Abe, O. (1988). Cell 
Tissue Kinet, 20:1.
King, C.R., Kraus, M.H., and Aaronson, S.A. (1985). Science, 229: 974.
Kishimoto, T.K., Jutila, M. A., & Butcher, E.C. (1990). Proc. Nad. Acad. 
Sci.USA., 87: 2244.
Kjeldsen, T., Clausen, H., Hirohashi, S., Ogawa, T., Iijima, H. &
Hakomori, S. (1988). Cancer Research, 48: 2214.
Knabble, C., Lippman, M.E., Wakefield, L.M., Flanders, F.C., Kasid, A., 
Derybck, R. & Dickson, R.B. (1987). Cell: 48: 417.
Knapp,W.,Rieber, P., Dorken, B., Schmidt, R.E.,Stein, H. & Borne,
A.E.G. (1989). Immunology Today, 10: 253.
Knudson, A.G. (1985). Cancer Res., 45: 1437.
Ko, H.S., Fu, S.M., Winchester, R.J., Yu, D.T.Y. & Kunkel, H.G. (1979). 
J. Exp. Med., 150: 246.
Kohler, G. & Milstein, C. (1975). Nature, 256: 495.
Koning, F. (1991). Immunol. Today, 12: 100.
Koning, F., Stingl, G., Yokoyama, W.M., Yamada, H., Maloy, W.L., 
Tschachler, E., Shevach, E.M. & Coligan, J.E. (1987). Science, 236: 834.
Komfeld, R. & Komfeld, S. (1985). Annual Review of Biochemistry 54: 
631.
Kovacs, G.Y. (1981). Cancer Genet Cytogenet., 3:125.
Krensky, A.M., Sanchez-Madrid, F., Robbins, E., Nagy,J., Springer, T.A.
& Burakoff, S.J. (1983). J. Immunol., 131: 611.
Krogerus, L. & Andersson, L.C. (1990). Cancer, 66: 1802.
Kufe, D., Inghirami, G., Abe, M., Hayes, P., Justi-Wheeler, H. & Schlom,
J. (1984). Hybridoma, 3: 223.
Kurosaka, A., Fukui, S., Kitagawa, H., Nakada, H., Numata, Y.,
Funakoshi, I., Kawasaki, T. & Yamashina, I. (1987). Febs Lett., 215: 137.
Kute, T.E., Muss, H.B., Hopkins, M., Marshall, R., Case, D. & Kammire, 
L. (1985). Breast Cancer Res. Treat., 6:113
Kuziel, W.A., Takashima, A., Bonyhadi, M., Bergstresser, P.R., Allison, 
J.P., Tigelaar, R.E. & Tucker, P.W. (1987). Nature, 337: 416.
Lacroix, H., Iglehart, J.D., Skinner, M.A. & Kraus, M.H. (1989).
Oncogene, 4: 145.
Lane,D.B. & Crawford,L.V.(1979). Nature, 278: 261.
Larsen, E., Celi, A., Gilbert, G.E., Furie, B.C., Erban, L.K., Bonfronti, R., 
Wagner, D.D., & Furie, B. (1989). Cell, 59: 305.
Leake, R.E., Laing, L., Caiman, K.C., Macbeth, F.P., Crawford, D. & 
Smith, D.C. (1981). Br. J. Cancer. 43: 59 .
Leathern, A., Atkins, N. & Eisen, T. (1985). J. Pathol., 145: 73A.
Leathern, A., Dokeal, I. & Atkins, N. (1984). J. Pathol., 142: 32A.
Leathern, A.J. & Brooks, S.A. (1987). Lancet, 1: 1054.
Lee,E.,To,H.,Shew,J.,Bookstein,R.Scully,P. & Lee,W. (1988). Science , 
241 : 218.
Leis, H.P. Jr. Epidemiology of breast cancer: identification of the high-risk 
woman. In "The Breast" Edited by Gallager, H.S., Leis, H.P. Jr., 
Snyderman, R.K., & Urban, J.A. 1978, The C.V. Mosby Company, Saint 
Louis.
Lelle, R.J., Heidenreich, W., Stauch, G. & Gerdes, J. (1987). Cancer, 59: 
83.
Lemione, N. (1990). Ras oncogenes in human cancers. In "Molecular 
Biology of cancer genes", Editor M. Sluyser, Ellis Horwood, London.
Lammie, G.A., Fand, V., Smith, R., Schwaring, E., Brookes, S., 
Michaelildes, R.& Dickson, C. (1991). Oncogene, 6: 439.
Lemon, H.M. (1970). Cancer, 25: 423.
Leone, A., Flatow, U., King, C.R., Sandeen, M.A., Marguiles, I.M.K., 
Liotta, L.A. & Steeg, P.S. (1991). Cell, 65: 25.
Levine,A.J.,Momand,J. & Finlay,C.A. (1991). Nature, 351: 453.
Li, E., Tabas, I. & Komfeld, S. (1978). J. Biol. Chem., 253:7762.
Liberman,T.A., Nusbaum, H.R., Razon, N.,Kris, R., Lax, I.,Soreq, H., 
Whittle, N., Waterfield, M.D., Ullrich, A., & Schlessinger, J. (1985). Nature 
313 144.
Lidereau, R., Callahan, R., Dickson, C., Peters, G., Escot, C. & Ali, I.U. 
(1988). Oncogene Res., 2: 285.
Lilienfeld, A.M. (1963). Cancer Research, 23: 1503.
Linsk, R.L. & Goodenow, R.S. (1986). Cancer Rev., 6: 40.
Linzer,D.I.H. & Levine,A.J. (1979). Cell, 17:43.
Longenecker, B.M., Willans, D.J., MacLean, G.D., Selvaraj, S., Suresh, 
M.R. & Noujaim, A.A. (1987). J. Natl. Cancer Inst., 78: 489.
Lopez-Nevot, M.A., Esteban, F., Ferron, A. & 6 others (1989). Br. J. 
Cancer. 59: 221.
Lovekin, C., Ellis, I.O., Locker,.A., Robertson, J.F., Bell, J., Nicholson,
R., Gullick, W., Elston, C.W., & Blarney, R.W. (1991). BritJ.Cancer 63 : 
439.
Ludwig, C.U., Hartmann, D., Landmann, R., Wesp, M., Rosenfelder, G., 
Stucki, D., Buser, M. & Obrecht, J.P. (1985). Cancer, 55: 1673.
Lundberg, C., Skoog, L., Cavanee,W.K. & Nordenskjold, M. (1987). 
Proc.Natl. Acad.Sci. USA, 84 : 2372.
Lupu, R., Colomer, R., Zugmaier, G., Samp, J., Shepard, M., Slamon, D.
& Lippman, M.E. (1990). Science, 249: 1552.
Lwin, K.Y., Zuccarini, O., Sloane, J.P. & Beverley, P.C.L. (1985). Cancer, 
48: 69.
Mackay,J.,Steel,C.M.,Elder,P.A. & Forrest,A.P.M. (1988). Lancet, II : 
1384.
MacMahon, B., Cole, P. & Brown, J. (1973). J. Natl. Cancer Inst., 50:
21 .
Mandeville, R., Lamoureux, G., Legault-Poissson, S. & Poisson, R. (1982). 
Cancer, 50: 1280.
Manning, A.M., Williams, A.C., Game, S.M. & Paraskeva, C. (1991). 
Oncogene, 6: 1471.
Mantovani,G., serri, F.G., Maccoi, A., Castelli, P., Benedetti, P., Scambia, 
G., Santus, S., Paderi, R., Murtas, M.G. & Ferreli, A. (1989). Cancer 
Detect. Prev., 13: 323.
Mariani-Costantini, R., Escot, C., Theillet, C., Gentile, A., Merio, G., 
Lidereau, R. & Callahan, R. (1988). Cancer Res., 48 :199.
Marlin, S.D., & Springer, T.A. (1987). Cell, 51: 813.
Marrack, P., Kushnir, E. & Kappler, J. (1991). Nature, 349: 524.
Marshall, R.D. (1972). Glycoproteins. Ann. Rev. Biochem., 41: 673.
May, E., Mouriesse, H., May-Levin, F., Qian, J.F., May, P. & Delarue, J.C.
(1990). Br. J. Cancer, 62: 430.
McCarty, K.S., Barton, T.K., Fetter, B.F.(1980). Cancer, 46:2851.
McDivitt, R.W., Stone, K.R., Craig, R.B., Palmer, J.O., Meyer, J.S. & 
Bauer, W,C. (1986). Cancer 57: 269 .
McGuire, W.L. & Dressier, L.G. (1985). J.Natl.Cancer Inst., 75: 405.
McGuire, W.L. (1986). Cancer Surveys, 5: 527.
Mendenhall, M.D., Jones, C.A. & Reed, S.I. (1987). Cell, 50, 927-935.
Meyer, J.S., Prey, M.U., Babcock, D.S., McDivitt, R.W. (1986). Lab. 
Invest., 54: 41.
Miller, S., Dykes, D.D. & Polesky, H.F. (1988). Nucleic Acids Research, 
16: 1215..
Miserez, A.R., Gunes, I., Muller-Brand, J., Walther, E., Fridrich, R. & 
Macke, H. (1991). Eur. J. Cancer, 27(2): 126.
Moll, R., Achtstatter, T., Becht, E., Balcarova-Stander, J., Ittensohn, M., 
Franke, W.W. (1988). Am. J. Pathol. 132: 123
Moll, R., Franke, W.W., Schiller, D.L., Geiger, G., & Krepler, R. (1982). 
Cell, 31: 11
Momburg, F. & Koch, S. (1989). J. Exp. Med., 169:309.
Momburg, F., Degener, T., Baccus, E., Moldenjauer, E., Hammerling, G.J. 
& Moller, P. (1986). Int. J. Cancer. 37:179.
Moran, R.E., Black, M.M., Alpert, L. & Straus, M.J. (1984) Cancer 54: 
1586
Moreno, S., Hayles, J. & Nurse, P.(1989). Cell, 58: 361. .
Moreno, S., Nurse, P. & Russel, R. (1990). Nature, 344: 449..
Morstyn, G., Hsu, S.M., Kinsella, T., Gratzner, A., Russo, A., Mitchell,
J.B. (1983). J. Clin. Invest., 72: 1844.
Morton, B.A., Ramey, W.G., Paderon, H. & Miller, R.E. (1986). Cancer 
Research, 46: 2121.
Morton, D.L., Miller, G.F. & Wood, D.A. (1969). J. Natl. Cancer Institute, 
42: 289.
Moss, L., Greenwalt, D., Cullen, B., Dinh, N., Ranken, R. & Parry, G. 
(1988). J. Cellular Physiology, 137:310.
Mossman, T. & Coffman, R.L. (1989). Adv. Immunol., 46: 111.
Muraro, R., Kuroki, M., Wunderlich, D. & 8 others. (1988). Cancer 
Research, 48: 4588.
Nasmyth, K.A. Cell, (1990). Cell, 63:1117.
Nau,M.M.,Brokks,B.J.,Carney,D.N.,Gazdar,A.F.Kirsch,I.R.,McBride,O. 
W., Bertness,V., Hollis,G.F. & Minna,J.D. (1985). Nature 318: 69.
Nemoto, T., Vana, J., Bedwani, R.N., et al. (1980). Cancer, 45: 2917.
Ng, R.C.Y., Roberts, A.N., Wilson, R.G., Latner, A.L. & Turner, G.A. 
(1987). Br. J. Cancer, 55: 249.
Nicolson, G.L. & Custead, S.E. (1982). Science, 215:176.
Nicholson, S., Halcrow, P., Sainsbury, J.R.C., Angus, B., Chambers, P., 
Famdon, J.R. & Harris, A.I. (1988). Br. J. Cancer, 58: 810.
Nicolson, G.L. (1982). Biochim. Biophys. Acta, 695: 113.
Nicolson, G.L. (1987). Cancer Research, 47: 1473.
Nicolson, G.L. (1988). Biochem. Biophys. Acta, 948: 175.
Nishiyama, T., Matsumoto, Y., Watanabe, H., Fujiwara, M. & Sato, S.
(1987). J. Natl. Cancer Inst., 78: 1113.
North,G. (1991). Nature, 351: 604.
Nowell, P.C. (1976). Science, 194: 23.
Nowell, P.C. (1986). Cancer Research, 46: 2203.
Nurse, P. (1990). Nature, 344: 503.
Nusse,R. & Varmus,H.E. (1982). C ell, 31: 99.
Nuti, M., Teramoto, Y.A., Mariani-Costantani, R., Horand Hand, P., 
Colcher, D. & Schlom, J. (1982). Int. J. Cancer, 29: 539.
O’Grady, P., Lijnen, H.R. & Duffy, M.J. (1985). Cancer Research, 45: 
6216.
O'Reilly, S.M., Barnes, D.M., Camplejohn, R.S., Bartkova, J., Gregory, 
W.M. & Richards, M.A. (1991). Br.J. Cancer, 63: 444.
O'Reilly, S.M., Campeljohn, R.S., Barnes, D.M., Millis, R.R., Allen, D., 
Rubens, R.D. & Richards, M.A. (1990). Br. J. Cancer 61: 671
Olszewski, W., Darznkiewicz, Z., Rosen, P.P., Schwartz, M.& Melamed, 
M.(1981). Cancer 48: 980
Olszewski, W., Darzynkiewicz, Z., Rosen, P.P., Claps, M.L., & Melamed, 
M.R. (1982). Anal. Quant. Cytology, 4: 275.
Ormerod, M.G., Steele, J.M., Westwood, J.M. & Mazzin, M. (1983). Br. 
J. Cancer, 48: 533.
Ossowski, O.L. & Reich, R.E. (1983). Cell, 35: 611.
Owainati, A.A.R., Robins, R.A., Hinton, C., et al. (1987). Br. J. Cancer, 
55: 449.
Paik, S., Hazan, R., Fisher, E.R. & 6 others. (1990). J. Clin. Oncol., 8: 
103.
Palmer, J.O., McDivitt, R.W., Stone, K.R., Rudloff, M.A., & Gonzalez, 
J.G.(1988). Cancer, 62: 2387.
Pancino, G. Osinaga, E., Vorauher, W. (1990). Hybridoma, 9: 389.
Pancino, G., Osinaga, E., Charpin, C., Mistro, D., Barque, J. Ph. & Roseto, 
A. (1991). Br. J. Cancer, 63: 390.
Parada,L.F.,Tabin,C.J.,Shih,C. & Weinberg,R.A. (1982). Nature 297: 
474.
Pardee, A.B. (1974). Proc. Natl. Acad. Sci. U.S.A, 71:1286.
Parkes, H.C., Lillycrop, K., Howell, A. & Craig, R.K. (1990). Br. J. 
Cancer, 61: 39.
Pari, F.F., Schmidt, P., Dupont, W.D. & Wagner, R.K. (1984). Cancer,
54: 2237.
Pari, F.F., Schmidt, P., Dupont, W.D. & Wagner, R.K. (1984). Cancer, 
54: 2237.
Parodi, A.J. & Leloir, L.F. (1979). Biochim. Biophys. Acta., 559: 1.
Pattanapanyasat, K., Hot, T.G., Jacobs, A., Courtney, S. & Webster, D.J.
(1988). Br. J. Cancer, 57: 193.
Patton, S. & Keenan, T.W. (1975). Biochim. Biophys. Acta, 415: 273.
Pawelec, G., Blaurock, M., Schneider, E.M., Shaw, S. & Wemet, P.
(1982). European J. Immunol., 12: 967.
Pearlman, A.W. (1976). Cancer, 38: 1826.
Penn, I. (1988). Annual Review of Medicine, 39:63.
Perez, M., Carbrera, T., Lopez-Nevot, M.A. & others. (1986). J. 
Immunogenet., 13: 247.
Perren, T.J. (1991). Br. J. Cancer, 63: 328.
Pierce, M. & Arango, J. (1986). J. Biol. Chem., 261: 10777.
Pons-Anicet, D.M.F., Krebs, B.P., Mira, R. & Namer, M. (1987). Br. J. 
Cancer, 55: 567.
Quinn, C.M., & Wright, N.A. (1990). J. Pathol. 160: 93.
Ramaekers, F.C.S., Beck, H., Vooijs, G.P., & Herman, C.J. (1984). Exp. 
Cell Res. 153:249
Quinn, C.M., & Wright, N.A. (1990). J. Pathol. 160: 93.
Ramaekers, F.C.S., Beck, H., Vooijs, G.P., & Herman, C.J. (1984). Exp. 
Cell Res. 153:249
Rastinejad, F., Polverini, P.J., Bouck, N.P. (1989). Cell, 56: 345.
Raulet, D.H. (1989). Nature, 339: 342.
Redding, W.H., Monaghan, P., Imrie, S.F., et al. (1983). Lancet, I: 1271.
Reinherz, E.L., Kung, P.C., Pesando, J.M., Rotz, J., Goldstein, G. & 
Schlossman, S.F. (1979). J. Exp. Med., 150: 1472.
Remvikos, Y., Magdelenat, H., Zajdela, A. (1988). Cancer, 61: 1629 .
Remvikos, Y., Veilh, P., Padoy, E., Benyahia, B., Voillemot, N., & 
Magdelenat, H. (1991). Br. J. Cancer, 64: 501.
Ridolfi, R.L., Rosen, P.P., Port, A., Kinne, D. & Mike, V. (1977). Cancer, 
40: 1365.
Riegrova, D. & Jansa, P. (1982). Neoplasma, 29: 481.
Ro, J., North, S.M., Gullick, G.E., Hortobagyi, G.N., Gutterman, J.U. & 
Blick, M. (1988). Cancer Res., 48: 161.
Roberts, A.W., Anzano, M.A., Wakefield, L.M., Roche, N.S., Stem, D.F.
& Spom, M.B. (1985). Proc. Natl. Acad. Sci. USA, 82:119.
Rochefort, H., Augereau, P., Briozzo, P. (1988). Biochimie., 70: 943.
Rochefort, H., Capony, F., Garcia, M. (1987). J. Cell. Biochem., 35: 17.
Rodgers, C.S., Hill, S.M., & Hulten, M.A. (1984). Cancer Genet. 
Cytogenet. 13: 95.
Ronai, Z. & Sulitzeanu, D. (1986). J. Natl. Cancer Inst., 77:1203.
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, 
S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A.,
Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J.P. &
White, D.E. (1988). New England Journal of Medicine, 319: 1676.
Rosenthal, A.S. & Shevach, E.M. (1973). J. Exp. Med., 138: 1194.
Roses, D.F., Bell, D.A., Flotte, T.J., Taylor, R., Ratech, H. & Dubin, N. 
(1982). American J. Clin. Pathol., 78: 817.
Roth, J. (1984). J. Cell Biol., 98: 399.
Rowe, D.J. & Beverley, P.C.L. (1984). Br. J. Cancer, 49: 149.
Roxby, D.J., Skinner, J.M., Morley, A.A., Weeks, S. & Burpee, M.
(1987). Br. J. Cancer 56: 734.
Rudd, C.E., Morimoto, C., Wong, L.L., & Schlossman, S.F. (1987). J.
Exp. Med., 166: 1758.
Sacks, N.P.M., Stacker, S.A., Thompson, C.H. & others. (1987). Br. J. 
Cancer, 56: 820.
Safi, F., Beger, H.G., Roscher, R. & Suhr, P. (1987). J. Turn. Mark. 
Oncol., 2: 3.
Sainsbury, J.R.C., Famdon, J.R., Needham, G.K., Malcolm, A.J. & Harris, 
A.L. (1987). Lancet, I: 1398.
Saito, J., Inoue, M., Azuma, C., Saji, F. & Tanizawa, O. (1991). Eur. J. 
Cancer, 27: 813.
Sambrook, J., Fritsch, E. & Maniatis, T. (1989). Molecular Cloning: A 
Laboratory Manual. Second Edition, Cold Spring Harbor Lab Press.
Sandberg, A.A., Turc-Carel, C. & Gemmill, R.M. (1988). Cancer Res., 48: 
1049.
Sanders, M.E., Makgoba, M.W., Sharrow, S.O., Stephany, D., Springer, 
T.A. Young, H.A., & Shaw, S. (1988). J. Immunol. 140: 1401.
Santer, U.V. & Glick, M.C. (1979). Biochemistry, 18: 2533.
Santer, U.V., Gilbert, F. & Glick, M.C. (1984). Cancer Res., 44: 3730.
Santos,E., Tronick,S.R.,Aaronson,S.A.,Pulciani,S. & Barbacid,M. (1982). 
Nature 298: 343.
Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F.,
Sakamoto, G. & Nakamura, Y. (1990). Cancer Research 50: 7184.
Satya-prakash, K.L., Pathak, S., Hsu, T.C., Olive, M. & Gailleau, R.
(1981). Cancer Genet, cytogenet. 3: 125.
Schechter, A.L., Hung, M.C., Vaidyanathan, L., Weinberg, R.A., Yang- 
Feng, T.L., Francke, U., Ullrich, A. & Coussens, L. (1985). Science, 229: 
976.
Schechter,A.L., Stern,D.F.,Vaiyanathan,l.,Decker,S.J.,
Drebin,J.A.,Greene,M.I. & Weinberg, R.A. (1984). Nature 312 513.
Schlom, J., Greiner, J., Horan hand, P., Colcher, D., Inghirami, G., Weeks, 
M., Pestka, S., Fisher, P., Noguchi, P. & Kufe, D. Monoclonal antibodies to 
breast cancer-associated antigens as potential reagents in the management of 
breast cancer. (1984). Cancer, 54: 2777.
Schmidt-Rhode, P., Schulze, K.D., Sturm, G., Raab-Frick, A. & Prinz, H. 
(1987). Int. J. Biol.Markers, 2: 135.
Schwab, M.,Alitalo, K.,Klempnauer, K.H.,Varmus, H.E.,
Bishop,J.M.,Gilbert, F.Brodeur, G.,Goldstein, M. & Trent, J. (1983). 
Nature, 305: 245.
Seeburg, P.H., Colby, W.W., Capon, D.J., Goeddel, D.V. & Levinson,
A.D. (1984). Nature, 312: 71.
Seidman, H. (1972). Cancer of the Breast. Statistical and Epidemiological 
data. New York, American Cancer Society.
Semba, K., Kamata, N., Toyoshima, K. and Yamamoto, T. (1985). Proc. 
Natl. Aca. Sci. 82: 62497.
Sharon, N. & Lis, H. (1989). Lectins. Chapman & Hall, London.
Shayamala, G. & Nandi, S. (1972). Endocrinology, 91: 861.
Shek, L.L.M. & Godolphin, W. (1988). Cancer Research, 48: 5565.
Shih, C., Padhy, L., Murray, M. and Weinberg, R.A. (1981). Nature 290: 
261.
Shimizu, M. & Yamauchi, K. (1982). J. Biochem. 91: 515.
Siddique, J., Abe, M., Hayes,D., Shani, E., Yunis, E. & Kufe, D. (1988). 
Proc. Natl. Acad. Sci. USA. 85: 2320.
Silverberg, S.G. (1975). Am. J. Clin. Pathol. 64: 756.
Silverberg, S.G., Chitale, A.R., Hurd, A.D., Frazier, A.B. & Levitt, S.H. 
(1970). Cancer, 20: 1177.
Silvestrini, R., Daidone, M.G., Gasparini, G. (1985). Cancer, 56: 1982.
Sistrunk, W.E. & MacCarty, W.C. (1922). Annals of Surgery, 75: 61.
Skutelsky, E., Shoshana, H. & Griffel, B. (1988). Path. Res. Pract., 183: 
469.
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. & 
McGuire, W.L. (1987). Science, 235: 177.
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, 
D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A. & Press, M.F.
(1989). Science, 244: 707.
Smeets, A.W., Pauwels, r.P., Beck, H.L., Geraedts, J.P.M., Debruyne, 
F.M., Laarakkers, L., Feitz, W.F., Vooijs, g.P. & Ramaekers, F.C.S.
(1987). Int. J. Cancer, 39: 304.
Smets, L.A. & Van Beek, W. (1984). Biochimica et Biophysica Acta, 738: 
237.
Smith, H.S., Liotta, L.A., Hancock, M.C., Wolman, S.R. & Hackett, A.J.
(1985). Proc. Natl. Acad. Sci. USA, 82: 1805.
Smith, J.A., Gamoz-Aranjo, J.J., Gallager, H.S., White, E. & McBride, C. 
(1977). Cancer, 39: 527.
Smith, K.A. (1989). Ann. Rev. Cell Biol., 5: 397.
Smith, M.E.F., Marsh, S.G.E., Bodmer, J.G., Gelsthorpe, K. & Bodmer, 
W.F. (1989). Proc. Natl. Acad. Sci. USA., 86: 5557.
Sonka, J., Stohr, M., Vogt-Schaden, & Volm, M. (1983). Cytometry, 4: 
141.
Southern, E. (1975). J. Mol. Biol., 98: 503.
Spandidos, D.A. & Anderson, M.L.M. (1989). J. Pathol., 157: 1.
Spencer, J. & Isaacson, P.G. (1989). Nature, 337: 416.
Spencer, J., Isaacson, P.G., Diss, T.C. & MacDonald, T.T. (1989). Eur. J. 
Immunol., 19: 1335.
Spielman, J., Rockley, N.L. & Carraway, K.L. (1987). J. Biol. Chem., 
262: 269.
Spom, M.B., Roberts, A.B., Wakefield, L.M. & Assoian, R.K. (1987). 
Science, 233: 532.
Spratt, J.S., Donegan, W.L. & Greenberg, R.A. (1988). Epidemiology and 
Etiology. In "Cancer of the Breast" by W.L. Donegan & J.S. Spratt, Third 
Edition, 1988, W.B. Saunders Company, Philadelphia.
Sprent, J. (1989). T lymphocytes and the thymus. In "Fundamental 
Immunology", Second Edition, Edited by W.E. Paul, Raven Press Ltd., New 
York.
Springer, G.F. & Desai, P.R. (1985). Mol. Immunol., 22: 1303.
Springer, G.F. (1984). Science 224: 1198.
Springer, G.F. (1989). Molecular Immunology 26 (1): 1.
Springer, G.F., Taylor, C.R., Howard, D.R., Tegtmeyer, H., Desai, P.R., 
Murthy, M.S. Felder, B. & Scanlon, E.F. (1985). Cancer, 55: 561.
Springer, T.A. & Lasky, L.A. (1991). Nature, 349: 196.
Springer, T.A. (1990). Nature, 346: 425.
Springer, T.A., Dustin, M.C., Kishimoto, T.K. & Morlin, S.D. (1987).
Ann. Rev. Immunal., 5: 223.
Spyratos, F., Brouillet, J , Defrenne, A., Rouesse, J., Maudelonde, T., 
Brunet, M., Andrieu, C., Desplaces, A. & Rochefort, H. (1989). Lancet, 2: 
1115.
Srivastava, A., Laidler, P., Davies, R.P., Horgan, K. & Hughes, L.E.
(1988). Am. J. Pathol. 133:419.
Stacker, S.A., Sacks, N.P.M., Golder, J & others. (1988). Br. J. Cancer,
57: 298.
Stal, O., Wingren, S. & Cartensen, J. (1989). Eur. J. Clin. Oncol., 25:
301.
Stanbridge, E.J. (1986). Bioessays, 3: 252.
Stanley, M.W., Kiang, D.T. & Sibley, R.K. (1986). Cancer 58: 2046.
Steck, P.A., & Nicolson, G.L. (1983). Exp. Cell Res., 147: 255.
Steeg, P.S. & Liotta, L.A. (1990). Proc. Am. Assoc. Cancer Res., 31: 504.
Steeg, P.S., Bevilacqua, G., Kopper, L., Thorgeirsson, U.P., Talmadge, 
J.B., Liotta, L.A. & Sobel, M.E. (1988). J. Natl. Cancer Inst., 80: 200.
Steinitz, M., Koskimies, S., Klein, G. & Makela, O. (1979). J. Clin. Lab. 
Immunol., 2: 1.
Stenkvist, B., Bengtsson, E., Eriksson, O. et al. (1983). J. Clin. Pathol.,
36: 392.
Stragmignoni, D., Bowen, R., Atkinson, B. & Schlom, J. (1983). Int. J. 
Cancer, 31: 543.
Strous, J.A.M., (1979). Proc. Natl. Acad. Sci. USA, 76:2694.
Taira,M.,Yoshida,T.,Miyagawa,K.,Sakamoto,H.,Terada,M.,& Sugimura,T. 
(1987). Proc. Natl. Acad. Sci. USA , 84: 2980.
Tandon, A.K., Clark, G.M., Chamness, G.C., Chirgwin, J.M. & McGuire, 
W.L. (1990). New Engl. J. Med., 322: 297.
Tandon, A.K., Clark, G.M., Chamness, G.C., Ullrich, A. & McGuire, 
W.L.(1989). J. Clin. Oncol., 7: 1120.
Tavassoli, M., Quirke, P., Farzaneh, F., Lock, N.J., Mayne, L.V. & 
Kirkham, N. (1989). Br. J. Cancer, 60: 505.
Taylor-Papadimitriou, J. (1987). Anticancer Research, 7:1069.
Taylor-Papadimitriou, J., Peterson, J.A., Arklie, J., Burchell, J., Ceriani, 
R.L. & Bodmer, W.F. (1981). Int. J. Cancer, 28: 17.
Tedder, T.D., Cooper, M.D., & Clement, L.T. (1985). J. Immunol. 134: 
2989.
Tedder, T.E., Matsuyama, t., Rothstein, D., Schlossman, S.E. & Morimoto,
C. (1990). Eur. J. Immunol., 20: 1351.
Theillet, C., Adnane, J., Le Roy, X., De Lapeyyriere, O., Grosgeorges, J., 
Raynaud, S.D., Simony-Lafontaine, J., Goldfarb, M., Escot, C., Bimbaum,
D. & Gaudray, P. (1989a). Oncogene, 4: 915.
Theillet, C., Adnane, J., Le Roy, X., De Lapeyyriere, O., Simony- 
Lafontaine, J., Escot, C., Bimbaum, D. & Gaudray, P. (1989b). Proto­
oncogene amplification in human breast cancer: Involvement of FGF-related 
genes in an amplicon located on chromosome 11. In "Molecular diagnostics of 
human cancer", Cold Spring Harbor Laboratory.
Theillet, C.,Lidereau, R.,Escot, C.,Hutzell, P.,Brunet, M.,Gest, J.,Schlom,
J. & Callahan, R. (1986). Cancer Res. 46:4776.
Thein, S.L., Jeffreys, A.J., Gooi, H.C.,. Cotter, F., O'Connor, N.T.J., 
Weatherall, D.J. & Wainscoat, J.S. (1987). Br. J. Cancer, 55: 353.
Thor, A.D., Schwartz, L.H., Koerner, F.C. & 8 others. (1989). Cance 
Res., 49: 7147.
Thorud, E., Fossa, S.D., Vaage, S., & 4 others. (1986). Cancer, 57: 808
Tijo, J.H. & Levan, A. (1956). Hereditas, 42: 1.
Tjandra, J.J. & McKenzie, F.C. (1988). Br. J. Surg., 75: 1067.
Toikkanen,S., Joensuu, H., & Klemi, P. (1989). Br. J. Cancer, 60: 693.
Topalian, S.L., Muul, L.M., Solomon, D., & Rosenberg, S.A. (1987). J. 
Immunol. Methods, 102:127.
Topalian, S.L., Solomon, D., Avis, F.P., Chang, A.E., Freerksen, D.L., 
Linehan, W.M., Lotze, M.T., Robertson, C.N., SEipp, C.A., Simpson,
C.G. & Rosenberg, S.A. (1988). Journal of Clilnical Oncology, 6: 839.
Townsend, A.R.M. (1989). Annu. Rev. Immunol. 7: 601.
Trejdosiewicz, L.K., Smart, C.J., Oakes, D.J., Howdle, P.D., Malizia, G. & 
Campana, D. (1989). Immunology, 68: 7.
Tribukait, B. (1987). World J. Urol., 5: 108.
Tsakraklides, E., Tsakraklides, V., Ashikari, H., Rosen, P.P., Siegal, F.P., 
Robbins, G.F. & Good, R.A. (1975). J. Natl. Cancer Inst., 54: 549.
Tsakraklides, V., Olson, P., Kersey, J.H. & Good, R.A. (1974). Cancer,
34: 1259.
Tsudo, M., Kozak, R.W., Goldman, C.K. & Waldmann, T.A. (1986).
Proc. Natl. Acad. Sci. USA., 83: 9694.
Tubiana, M., Pejovic, M.J., Renaud, A. (1981). Cancer, 47: 937.
Turner, G.A. (1982). Invasion & Metastasis, 2: 197.
Unanue, E.R., Harding, C.V., Luescher, I.F. & Roof, R.W. (1989). Cold 
Spring Harbor Symp. Quant. Biol., 54: 383.
Underwood, J.C.E. (1974). Brit. J. Cancer, 30: 538.
Underwood, J.C.E., Giri, D.D., Rooney, N. & Lonsdale, R. (1987). Brit.
J. Cancer j 56: 744-.
Urdal, D.L., March, C.J., Gellis, S., Larsen, A. & Dower, S.K. (1984). 
Proc. Natl. Acad. Sci. USA., 81: 6481.
Uyterlinde, A.M., Baak, J.P.A., Schipper, N.W., Peterse, H., Matze, E., & 
Meijer, C.J.L.(1990). Int. J. Cancer, 45: 1.
Van de Velde, H., von Hoegen, I., Luo, W., Parbes, J.R. & Thielemans, K. 
(1991). Nature, 351: 662.
Van de Vijver, M. & Nusse, R. (1991). Biochim. Biophys. Acta, 1072: 33.
Uyterlinde, A.M., Baak, J.P.A., Schipper, N.W., Peterse, H., Matze, E., & 
Meijer, C.J.L.(1990). Int. J. Cancer, 45: 1.
Van de Velde, H., von Hoegen, I., Luo, W., Parbes, J.R. & Thielemans, K. 
(1991). Nature, 351: 662.
Van de Vijver, M. & Nusse, R. (1991). Biochim. Biophys. Acta, 1072:33.
Van de Vijver, M.J., Peterse, J.L., Mooi, W.J., Wisman, P., Lomans, J., 
Dalesio, O. & Nusse, R. (1988). N. Engl. J. Med., 319: 1239.
van Dam, P.A., Van Bockstaele, D.R., Keersmaeckers, G.H., & 
Uyttenbroeck, F.L.(1990). Cytometry, 11: 300.
van Dierendonck, I., Keijzer, R., van Velde. C. & Comelisse, C.J. (1989). 
Cancer Res., 49: 2999.
Varley, J.M., Brammar, W.J., Lane, D.P., Swallow, J.E., Dolan,C., & 
Walker,R.A. (1991). Oncogene, 6: 413.
Varley, J.M., Swallow, J.E., Brammar,W.J.,Whittaker, J.L. & Walker, R.A. 
(1987a). Oncogene, 1: 423.
Varley,J.M., Wainwright,A.M. &Brammar,W.J. (1987b). Oncogene 1 431.
Varley,J.M.,Walker,R.A.,Casey,G. & Brammar,W.J. (1988). Oncogene , 3 
: 87.
Varmus, H. & Bishop, J.M. (1986). Cancer Survey, 5: 153.
Venter, D.J., Tuji, N.L., Kumar, S., Gullick, W.J. (1987). Lancet, II: 69.
Verheijen, R., Kuijpers, H.J.H., Schlingeman, R.O. (1988). J. Cell Sci., 
92:123.
Verheijen, R., Kuijpers, H.J.H., van Driel, R. (1989). J. Cell Sci., 92: 531.
Verma, R.S. & Dosik, H. (1982). Pathol. Annu. 17: 261.
Vijver, M.J. van de, Peterse, J.L., Mool W.J., Wisman, P., Loman, J., 
Dalesiom O., Nusse, R. (1988). N Engl J Med. 319: 1239.
Vindel(J)v, L.L., Christensen, I.J., & Nissen, N.I.(1983). Cytometry, 3(50): 
323-327.
Visscher, D.W., Zarbo, R.J., Greenawald, A. & Crissman, J.D. (1990a). 
Pathol. Annu., 25(1): 171
Visscher, D.W., Zarbo, R.J., Jacobsen, G., Kambouris, A., Talpos, G.,
Sakr, W. & Crissman, J.D. (1990b). Lab. Invest. 62: 370.
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., 
leppert, M., Nakumura, Y., White, R., Smits, A.M.M. & Bos, J.L. (1988).
N. Eng. J. Med., 319: 525.
von Kleist, S., Berlling, J., Bohle, W. & Wittekind, C. (1987). Int. J.
Cancer, 40: 18.
von Rosen, A., Rutqvist, L.E., Carstensen, J., Fallenius, A., Skoog, L. & 
Auer, G. (1989). Breast Cancer Research & Treatment, 13: 23.
Walker, R.A. & Camplejohn, R.S. (1988). Br. J. Cancer, 57: 281.
Walker, R.A. (1984a). J. Pathol. 142:279.
Walker, R.A. (1984b). J. Pathol., 144: 101.
Walker, R.A. (1984c). J. Pathol., 144: 109.
Walker, R.A. (1985). J. Pathol. 145:269.
Walker, R.A. (1990). Br. J. Cancer. 62:462.
Walker, R.A., & Camplejohn, R.S. (1988). Br. J. Cancer, 57: 281.
Walker, R.A., Hawkins, R.A. & Miller, W.R. (1985). 147: 103.
Warren, L. Buck, C.A. & Tuszynski, G.P. (1978). Biochim. Biophys. 
Acta., 516: 127.
Weidner, N., Semple, J., Welch, W.R. & Folkman, J. (1991). New Engl. J. 
Med.,
324 (1): 1.
Weiner,D.B.,Liu,J.,Cohen,J.A.,Williams,W.V. &Greene,M.I. (1989). 
Nature, 339 230.
Whiteside, T.L., Miescher, S., Hurlimann, J., Moretta, L. & von Fliender, V. 
(1986). Cancer Immunol. Immunother., 23: 169.
Whitford, P., George, W.D. & Campbell, A.M. (1992a). Cancer Letters,
61: 157.
Whitford, P., Alam, S.M., George, W.D., & Campbell, A.M. (1992b). Eur. 
J. Cancer, (in press).
Whitford, P., Mallon, E.A., George, W.D. & Campbell, A.M. (1990). Br.
J. Cancer, 62: 971.
Whitford, P. (1991). Flow cytometric analysis of the lymphocyte populations 
in patients with breast carcinoma. M.D. Thesis.
Wilkinson, M.J., Howell, A., Harris, J., Taylor-Papadimitriou, J., Swindell, 
R. & Sellwood, R.A. (1984). Int. J. Cancer, 33: 299.
Wilkinson,D.G., Peters,G.,Dickson,C. &McMahon,A.P. (1988). EMBO J , 
7: 691.
Wilson, G.D., McNally, N.J., Dusche, S. (1988). Br. J. Cancer, 58: 423..
Winstanley, J., Cooke, T., Murray, G.D., Platt-Higgins, A.,George,W.D., 
Holt,S., Myskov ,M., Spedding, A., Barraclough, B.R. & Rudland, P.S.
(1991). Br. J. Cancer, 63: 447.
Wintzer, H.O., Benzing, M. & von Kleist, S. (1990). Br. J. Cancer, 62: 
289.
Wolman, S.R. Smith,H.S. Stampfer, M. & Hackett, A.J. (1985). Cancer 
Genet. Cytogenet. 16: 49.
Wreschner, D.H., Hareuveni, M., Tsarfaty, I., Smorodinsky, N., Horev, J., 
Zaretsky, J., Kotkes, P., Weiss, M., Lathe, R., Dion, A. & Keydar, I.
(1990). Eur. J. Biochem., 189: 463.
Wright, C., Angus, B., Nicholson, S. & 6 others. (1989). Cancer Res., 49: 
2087.
Yamashita, K., Hitoi, A., Taniguchi, N., Yokosaw, Y. & Kobata, A. (1983). 
Cancer Res., 43: 5059.
Yamashita, K., Tachibana, Y., Okhura, T. & Kobata, A. (1985). J. Biol. 
Chem., 260: 3963.
Yamaue, H., Tanimura, H., Tsunoda, T., Iwahashi, M., Tani, M., Tamai, M. 
& Inoue, M. (1990). Biotherapy, 2: 247.
Yokota, J., Tsunetsugu-Yokota, Y., Battifora, H., Le Fevre, C.& Cline, M.J.
(1986). Science, 231: 261.
Yonezawa, S., Takahashi, T., Wang, X.J., Wong, R.N., Hartsuck, J.A. & 
Tang, J. (1988). J. Biol.Chem. 263: 16504.
Y oshida,M.C., Wada,M., S atoh,H., Y oshida,T. ,S akamoto,H. ,Miy agawa,K., 
Yokota,J, Koda,T.,Kakinuma,M.,Sugimura,T.& Terada,M. (1988). 
Proc.Natl.Acad.Sci.USA , 85: 4861.
Zarbo, R.J., Visscher, D.W., & Crissman, J.D. (1989), Anal. Quant. Cytol. 
Hist., 11(6): 391.
Zhang, R., Wiley, J., Howard, S.P., Meisner, L.F., & Gould, M.N. (1989). 
Cancer Research, 49: 444.
Zhou, D.J., Ahuja, H. & Cline, M.J. (1989). Oncogene, 4: 105.
Zhou, D.J., Casey, G. & Cline, M.J. (1988). Oncogene, 2: 279.
Zinkemagel, R.M. & Doherty, P.C. (1974). Nature, 248: 701.
Zinkemagel, R.M. & Doherty, P.C. (1979). Adv. Immunol., 27:51.
GLASGOW
UNIVERSITY 
TXBRiiKY _
